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African swine fever virus (ASFV) is a large double-stranded DNA virus which causes 
a lethal haemorrhagic fever in domestic pigs. This virus primarily infects cells from 
the monocyte/macrophage lineage and its ability to manipulate the function of these 
cells is key to the pathogenesis of this disease. ASFV encodes several proteins 
involved in immune evasion. One of these proteins, A238L, has been shown to inhibit 
host macrophage gene transcription. This protein has been shown to interact with 
several cellular proteins involved in signal transduction: a serine/threonine protein 
phosphatase, calcinerurin (CaN), the transcription factor NF-кB, and most recently the 
transcriptional co-activator CREB binding protein (CBP/P300). However its exact 
mechanism of action is not fully understood. Previous work has been limited to the 
investigation of individual signaling pathways and/or the expression of individual host 
genes. The aim of this study was to investigate the global effect of A238L on host 
macrophage gene transcription and also to carry out further investigation into the 
mechanism by which this protein functions.  
 
To determine the global effect of A238L on host macrophage gene transcription 
differential gene expression between porcine cells expressing A238L and control cells 
was examined using a porcine oligonucleotide microarray. These results demonstrated 
that A238L was a potent inhibitor of host macrophage gene expression. Functional 
characterisation of the annotated genes showed that a large proportion of A238L 
down-regulated genes are typically induced in response to cell stress. Significantly, 
genes regulated by the I kappa B kinase (IKK), mitogen-activated protein kinase 
(MAPK) and janus kinase/signal transducers and activators of transcription 
(JAK/STAT) signaling pathways were all shown to be down regulated by A238L. 
Genes associated with the MAPK pathways were particularly enriched. The 
transcription of A238L-regulated genes is controlled by numerous different 
transcription factors, including NF-кB. All of the transcription factors identified 
interact with the transcription co-activator CBP/P300. This provides a common link 
between these factors, and indicates that A238L may target CBP/P300 to inhibit gene 
transcription. This observation supports recent work demonstrating that A238L 
interacts with and inhibits CBP/P300 function. 
 
To explore the potential mechanisms involved in the nuclear localisation of A238L, 
ASFV-infected Vero cells, expressing A238L under the control of its own promoter, 
were examined under a range of conditions using confocal microscopy. The results 
demonstrated that A238L was actively imported into the nucleus and exported by a 
CRM 1 mediated pathway, although a pool of A238L protein remained in the 
cytoplasm.  Sequence analysis of A238L identified the presence of two putative 
nuclear localisation signals (NLS-1 and NLS-2). NLS-2 was located within A238L’s 
CaN docking motif. Mutation of these motifs indicated that both NLS-1 and NLS-2 
are active and exhibit functional redundancy. Mutation of the CaN docking motif 
alone, in the presence of intact NLS-2, resulted in a dramatic increase in the nuclear 
localisation of A238L.  These results are consistent with a model in which A238L 
functions within both the nucleus and the cytoplasm and suggest that binding of CaN 
to A238L masks NLS-2, contributing to the cytoplasmic retention of A238L. 
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1.1 African swine fever 
 
African swine fever (ASF) is a devastating disease of domestic swine. The disease is 
characterised as a severe haemorrhagic fever with up to 100 % mortality in infected 
herds (Montgomery, 1921). ASF was first described in Kenya in the 1920s and contact 
of domestic pigs with warthogs was identified as the source of infection. The infectious 
agent was identified as a virus named African swine fever virus (ASFV). Since then 
ASF has been reported from most sub-Saharan countries in Africa. In 1957 and 1960 
ASF was introduced to Portugal via infected meat products from airline waste. The 
disease spread throughout the Iberian peninsula and remained endemic there between 
1960 and the mid-1990s (Perez-Sanchez et al., 1994; Wilkinson, 1989). Outbreaks in 
France, Italy, Malta, Belgium, Holland, Sardinia, Cuba, Dominican Republic, Haiti and 
Brazil were thought to have been introduced from the Iberian peninsula. These outbreaks 
were eradicated with the exception of Sardinia where disease has remained endemic 
since its introduction in 1982 (Perez-Sanchez et al., 1994; Dixon, 2005). In Africa ASF 
remains endemic in many sub-saharan countries and more recently has spread to 
previously uninfected countries including Madagascar.  Recent outbreaks of ASFV in 
Georgia and surrounding countries in the Caucasus have lead to the slaughter of over 
20,000 animals (Northoff, 2007). There is no vaccine available and control methods rely 
on quarantine and slaughter, which are difficult to implement in many developing 
countries due to the lack of appropriate infrastructure.  
 
In Africa ASFV is maintained in a natural transmission cycle between its natural hosts, 
warthogs (Phacochoerus aethiopicus), bushpigs (Potomochorus porus) and soft ticks of 
the Ornithodoros species,  and these provide a reservoir of disease. The virus is highly 
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adapted to these hosts and causes a sub-clinical persistent infection. In the transmission 
cycle involving these wildlife hosts the tick vector is thought to play a very important 
and possibly essential role since direct transmission between warthogs is thought to 
occur rarely.  In contrast the virus can be transmitted directly between domestic pigs 
without the need for a tick vector and therefore is a risk to pig populations even in 
countries which do not contain the arthropod vector (reviewed in Wilkinson 1989). 
 




African swine fever virus (ASFV) is the etiological agent of ASF. It is a large, 
enveloped, double-stranded DNA virus which replicates predominantly in the cytoplasm 
of infected cells. The virus is morphologicaly similar to the Iridoviridae virus family but 
has a similar genome structure and replication strategy  to the Poxviridae and therefore 
has been placed in a separate virus family the Asfarviridae, genus Asfivirus (Dixon, 
2000) in which it is the only member. ASFV is currently the only known DNA 
arbovirus. The Iridoviridae, Poxviridae and Asfarviridae virus families  all belong to a 
group of nucleocytoplasmic large DNA viruses (NCLDV) which also includes the 
Phycodnaviridae, and Mimivirus (Iyer et al., 2001; Raoult et al., 2004; Iver et al., 2006).  
All of these virus families either replicate exclusively in the cytoplasm of the host cell or 
start their life cycle in the host nucleus but complete in the cytoplasm. Typically these 
viruses do not depent on the host replication or transcription systems for completing 
their replication cycle and encode several conserved proteins responsible for DNA 
replication and transcription. Comparative analysis between the genome sequences of 
viruses belonging to these virus families identified 9 genes that are shared by all of these 
viruses and 22 genes that are shared between the majority of the virus families (Iver et 
al., 2001). This and subsequent comparisons indicate that all NCLDV families 
descended from a common ancestor which was a nucleocytoplasmic virus with an 
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icosahedral capsid, and encoded complex systems for DNA replication and transcription 
(Iver et al., 2006). 
 
1.2.2 Virus morphology 
 
The virus particles exhibit a complex structure with several concentric layers and are 
approximately 200 nm in diameter (Andres et al., 1998; Carrascosa et al., 1984). The 
viral core consists of a DNA containing nucleoid surrounded by a layer of  core protein 
to form a shell (Carrascosa et al., 1984). The core is wrapped in a single lipid bilayer 
thought to be derived from the endoplasmic reticulum (ER),  on which an outer 
icosahedral capsid is assembled (Hawes et al, 2008; Andres et al., 1998). Extracellular 
virons usually have an outer envelope, gained by budding through the plasma membrane 
of infected cells (Breese, 1966; Carrascosa et al., 1984) (Figure 1.1). A diagram of the 




The viral genome consists of a single linear molecule of DNA, which is approximately 
170-182 kbp in length, varying between isolates, with inverted terminal repeats and 
covalently closed hairpin-loops at each end (Gonzalez et al., 1986; Sogo et al., 1984). 
The complete genome sequence of several ASFV isolates has been determined and these 
are available on the website www.virology.ca. The genomes are predicted to encode 
between 151 and 167 ORFs, which are read from both DNA strands across the length of 
the genome (Chapman et al., 2008; Yanez et al., 1995). The genome organisation map 
of the Malawi LIL20/1 isolate, a virulent field isolate of ASFV, is shown in  Figure 1.2 
(Dixon & Chapman, 2008). The genome consists of a central region, which is conserved 
in length, with variable length regions at either end. The variable regions encode a 
number of multigene families (MGF) which vary considerably in number between virus 
isolates (Dixon & Wilkinson, 1988). The functional significance of these genes is not 
fully understood, but they are thought to play a role in determining host range and  
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Figure 1.1 African swine fever virus morphology.
(Top left) Diagram of a viron section with lipid membranes, capsid and 
nucleoprotein core visualised of ASFV particle. (Top right) Thin section, 
(Bottom left) cryo-section and (Bottom right) a negative contrast electron
micrograph of ASFV particles. The arrow indicated the membrane 
components of the virus; pm=plasma membrane. (EMs were provided 
by Dr S. Brookes, IAH Pirbright). The bar represents 200nm. Diagram 
courtesy of Dr L. Dixon (Dixon 2003).
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Figure 1.2 Genome map of the ASFV strain Malawi Lil-20-1.The orientations of the 
arrows denote the direction in which the open reading frame is read.  Diagram provided 
by Dr. Linda Dixon (Dixon 2008).
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virulence (Zsak et al., 2001). Deletion of 6 copies of MGF 360 and 2 of MGF 505/530 
has been shown to affect viral growth in macrophage cell cultures and virulence in pigs. 
These MGF family members have been also been implicated in modulating the host IFN 
response (Afonso et al., 2004; Neilan et al., 2002; Zsak et al., 2001). MGF 360 genes 
have also been shown to affect virus replication and generalization of infection in 
Ornithodoros porcinus ticks (Burrage et al., 2004).  
 
A comparison between the genomic sequences of non-pathogenic and pathogenic ASFV 
isolates has identified 109 non-duplicated open reading frames (ORFs) that are 
conserved between all 10 of the available ASFV genomes. These ORFs encoded 
proteins which include enzymes involved in nucleotide metabolism, DNA replication 
and repair, mRNA transcription and processing, enzymes involved in post-translational  
momodification of proteins, structural proteins and proteins involved in evading the host 
defence system (Chapman et al., 2008) (see Table 1.1). Although the MGF family 
members vary between isolates some copies are conserved between isolates, indicating 
selective pressure to retain these genes.  
 
1.2.4 Virus proteins 
 
The virion contains approximately 50 proteins. These include structural proteins and 
enzymes and factors necessary for early mRNA transcription and processing. The  
enzymes packaged include RNA polymerase, poly A polymerase, guanyl transferase, a 
protein kinase, two nucleoside tri-phosphydrolases, an acid phosphatase and a 
deoxyribonuclease active on single stranded DNA (Tables 1.1) (Dixon, 2003; Salas, 
1999). The A224L inhibitor of apoptosis (IAP) homolog protein is also packaged within 
the virion core. The genes encoding 15 viron structural proteins have been identified: 
p72, p30, p12, p17, p22, p54 (J13L), p49, j18L, 5JR,  and 6 core proteins derived form 2 
polyprotein precursor molecules, pp220 and pp62 (Dixon, 2005; Salas, 1999). p150, 
p37, p34 and p14 are derived from pp220 (Andres et al., 1997; Simon-Mateo et al., 
1997) and p35 and p15 are derived from pp62. The proteolytic processing of these 
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Table 1.1 Functions of ASFV encoded proteins 
 








Thymidylate kinase A240L 27.8 
Thymidine kinase K196R 22.4 
dUTPase* E165R 18.3 
Ribonucleotide reductase (small subunit) F334L 39.8 
Ribonucleotide reductase (large subunit) F778R 87.5 
DNA polymerase β  G1211R 139.8 
DNA topoisomerase type II* P1192R 135.5 
Proliferating cell nuclear antigen (PCNA) like E301R 35.3 
DNA polymerase family X * O174L 20.3 
DNA ligase* NP419L 48.2 
Putative DNA primase C962R 111.2 
AP endonuclease class II* E296R 33.5 
RNA polymerase subunit 2 EP1242L 139.9 
RNA polymerase subunit 6 C147L 16.7 
RNA polymerase subunit 1 NP1450L 163.7 
RNA polymerase subunit 3 H359L 41.3 
RNA polymerase subunit 5 D205R 23.7 
RNA polymerase subunit 10 CP80R 8 
TFIIB like C315R 31.5 
Helicase superfamily II A859L 27.8 
Helicase superfamily II  similar to origin binding protein F1055L 123.9 
Helicase superfamily II B962L 109.6 
Helicase superfamily II VV D6/D11 like involved in 
transcription termination 
D1133L 129.3 
Helicase superfamily II VV D5 like  Q706L 80.4 
Helicase superfamily II VV A18 like  QP509L 58.1 
Transcription factor SII I243L 28.6 
Guanyl transferase* NP868R 29.9 
Poly A polymerase large subunit C475L 54.7 
FTS J like methyl transferase domain EP424R 49.3 
ERCC4 nuclease domain EP364R 40.9 
Lambda-like exonuclease D345L 39.4 
VV A2L like transcription factor B385R 38.5 
VV A7L like transcription factor G1340L 134 
VV VLTF2 like late transcription factor, FCS like fnger B175L 17.5 
VV D5 like ATPase involved in replication C962R 96.2 
   
Other enzymes with unknown roles   
Prenyl transferase* B318L 35.9 
Serine protein kinase* R298L 35.1 
Ubiquitin conjugating enzyme* I215L 24.7 
Nudix hydrolase* D250R 29.9 
   
Host cell interactions   
IAP apoptosis inhibitor* A224L 26.6 
Bcl 2 apoptosis inhibitor* A179L 21.1 
IkB homolog and inhibitor of calcineurin phosphatase* A238L (5EL) 28.2 
C type lectin like* EP153R 18.0 







Similar to HSV ICP34.5 neurovirulence factor  DP71L  8.5 
Nif S like PLP dependent transferase QP383R 42.5 
Mn dependent superoxide dismutase C129R 12.9 
   
Structural proteins and proteins involved in 
morphogenesis 
  
P22  Transmembrane domain.  KP177R 20.2 
A104R Histone-like structural protein.HF-like DNA 
binding protein 
A104R 11.5 
P11.5 A137R 21.1 
P10 A78R 8.4 
P72 Major capsid protein. Involved in virus entry B646L 73.2 
B438L Required for formation of vertices in icosahedral 
capsid. 
B438L 49.3 
B602L Chaperone. Involved in folding of p72 capsid 
protein. Not incorporated into virus particles. 
B602L 45.3 
B119L ERV 1 like. Involved in redox metabolism* Not 
incorporated into virus particles 
B119L 14.4 
Sumo 1 like protease. Involved in polyprotein cleavage S273R 31.6 
P220 Polyprotein precursor of p150, p37, p14, p34 core 
shell components. Required for packaging of 
nucleoprotein core. 
CP2475L 281.5 
P30 Phosphoprotein. Involved in virus entry. CP204L 23.6 
P60 Polyprotein precursor of p35 and p15. Present in 
core shell. 
CP530R 60.5 
P12 Attachment protein involved in virus entry. 
Transmembrane domain. 
O61R 6.7 
P17 Transmembrane domain. D117L 13.1 
J5R  Transmembrane domain. H108R 12.5 
P54 Binds to LC8 chain of dynein, involved in virus entry. 
Transmembrane domain. Required for recruitment of 
membranes to virus factories. 
E183L 19.9 
J18L  Transmembrane domain. VV J5 like membrane 
protein 
E199L 22.0 
E248R  Possible component of redox pathway required 
disulfide bond formation. Structural protein. 
E248R 24.8 
A151R Contains CXXC motif similar to that in 
thioredoxins. Binds to E248R protein. Possble 
component of redox pathway. 
A151R 15.1 
P14.5 DNA binding. Required for movement of virions to 
plasma membrane 
E120R 13.6 
XP124L Multigene family 110 member. Contains KDEL 
ER retrieval sequence and transmembrane domain. 
Involved in modification of ER in preparation for virus 
assembly. 
XP124L 10.6 
   
 





Table 1.1 –continued 
 
  





polyproteins is catalyzed by the viral protease pS273R, which is also located in the core 
shell and is related to the Sumo-like family of proteases (Alejo et al., 2003). Proteins 
involved in virus entry include p12, p30, p54 and also the major capsid protein p72. 
Other proteins present in the capsid include 3 DNA binding proteins and pE120R which 
associates with p72 and is essential for virus transport from assembly sites to the plasma 
membrane 
 
1.2.5 ASFV replication 
 
(Rodriguez et al., 2004).  
ASFV replicates mainly in cells derived from the monocyte/macrophage lineage and 
exhibits a predominantly cytoplasmic replication cycle. A diagram of the replication 
cycle of ASFV is shown in Figure 1.3. Virus attachment to porcine macrophages may be 
mediated by porcine CD163 (Sanchez-Torres et al., 2003).  Expression of CD163 on 
porcine monocytes and macrophages has been shown to correlate with permissiveness to 
ASFV infection and monoclonal antibodies against CD163 were able to inhibit ASFV 
infection and virus binding to alveolar macrophage in a dose dependent manner. Entry 
occurs via receptor-mediated endocytosis, and is energy and temperature dependent 
(Valdeira et al., 1998; Valdeira & Geraldes, 1985). Following internalisation, the viral 
envelope fuses with that of endosomes at an acidic pH releasing the viral core to the 
cytoplasm of the host cell (Valdeira et al., 1998). The virus initiates gene expression 
immediately following entry into the cytoplasm, using enzymes and factors packaged 
into the virus core. Viral gene transcription does not require the host RNA polymerase 
and is dependent on the viral RNA polymerase and specific virus-encoded transcription 
factors. The temporal expression of ASFV genes is strongly regulated and four temporal 
classes of ASFV genes have been described: early, immediate-early, intermediate and 
late. The expression of early and immediate-early genes begins immediately after 
infection. Early gene expression can continue throughout infection; however a sub-class 
of early genes (immediate-early) are silenced before the onset of virus DNA replication 
(Almazan et al., 1992). Intermediate gene expression is detected 4 to 6 hours 
postinfection, and coincides with the maximum expression of early genes. The 
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Figure 1.3 African Swine Fever virus replication cycle. 1. ASFV binds to 
receptors on target cells and enters cells by receptor mediated endocytosis
. This is followed by low pH-mediated fusion of the viral membrane with the 
endosomal/lysosomal membrane. 2.  Early mRNA synthesis begins in the 
cytoplasm immediately following virus entry using enzymes and factors that 
are packaged in the virion. 3. a) An early stage of DNA synthesis takes in 
the nucleus b) followed by the synthesis and formation of mature DNA in 
the cytoplasm from about 6 hours post infection, 4. Late gene expression is 
dependent on onset of DNA replication. Late mRNAs encode structural 
proteins and enzymes needed for early stages of next round of infection. 5. 
Virus assembly takes place in cytoplasmic factory areas and involves 
wrapping of the nucleoprotein core in a membrane layer on which the virus 
capsid is formed. 6.Progeny virus are transported via microtubules to the 
cell membrane where they exit by budding through membrane or cell lysis. 




































expression levels of intermediate genes decrease as late mRNA synthesis increases. Late 
genes are expressed after the initiation of DNA synthesis (Rodriguez et al., 1996). This 
temporal expression of genes suggests that ASFV genes are expressed in a cascade 
model, similar to that described for vaccinia virus, with factors required for transcription 
of one class of genes synthesised during the previous temporal stage (Moss, 2001). 
 
Newly synthesised viral DNA is found in the nucleus and cytoplasm in the early stages 
of DNA replication, and is found only in the cytoplasm at later stages (Garcia-Beato et 
al., 1992; Rojo et al., 1999). This may indicate the involvement of cellular nuclear 
factors in the early stages of viral DNA synthesis. Smaller DNA fragments are 
synthesised in the nucleus, with larger genome length fragments found in the cytoplasm  
at later time points. Pulse-chase experiments are consistent with the hypothesis that these 
nuclear fragments are precursors of the mature cross-linked viral DNA found in the 
cytoplasm (Rojo et al., 1999).  However it is not clear if the nuclear stage of DNA 
replication is essential.  Replication of the full length ASFV genome takes place in virus 
factory areas via head-to-head concatemers, as has been described for poxvirus genome 
replication (Gonzalez et al., 1986; Sogo et al., 1984). Following resolution of these 
concatameric forms into unit length genomes, the complete genomes are then packaged 
into virus particles (Brookes et al., 1996). Virus morphogenesis takes place in virus 
factories that are located in discrete perinuclear foci, that are located next to the 
microtubule organising center (Heath et al., 2001). The microtubule network is required 
for maintenance of virus factories. The virus factories resemble aggresomes, which are 
formed in cells in response to misfolded proteins (Heath et al., 2001). Following 
assembly mature virus particles are transported from the virus factories along 
microtubules to the cell surface (Jouvenet et al., 2004) and are released by budding from 
the plasma membrane from projections that resemble filopodia (Jouvenet et al., 2006).  
 
1.3 Pathogenesis of ASFV 
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The clinical symptoms of ASF vary considerably between the virus isolate and host 
species. In domestic pigs the disease is characterised into 4 forms: peracute, acute, 
subacute and chronic (Boinas et al., 2004; Hess, 1981; Wardley et al., 1983). The 
clinical symptoms associated with these forms are presented in Tables 1.2. Symptoms 
range from 100 % mortality within a few days of infection before clinical signs are 
detected (peracute), to chronic infections where pigs exhibit few signs of illness. Pigs 
infected with moderately virulent isolates of ASFV can recover from infection, but 
remain persistently infected, providing a potential reservoir of virus in domestic herds. 
Virus has been isolated from the lymph nodes of recovered animals up to 48 days post-
infection (Oura et al., 1998) and viral DNA has been detected in peripheral blood 
mononuclear leukocytes (PBML) at greater than 500 days post-infection by a PCR assay 
(Carrillo et al., 1994). In its most  
Table 1.2 Clinical effects of ASF 
 
Clinical symptoms are presented 5-15 days after infection, and can include one or more of the following 
forms of disease. Adapted from www.pighealth.com/ASF.htm#Clinical. 
 
Classification Clinical Symptoms 
 
Peracute 
Pigs are suddenly found dead, or close to death. 
 
Acute 
Pigs exhibit fever, loss of appetite and inactivity. Red or blue skin 
discolouration may be present on the chest or abdomen, tips of ears or 
distal limbs. Diarrhoea, vomiting, coughing, breathing difficulty and 
abortion may also occur. Almost 100% of pigs with these symptoms will 
die within 7 days.  
 
Subacute 
Affected pigs show mild symptoms, with intermittent fever for up to one 
month, followed by recovery in most cases. Mortality ranges from 30-70% 
and pregnant sows may abort. Recovered animals can still excrete virus for 
up to six week following infection. 
 
Chronic 
Pigs show few clinical signs with the exception of occasional bouts of 
fever, reduced growth stunting and emaciation. Patches of necrotic skin, 
may be present and chronically infected animals are vulnerable to 





acute form ASF is characterised by multiple haemorrhages, lymphopenia associated with 
intense destruction of lymphoid tissue and disseminated intravascular coagulation, 
leading to death within a few days as a result of shock.  
 
The ability of ASFV to infect and replicate in cells of the monocyte/macrophage lineage 
is considered to play a critical role in the pathogenesis of this disease. ASFV has been 
reported to infect other cell types, including endothelial cells, fibroblasts and reticular 
cells (Carrasco et al., 1997; Gomez-Villamandos et al., 1997). However, infection of 
these cells is limited to the late stages of infection after the characteristic symptoms of 
ASFV have been observed and therefore is not thought to play a central role in disease 
pathology.  
 
Immunocytochemistry on infected tissues from domestic pigs infected with Malawi, a 
highly pathogenic isolate of ASFV, exhibited extensive apoptosis of uninfected 
lymphocytes in association with ASFV infected macrophages in the lymphoid tissue 
(Oura et al., 1998). The mechanisms involved in ASFV-induced lymphocyte apoptosis 
have not been defined, but are thought to include the release of proinflammatory 
cytokines, such as TNF-α and IL-1β from infected monocytes/macrophages. Salguero et 
al (2002, 2005) demonstrated an increase in the serum levels of TNF-α and IL-1β  which 
was shown to coincide with lymphocyte apoptosis. These studies also showed an 
increase in the immunohistochemical detection of macrophages expressing TNF-α, IL-1 
and IL-6 in proximity to lymphocytes undergoing apoptosis (Salguero et al., 2002; 
Salguero et al., 2005).  
The removal of positive cell survival signals has also been proposed as an indirect 
mechanism involved in B cell apoptosis. T cell apoptosis has been shown to precede that 
of B cells in pigs infected with Malawi (Oura et al., 1998).  One study investigating the 
effect of ASFV on B cells in pigs infected with the Malawi isolate Lilongwe 20/1, 
demonstrated that the CD40 ligand (CD154), a cell survival signal expressed by T-cells, 
was able to rescue B cells from ASFV infected pigs from apoptosis. The hypothesis 
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suggested by the authors is that B cells are activated during ASFV infection and would 
normally receive survival signals from CD154 expressed on T cells. However, due to the 
drastic depletion of T cells, which occurs early during ASFV infection, these survival 
signals may not be delivered to rescue the B cells from apoptosis (Takamatsu et al., 
1999).  
 
Factors from ASFV infected macrophages have also been associated with increased 
vascular permeability and the stimulation of adjacent endothelial cells, leading to 
haemorrhage (Carrasco et al., 1997). An increase in the levels of TNF-α has been shown 
to coincide with ASFV disease pathology (Carrasco et al., 2002; Gomez del Moral et al., 
1999; Salguero et al., 2002), and is thought to make a significant contribution to some of 
the major clinical manifestations of acute ASF. In addition to providing signals involved 
in the induction of apoptosis, TNF-α induces vasodilation, an increase in vascular 
permeability and activation of the vascular endothelium (Mantovani, 1997). These 
contribute to damage to the vascular endothelial cells and result in haemorrhage.  
 
The pathogenesis of ASFV shares several similarities with other viral haemorrhagic 
fevers, including Ebola and Marburg viruses. These viruses also primarily infect cells of 
the mononuclear phagocytotic system but spread to other cell types as the disease 
progresses. Infected monocytes release cytokines and chemokines which can indirectly 
lead to the destruction of endothelial cells (Feldmann et al., 1996; Stroher et al., 2001) 
and induce apoptosis of uninfected lymphocytes (Geisbert et al., 2000). Virus infected 
macrophages, in combination with the cytotoxic properties of the virus’s surface 
glycoproteins (Feldmann et al., 1999) are considered to be the main pathological 
determinants of these diseases.  
 
1.4 Host Immune response to ASFV infection 
 
At present there is no vaccine available against ASFV. Homologous protective 
immunity against ASFV infection has been demonstrated in pigs that survive infection 
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with moderately virulent or attenuated variants of ASFV are protected against closely 
related but not more distantly related isolates (Boinas et al., 2004; Hamdy & Dardiri, 
1984; Leitao et al., 2001). The exact mechanism of protective immunity is not fully 
understood.  Antibody-mediated immune mechanisms have been shown to play a role in 
protection. An antibody-mediated reduction of infectivity of virulent ASFV isolates in 
Vero cells and swine macrophages has been demonstrated in vitro in the presence of 
ASFV hyperimmune serum (Ruiz Gonzalvo et al., 1986a; Ruiz Gonzalvo et al., 1986b) 
and passive antibody transfer delayed onset of symptoms and reduced mortality in 
infected pigs treated with anti-ASF immunoglobulin (Ig) (Wardley et al., 1985). The 
effectiveness of antibodies against the virus proteins p30, p54 and p72 in inhibiting virus 
attachment and entry has been demonstrated (Gomez-Puertas & Escribano, 1997; 
Gomez-Puertas et al., 1996). In one report partial protection of pigs was demonstrated 
using a mixture of recombinant proteins p30 and p54 (Barderas et al., 2001). However in 
another study immunisation with these recombinant proteins was shown to induce some 
neutralising activity but failed to protect pigs from viral challenge and merely delayed 
the onset of clinical symptoms by two days (Neilan et al., 2004). It is therefore likely 
that ASF antibody-mediated protection is complex and requires responses to several 
different viral proteins.  
 
Components of the cell mediated immune response have also been shown to play a 
significant role in protective immunity to ASFV. Cytotoxic T lymphocytes specific for 
ASFV infected macrophages have been identified in pigs infected with the non-lethal 
ASFV isolate (NHVP68) (Martins et al., 1993).  In addition, diminished protection 
against OUR/T88/1 isolate was observed following depletion of CD8+ cells from pigs 
vaccinated with the non-pathogenic ASFV isolate OURT88/3 (Oura et al., 2005). 
Natural killer cell activity has also been associated with protection following infection 
with (NHVP68) (Leitao et al., 2001). Overall the host mechanisms involved in the 
protective immune response are complex and evidence suggests they include both 
cellular and serological components. 
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1.5  Modulation of macrophage function by ASFV infection 
 
Macrophages are key cells involved in activating and co-ordinating the innate and 
adaptive immune response to infection. The ability of ASFV to infect and replicate in 
macrophages is thought to play a critical role in ASFV disease pathology. ASFV 
infection has a direct effect on host macrophage function in vitro. Antibody mediated 
phagocytosis, chemiluminesence and chemotaxis are all modulated in ASFV-infected  
macrophages (Martins et al., 1987). Whittall et al (1997) demonstrated inhibition of 
TNF-α and  IL-1β transcription and protein expression in primary macrophage cells 
infected in vitro with Malawi, a virulent isolate of ASFV. Powell et al (1996) also 
demonstrated the inhibition of TNF-α, IL-8 and interferon (IFN)-α gene transcription in 
macrophages infected with this isolate. In both studies the inhibition was limited to pro-
inflammatory cytokines, as transforming growth factor (TGF)-β, a pleuripotic cytokine 
with anti-inflammatory properties was expressed throughout ASFV infection. The 
inhibition of TNF-α production in these studies contrasts with a more recent study 
investigating the effect of E75 (a virulent isolate of ASFV) on TNF-α expression during 
infection (Gomez del Moral et al., 1999). This study demonstrated the induction of 
TNF-α mRNA and  TNF-α protein, in infected macrophages and cell supernatants 
respectively, following ASFV infection in vitro. This discrepancy between results could 
be due to inherent differences between the ability of different ASFV isolates to modulate 
the expression of TNF-α. This suggests that the ability of ASFV to modulate the 
expression of TNF-α alone may not be responsible for the disease pathogenesis as both 
Malawi and E-75 are virulent isolates causing high levels of mortality. 
 
ASFV has also been shown to inhibit the ability of macrophages to respond to 
stimulation with IFN-γ (Whittall & Parkhouse, 1997). IFN-γ and  IFN-α have been 
shown to inhibit ASFV replication in porcine monocytes and alveolar macrophages 
(Esparza et al., 1988) and have also been shown to cure Vero cells from lytic and 
persistent infection with ASFV (Paez et al., 1990). Therefore the ability of ASFV to 
inhibit the expression of IFN-α in infected macrophages (Powell et al., 1996), in 
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addition to suppressing the response of infected cells to IFN-γ activation could play an 
important role in the ability of ASFV to replicate and in host macrophages. 
 
1.6 Viral immune evasion 
 
Viruses are obligate intracellular parasites dependent on the host cell for survival. This 
coexistence between viruses and their hosts exerts an evolutionary pressure on both 
organisms, leading to the development of a complex anti-viral host immune response 
and the evolution of numerous viral strategies to counteract it.  
 
Immune evasion strategies vary greatly between individual viruses however in general 
viruses with a large coding capacity, such as large DNA viruses, tend to produce a wide 
array of proteins with specific immune-evasion functions. These proteins can include 
viral homologues of host genes. For example several poxviruses and herpesviruses 
encode homologues of cytokines (virokines) and cytokine receptors (viroceptors) 
(Johnsen et al., 2003). Virokines include the herpesvirus cytokine homologues vIL-6 
and vIL-17 and the poxvirus vIL-18 binding protein(vIL-18BP). vIL-18BP functions in 
the same was as it’s mammalian homologue binding to host IL-18 and inhibiting it’s 
action. IL-1 8  is a p otent ind u cer of IFN γ, therefore in h ibition of IL-18 indirectly 
regulates IFN action. In addition many poxvirus also produce viral mimics of both IFN 
α/β and IFN γ receptors (IFN-Rs). These proteins are secreted from virus infected cells 
where they bind with high affinity to IFNs. This effectively decreases the amount of IFN 
available to interact with host IFN-Rs (Johnson et al., 2003). The similarity between 
these genes and the host counterpart suggests that they have been ‘stolen’ from the host 
and modified for the benefit of the virus. Herpesviruses also have an additional capacity 
to hide from the host’s immune system by their ability to establish latency. (Vossen et 
al., 2002). In contrast to large DNA viruses, viruses with small genomes, common 
among many RNA viruses, are constrained by their coding capacity. These viruses often 
encode multifunctional proteins which carry out immune-evasion functions and 
functions essential for virus replication. For example the Flavivirus nonstructural protein 
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(NS1), described below, is an essential gene which functions as a cofactor for viral RNA 
replication and also inhibits complement activation by a separate mechanism (Chung et 
al., 2006). 
 
1.6.1 Viral mechanisms to evade host defence 
 
Viral immune evasion strategies cover all aspects of the host response to infection, 
including the humoral immune response, the cellular immune response and immune 
effector functions such as cytokines and apoptosis. Some specific examples of inhibition 
of the humoral and cellular immune response are described below. Examples of ASFV 
strategies to counteract immune effector functions are discussed in section 1.7. 
 
Inhibition of the humoral Immune response 
 
Antigenic drift is an important strategy for avoiding immune detection by neutralising 
antibody. Due to the low fidelity of RNA-polymerases, RNA viruses such as 
picornaviruses, and retroviruses are constantly subject to random mutations leading to 
changes in their envelope proteins and the selection of variants with different antigenic 
properties. In addition, RNA viruses with segmented genomes such as Influenza can 
exhibit both antigenic drift, resulting in small mutations due to errors in transcription 
and antigenic shift, a major alteration which occurs when RNA segments from different 
viruses recombine.  
 
The complement system is also a target for virus subversion. Activation of the 
complement system can lead to neutralization of cell-free viruses, phagocytosis of C3b-
coated viral particles, lysis of virus-infected cells, and generation of inflammatory and 
specific immune responses. Therefore many viruses have developed mechanisms to 
counteract it. Several large DNA viruses encode viral homologues of complement 
regulatory proteins which block complement activation. vaccinia, cowpox and variola 
members of the poxvirus family all encode complement homologues (Bernet et al., 
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2007). In contrast the West Nile virus nonstructural protein NS1 has no similarity to 
cellular counterparts. This protein binds to the regulatory protein factor H and promotes 
the fI-mediated cleavage of C3b. In addition cell surface-associated NS1 attenuates the 
deposition of C3b and C5b–9 membrane attack complexes (Chung et al., 2006). Other 
viruses such as HIV and human cytomegalovirus (HCMV), ‘borrow’ host cellular 
factors involved in complement control such as CD59 and incorporate them into the 
viral envelope. There by protecting the virions from complement lysis (Favoreel et al., 
2003). 
 
Inhibition of cell-mediated immune responses 
 
The cellular immune response to infection plays an important role in host defence. 
CD8+ cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, in particular, play a 
critical role in the destruction of virus infected cells. In general, CD8+ CTLs recognize 
antigenic peptides in the complex with major histocompatibility complex (MHC) class I 
molecules. Therefore many viruses have developed strategies to interfere with the 
activation of CTLs cells by blocking MHC class 1 antigen processing and presentation. 
For example the HCMV protein unique short 6 (US6) inhibits the loading of viral 
peptides into MHC class 1 complexes by blocking the transporter associated with 
antigen processing (TAP-1) protein function. TAP is a transmembrane protein that 
delivers cytosolic peptides into the endoplasmic reticulum (ER) (Hewitt et al., 2001). 
The adenovirus protein E3/19K prevents expression of newly synthesized MHC 
molecules by inhibition of ER export (Windheim et al., 2004).  
 
Down regulation of MHC class 1 molecules has the potential to make virus infected 
cells vulnerable to natural killer (NK) cell recognition. Therefore some viruses have 
additional strategies to counteract this effect. Molluscum contagiosum virus (MCV) has 
been shown to encode an an MHC I homologue, MC080R which binds to b2-
microglobin a sub-unit of the MHC class molecule (Johnston et al., 2003). HCMV has 
been shown to encode several genes capable of suppressing NK cell recognition. These 
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include UL16, UL18, UL141 and UL142. UL16, UL142 act together with a HCMV 
microRNA (miR-UL112) to suppress the presentation of ligands on the cells surface for 
the NK cell activating receptor NKG2D. UL18 acts as a MHC-I homologue and UL141 
acts post-translationally to suppress cell surface expression of CD155 a NK cell 
activating receptor (Wilkinson et al., 2008). 
 
MHC class II molecules are also a target for virus subversion. These molecules present 
antigen to CD4+ T cells. CD4+ T cells regulate the induction of CTLs, antibodies and 
memory T cells. For example HMCV protein US3 causes the rapid retrotranslocation of 
MHC class II proteins from the ER, followed by their proteasome-mediated 
1.6 ASFV proteins involved in immune evasion 
degradation 
(Hedge et al., 2002). 
 
 
The ability of ASFV to modulate macrophage function and to persist in its natural hosts 
and in domestic pigs, which recover from infection with less virulent isolates, indicates 
that this virus has effective mechanisms for evading the host immune system and 
avoiding viral clearance. Several ASFV proteins involved in modulating the host’s 
defence response to infection have been identified. These include proteins involved in 
inhibiting apoptosis, cell adhesion proteins and proteins which interfere with host 
macrophage signalling pathways to inhibit the transcriptional activation of immune 
response genes (Dixon et al., 2004). ASFV strategies involved in evading the immune 
response to infection are represented in Figure 1.4 and individual proteins are discussed 
in more detail below. 
 
1.6.1 ASFV and Apoptosis  
 
Apoptosis is the process whereby cells undergo systematic programmed cell death in 
response to a wide variety of stimuli, and is an important cellular strategy to limit virus 
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replication and reduce virus spread. Apoptosis is observed both in ASFV infected 
macrophages and bystander non-infected lymphocytes (Oura et al., 1998).  In ASFV 
infected Vero cells apoptosis was shown to be triggered at early time points after virus 
internalization, before early ASFV protein synthesis. However, the onset of apoptosis is 
only observed at late times (between 16 and 18 hours post-infection) following ASFV 
infection (Carrascosa et al., 2002; Hernaez et al., 2006). At this time point progeny 
virions have been produced and induction of apoptosis is therefore unlikely to limit 
replication and the spread of progeny virus.  This suggests that although the process of 
infection triggers apoptosis the virus must have mechanisms which delay the onset of 
apoptosis until later in infection. This is likely to be a tightly regulated process, where 
the action on cellular apoptotic proteins is balanced by the expression of viral anti-
apoptotic genes. 
 
Mammals have two distinct apoptosis signalling pathways: one initiated by members of 
the TNF receptor family, known as death receptors and the other initiated by cell stress 
and is regulated by pro- and anti-apoptotic members of the Bc1-2 protein family 
members. Bcl-2 protein is the prototypical member of the anti-apoptotic members of the 
Bc1-2 family and interacts with pro-apoptotic members to preserve mitochondrial 
integrity (Petros et al., 2004). Pro-apoptotic members of this family function by  
inactivating the protective function of the pro-survival members of the Bcl-2 family and 
by activating the Bax/Bax-like pro-apoptotic family members. These pro-apoptotic 
family members permeabilise the mitochondrial membrane leading to the release of 
cytochrome c and subsequent activation of caspases (Bouillet & Strasser, 2002). 
Caspases, a family of cell death proteases, exist as inactive precursor molecules which 
require proteolytic cleavage for activation. Once activated, the effector caspases are 
responsible for the proteolytic cleavage of a broad spectrum of cellular targets, leading 
ultimately to cell death. The known cellular substrates include structural components 
(such as actin and nuclear lamin), regulatory proteins (such as DNA-dependent protein 
kinase) and other proapoptotic proteins and caspases (Shi, 2002). 
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Figure 1.4 Mechanisms that the African swine fever virus uses to evade the 
hosts immune defence. 1. The virus encoded A238L protein inhibits activity of NF-KB 
directly and NFAT indirectly via inhibition of calcineurin activity. Hence this protein can 
inhibit the expression of a wide range of immunomodulatory proteins in macrophage 
whose expression depends on these factors. 2. CD2v protein encoded by the virus is 
expressed on the surface of infected cells and causes red blood cells to adhere to their 
surface, camouflaging them from the immune system. 4. CD2v is also present on 
extracellular virus particles, which adhere to red blood cells, facilitating dissemination 
of ASFV in infected animals. 3. Expression of CD2v in infected macrophage also 
interferes with the ability of T cells to divide, and 5 may send signals to the nucleus by 
interaction between its cytoplasmic tail and host cell signalling pathways. 6. Virus 
infection causes apoptosis in neighbouring T and B cells, thus reducing populations of 
these important immune cells. 7. The virus also encodes proteins which inhibits 
apoptosis of the host cell, thereby promoting virus replication. Courtesy of Dr. Linda 
Dixon (Dixon, Abrams et al. 2000).
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ASFV encodes three proteins which have been shown to inhibit apoptosis in infected 
cells; A224L, A179L and EP153R. These proteins are expressed at different times 
during the ASFV replication cycle and target different components of the cellular 
apoptosis machinery. A179L, is a viral Bcl-2 homologue which is expressed throughout 
ASFV infection and is essential for virus replication (Brun et al., 1996; Neilan et al., 
1993). This protein has been shown to inhibit the apoptotic activity of porcine BID, a 
member of the core Bc1-2 apoptotic machinery, which acts in the death receptor 
apoptosis pathway downstream of caspase 8 (Galindo et al., 2008). A224L, an IAP 
homologue, is expressed late in ASF infection and has been shown to inhibit the 
proteolytic processing of caspase-3 and also interacts with the proteolytic fragment of 
this protein inhibiting it activity (Chacon et al., 1995; Nogal et al., 2001). This protein is 
thought to play a role in controlling the survival of the infected cell during virus 
morphogenesis. EP153R has been demonstrated to inhibit apoptosis, possibly by 
inhibiting the transactivating activity of p53 (Hurtado et al., 2004).   
 
The ability of ASFV to induce apoptosis in bystander immune cells could also be an 
effective strategy to limit the immune response to infection. 
 
1.6.2 CD2v: an ASFV cell adhesion protein  
 
The CD2v protein, encoded by the EP402R gene, is a transmembrane protein which is 
expressed on the surface of ASFV infected cells and also in the external membrane of 
extracellular virus. This protein encodes an extracellular domain, which exhibits 
significant similarity to the T-cell adhesion molecule CD2 (Borca et al., 1994; 
Rodriguez et al., 1993). CD2v is transcribed in the late stages of ASFV replication and 
is responsible for the haemoadsorbtion of swine erythrocytes to virally infected cells and 
extracellular virus particles (Borca et al., 1994; Rodriguez et al., 1993). The expression 
of another ASFV protein, EP153R, which resembles a C-type lectin, has been shown to 
enhance the interaction between CD2v and red blood cells. The heamadsorbtion of 
erythrocytes to extracellular virus is responsible for the predominantly erythrocyte 
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associated viremia exhibited in pigs infected with heamadsorbing isolates of ASFV and 
this facilitates dissemination of the virus around the host (Borca et al., 1998). CD2v is 
non-essential for virus replication in primary porcine macrophage cell cultures, and 
deletion of the gene does not reduce mortality of virulent isolates for pigs (Borca et al., 
1998). However, pigs infected with CD2v deletion mutants of ASFV exhibited a delay 
in the spread of virus infection to the lymph nodes, a delay in vireamia and also reduced 
viral titres in the blood (Borca et al., 1998). 
 
CD2v is also required for the inhibition of mitogen-dependent lymphocyte proliferation 
of swine peripheral blood mononuclear cells in vitro. The mechanism of inhibition is not 
known  (Borca et al., 1998). ASFV does not infect lymphocytes indicating that this 
effect is mediated through factors on the surface or secreted from ASFV infected cells. 
The similarity in structure and function of CD2v to the T-cell adhesion molecule CD2 
and requirement of CD2v expression to suppress the proliferation of lymphocytes, 
suggests that its plays an important role in evading the host immune system.   
 
1.6.3 Modulation of host gene transcription by ASFV 
 
Regulation of host macrophage gene transcription appears to be an important strategy 
used by ASFV to modulate the hosts’ immune response. A238L is an important protein 
involved in the modulation of host macrophage signalling pathways and is described 
below. Other ASFV proteins with the potential to regulate gene transcription include 
j4R, and the ASFV ubiquitin conjugating (UBCv) enzyme. j4R has been demonstrated 
to bind to the the host α-NAC protein (Goatley et al., 2002). α-NAC can act as a 
transcriptional co-activator potentiating transcription dependent on c-Jun (Moreau et 
al.1998). The transcription factor c-Jun is activated in response to cell stress and is 
involved in the transcription of many immunomodulatory genes (Foletta et al., 1998). 
Therefore j4R could regulate c-Jun dependent gene transcription through interaction 
with α-NAC. UBCv, encoded by the I215L gene has been shown to bind to the host 
nuclear protein SMCy which is involved in transcription regulation (Bulimo 2000). In 
 38 
addition, deletion of members of multigene families 360 and 530 has been shown to 
increase production of type I IFN and activation of IFN induced genes in infected 
macrophages. This suggests that these genes may have a role in inhibiting transcription 





The A238L protein varies between 238 and 239 amino acids in length and is highly 
conserved between different ASFV field isolates (Neilan et al., 1997), indicating that it 
has an essential role in the survival of ASFV in its natural hosts. The protein is predicted 
to encode 4 ankyrin repeat domains, located in the central region of the protein. Ankyrin 
repeats are structural motifs involved in protein-protein interactions (Yanez et al., 1995). 
Database comparisons with annotated proteins demonstrated that A238L (also known as 
5EL) was significantly similar to the cellular inhibitor of NF-кB (IкB-α) protein, 
suggesting that it may function as a viral IкB-α homologue (Yanez et al., 1995). At the 
amino acid level A238L exhibits 20 % identity and 40 % similarity to porcine inhibitor 
of NF-кB (IкB-α) (Figure 1.5)(Revilla et al., 1998). This sequence similarity is limited 
to the ankyrin repeat domains and does not extend to the amino or carboxyl- terminus of 
A238L. Expression of A238L in porcine and monkey kidney cells has been shown to 
inhibit the expression of an NF-кB-dependent luciferase reporter gene and also inhibits 
binding of NF-kB to oligonucleotides containing its DNA binding site. AP-1 dependent 
gene expression and DNA binding were not inhibited, indicating that this action was 
specific to NF-кB and that A238L acts a functional homologue of IкB-α (Powell et al., 
1996; Revilla et al., 1998; Tait et al., 2000). The NF-KB family of transcription factors is 
involved in regulating the expression of a diverse range of genes involved in the immune 
response, including proinflammatory cytokines and chemokines, anti-apoptotic genes 
such as IAP proteins and Bcl-2, acute phase proteins and adhesion molecules (Ghosh et 
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al., 1998). Therefore, through inhibition of NF-кB, A238L has the potential to play a 
significant role in counteracting the host’s immune response to ASFV infection. 
 
A238L has also been shown to bind to and inhibit the activity of the cellular 
calcium/calmodulin regulated phosphatase, calcineurin (CaN) (Miskin et al., 1998). This 
phosphatase was previously known as protein phosphatase 2B but has been renamed 
protein phosphatase 3C or PP3C. This work also demonstrated that A238L was capable  
 
of inhibiting the activation of the CaN regulated transcription factor Nuclear Factor of  
Activated T Cells (NFAT). Calcineurin and NFAT, regulate the expression of a large 
number of inducible genes encoding cytokines and cell-surface receptors that are 
essential for a productive immune response (Rao et al., 1997).  
 
Surprisingly, despite the potential ability of A238L to inhibit the expression of a wide 
range of host immunomodulatory genes during ASFV infection, deletion of the A238L 
gene does not reduce virus replication in primary porcine macrophages or established 
cell lines and deletion of the A238L gene does not reduce viral virulence in domestic 
swine (Neilan et al., 1997).  This observation has been supported in a recent study 
examining the infection of pigs with the highly virulent ASFV E-70 isolate, compared to 
an E-70 A238L deletion mutant. No significant differences were observed in the clinical 
signs or pathology between both groups. However, peripheral blood monocyte cultures 
(PBMC) from pigs inoculated with the virus deleted in A238L showed elevated levels of 
TNF-α and IL- 1 mRNA compared to those from the parental E-70 isolate. This 
demonstrates that A238L does inhibit proinflammatory cytokine expression in vivo. 
Upregulation of transcription of these proinflammatory cytokine genes was not observed 
in the PBMC of animals inoculated with parental E-70 isolate, even though apoptosis of 
bystander lymphocytes and haemorrhages were evident. Possibly this disease pathology 
may be  caused by secretion of these cytokines by bystander non-infected monocytes or 
macrophages (Salguero et al., 2008) or may be induced by other factors from infected 
macrophages. A238L may have an important role in viral persistence in its natural hosts 
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(a)
Figure 1.5 Schematic representation of A238L. Panel (A) represents the A238L protein 
which is 238 aa in length. A238L is predicted to encode four ankrin repeat domains (Ank) 
(represented by red boxes). A238L also contains a CaN binding motif  located at the C-
terminus and depicted in red (Misken et al 2000). Diagram is not to scale. Panel (B) 
Homology of A238L to IκBα proteins.The amino acid sequence of  A238L was compared to 
the IκBα sequences f rom several mammalian species: Mad3, human; Pig, porcine  and 
Rat. The black lines above the sequence show the positions of  the ankrin repeats in IκBα
and the black lines below the sequence represent putative Ankrin repeat motifs identif ied 





or recovered pigs rather that being directly responsible for viral virulence in domestic 
swine. Considering the important role of NF-κB and NFAT in regulating the expression 
of immune response genes, it is also possible that A238L exhibits functional redundancy 
with other ASFV proteins that can compensate for the loss of A238L.  
 
A238L is expressed throughout infection as two molecular mass forms of 28 kDa and 32 
kDa (Tait et al., 2000). Both forms of A238L can be expressed from cDNA in 
uninfected cells, indicating that the difference between these forms is due to post- 
translation modification. However, the nature of this modification has not yet been 
determined (Tait et al., 2000).  
 
A238L contains 4 ankyrin repeat domains located in the central region of the protein 
(Figure 1.5). These domains are a common motif found in a large number of 
functionally diverse proteins including proteins involved in cell cycle control, 
transcriptional regulation, innate immunity and apoptosis. They are most common in 
eukaryotes, but have been found in a small number of prokaryotes and viruses. The 
presence of these domains in prokaryotes and viruses is thought to be the result of 
horizontal gene transfer (Bork et al., 1993). Ankyrin repeats are characterized as 30-33 
amino acid residues which consist of two alpha helices separated by beta hairpin loops. 
Several ankyrin repeat motifs are usually present within any individual protein where 
they combine to produce a stacked structure unit which acts to present critical residues 
on the proteins surface and promote protein-protein interaction (Li et al., 2006).  
Ankyrin repeat proteins do not recognise specific sequences and interacting residues are 
discontinuously dispersed throughout the protein. The repeats act as structural motifs 
providing protein stability and promoting specific binding. A238L was originally 
proposed as an IkBα homologue based on the similarity between the ankyrin repeat 
domains of these proteins (Yanez et al., 1995). Therefore considering the known 
function of these repeats it could be that the similarity between these proteins is confined 
to the conserved structure of ankrin repeat domains and not specific interacting residues. 
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Thus A238L may not function b y the same mech an ism as Ik Bα to in h ibit NF-κB 
mediated gene transcription.  
1.6.3.1.1 NF-кB  
 
The NF-кB family of transcription factors consists of 5 members: RelA/p65, p50, p52, 
c-rel and rel-B. These proteins are characterised by the presence of a REL homology 
domain (RHD) that consists of a DNA binding domain, dimerisation domain and a 
Nuclear Localisation Signal (NLS). These proteins associate as homo- or heterodimers 
wh ich b in d  to κB sites with in p romoters/enhancers of targ et g enes and  regulate 
transcription through the recruitment of coactivators and corepressors. NF-κB proteins 
are classified into 2 groups based on the properties of their carboxy-terminal regions. 
Class one proteins ( p65, c-REL and REL-B), contain transactivation domains (TAD) 
within the carboxy-terminal regions, which interact with components of the basal 
transcriptional apparatus and also the transcriptional co-activators, p300 and cyclic-
AMP-response element (CREB) binding protein (CBP) (Chen & Greene, 2004). Class 
two proteins, p50 and p52, are synthesised as the precursor proteins p105 and p100 
respectively. p105 and p100 contain a series of ankyrin repeat domains in their carboxy-
terminal regions which can associate with NF-κB within the cell and act as IκB proteins. 
p50 and p52 contain no TAD, and therefore p50 and p52 homodimers can act as 
repressors to NF-κB specifc gene transcription (Ghosh et al., 1998). 
 
Heterodimers composed of p50 and p65 are the most common cellular form of NF-KB. 
The p50-p65 heterodimer is predominantly regulated through its sub-cellular 
localisation. In resting cells, NF-KB is associated with an inhibitory molecule IKB-α, 
which binds to NF-KB in such a way as to mask the NLS on the p65 sub-unit, but leaves 
the NLS on p50 partially exposed (Baeuerle, 1998). This leads to the continual shuttling 
of the NF-KB complex between the cytoplasm and nucleus and results in a 
predominantly cytoplasmic localisation in resting cells (Carlotti et al., 2000). Activation 
of the IKB kinase complex, which can occur by a range of different stimuli including 
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lipopolysaccharide (LPS), TNF-α and IL-2, results is the phosphorylation of IKB-α at 
two conserved serine residues in the C-terminus (ser-32 and ser-36). This leads to the 
polyubiquitination of IKB-α and its subsequent degradation by the 26s proteasome 
(Karin & Ben-Neriah, 2000). Degradation of IKB-α exposes the NLS on p65 enhancing 
the nuclear translocation of NF-kB (Figure 1.6). One of the target genes of NF-κB 
transcription is IkB-α. Newly synthesised IκB-α proteins enter the nucleus to bind to and 
remove NF-κB from gene promoters and export the complex to the cytoplasm mediated 
by nuclear export signals on IκB-α. This auto-regulatory loop leads to shut-off of NF-κB 
induced genes. 
 
The transcriptional activity of p65 is also regulated through post-translation 
modifications; phosphorylation and acetylation. P65 is phosphorylated at several 
different sites within both the RHD and TAD, by several different kinases including 
protein kinase A (PKA) and the mitogen and stress-activated kinase-1 (MSK 1) (Chen & 
Greene, 2004; Zhong et al., 2002; Zhong et al., 1998). Phosphorylation of p65 has been 
shown to regulate the DNA binding and oligomerization of p65 and also the recruitment 
of various transcriptional co-activators such as p300 and CBP. Interaction of p300/CBP 
with p65 leads to its acetylation and this enhances binding of p65 to DNA and impairs 
its assembly with IkB-α (Chen et al., 2001b; Chen et al., 2002).   
 
The molecular mechanism by which A238L inhibits NF-кB gene transcription has not 
been resolved. The addition of recombinant A238L to the nuclear extracts of Vero cells 
was shown to inhibit the binding of NF-κB complexes to κB DNA seq u ences, as 
identified using electrophoretic mobility shift assays (EMSA), of the DNA protein 
complex formed. Supershift assays with specific antibodies against p65 and p50 (Revilla 
et al., 1998) demonstrated that A238L inhibited formation of complexes between p50-
p65 and DNA. A238L has also been shown to co-precipitate with p65 from extracts 
from cells either transfected with a plasmid expressing A238L, or infected with ASFV 




Figure 1.6 Schematic diagram of the NF- кB activation pathway. In 
resting cells the NF-кB :IкBα complex is predominantly located in the 
cytoplasm in a complex with several other cellular proteins including 
Phosphatase Kinase A (PKA), which is inhibited through its interaction with 
IкBα. Cell activation leads to the activation of the IKB Kinase complex (IKK). 
Activated IKK phosphorolates IкBα at two conserved Serine residues (1), 
leading to polyubiquitination of IкBα and its subsequent degredation via the 
26s proteasome. Degradation of IкBα exposes a NLS on p65 leading to the 
nuclear import of NF-kB, and also induces the activation of PKA which 
phosphorolates p65 at serine-276 (2). Once in the nucleus phosphorolated
NF-кB associates with CBP/p300 transcriptional co-activators. Acelylation of 
p65 by p300 and CBP acetytransferrases enhances p65 DNA binding and 
impairs assembly I к Bα assembly (3). De-acetylation of p65 by the histone
de-acetylase 3(HDAC3) regulates NF- кB gene transcription by promoting 
IKBα binding and nuclear export. Adapted from Ghosh 1997, Chen 2002, 
Chen 2001 and Zhong 1998). A238L binds directly to the p65 sub-unit of NF-
кB (Tait, Reid et al. 2000) and is thought to inhibit NF-кB activity by either 
masking the NLS on p65 (thus preventing nuclear translocation of NF-кB) or 
























complex with NF-кB p50-p65 heterodimers. The p32 kDa form of A238L has been 
shown to preferentially co-precipitate with the p65 sub-unit of NF-κB in virus infected 
cells (Tait et al., 2000). This interaction was reduced by the inhibition of IκB-α 
proteasomal degradation suggesting that A238L cannot displace IκB-α from preformed 
NF-κB/IκB-α complexes, but interacts with NF-κB following IκB-α degradation. These 
results suggest that A238L may act by inhibiting the binding of the p65-p50 NF-KB 
heterodimer to kB binding sites and that post-translational modification of A238L may 
regulate this activity. Unlike IKB-α, A238L is not degraded in activated cells (Tait et al., 
2000) and therefore is thought to provide a mechanism for the prolonged inhibition of 




Calcineurin (CaN) is a serine/threonine protein phosphatase that is directly regulated by 
calcium and calmodulin. CaN is activated by the release of calcium within the cell, 
which triggers the binding of calmodulin to CaN. This induces a conformational change 
in CaN, displacing the autoinhibitory domain of this protein from its catalytic active site 
(Rao et al., 1997). The immunosuppressive drugs cyclosporin A (CsA) and FK506 bind 
to and inhibit CaN phosphatase activity in a complex with the immunophilin proteins 
cyclophilin A (CypA) and FKBP12, respectively (Schreiber & Crabtree, 1992). The 
crystal structure of the FK506-FKBP12 complex bound to CaN has been solved, and this 
indicates that this complex 
CaN modulates the phosphorylation state of several proteins involved in signal 
transduction. BAD, a pro-apoptotic member of the Bcl-2 family is a direct substrate of 
CaN, and CaN is involved in promoting Ca
blocks access to the CaN active site (Kissinger et al., 1995; 
Stoddard & Flick, 1996).  
 
+2 induced apoptosis through the de-
phosphorolation of this protein (Wang et al., 1999). CaN also dephosphorylates two 
cellular transcription factors: Elk-1, a transcription factor activated by mitogen activated 
protein kinases (MAPK), and NFAT.  
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NFAT proteins are found in many different cell types and play a central role in the 
transcription of cytokine genes and other genes involved in the immune response 
(Crabtree & Olson, 2002; Rao et al., 1997). 5 NFAT family members have been 
identified and four of these (NFAT1-4) are regulated through dephosphorylation by 
CaN. In resting cells NFAT is present in the cytoplasm in a hyperphosphorylated form. 
An increase in intracellular calcium levels leads to activation of CaN and this results in 
the dephosphorylation of NFAT. This exposes a NLS on NFAT and also enhances its 
DNA binding affinity. Translocation of NFAT to the nucleus results in binding to 
specific DNA sequences (Figure 1.7) (Rao et al., 1997). Within the nucleus NFAT 
proteins bind co-operatively with activator protein (AP)-1 transcription factor, which 
consist of c-Fos - c-Jun heterodimers, to induce the expression of many genes involved 
in the immune response. The AP-1 complex is formed in cells where both c-Fos and c-
Jun have been activated, through stimulation of the Ca+2 and PKC/Ras pathways 
respectively (Karin, 1995). In the absence of PKC/Ras activation, NFAT has the 
capability of initiating gene transcription in an AP-1 independent manner (Macian et al., 
2000). NFAT can be phosphorylated by protein kinases within the nucleus resulting in 
its export to the cytoplasm and switching off of NFAT-dependent gene transcription. 
 
A238L has been shown to bind to and inhibit the activity of CaN through interaction 
with the CaN catalytic subunit (Miskin et al., 2000; Miskin et al., 1998). This activity 
has been mapped to an 82 amino acid region based in the c-terminus of A238L (Abrams 
et al., 2008). This region also contains a PxIxITxC/S motif, which is required for 
binding of A238L to CaN. This motif closely resembles those in substrate proteins of 
CaN, including NFAT (Aramburu et al., 1998; Aramburu et al., 1999; Miskin et al., 
2000b). NFAT 2 cDNA has been isolated from porcine macrophages and A238L has 
been shown to inhibit NFAT dependent gene expression. The suggestion was that 
A238L may inhibit NFAT-regulated gene transcription through inhibition of CaN 
phosphatase activity, thus preventing the dephosphorylation and the subsequent nuclear 
translocation of NFAT (Miskin et al., 1998).  However, a direct effect on the 
phosphorylation status and nuclear localisation of NFAT, mediated by A238L was not  
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Figure 1.7 Schematic diagram of NFAT proteins activation.1) NFAT in 
association with Calcineurin (CaN) is held in the cytoplasm of resting cells. 2) 
Ca+2 release within the cell, following cell activation, triggers calmodulin to 
bind to Calcineurin. This activates calcineurin by inducing a conformational 
change in the enzyme to expose its catalytic site. CaN activity can be 
inhibited by the immunosupressive drug cyclosporin A (CsA), which in 
complex with cyclophilin A (CyA), binds to CaN inhibiting its activity. A238L 
also binds to CaN inhibiting its activity. 3) Activated calcinurin
dephosphorolates NFAT. This induces a conformational change in NFAT 
exposing a Nuclear localisation Signal (NLS) and residues within the DNA 
binding Domain (DBD) that associate with NFATs complementary DNA 
binding site. This results in nuclear import of NFAT, where NFAT is involved 
in initiating gene transcription. Gene transcription can occur independently or 
in association with members of the AP-1 family of transcription activators. 
Rephosphorylation of NFAT proteins returns them to their original state in the 



























demonstrated in this work. Through inhibition of CaN, A238L has the potential to 
regulate the activity of other cellular proteins dependent on CaN activity, such as BAD 
and Elk-1. This raises the possibility that A238L could function as an anti-apoptotic 
protein, inhibiting Ca+2
Recent work published during the course of this study has shown that A238L inhibits the 
expression of the Cyclooxygenase-2 gene (COX-2) through an NFAT dependent 
transcriptional transactivation pathway (Granja et al., 2004b). COX-2 is transiently 
expressed following cell stimulation and is the key enzyme involved in prostaglandin 
synthesis. Prostaglandins are important mediators of inflammation. This study 
demonstrated that A238L did not prevent the nuclear translocation of NFAT in virus 
infected cells and that inhibition of Cox-2 gene expression did not involve inhibition of 
the binding between NFAT and its specific DNA sequences in the Cox-2 gene promoter. 
However, NFAT-mediated transactivation was strongly inhibited, suggesting that 
A238L may act through an alternatively mechanism to inhibit NFAT dependent gene 
transcription (Granja et al., 2004b). Subsequent studies have demonstrated that A238L is 
able to inhibit the expression of TNF-α and iNOS through a mechanism that involves the 
transcriptional co-activators p300/CBP, presenting an additional mechanism of A238L 
action (Granja et al., 2006a; Granja et al., 2006b). This work is discussed in more detail 
in Chapters 5 and 7. 
 induced apoptosis or alternatively could act to promote gene 
transcription through Elk-1.  
 
 
1.7 Project Aims 
 
A238L is predicted to have a significant effect on the expression of host macrophage 
immune response genes. Previous work on A238L has demonstrated that this protein has 
the potential to interact with and inhibit the activity of several cellular proteins involved 
in signal transduction. However the exact mechanism of A238L action and the overall 
effect on host macrophage gene transcription is not known. Previous work on A238L 
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has been limited to investigating the effect of A238L on specific cell signalling 
pathways and/or the expression of individual host genes, and several potential effects of 
A238L, mediated through inhibition of CaN have not been investigated.  
 
1.7.1 Investigation of the effect of A238L protein on host macrophage gene 
transcription 
  
The first aim of this study was to examine the global effect of A238L on host 
macrophage gene transcription using a porcine microarray. Using this approach 
transcripts for thousands of genes can be examined at one time, providing a global 
overview of the effect of A238L on host macrophage gene transcription. Microarrays 
have already provided valuable insights into previously unknown mechanisms of how 
viruses modify the expression of cellular genes to counteract the host immune response 
to infection and/or promote the expression of cellular genes required for viral 
replication. For example, gene expression profiling of cells expressing the HIV Nef 
protein, demonstrated that this protein induces a transcriptional program similar to anti-
CD3 activated T-cells. Many of the proteins up-regulated by Nef have been shown to be 
involved in enhancing HIV replication (Simmons et al., 2001). Analysis of changes in 
host gene transcription induced by Herpes simplex virus, showed that expression of 
early virus genes can suppress the host cells antiviral responses to viral penetration 
(Mossman et al., 2001).  
 
It was expected that this approach would provide a more comprehensive view into how 
A238L functions to modulate macrophage gene transcription and identify new targets 
for A238L. This information will contributed to a greater understanding into the 
functional significance of A238L expression during ASFV infection.  
 
1.7.2 Investigation of the subcellular localisation of A238L. 
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Previous work has demonstrated that A238L is present in both the nucleus and 
cytoplasm of ASFV infected cells and has indicated that A238L could function within 
either/or both of these compartments. However the mechanism of A238L action is not 
fully understood. One study suggested that A238L may inhibit NF-κB by retaining it in 
the cytoplasm (Tait 2000), whereas another study suggested A238L acted in the nucleus 
to prevent NF-κB binding to кB binding sites (Revilla et al., 1998). The activity of many 
proteins can be regulated through the control of their subcellular localisation. For 
example both NF-κB and NFAT transcriptional activity is partially regulated through the 
retention of these proteins in the cytoplasm of resting cells (Ghosh & Karin, 2002; Rao 
et al., 1997) .  The second aim of this study was to investigate the nuclear/cytoplasmic 
shuttling of A238L to gain better understanding into the mechanism of A238L action. 
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Chapter 2 
Materials and methods 
2.1 Suppliers 
 
Unless otherwise stated all chemicals were obtained from Sigma Aldrich and enzymes 
and reagents were purchased from Promega UK.  
2.2 Bacteria Strains 
 
Escherichia coli XL-1 Blue strain (recA1 / endA1 / gurA96 / gurA96 / thi-1 / hsdR17 / 
supE44 / relA1 / La [F’ pro AB lacIq Z∆ M15 Tn10 (tetr)]) was obtained from Stratagene. 
2.3 Reagents 
2.3.1 Antibodies and antibody detection reagents 
 
Antibodies and secondary antibody detection reagents are listed in Table 2.1. Supplier 
information and reagent concentrations for western blot (WB) and immuno- 




Sequences of the primers used in this study are given in Table 2.2. Primers, PcNcoI, 
PcHindIII, TriExUp, and ORF1629 were manually selected directly from available 
sequence information. The remaining primers were designed using the Primer3 program 
(http://www.genome.wi.mit.edu/genome_software /other/ prime3). Primers were 




 Table 2.1 Antibodies and secondary antibody detection reagents 
 





Mouse Anti Pk-Tag 
(SV5-Pk) 
Serotec 2 μg/ml 20 μg/ml 




0.2 μg/ml N/A 




0.2 μg/ml 2 μg/ml 
C18, anti-p30 mouse 
monoclonal (hybridoma 
supernatant) 
IAH (Afonso et 
al 1992 ) 
NA 1/10  
Anti-pE120R polyclonal 
rabbit serum 
IAH (Jouvenet et 
al. 2004) 
N/A 1/500 dilution 
ProteinA – ab7456 Abcam 2 μg/ml N/A 




N/A 10 μg/ml 




N/A 10 μg/ml 
4H3, anti-vp72 mouse 
monoclonal (hybridoma 
supernatant) 
IAH (Cobbold et 
al. 1996) 
N/A 1/5 dilution 
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Table 2.2 Primer sequences.  
 









5’ gttattgtgctgtctcatcat 3’ 5’ tgcaccatcgctttctaacg 3’ 55 oC 
AMCF-1 5’ atgacttccaaactggctg 3’ 5’ gtacaaccttctgcaccc 3’ 55 oC 
TNFα 5’ cccagaaggaagagtttccag 3’ 5’ cagcaaagtccagatagtcgg 3’ 55 oC 
IL-8 5’ tttctgcagctctctgtgagg 3’ 5’ ctgctgttgttgttgcttctc 3’ 55oC 
β-actin 5’ ggacttcgagcaggagatgg 3’ 5’ gcaccgtgttggcgtagagg 3’ 55oC 
IL-6 5’ ttcacctctccggacaaaac 3’ 5’ tctgccagtacctccttgct 3’ 55oC 
IkBζ 5’ tctggaactcattcgcctct 3’ 5’tcaaccgatactgcaagctg 3’ 55oC 
Cox-2 5' ttcaaatgagattgtgggaaattggt 
3' 














2.4 Cell culture and ASFV infection 
2.4.1 Cell cultures 
 
An immortalised porcine alveolar monocyte cell line (IPAM), was obtained from Dr H. 
M. Weingartl (Weingartl et al., 2002a). IPAM cells were maintained in RPMI cell 
culture medium supplemented with 5  %  bov in e foetal calf serum (FCS), 5  μg /ml 
Gentamycin (Gibco Invitrogen) and 1 x Non Essential Amino Acids (Gibco invitrogen). 
Primary alveolar macrophages (PAM) were harvested from normal, out-bred pigs, by 
lung lavage and maintained in RPMI supplemented with 10 % fetal calf serum (FCS). 
Spodoptera frugiperda (Sf9, ATCC® CRL-1711), fall armyworm insect cells, were 
maintained at 28 oC in SF900 II medium containg 2 % FCS. Cercopithecus aethiops 
(Vero, ATCC® CCL-81), African green monkey kidney cells,  were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 25 mM HEPES and 
supplemented with 2 mM glutamine and 5 % FCS. Unless stated otherwise the cells 
were maintained at 37 oC with 5 % CO2 and culture media was supplemented with 
Penicillin (100 μg/ml), Streptomycin (100 μg/ml), and Fungizone (2.5 μg/ml).  
 
2.5 Viruses and cell culture 
2.5.1 Virus isolates 
 
Initial virus stocks were obtained from Dr. Charles Abrams, IAH. BA71V is an 
attenuated, tissue culture-adapted strain which has been described previously (Enjuanes 
et al., 1976) SV5Gal and vIKGAL are recombinant viruses derived from BA71V 
(Miskin et al., 1998). SV5GAL has a Pk epitope tag from SV5 virus inserted at the N-
terminus of the A238L gene and vIKGAL is a deletion mutant from which the A238L 
gene has been removed and replaced with a reporter cassette expressing β-galactosidase.  
2.5.2 Production of virus stocks. 
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Vero cells, at 80-90 % confluence, were incubated in serum free medium containing 
ASFV at a multiplicity of infection (m.o.i) of 5. After 1 hr, at 37 oC, the medium was 
removed and replaced with medium containing 2 % FCS. 3 days following infection, the 
cells were scraped into the culture medium, sonicated twice for 5 seconds using a cup 
horn sonicator and then centrifuged at 2000 g for 20 min to remove cell debris. The 
supernatant, containing ASFV, was stored at 4 oC  for up to 6 months or at -70 oC  for 
long term storage. 
 
2.5.3 Virus titration 
 
96 well plates containing Vero cells at 80-90 % confluence were infected in triplicate 
with 10 fold serial dilutions of ASFV supernatant. The cells were incubated at 37 oC for 
16 hrs, washed twice with PBS and then fixed in ice cold methanol for 20 min. After 
washing with PBS, the cells were blocked in blocking buffer consisting of PBS 
containing 3 % (w/v) Bovine Serum Albumin. Hybridoma supernatant containing the 
4H3 mouse monoclonal (anti-vp72) was diluted 1/5 in blocking buffer and 50 μl was 
added to each well. Following incubation, the plate was washed three times with PBS 
and then incubated with AlexaFlur ® 488 goat anti-mouse polyclonal diluted in blocking 
buffer. All incubation steps took place at room temperature and lasted for 20 min. The 
plate was then washed three times with PBS and ASFV-infected cells were detected 
using an inverted fluorescent microscope. Wells containing infected cells were scored as 
positive and the TCID50 calculated (Reed & Muench, 1938). 
 
2.6 DNA Manipulation Techniques 
2.6.1 Polymerase chain reaction (PCR) amplification of DNA 
 
Unless stated otherwise, PCR reactions were carried out using the TripleMaster®PCR 
reagents (Eppendorf). Reaction mixtures of 50 μl contained HighFidelity Buffer with 
Mg2 (x1), 10 pMol of each primer, dNTPs (200 μM), triple master DNA polymerase (1 
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unit), and 50-100 ng of DNA. Thermal cycling was carried out using an Eppendorf 
Mastercycler. The PCR program consisted of 95 oC for 2 min, 30 cycles of 96 oC for 1 
min, optimised primer annealing temperature for 45 secs, 72 oC for 1 min followed by a 
final elongation step of 72oC for 5 min. Samples were held at 4 oC prior to use. Primer 
annealing conditions are shown in Table 2.2.  
 
2.6.2 Agarose gel electrophoresis 
 
DNA samples were mixed with DNA loading buffer (Biogene), loaded onto an 1 % 
agarose/TAE gel containing ethidium bromide (0.3 ug/ml), and separated at 100 v for 1 
hr in TAE buffer. DNA fragments were detected by a GeneDoc gel viewer (BioRad) and 
imaged using Quantity One-4.1.0 software (BioRad). The size of the DNA fragments 
was estimated by their relative mobility compared to a 1 kbp or 100 bp molecular weight 
ladder (Biogene). 
 
2.6.3 DNA purification  
 
Restriction enzyme digested DNA fragments and PCR products were purified using a 
GFX PCR DNA and Gel Band Purification Kit (Amersham Biosciences). 
Manufacturer’s guidelines were followed. PCR products or DNA in solution were mixed 
thoroughly with 500 μl of capture buffer and added to a GFX column. DNA fragments 
separated using agarose gel electrophoresis were excised from the gel, mixed with 10 μl 
of capture buffer for every 10 mg of agraose gel and incubated at 60oC for 5 - 10 min 
until the agarose had completely dissolved. The solution was then loaded onto a GFX 
column. From then on both types of sample were centrifuged, washed once with GFX 
wash buffer and  then elu ted  from the GFX column in  50  μl of H20. All centrifugation 
steps were at 12,000 g for 1 min. 
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2.6.4 Restriction enzyme digestion 
 
Restriction enzyme digestions were carried out in a volume of 20 μl per 1 μg of DNA 
using cuts all enzyme buffer (CAB) containing 5 units of each restriction enzyme 
(Promega). Reactions were incubated at 37 oC for 2 hrs. The required product was 
separated by agarose gel electrophoresis and then purified by gel extraction.   
 
2.6.6 Formation of blunt-ends using the Klenow fragment of DNA polymerase 1 
 
DNA polymerase 1 Klenow fragment (Promega) has 5’→  3’ p oly merase and 3 ’→ 5’ 
exonuclease activities. To generate blunt-ended fragments from restriction enzyme 
digestion products containing 5’ protruding ends, 1 unit of Klenow fragment and 40 µM 
of dNTPs were added to the restriction enzyme reaction mix after the digestion had been 
completed. The reaction was carried out at room temperature for 10 min. Enzyme 




To prevent re-ligation of  linearised vector DNA with compatible ends, calf intestinal 
alkaline phosphatase (CIP) (Promega) was used to remove the 5’-phosphate groups from 
the vector 5’-termini. Reaction mixtures containing 0.01 units of CIP and ~1 μg of DNA 
were incubated at 37 oC for 30 min in 1 x CIP buffer (Promega). Following the addition 
of another 0.01 units of CIP the reaction was incubated for a further 30 min and then 





50 ng of vector was incubated with a 16 ng of insert in a 10 μl reaction volume of 1 x T4 
ligase buffer (Promega) containing T4 ligase (3 Weiss units)(Promega). The reaction 
mix was incubated overnight at 16 oC.  
 
2.6.9 Preparation of plasmid DNA 
 
2.6.9.1 Preparation of competent Escherichia coli  
 
All incubation steps took place at 37 oC with constant shaking unless otherwise stated. 
E. coli cultures were streaked onto luria broth (LB) agar plates and incubated overnight, 
without shaking, to obtain individual colonies. The next day 10 ml of LB medium was 
inoculated with 2-3 individual colonies and incubated overnight. 2-3 mls of this culture 
was used to inoculate 100 mls of LB medium in a 500 ml conical flask. The culture was 
incubated until it reached an OD 600 of 0.3-0.5, placed on ice for 15 min and then 
centrifuged at 10,000 g to harvest the cells. The cells were re-suspended in 33 ml of ice 
cold RF1, incubated on ice for 15 min, pelleted at 10,000 g and then re-suspended in 8 
mls of ice-cold RF2. The solution was then incubated on ice for 15 min, dispensed into 
pre-chilled 1.5 ml microfuge tubes (Eppendorf), flash-frozen in liquid nitrogen and 
immediately stored at –70 oC. 
 
2.6.9.2 Transformation of E.coli 
 
Competent XL-Blue cells (stored at –70 oC) were rapidly defrosted, and dispensed into 
40 μl volumes which were stored on ice. 1 μl of ligation mixture was added to individual 
aliquots. After 30 min incubation, on ice, the cells were heat-shocked at 42 oC for 45 
secs and immediately placed back on ice for a minimum of 2 min. The aliquots were 
then made up to a final volume of 500 μl using antibiotic free LB broth and incubated at 
37 oC with constant shaking for 1 hr. To isolate transformed colonies, 100 µl of 
transformed XL1-blue culture was spread on LB agar plates supplement with ampicillin 
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(100 µg/ml) and incubated over night at 37 oC. Single colonies were selected for further 
analysis. 
 
2.6.9.3 Small scale preparation of plasmid DNA 
 
Plasmid DNA was purified using a GenElute™ Plasmid Miniprep Kit. The procedure 
was carried out following the manufacturer’s guidelines. All centrifugation steps were 
carried out at 12,000 g for 1 min unless stated otherwise. Single colonies were 
inoculated into 10 mls of LB broth supplemented with ampicillin (100 µg/ml) and 
incubated overnight at 37 oC with constant agitation. 1.5 mls of culture was centrifuged 
to harvest cells. Following re-suspension of the cells in 200 μl of resuspension solution, 
the cells were lysed by the addition of 200 μl of lysis solution. Genomic DNA and cell 
debris was precipitated by the addition of 350 μl of neutralisation solution and removed 
by centrifugation. The supernatant was transferred to a GenElute Miniprep binding 
column for plasmid purification. Following centrifugation, the column was washed once 
with 7 5 0 μl of wash solution and the flow-through discarded. The column was then 
centrifuged again to remove excess ethanol and the plasmid DNA eluted in 50 μl of 
ddH20. The plasmid DNA was stored at –20 oC until use. 
 
2.6.9.4 Large scale preparation of plasmid DNA 
 
Plasmid DNA was isolated using alkaline-SDS lysis followed by purification using a 
CsCl-ethidium bromide density gradient. 200 ml of LB broth supplemented with 
ampicillin (100 µg/ml) was inoculated with a single bacterial colony and incubated over 
night at 37 oC with constant shaking. Cells were harvested by centrifugation at 6,000 g 
for 10 min, re-suspended in 10 mls of Solution 1 containing 2 mg/ml of lysozyme and 
incubated at room temperature for 5 min. 20 ml of freshly prepared solution 2 was added 
and the tube placed on ice. After 10 min incubation 15 ml of solution 3 was added and 
the solution incubated for a further 20 min on ice. Cell debris and chromosomal DNA 
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was pelleted by centrifugation at 7,000 g for 30 min at 4 oC and the supernatant, 
containing the plasmid DNA, transferred to a new tube. The plasmid DNA was 
precipitated by the addition of an equal volume of isopropanol and, after 20 min 
incubation on ice, the pellet was collected by centrifugation at 8,000 g for 10 min. The 
pellet was washed once in 70 % ethanol, re-suspended in 8 ml of TE buffer and mixed 
with 8 g of CsCl and 200 ul of ethidium bromide solution at 10 mg/ml. The solution was 
transferred to a Quick-Seal™ 16 x 76 mm Beckman centrifuge tube, which was sealed, 
and then centrifuged at 55 K overnight in a Beckman Type 70.1 Ti rotor, using a 
Beckman Ultracentrifuge, to create a CsCl density gradient. The band of closed circular 
DNA was removed using a syringe and the ethidium bromide extracted by repeatedly 
mixing the sample in an equal volume of water saturated n-butanol. This was continued 
until the organic phase became colourless. The aqueous phase was removed, made up to 
10 ml in TE buffer and diluted at a ratio of 1:3 in ethanol to precipitate the DNA. The 
DNA was pelleted using centrifugation at 3,000 g for 15 min, washed once in 70 % 
ethanol and then re-suspended in 250 μl of H2O. Plasmid DNA was stored at –20 oC 
until use. 
 
2.6.9.5 Quantification of DNA  
 
The DNA concentration in samples was estimated using an Ultrospec 2100 pro 
UV/visible Spectrophotometer.  One OD 260 unit represents 50 μg/ml of DNA. 
 
2.6.9.6 Sequencing DNA  
 
Plasmid DNA was sequenced on the Beckman Coulter CEQ 8000 Genetic Analysis 
System using the CEQ DTCS Quick Start Kit 608120 (Beckman Coulter) following 
manufactures guidelines. 350 fmol of plasmid DNA combined with 3.2 pmol of primer 
was used  for each seq u encin g  reaction. Th is was ad d ed to 8  μl of DTCS q uick start 
Master Mix (diluted at a 1:1 ratio in Dilution Buffer supplied with the kit) and made up 
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to a total volume of 20 μl with dd H2O. The template was heated at 96 oC for 20 secs, 
followed by 50 oC for 20 secs and 60 oC for 4 min, this was repeated for 30 cycles and 
the samples held at 4 oC. Following amplification, the reaction was stopped by the 
addition of 5  μl of Stop  Sou ltion/Glycog en mixtu re wh ich con sisted  of 2 ul of 3 M 
sodium acetate (pH 5.2), 2 μl of 100mM Na2-EDTA (pH 8.0) and 1 μl of 20 mg/ml of 
glycogen. 60 μl of 95 % cold ethanol (stored at – 20 oC) was then added and the sample 
centrifuged at 13,000 g for 15 min at 4 oC. The resulting pellet was then washed twice 
with 200 μl of 70 % cold ethanol (stored at – 20 oC) and the  pellet left to air dry at 37 oC 
for 10 min. The sample was then resuspended in 40 μl of Sample Loading Solution 
(Beckman), loaded onto the sample plate (PN 609801), overlaid with mineral oil and 
then processed by the Beckman Coulter CEQ 8000 Genetic Analysis System. 
 
2.7 RNA manipulation techniques 
 
2.7.1   DEPC treated water 
 
0.1% diethylpyrocarbonate (DEPC) was added to ddH20 and mixed overnight at room 
temperature. The solution was then autoclaved for 20 min to inactivate residual DEPC. 
 
2.7.2 Isolation of total RNA from mammalian cells 
 
Total RNA was extracted using TRI REAGENT™ (Sigma), following manufacturer’s 
guidelines. All consumables used for this procedure were certified RNase free. 
Monolayer cultures of IPAM cells were washed once with PBS and then lysed by the 
addition of 1 ml of TRI REAGENT™ . The cell lysate was transferred to a 2 ml 
microfuge tube and incubated at room temperature for 5 min. Following the addition of  
200 μl of chloroform, the sample was vortexed for 15 seconds, allowed to settle for 10 
min at room temperature and then centrifuged at 12,000 g for 15 min at 4 oC to separate 
the mixture into an organic phase and an aqueous phase (containing RNA). The aqueous 
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phase was transferred to a fresh tube, mixed with 0.5 ml of isopropanol and incubated at 
room temperature for 10 min. Precipitated RNA was pelleted at 12,000 g for 10 min at 4 
oC. The pellet was washed once in 75 % ethanol and then re-suspended in 0.1 % DEPC  
treated H2O.  
 
2.7.3 Quantification of RNA 
 
The concentration of RNA in samples was estimated using either an Ultrospec 2100 pro 
UV/visible Spectrophotometer or the Nanodrop ND-1000 spectrophotometer (Agilent).  




Unless otherwise stated, RT-PCR reactions were carried out using SuperScriptTM III 
First-Strand Synthesis System for RT-PCR (Invitrogen). Manufacturer’s guidelines were 
followed. Briefly, 0.5 - 5 µg of RNA was added to 5 µM oligo(dT)20 and 1 mM dNTP’s 
and made up in a total volume of 10 µl, in DEPC-treated water. This was incubated at 65 
oC  for 5 min, placed on ice for a minimum of 1 minute, and then added to 10 µl of 
cDNA synthesis mix (1 x RT buffer, 5 mM MgCl2, 10 mM DTT, RNaseOUTTM (40U) 
and SuperScriptTM III RT (200 U). Samples were incubated at 50 oC for 50 min and the 
reactions terminated by heating at 85  oC for 5 min. After cooling on ice, RNase H (2 U) 
was added and samples incubated at 37  oC for 20 min. The resulting cDNA was either 
used immediately for PCR or stored at – 20  oC. 
 
2.7.5 Analysis of RNA integrity 
 
The size distribution of RNA fragments within total RNA and aaRNA samples was 
assessed using the Agilent 2100 bioanalyzer with an RNA 6000 LabChip kit. This 
procedure was carried out according to manufacturers’ guidelines. Briefly, Agilent RNA 
6000 nano chips were prepared by the addition of 9 µl of gel-dye mix into specifically 
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marked wells. Prior to loading, the RNA samples and the RNA 600 Nano marker were 
heat denatured at 70 oC for 2 min and then stored on ice until use. 1 µl of RNA 600 
Nano marker was added into a well marked with a ladder symbol and 1 µl of each of the 
test samples were loaded into the sample wells. Empty sample wells were loaded with 1 
µl of double distilled H20 (ddH20). The chip was then vortexed for 60 seconds at 2000 
rpm using an IKA vortex mixer and loaded immediately onto the Agilent 2100 
bioanalyzer for analysis. The resulting electropherograms of the RNA ladder and of each 
sample tested was compared against standard manufacture sample profiles to assess the 
quality of the RNA. 
2.7.7 RNA amplification  
 
Messenger RNA was amplified from total RNA samples using an Amino Allyl 
MessageAmpTM II aRNA Amplification Kit (Ambion). Manufacturer’s guidelines were 
followed. Briefly, 1 µg of total RNA and 1 µl of T7 Oligo (dT) Primer in a total volume 
of 12 µl was incubated at 70 oC for 10 min and then placed on ice. 8 µl of Reverse 
Transcription master mix was then added and the samples incubated at 42 oC for 2 hrs 
and then placed on ice. Following the addition of 80 µl of Second Strand Master Mix, 
the samples were incubated at 16 oC for 2 hrs. 250 µl of cDNA binding buffer was added 
to each sample and the samples were then loaded onto cDNA Filter cartridges. 
Following one wash with 500 µl of Wash buffer the cDNA was eluted into 2 x 9 µl of 
Nuclease-free water. 26 µl of In Vitro Transcription (IVT) Master Mix (containing 1:1 
ratio of UTP to amino allyl UTP) was then added to the purified cDNA, mixed, and the 
samples were incubated for 14 hrs at 37 oC. 60 µl of Nuclease-free Water was then 
added to each sample to stop the IVT reaction. The resulting aminoallyl-amplified RNA 
(aRNA) was purified using aRNA filter cartridges. This involved combining the IVT 
reaction mixtures with 350 µl of aRNA Binding Buffer followed by the addition of 250 
µl of 100 % ethanol to each sample. Each sample was then loaded onto an aRNA 
cartridge, centrifuged and washed with 650 µl of Wash Buffer. aRNA was eluted in 100 
µl of Nuclease-free water at 50 oC and then stored at -20 oC until use. Prior to labelling 
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the quality of the aaRNA was assessed using the Agilent 2100 bioanalyzer. Unless 
otherwise stated all centrifuge steps took place at 10,000 g for 1 min at 4 oC. 
 
2.7.8 Coupling CyeDye to aRNA 
 
aRNA was labelled using an Amersham CyDye (Cy3/Cy5) kit (RPN5661). 
Manufacturer’s guidelines were followed. 8 µl of aRNA was used in each dye coupling 
reaction. Where appropriate the aRNA sample was reduced to a volume of ~ 5 μl by spin 
drying before re-suspension in 0.1 M sodium bicarbonate buffer (pH 8.7) to a final 
volume of 40 µl. This sample was then added directly into a single tube of either Cy 3 or 
Cy 5 reactive dye, mixed thoroughly using a pipette and then incubated at room 
temperature for 90 min in the dark. 15 μl of 4 M hydroxylamine was then added to the 
reaction and the reaction incubated for a further 15 min. 
 
2.7.9 Purification of CyDye labelled aaRNA 
 
Cy3 and Cy5 labelled aaRNA was purified using the reagents provided in the Amino 
Allyl MessageAmpTM II aRNA Amplification Kit (Ambion). This procedure was carried 
out following manufacture guidelines. Cy3 or Cy5 labelled aaRNA was mixed with 140 
μl of aRNA binding buffer 100 μl of 100 % ethanol was then added, mixed three times 
with a pipette and the sample was placed immediately onto an aRNA Filter Cartridge. 
Following centrifugation the cartridge was washed once with 500 μl of Wash Buffer and 
then eluted into two times 10 μl of Nuclease-free water at 50 oC. The purified labeled 
RNA was then stored at -80 oC in the dark. All centrifugation steps took place at 10,000 
g for 1 min at 4 oC. Final RNA concentration and dye incorporation rates were measured 
using the Nanodrop ND-1000 spectrophotometer (Agilent). Dye incorporation rates 
were calculated using the dye incorporation calculator on the Ambion website 







Figure 2.1 Method to calculate Cy3 and Cy5 dye incorporation rates into aaRNA. 
 
A dye incorporation rate of 30 – 60 dye molecules per 1000 nt was required for 
microarray analysis. 
 
2.7.10 Porcine Oligonucleotide Microarray slides 
 
Microarray slides were produced in house by printing the Array-Ready Oligo Sets™ for 
the Pig Genome, version 1.0 and the Pig Genome Oligo extension Set, Version 1.0 
(Operon) onto Nexterion® Slide HiSens E (SCHOTT). This procedure was carried out 
by Dr Charles Abrams, IAH, Pirbright, Surrey. An additional set of 360 oligonucleotides 
specific for genes present on the 
Microarray hybridisations were carried out following Nexterion® Slide HiSens E 
(SCHOTT) manufactures guidelines. Prior to hybridisation the microarray slides were 
washed in 0.1 % Triton X-100 for 5 min, followed by two washes in 1mM HCL solution 
for 2 min, with a final wash in 100 mM KCL for 1 min. The slides were then rinsed in 
Pig 3K Immune cDNA (Zhang et al., 2006b), but not 
identified within the Operon Oligonucleotide sets were also produced by Operon and 
included on this array.  
 
2.7.11 Microarray Hybridisation 
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dd H20 for 1 min and immediately placed in Nexterion®   Blocking Solution for 15 min 
at 50 oC. After a final rinse in ddH20 for 1 min the slides were dried by centrifugation at 
200 g for 5 min and used immediately for hybridisation. Hybridisations were carried out 
using the HS400Pro automated hybridisation chamber (Tecan). The hybridisation 
programme involved an initial 30 second prime with pre-hybridisation buffer, followed 
by sample injection and denaturisation at 95 oC for 3 min and hybridisation for 12 hrs at 
60 oC . The slides were washed with Wash 1 solution at 25 oC, followed by wash 2 
solution at 23 oC and finally at 23 oC with wash 3 solution. All washing steps consisted 
of 1 min constant flow followed by 45 s static. The slides were then dried within the 
hybridisation chambers and stored at room temperature in the dark. Pre-hybridisation 
and Wash solutions were filtered and degassed by sonication for 30 min before use in 
the h yb ridisation  chamb er. Hybridisation samples con sisted  of 2 μg  of each test and 
control labelled aRNA combined together and suspended in Nexterion® hybridisation 
buffer to a total volume of 130 μl, with a minimum composition of 90 % (v/v) buffer. 
Slides were scanned using a GenePix 4000B instrument (Molecular probes) and the raw 
data captured using GenePix Pro6.0 software. 
2.7.12 Microarray sample processing 
 
Total RNA samples were isolated and analysed using a spectrophotometer at both 260 
and 280 nm to test the purity of the sample and quantify the yield. All of the samples 
tested exhibited a ratio of A260 to A280 between 1.7 and 2.1 indicating they were free 
from DNA and protein contamination. The integrity of the samples was also examined 
using an Agilent 2100 bioanalyser to produce a size distribution profile of the RNA 
sample and to compare the ratio of 28S to 18S ribosomal RNA. The size distribution 
profiles of three representative samples can be seen in Figure 2.2. The traces 
demonstrate that nearly equal amounts of 28S and 18S rRNA are present within the 
samples, indicating a small degree of degradation has occurred. This is typical of 
standard RNA preparations and was considered to be within acceptable limits for further 
analysis, according to the manufacturers guidelines (Agilent). All of the test and control 
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RNA samples analyzed exhibited similar traces and were therefore suitable for further 
analysis. 
To expand the amount of RNA harvested and produce enough RNA for the microarray 
hybridizations, mRNAs from all of the RNA samples, including the common reference, 
were amplified using an Amino Allyl MessageAmpTM II aRNA Amplification Kit 
(Ambion). mRNA within the sample was reverse transcribed using an oligo(dT) primer 
encoding a T7 promoter, to produce cDNA. Following a second strand synthesis and 
clean up, the cDNA was amplified, in the presence of 5-(3-aminoallyl)-UTP, by in vitro 
transcription with T7 RNA polymerase. This resulted in the generation of many 
thousands of antisense RNA (aRNA) copies of each mRNA, containing modified uracil 
bases to facilitate labeling. Following amplification the aRNA size distribution profiles 
of the samples were evaluated using an Agilent bioanalyzer to ensure successful and 
representative amplification of the RNA sample. Traces of three representative samples 
can be seen in Figure 2.2. The samples tested exhibited traces consistent with the 
manufacturer’s guidelines; a distribution of sizes between 250 to 5500 bases with most 
of the aRNA between 1000 to 1500 bases ( Agilent).   
 
Amplified aRNA was labeled using Amersham CyDye (Cy3/Cy5) kit. Cy3 or Cy5 
reactive dyes were chemically coupled to aaUTP present in the aRNA. Following 
purification, aRNA yield and dye incorporation rate was determined using a 
spectrophotometer. Dye incorporation rates of 30-60 (one label every 30 to 60 nt) as 
required were obtained in all samples to ensure adequate signal for downstream 
microarray analysis. Equal quantities of test and control samples, labeled with either 
Cy3 or Cy5 were combined and co-hybridised onto the Operon Sus scrofa (pig) v1.0 and 
Sus scrofa (pig) extension OligoTM microarray (Operon). Hybridisatations were carried 
out using an automated hybridization station to minimise variability between slides. Two 
hybridisations were carried out for each comparison, with the dye assignments reversed 
in the second hybridisation to account for labeling bias between dyes. Images of the 
hybridised arrays were obtained by laser confocal scanning. 
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Figure 4.4 Bioanalyzer images of IPAM RNA preparations before and after 
RNA ampilfication. Fluorescent labelled total RNA and aaUTP modified amplified 
RNA samples were analysed on an Agilent bioanalyser 2100 using the RNA 600 
marker and Nano LabChip Kit. The graphs show the bioanalyzer electropherogram
from two RNA samples isolated from Baculovirus treated and LPS, PMA and 
ionomycin stimulated IPAM cells (S) at 1 and 4 hrs following stimulation and a 
common reference, untreated IPAM RNA. The samples show the size distribution 
profile of the RNA samples both before (total RNA) and after amplification (aRNA. 
The vertical axis represents fluorescence and the horizontal line represents the 
migration time (s). The graphs represent samples both before and after RNA 
amplification. 












2.7.12 Microarray data analysis.  
 
Raw data files were processed using BlueFuse for microarrays version 3.3 to extract 
feature information and remove background noise and artifacts. Processed data files 
were then analyzed using software tools from the TM4: microarray software suite. 
Microarray Data Analysis System (MIDAS) was used to normalize the data sets both 
within slides (locally weighted scatterplot smoothing (Lowess)) and between slides (SD 
regularization). This was followed by dye swap consistency checking to account for 
labeling bias between dyes. Multiexperiment Veiwer (MeV) was used to filter out poor 
quality data and identify differentially regulated mRNA using Significant Analysis of 
Microarrays (SAM) analysis (Tusher v.G, Chu 20001). SAM identifies genes with 
statistically significant changes in expression by assimilating a set of gene-specific t-
tests. Each gene is assigned a score on the basis of its change in gene expression relative 
to the standard deviation of repeated measurements for that gene. Genes with scores 
greater than a threshold are deemed potentially significant. This method has the 
advantage over typical parametric t-tests in that it also calculates the number of these 
potentially significant genes which have been identified by chance - the False Discovery 
Rate (FDR). To estimate the FDR, nonsense genes are identified by analysing 
permutations of the measurements. 
 
Annoatated gene lists were analyzed using the Database for Annotation, Visualisation 
and Intergrated Discovery (DAVID) 2008 (Dennis et al., 2003) to identify significantly 
enriched terms associated with biological processes and signaling networks. DAVID is a 
large integrated knowledge base linking information from most of the common genomic 
bioinformatics resources including: National Center for Biotechnology Information 
(NCBI), SWISS-PROT, gene ontonlogy (GO) and Kyoto Encyclopedia of Genes and 
genomes (KEGG). DAVID therefore provides access to a diverse array of functional and 
sequence annotation. The platform provides a range of functional annotation tools which 
allow query based access to the database. These tools provide batch annotation of up-
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loaded gene lists and the identification of significant biological themes within these lists. 
Genbank accession numbers from annotated gene lists were uploaded onto DAVID and 
compared against a default Human background of 30,000 genes. EASE, a modified 
Fischer's exact P-value was used to determine the probability that gene-enrichment for a 
specific annotation was not due to chance alone (Hosack et al., 2003). 
 
2.8 Protein Expression and Analysis 
 
2.8.1 Mammalian Cell transfection 
 
Mammalian cells were transfected using Lipofectamine™ 2000 (Invitrogen). 
Manufacturer’s guidelines were followed. Mammalian cells at 90 – 95 % confluence 
were washed once in PBS and overlayed with transfection reagent. The transfection 
reagent was prepared following the manufacturer’s guidelines: Lipofectamine™ 2000 
was diluted in an appropriate amount of Opti-MEM® I Reduced Serum Medium, 
incubated for 5 min at room temperature and then combined with plasmid DNA which 
was also prepared in Opti-MEM® I Reduced Serum Medium. The reaction mixture was 
incubated for a further 20 min at room temperature. After 4 hrs at 37 oC, 5 % CO2, the 
transfection reagent was replaced with antibiotic free culture medium and the cells 
incubated for a further 16 hrs unless otherwise stated. 
 
2.8.2 Gel electrophoresis of proteins using SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Cell monolayers were detached by trypsinisation, collected by centrifugation at 15000 g 
for 5 min and then washed twice in ice cold PBS. The cells were then solubilised in cell 
lysis buffer at  4 oC for 5 min, vortexed briefly and then centrifuged at 12,000 g for 10 
min to pellet insoluble cell debris. The supernatant was transferred to a clean tube, 
diluted in 5 x SDS-PAGE sample loading buffer and heated at 90 oC for 5 min to 
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denature the protein sample. Proteins were resolved at 100 v  on polyacrylamide gels 
with a 4 % polyacrylamide stacking gel.   
 
2.8.3 Western Blotting 
 
Proteins resolved using SDS-PAGE were transferred onto Hybond-C extra nitro-
cellulose membrane (Amersham Biosciences) using a transfer cassette submerged in 
transfer buffer for 1 hr at 100 v. The system was cooled using a pre-frozen cooling 
block.  Following protein transfer the membrane was incubated in blocking buffer for 1 
hr, washed once in PBST for 15 min, and then incubated with primary antibody (Table 
1) diluted in blocking buffer. After 1 hr the membrane was washed twice in PBST for 15 
min, incubated with horse radish peroxidase (HRP) conjugated Protein A (Abcam) 
diluted in blocking buffer for 45 min, washed twice in PBST and once in PBS for 10 
min. All incubation steps took place at room temperature with gentle agitation. To detect 
bound antibodies, the membrane was incubated in freshly prepared ECL reagent for 1 
min, placed in a cassette and exposed to Kodak MX1 film for variable time periods. The 
film was developed using a X-ograph Imaging System Compact X-4 machine.  
 
2.8.4 Indirect Immunofluorescence Microscopy 
 
Cell monolayers were grown on 22 x 22 mm glass cover slips in 35 mm wells. 
Following cell transfection and a subsequent incubation period the cells were fixed for 1 
hr in PBSe containing 4 % paraformaldehyde. The cover slips were washed once in 
PBSe, incubated in 1 % Triton x-100 PBSe for 15 min to permeablise the cytoplasmic 
and nuclear cell membranes and then washed again in PBSe. The cells were initially 
incubated in 5 % BSA/PBSe for 30 min to inhibit non-specific antibody binding and 
then incubated for a further 1 hr with primary antibody diluted in 0.5%BSA/PBSe. 
Excess antibody was removed by washing the cells three times in PBSe for 5 min, and 
secondary antibody diluted in 0.5 % BSA/PBSe was applied. After 1 hr the coverslips 
were washed three times in PBSe for 5 min, dipped into ddH2O and then mounted onto 
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glass slides, cell-side down, using VectaShield mounting medium with Dapi (Vector 
Laboratories). The edges of the cover slips were sealed using nail varnish to prevent 
desiccation. The cells were visualized using a Leica TCS SP2 confocal laser scanning 
microscope. Data was collected sequentially to prevent cross-talk between detection 
channels and was analysed using LCS (Leica Confocal Software). The images shown are 
representative of three independent experiments.  
 
2.9 Recombinant Baculovirus 
2.9.1 Production of recombinant baculovirus 
 
35 mm wells of a 6-well plate were seeded with 9 x 105, mid-log culture, SF9 cells in 2 
mls of SF900 II S medium. After cell attachment, at 28 oC for a minimum of 1 hr, the 
cells were washed once in antibiotic free SF900-II S medium and then overlayed with 1 
ml of transfection reagent. The transfection reagent was prepared following 
manufacturers guidelines: 0.5 μg of linearised baculovirus DNA , 1 μg of transfer vector 
and 6 μl of CELLFECTIN® were diluted in antibiotic free SF900-II S, incubated for 30 
min at room temperature and then made up to a final volume of 1 ml using antibiotic 
free SF900-II S. Following incubation at 28 oC for 5 hrs the transfection reagent was 
replaced with 2 mls of antibiotic free SF900-II S. Cell medium, containing recombinant 
baculovirus, was harvested 72 hrs post-transfection, centrifuged at 500 g for 5 min to 
remove cell debris and then stored at 4 oC for further analysis.  
 
2.9.2 Amplification and concentration of baculovirus stocks 
 
 
A 200 ml suspension of SF9 cells, at a concentration of 2 x 106 cells/ml, was inoculated 
with recombinant baculovirus at a multiplicity of infection (MOI) of 0.1, incubated at 28 
oC, with constant agitation for 48 hrs, and then centrifuged at 500 g for 5 min to remove 
cell debris. To concentrate the virus, 33 mls of virus containing supernatant was loaded 
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into each of six Beckman SW28 tubes and underlayed with 3 mls of 25 % sucrose (w/w) 
in 5 mM NaCl, 10 mM EDTA. Following centrifugation at 80,000 g for 75 min at 4 oC, 
the supernatant was discarded. The resulting virus pellet was resuspended in 2 mls of 
PBS, filtered through a 0.2 μm filter and stored at 4 oC until use. 
 
2.9.3 Baculovirus DNA purification from cultured cells 
 
Baculovirus DNA was purify from cell culture supernatants using a GFX™ Genomic 
Blood DNA and Cell Culture DNA purification kit (Amersham Biosciences). The 
procedure was carried out following manufacturer guidelines. All centrifugation steps 
were at 12,000 g for 1 min unless stated otherwise. 100 μl of cell supernatant was 
incubated in 500 μl of extraction solution for 5 min at room temperature, loaded onto a 
GFX column, centrifuged and the flow-through discarded. The GFX column contains a 
glass fibre matrix that binds DNA at high salt concentrations, which are present in 
extraction solution. The matrix bound DNA was washed once with 500 μl of Extraction 
solution and once with Wash solution to remove contaminants. The column was then 
centrifuged at standard speed for a further 2 min to dry the column. Baculovirus DNA 
was eluted in 200 μl of ddH20 at 70 oC following 1 min  incubation at room temperature. 
 
2.9.4 Baculovirus plaque assays 
 
SF9 cell monlayers at 20-30 % confluence (approximately 2.5 x 105 cells per 35 mm 
well) were inoculated with sequential dilutions of recombinant baculovirus. Following 1 
hr incubation at room temperature the inoculum was removed and replaced with 3 mls of 
SF900-II S containing 1 % low melting temperature agarose. The agar overlay was 
maintained at 40 oC prior to addition to the SF9 cell monolayers. Once the overlay had 
set, the SF9 cells were incubated at 28 oC for 14 days or until visible plaques could be 
detected. Each dilution was tested in duplicate and the procedure was repeated on 3 
separate occasions. The virus titre was estimated from the virus dilution which produced 
 74 
between 10-50 plaques. The average number of plaques counted was calculated and 
multiplied by the dilution factor to produce the final virus titre. 
 
2.10 Buffers and solutions 
 
2.10.1 DNA manipulation techniques 
 
Agarose Gel Loading Buffer: 3.73 mM Bromophenol blue and 1.17 M Sucrose. 
 
CIAP stop buffer: Tris-HCL (pH 7.5) 10 mM, EDTA (pH 7.5) 1 mM,  NaCl 200 mM 
and SDS 0.5 %. 
 
Cuts All Buffer (CAB): 200 mM Tris-HCl (pH 7.5), 70 mM MgCl2, 1000 mM KCl and 
20 mM β-mecaptoethanol.  
 
Luria Broth (LB): 1 % Tryptone, 0.5 % Yeast extract and 1 % NaCl. 
 
LB Agar: 1.5 % Agar in LB 
 
PBST: 0.05 % Tween 20 in PBS  
 
RF1: RbCl 1.21 % w/v, MnCl2.4H2O 0.99 % w/v, KC2H3O2 0.29 % w/v, CaCl2.2H2O 
0.29 % w/v and 15 % glycerol made to a pH 5.8 with 10 M NaCL. 
 
RF2: MOPS 0.21 % w/v, RbCl 0.12 % w/v, CaCl2.2H2O 1.1 % w/v and glycerol 15 % 
w/v at pH 6.8 
 
Solution 1: 50 mM glucose, 25 mM Tris-HCl (pH 8.0) and 10 mM EDTA (pH 8.0).     
                  
Solution 2: 0.2 M NaOH and 1 % (w/v) SDS. 
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Solution 3: 3 M  KCl2H3O2  and 11.5 % (v/v)Acetic acid. 
 
TAE (50X): 2M Tris, 5.7% v/v Acetic Acid and 50 mM EDTA at pH7.7  
 
TE buffer: 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA (pH 7.7). 
2.10.2 Protein Expression and Analysis 
 
Cell Lysis Buffer : 500 mM NaCl, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA (pH 7.5), 
0.05 % IGEPAL NP-40 and 1ug/ml small protease inhibitors (Pierce). 
 
IF Blocking solution: PBSe containing 5% BSA. 
 
ECL reagent: 22 μl of Reagent A (p-coumaric acid;  90 mM in DMSO) combined with 
50 μl of Reagent B (Luminol; 250 mM in DMSO), dissolved in 10 mls of 0.1  M Tris-
HCL (pH 8.5) and 3 mM H2O2. 
 
PBSe: 138 mM NaCl, 2.70 mM KCl, 1.47 mM KH2PO4 and 9.67 mM  
Na2HPO4. 
 
PBS: 138 mM NaCl, 2.70 mM KCl, 0.49 mM MgCl2.6H2O, 1.47 mM KH2PO4, 9.67 
mM Na2HPO4 and 6.80 mM CaCl2.2H2O. 
 
WB Blocking solution: dried low-fat skimmed milk 5 % in PBS. 
 
SDS-PAGE resolving gel (10 %) : 40% stock acrylamide solution [acrylamide:N,N′ -
methylene bisacrylamide, 37.5:1] 25% (v/v), 0.4 M Tris-HCl pH 8.8, 0.1% (w/v) SDS, 
0.2% (v/v) ammonium persulphate and TEMED (N,N,N',N'-
Tetramethylethylenediamine) 0.1% (v/v). 
 
SDS-PAGE stacking gel (4 %): 40% stock acrylamide 10% (v/v), Tris-HCl pH 6.8 
100mM, SDS 0.1% (w/v), ammonium persulphate 0.2% (w/v) and TEMED 0.1% (v/v). 
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Protein gel resolving buffer: 15.4 % (w/v) Glycine, 3 % (w/v) Tris and 0.5 % (w/v) SDS. 
 
Protein gel sample buffer (3x): 3 % (w/v) SDS, 3 % (v/v) β-mecaptoethanol, 20 % (v/v) 
Glycerol and 0.001 % (w/v) Bromophenol Blue.  
 
Transfer Buffer: 25 mM Tris, 190 mM Glycine and 20 % (v/v) Methanol.  
 
2.10.3 Cell culture 
 
RMPI S: RMPI 1640 (sigma), 100 μg/ml penicillin, 100 μg/ml Streptomycin, 2.5 μg/ml 
Fungizone, 5 μg/ml Gentamycin, 1:100 Non Essential Amino acids (Gibco) and 10 % 
(v/v) FCS. 
 
SF900-II S: SF900 II (sigma), 100 μg/ml Penicillin, 100 μg/ml Streptomycin, 2.5 μg/ml 
Fungizone, and 10 % (v/v) FCS. 
  
2.9.4 Microarray hybridisation buffers 
 
20 x SSC: 3 M NaCl and 0.3 M sodium citrate buffer (pH 7.0) 
 
Pre-hybridisation buffer: 3 x SSC containing 0.1 % SDS 
 
Sodium citrate buffer: 3.0 M NaCl and 0.3 M sodium citrate made up to pH 7.0 with 10 
M NaOH. 
 
Wash 1: 2x SCC containing 0.2 % SDS 
 
Wash 2: 2x SCC 
 






Development of an A238L gene expression and delivery system 




The aim of this project was to investigate the individual effect of the ASFV protein 
A238L on host cell gene transcription using a porcine microarray. To achieve this it was 
necessary to develop a gene expression system capable of expressing A238L under the 
control of a mammalian cell active promoter and then to deliver this gene to a high 
proportion of the target cells with minimal disruption to normal cell function.  
 
One approach to ensure that a high proportion of the target cells are expressing the target 
gene would be to generate a cell line stably expressing A238L under the control of an 
inducible promoter, such as the tetracycline inducible promoter (T-Rex, Invitrogen). 
However, this approach is only suitable for an immortalized cell line. A transient gene 
delivery system offers a more flexible approach with the potential to mediate gene 
delivery to a range of both primary and immortalized cells.  
 
3.1.1 A238L gene expression  
 
Previous work carried out at the IAH has shown that A238L protein expression levels 
are low and often undetectable when transcribed under the control of the nuclear 
polymerase II promoter present in pcDNA3. However, A238L is expressed efficiently 
from a T7 RNA polymerase promoter when transfected into cells infected with Vaccinia 
virus (MVA-T7) expressing T7 RNA polymerase(Miskin et al., 2000b; Tait et al., 
2000).  
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ASFV replicates in the cytoplasm of infected cells using its own transcriptional 
apparatus. Therefore, unlike mammalian genes and viruses that replicate in the nucleus 
of infected cells, ASFV gene transcripts are unlikely to be optimized for transcriptional 
processing and the nuclear export of newly synthesized mRNA in mammalian cells. 
Thus, low levels of A238L protein expression produced using pcDNA3 could be due to 
the poor post-transcriptional processing and export of A238L mRNA and the retention 
of pre-processed A238L mRNA in the nucleus of transfected cells. Previous research has 
shown that the addition of cis-acting regulatory modules, such as splice sites and viral 
RNA regulatory elements, can significantly improve the expression of intronless genes 
from plasmid or viral vectors (Schambach et al., 2000); Callendrat et al 2007). 
Schambach et al investigated the ability of three different RNA modules to enhance the 
expression of intronless genes from reteroviral gene transfer vectors. The modules tested 
were: splice signals (SS), used to create an intron in the 5’ untranslated region of the test 
gene; a constitutive RNA transport element (CTE), found in D-type retroviruses; and a 
post-transcriptional regulatory element present in the woodchuck hepatitis virus 
(WPRE), which enhances post transcriptional processing and nuclear export of mRNA. 
Both the CTE and WPRE interact directly with cellular factors in the nucleus and do not 
require additional viral proteins to function (Gruter et al., 1998; Zufferey et al., 1999). 
The results from these studies demonstrated that the function and potential synergy of 
the RNA elements investigated was dependent on the characteristics of the individual 
gene tested. Overall the WPRE demonstrated the most uniform and strongest capability 
to promote transgene expression. This was particularly apparent in the expression of two 
genes (enhanced green fluorescent protein (EGFP) and human multidrug resistance-
1(MDR1)). These genes were selected due to the ability of their transcripts to be 
processed in the absence of introns but only at low, sub-optimal levels. These 
characteristics are similar to those exhibited by A238L when expressed under the control 
of the nuclear polymerase II promoter present in pcDNA3. Therefore the ability of the 
WPRE to improve A238L gene expression was investigated.  
 




To obtain results representative of the effect of A238L on individual host cell gene 
transcription, and reduce background noise from cells not expressing A238L, a high 
level of transfection efficiency is required. Porcine cells derived from the 
monocyte/macrophage cell lineage are the main target cells for ASFV infection in vivo 
and therefore offer the most biologically relevant system for examining the effect of 
A238L on host cell gene expression. Primary porcine alveolar macrophage (PPAM) 
obtained by lung lavage from domestic pigs are used for the culture and scientific 
investigation of ASFV field isolates in vitro. These cells are extremely difficult to 
transfect using conventional methods and work in our laboratory has shown that 
PPAM’s  typically exhibit a transfection efficiency of less than 1 % using standard 
cationic lipid reagents such as lipofectamineTM 2000 (Invitrogen) (Lynnette Goatley 
personal communication). In addition the quality, composition and activation status of 
isolated cells is variable between animals, introducing a significant amount of variability 
between biological replicates. As a potential alternative to PPAM a continuous clonal 
porcine monomyeloid cell line derived from alveolar macrophage, has been obtained 
from Dr Weingartl (Weingartl et al., 2002b). This cell line has been shown to support 
the replication of ASFV. Compared to primary macrophages this cell line offers an 
unlimited quantity of RNA with minimal variability between cultures due to its clonal 
origin. Higher levels of transfection (approximately 40%) were achieved using 
lipofectamineTM 2000 in these cells, compared to primary macrophages, however the 
number of un-transfected bystander cells still exceeds those expressing the target 
protein. Therefore a gene delivery system capable of achieving high levels of 
transfection in both primary and immortalised porcine alveolar macrophage cells was 
required.   
  
Defective virus vectors are capable of delivering genes to target cells but unable to 
initiate a productive infection. Several of these have been shown to achieve high levels 
of transfection efficiency in primary mammalian cells. Baculoviruses naturally replicate 
in insect cells, but also have the ability to enter mammalian cells by a mechanism 
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involving clathrin-mediated endocytosis (Long et al., 2006). Recombinant 
baculoviruses, which have been modified to contain mammalian cell active promoters, 
have several advantages over other mammalian virus vectors. These include their 
inability to produce a productive infection in mammalian cells, their apparent lack of 
cytotoxicity, ability to target many different cell types, and safety features relative to 
mammalian virus-based transduction systems (Kost et al., 2005). Recombinant 
baculoviruses have previously been successfully used to deliver genes to both 
immortalised and primary porcine cells, with a transfection efficiency of  90-100 % 
achieved in a porcine kidney cell line. No visible cytopathic effect could be detected in 
porcine kidney cells inoculated with this virus (Kost & Condreay, 2002). Therefore the 
ability of recombinant baculovirus to deliver ASFV genes to porcine alveolar 




3.2.1 Cloning of the Woodchuck hepatitis postranscriptional regulatory element 
into an A238L expression vector. 
 
To test if the WPRE could enhance the expression level of A238L, this element was 
cloned into the plasmid pcDNA3-SV5A238L to produce pcDNA3-SV5A238L-WPRE. 
PcDNA3-SV5A238L encodes the A238L protein fused to an N-terminal, 14 amino acid 
Pkepitope tagdownstream of the CMV immediate early promoter. The Pk epitope is 
derived from the paramyxovirus, Simian Virus 5 (SV5) proteins P and V. No antibodies 
specific to A238L are available in our laboratory therefore this tag allows the detection 
of A238L using PK epitope specific antibodies. Pervious work has shown thatthis tag 
does not interfere with the biological function of A238L (Miskin et al., 1998). To 
generate pcDNA3-SV5A238L-WPRE a 600 nucleotide cassette containing the WPRE 
was digested from pHR’CMV-GFP (Zufferey et al., 1999) at EcoR I sites either side of 
the WPRE element.  The resulting 5’ overhangs were end-filled using the Klenow 
fragment of DNA polymerase I in the presence of excess dNTP’s. The WPRE was then 
gel purified and ligated into pcDNA3-SV5A238L at an EcoR V site located in the 3’ 
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untranslated region of A238L, between the stop codon of A238L and a polypurine tract 
present in pcDNA3 (Figure 3.1). WPRE is sense dependent and therefore its insertion in 
the correct orientation was confirmed (Zufferey et al., 1999). Since sequence analysis of 
the WPRE identified a unique Nco I restriction site at nucleotides 413 - 419, restriction 
mapping of pcDNA3-SV5A238L-WPRE with Nco I was used to confirm the presence of 
the WPRE and determine its orientation (Figure 3.2). 
 
3.2.2 Analysis of the effect of WPRE on A238L expression 
 
The effect of the WPRE on SV5-A238L gene expression was initially examined using 
Western blotting (WB). IPAM cells were transfected in parallel with pcDNA3, 
pcDNA3-SV5A238L or pcDNA3-SV5A238L-WPRE. At 16 hrs post-transfection cell 
lysates were harvested, resolved using SDS-PAGE and then blotted onto a nitrocellulose 
membrane. The membrane was probed for the presence of SV5-A238L using anti-Pk tag 
antibodies, which were detected using HRP conjugated protein A. A band migrating at 
approximately 30 kDa, corresponding to SV5A238L, was detected in cell lysates 
transfected with pcDNA3-SV5A238L and pcDNA3-SV5A238L-WPRE. No band was 
detected in cell lysates transfected with pcDNA3 alone. A parallel blot probed with 
antibodies against α-tubulin was used to confirm that relative levels of protein loaded 
between samples were similar. From Figure 3.3 (a) it can be seen that cell lysates 
transfected with pcDNA3-SV5A238L-WPRE contained  higher levels of SV5-A238L 
than cell lysates transfected with pcDNA3-SV5A238L. This suggests that the WPRE 
can enhance the level of A238L expression using the pcDNA3-SV5-A238L expression 
vector, in IPAM cells. To confirm if this overall increase in the level of A238L gene 
expression was due to the direct effect of the WPRE within individual cells and not due 
to the more efficient transfection of pcDNA3-SV5A238L-WPRE compared to pcDNA3-
SV5A238L, transfected cells were examined by Immuno-Fluorescence (IF) followed by 
confocal microscopy. IPAM cells were transfected using the conditions described above. 
At 16 hrs post-transfection the cells were fixed, permeabilised and stained with an 
antibody specific to the Pk tag followed by a fluorescently labeled secondary antibody. 
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Figure. 3.1 Illustration of the cloning strategy to clone WPRE into 
pcDNA3-SV5A238L. A 600bp WPRE cassette was digested from PHR’CMV-
GFP using Eco RI. 5’ overhangs were then end filled using the Klenow
fragment of E.coli DNA polymerase 1, in the presence of excess dNTPs. The 
resulting blunt-ended WPRE fragment was then ligated into pcDNA3-
SV5A238L at an EcoR V site located between the stop codon of A238L and a 
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DNA was stained with DAPI to detect the cell nuclei. Images were produced at the same 
brightness and gain to allow comparison between the relative levels of SV5-A238L 
expression. The transfection efficiency between pcDNA3-SV5A238L and pcDNA3-
SV5A238L-WPRE transfected cells was comparable at approximatley 8%. No pcDNA3 
transfected cells could be detected using the anti-Pk tag antibody demonstrating that this 
antibody is specific to SV5-A238L expressed in IPAM cells (data not shown). SV5-
A238L staining exhibits a diffuse pattern throughout both the cytoplasm and nucleus of 
transfected cells (see Figure 3.3 (b)). Staining of SV5-A238L was  higher in cells 
transfected with pcDNA3-SV5A238L-WPRE compared to cells transfected with 
pcDNA3-SV5A238L. This increase in SV5-A238L expression was limited to within 
individual cells and not due to an increase in the overall number of cells transfected, 
supporting the predicted function of the WPRE, in enhancing post-transcriptional 
processing of mRNA in cells (Zufferey et al., 1999). Together, these results demonstrate 
that the addition of the WPRE to pcDNA3-SV5A238L can enhance A238L gene 
expression to a level that is readily detectable by WB and IF and therefore suitable for 
future experiments.  
 
3.2.3 Generation of recombinant baculovirus for A238L gene delivery 
 
Following the optimisation of A238L gene expression through the addition of the 
WPRE, two separate recombinant baculoviruses were produced to investigate the effect 
of A238L on host macrophage gene expression: a test virus encoding the A238L gene 
and the second, not containing the A238L gene, to act as a negative control. Autographa 
californica nucleopolyhedrovirus (AcNPV) were selected as an appropriate baculovirus 
virus vector, since  previous work with these viruses has shown they are capable of 
mediating gene transfer to a wide range of mammalian cell lines with minimal 
cytopathic effect (Shoji et al., 1997). 
AcNPV recombinant baculoviruses were produced using a system which relies on 
homologous recombination between baculovirus DNA (encoded on the bacmid, 
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Figure 3.2  NcoI restriction enzyme site maps of plasmids pcDNA3-
SV5A238L, pcDNA3-SV5A238L-WPRE (-) and pcDNA3-SV5A238L-
WPRE(+ve). Panel A shows the expected maps of Nco1 sites on SV5A238L-
WPRE (-)(1), pcDNA3-SV5A238L-WPRE(+ve) (2) and pcDNA3-SV5A238L 
(3). Solid lines indicate the positions of NcoI restriction sites and the numbers 
represent the number of nucleotide base pairs between each restriction site 
(restriction maps are not drawn to scale). The predicted size and number of 
DNA fragments produced by each plasmid following digestion with Nco1 is 
shown in Panel B.Panel C shows 1% agrose gel electrophoresis of NcoI
digests of the above plasmids. The positions of the molecular weight 
markers, run in parallel, are indicated. Lane 1 shows a digest of pcDNA3-
SV5A238L-WPRE (-), Lane 2 of pcDNA3-SV5A238L-WPRE(+ve) and lane 3  
pcDNA3-SV5A238L. Lane 2 appears to shows only 4 fragments instead of 
the predicted 5 as the 1.26 and 1.10 Kbp fragment are not clearly resolved.
1.
1.460.90
WPRE  - veSV5 A238L
2.
1.261.10
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Figure 3.3 The WPRE increases A238L gene expression in IPAM
cells. Panel A. Western blot analysis of IPAM cells transfected with
either pcDNA3 (as a negative control), pcDNA3-SV5A238L or pcDNA3-
SV5A238L-WPRE. Cell lysates were harvested at 16 hrs post-
transfection. SV5-A238L was detected using an anti-PK mouse
monoclonal antibody (Serotec). α-tubulin is shown as a loading control.
Panel B. Images of IPAM cells transfected with either pcDNA3-
SV5A238L or pcDNA3-SV5A238L-WPRE. Cells were fixed and stained
16 hrs following transfection. SV5-A238L is shown in green and cell
nuclei are blue. Images were taken sequentially, at the same brightness
and gain using confocal microscopy and then merged. Bar, 10 µm.
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Bac10:KO1629 ) and a suitable transfer vector containing the target gene flanked by 
baculovirus DNA (Zhao et al., 2003). The polyhedrin gene, which is flanked by ORF603 
and ORF1629, was used as the locus of recombination. ORF603 encodes a 21 kDa non-
essential protein and ORF 1629 encodes the 61 kDa viral capsid-associated protein 
which is essential for baculovirus replication (Possee et al., 1991; Valdeira et al., 1998). 
Bac10:KO1629 has been specifically modified to encode a truncated, non-functional ORF 
1629. Viral DNA prepared from this knockout virus fails to initiate an infection unless 
rescued by recombination with a baculovirus transfer vector containing a complete, 
functional ORF 1629. This approach ensures that any baculovirus progeny produced 
must result from a successful recombination event and therefore eliminates the need for 
subsequent virus selection and the purification of recombinants (Figure 3.4). 
Bac10:KO1629 also contains a unique Bsu361 restriction enzyme site allowing 
linearisation of the DNA prior to co-transfection. This facilitates recombination, as 
linear DNA is recombined more efficiently  than circular DNA (Kitts & Possee, 1993).  
 
3.2.4 Construction of transfer plasmids for the production of test and control 
recombinant baculovirus  
 
pTriEx1.1 (Novagen) was selected as a suitable transfer vector to generate control and 
test recombinant baculovirus. This plasmid contains both a late p10 baculovirus 
promoter and CAG promoter, allowing expression of the target gene in both insect and 
mammalian cells respectively. pTriEx1.1 also contains a 256bp intron. Introns have been 
reported to enhance mRNA processing and export in eukaryotic cells (Nott et al., 2003).  
The mammalian cell active promoter CAG is a composite promoter consisting of a CMV 
enhancer element fused to the chicken β-actin promoter. Previous work has shown that 
this promoter can successfully drive luciferase gene expression in a porcine kidney cell 
line (CPK) following baculovirus-mediated gene transfer (Shoji et al., 1997). 
 
To produce test recombinant baculovirus expressing A238L, the SV5A238L-WPRE 
expression cassette was cloned into pTriEx1.1 to produce pTriEx1.1-SV5A238L-WPRE. 
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To generate pTriEx1.1-SV5A238L-WPRE a 756 bp fragment containing SV5A238L 
was amplified from pcDNA3-SV5A238L by PCR, using the primers PcNco and PcHind, 
which contain Nco I and Hind III restriction sites respectively. Following digestion with 
Nco I and Hind III the PCR fragment was gel purified and ligated into Nco I and Hind  
III digested TriEx1.1 to produce pTriEx1.1-SV5A238L. A 600 bp WPRE cassette was 
then digested from pHR’CMV-GFP using EcoR I and, following gel purification, ligated 
into TriEx1.1-SV5A238L at a unique EcoR I site downstream of the SV5A238L coding 
sequence to produce TriEx1.1-SV5A238L-WPRE. To confirm the correct orientation of 
the WPRE, TriEx1.1-SV5A238L-WPRE was digested with Nco I and then analysed 
using agarose gel electrophoresis (Figure 3.5). The insert in the selected plasmid was 
then sequenced to confirm it was as expected. 
 
To ensure that SV5-A238L could be expressed under the control of the CAG promoter 
in porcine macrophages, cells were transfected with TriEx1.1-SV5A238L-WPRE and 
examined for the expression of SV5-A238L. Expression levels of SV5-A238L were 
compared between the vectors TriEx1.1 and pcDNA3, both with and without the WPRE. 
IPAM cells were transfected with either pcDNA3-SV5A238L, pcDNA3-SV5A238L-
WPRE, pTriEx1.1-SV5A238L or pTriEx1.1-Sv5A238L-WPRE. Cells transfected with 
pcDNA3 and TriEx1.1 were used as negative controls. At 16 hours post-transfection the 
cells were examined for the presence of SV5-A238L using western blotting and 
immunofluorescent confocal microscopy. Western blot analysis of the cell lysates using 
anti-Pk tag antibodies showed that SV5-A238L migrated as a 28 kDa molecular weight 
protein in all the cell lysates with the exception of the controls (Figure 3.6). Levels of 
SV5-A238L expressed in cells transfected with the TriEx1.1 vector (both with and 
without the WPRE) consistently showed higher levels of expression than in cells 
transfected with the pcDNA3 vector. This could be due to the CAG promoter being 
more active than the CMV promoter in IPAM cells and/or the presence of the intron 
enhancing SV5A238L mRNA processing. Consistent with previous results, the WPRE 
caused an  increase in gene expression when SV5-A238L was expressed using pcDNA3. 
The WPRE also increased the level of SV5-A238L expression using the TriEx1.1 
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Co-Transfection of SF9 cells with 
the bacmid and transfer vector.
Recombination of bacmid DNA and 
generation of viral progeny within 48 
hrs.
Figure 3.4 A schematic representaion of the generation of recombinant 
baculovirus using Bac10:KO1629. SF9 insect cells are transfected with 
linearised Bac10:KO1629 (which encodes a non-viable baculovirus genome, 
containing lethal deletion in ORF1629) and a transfer vector containing the 
target gene flanked by the baculovirus sequences to ORF603 and ORF1629. 
Homologous recombination between Bac10:KO1629 and the transfer vector 
repairs the lethal deletion in ORF1629 producing an infectious baculovirus
DNA containing the target gene. Recombinant baculovirus encoding the 
target gene are then produced. 
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expression vector, although the results were much less pronounced than those seen for 
pcDNA3.  These results demonstrate that higher levels of SV5-A238L are expressed 
from the plasmid pTriEx1.1 containing the WPRE compared to the plasmid pcDNA3, 
and this is therefore a suitable transfer vector for the production of recombinant 
baculovirus. 
 
A transfer vector encoding the WPRE in the absence of the A238L gene was also 
produced to generate control baculovirus. To achieve this the WPRE element was 
digested from pHR’CMV-GFP using Eco RI and, ligated into TriEx1.1 at an unique Eco 
RI site located in the multiple cloning region of TriEx1.1, to produce TriEx1.1-WPRE. 
To confirm the presence of the 600 bp WPRE, TriEx1.1-WPRE was digested with Eco 
RI and then analyzed using agarose gel electrophoresis. Selected plasmids were then 
sequences to confirm the correct orientation of the WPRE. 
 
3.2.3 Production of recombinant baculoviruses  
 
To produce recombinant baculovirus, SF9 insect cells were co-transfected (using 
Cellfectin™) with linearised Bac10:KO1629  and  either pTriEx1.1-SV5A238L-WPRE or 
pTriEx1.1-WPRE to produce both test and control recombinant baculoviruses. Cells 
were also transfected with Bac10:KO1629  alone to act as a negative control. Following 
incubation at 28 oC for 72 hrs, cell supernatants were harvested, centrifuged to remove 
cell debris and then tested for the presence of viable baculovirus using a plaque assay. 
Plaques were detected from supernatants isolated from cells co-transfected with 
Bac10:KO1629 / pTriEx1.1-SV5A238L-WPRE and Bac10:KO1629  /pTriEx1.1-WPRE. No 
plaques were detected from cell lysates transfected with Bac10:KO1629 alone, indicating 
that the viruses isolated from the other samples were the result of a successful 
recombination. Test (Bac-SV5A238L) and control (Bac-WPRE) baculovirus were then 
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Figure 3.5 Cloning SV5-A238L-WPRE into the transfer vector TriEx1.1 
A 756 bp fragment containing SV5A238L (blue) was PCR amplified from 
pcDNA3-SV5A238L using the primers PcNco I and PcHind, which contain Nco I 
and Hind III restriction sites respectively. TriEx1.1 and the PCR product were 
then restriction digested with NcoI and HindIII and ligated together to produce 
TriEx1.1-SV5A238L. TriEx1.1-SV5A238L digested with Nco 1 and EcoR I is 
shown (A). A 600bp WPRE (yellow) cassette was digested from pHR’CMV-GFP 
using EcoRI and ligated into TriEx1.1-SV5A238L to produce TriEx1.1-
SV5A238L-WPRE. TriEx1.1-SV5A238L-WPRE was restriction digested with Nco
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To confirm the presence of the SV5A238L-WPRE expression cassette in Bac-
SV5A238L and the WPRE in Bac-WPRE, baculovirus DNA from these recombinant 
viruses was purified and then fragments containing the inserted sequences were 
amplified by PCR using the primers TriExUP (Novagen) and pORF1629. TriExUP is 
specific for the transfer vector pTriEx1.1 and is located upstream of the p10 promtor 
region and pORF1629 is located within ORF1629. Together theses primers flank the 
target insertion sequences. From Figure 3.7 it can be seen that PCR amplification of the 
baculovirus DNA from both Bac-SV5A238L and Bac-WPRE produced products of the 
correct size, approximately 2.7 Kbp and 1.8 Kbp respectively. This result confirms the 
presence of the target DNA sequences in the recombinant viruses.  
 
3.2.5 Susceptibility of porcine cells to baculovirus-mediated gene transduction 
 
To investigate the ability of Bac-SV5A238L to mediate gene transfer to porcine 
macrophage cells, the expression of SV5-A238L was examined in both an immortalised 
porcine alveolar macrophage cell line (IPAMs) and primary porcine alveolar 
macrophage (PPAM) by western blotting. Previous work using porcine kidney cells 
demonstrated that a m.o.i. of 10 to 100 was required to obtain high levels of gene 
transfection using recombinant baculovirus (Shoji et al., 1997). Therefore, cultures of 
IPAM cells and PPAM were treated with either Bac-SV5A238L at an m.o.i. of both 10 
and 50, Bac-WPRE at an m.o.i. of 50 or mock-infected at 37 oC in serum free medium. 
One hour following treatment the cell supernatant was removed along with excess virus 
and replaced with standard culture medium. Cell lysates from IPAM and PPAM cells 
were harvested at 24 and 48 hrs, respectively, following virus treatment, and analysed by 
western blotting. From Figure 3.8 it can be seen that SV5-A238L could be detected in 
cell lysates from both IPAMs and PPAM treated with Bac-SV5A238L. No bands were 
detected in cell lysates treated with the control baculovirus, Bac-WPRE, indicating that 
the the anti-Pk antibody was specific for SV5-A238L in this experiment and does not 
cross react with baculovirus proteins. In IPAM cells the SV5-A238L band present in 
cells treated at an m.o.i. of 50 appeared to be slightly more intense than the band 
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Figure 3.7 PCR analysis of recombinant baculovirus DNA. Panel A. 
Comparative maps of the baculovirus genome at the site of recombination 
are shown for Bac-SV5A238LWPRE ( i ) and Bac-WPRE ( ii ). The position 
and direction of the primers TriExUp and ORF1629 are indicated by the 
presence of an an arrow below the primers name. Panel B. PCR products 
produced from Bac-WPRE (lane 1) and Bac-SV5A238L DNA (Lane 2) using 
the primers TriExUp and ORF1629. DNA markers with their molecular mass 
(in Kbp) are shown in Lane 3.





























detected in cell lysates treated at an m.o.i.of 10. The results for PPAM were similar, 
although less pronounced.  Higher levels of SV5-A238L protein expression associated 
with an m.o.i. of 50 probably indicate a higher rate of gene delivery at this m.o.i..  
 
3.2.6 Transfection efficiency of baculovirus-mediated gene transduction to 
porcine cells 
 
To investigate the efficiency of baculovirus-mediated gene transfer, IPAM cells were 
inoculated with Bac-SV5A238L at an m.o.i of 0, 10, 50 and 100 in duplicate. 16 hrs 
following inoculation the cells were fixed, permeabilised and stained for the presence of 
SV5-A238L using indirect immunofluorescence. Cells were imaged using confocal 
microscopy. 3 independent experiments were carried out. Visual inspection of the cells 
by light microscopy prior to fixation identified no difference in the morphology between 
mock-treated cells and Bac-SV5A238L treated cells; no cytopathic effect (CPE) was 
detected in either case. For each replicate in each experiment, 100 cells were counted 
and the percentage of cells expressing SV5-A238L calculated. Figure 3.9 represents the 
combined results from 3 independent experiments. From this Figure it can be seen that 
the proportion of cells expressing SV5-A238L increased in a dose-dependent manner 
with increasing m.o.i.. High levels of gene transfer of approximately 90 and 85 % were 
achieved at m.o.i.s of 50 and 100, dropping slightly to approximately 70 % at an m.o.i. 
of 10. The absence of any visual CPE and high level of transfection efficiency at high 
m.o.i.s is consistent with previous work investigating baculovirus-mediated gene 
transfer to mammalian cells (Shoji et al., 1997) and supports the use of this virus vector 
for gene delivery to porcine macrophage cells. Unfortunately it was not possible to 
calculate the transfection efficiency of Bac-Sv5A238L to PPAM, due to high levels of 
background fluorescence observed in mock-inoculated cells.  
 
3.2.7 Comparison of SV5-A238L gene expression between ASFV infected and 















Figure 3.9 Recombinant baculovirus show a high level of transfection
efficiency in IPAM cells. IPAM cells were treated with BAC-SV5A238L at the 
indicated m.o.i.. 16 hrs following treatment the cells were fixed and stained for 
SV5A238L using an anti-PK antibody followed by an Alexa-488 conjugated 
goat anti-mouse IgG secondary antibody. The cells were then examined  by 
confocal microscopy and the percent of cells expressing SV5A238L 
calculated. Data presented is the mean ( +/- S.D) of duplicate samples 
repeated on three separate occasions.
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To provide an indication of relative levels of A238L gene expression between cells 
infected with ASFV or inoculated with Bac-SV5A238L, expression levels were 
compared between Vero cells infected with a recombinant ASFV which contains a Pk-
tagged A238L gene (SV5GaL) (Miskin et al., 1998) and Bac-SV5A238L inoculated 
IPAM cells using indirect immunofluorescence microscopy. Using this approach it was 
possible to compare SV5-A238L gene expression within individual cells, rather than the 
total level of gene expression within the cell population, therefore taking into account 
differences in infection efficiencies between SV5GaL and Bac-SV5A238L. It was not 
possible to directly compare levels of A238L gene expression within the same cell line 
as SV5GaL does not infect IPAM cells. At 16 hrs post-infection cells were fixed and 
stained for the presence of SV5A238L. Cells infected with ASFV were also stained with 
rabbit polycolonal antibodies against the late viral protein pE120R (Jouvenet et al., 
2004) to identify infected cells. Images were taken at the same brightness and gain to 
allow comparison between relative expression levels (Figure 3.10). The level of SV5-
A238L detected in Vero cells infected with SV5-Gal was extremely low and only just 
above background level. In contrast images taken of IPAM cells inoculated with Bac-
SV5A238L, were considerably brighter indicating a much higher level of gene 
expression within these cells. This result indicates that A238L gene expression is higher 





The aim of this chapter was to develop a gene expression and delivery system to produce 
detectable levels of A238L protein at a high rate of transfection efficiency in porcine 
alveolar macrophage cells and in a porcine macrophage cell line. This was achieved 
through the addition of the cis-acting WPRE element into the 3’ UTR of the A238L 
gene, followed by the incorporation of this modified A238L gene into a recombinant 





3.1 A238L gene delivery 
 
The WPRE is a viral RNA element which is being increasingly used to enhance the 
expression of intronless genes which exhibit low levels of gene expression using 
conventional DNA expression vectors (Callendret et al., 2007; Garg et al., 2004). This 
element consists of three cis-acting regulatory elements, which are responsible for 
enhancing the post-transcriptional processing of mRNA and mediating its nuclear export 
in a CRM-1 dependent and independent manner (Popa et al., 2002; Zufferey et al., 
1999). This leads to increased levels of mRNA available for translation and greater 
protein production. The results presented in this chapter show that the addition of the 
WPRE to the 3’ untranslated region of A238L increased the levels of A238L expressed 
in transfected cells using the expression vector pcDNA3. This suggests that the 
expression of A238L, using a mammalian system, is dependent on the efficient nuclear 
processing and export of A238L mRNA.  
 
Interestingly higher levels of A238L expression were achieved using the pTriEx1.1 
expression vector, both with and without the WPRE, than with pcDNA3 encoding 
A238L and the WPRE. Both of these plasmids utilise RNA polymerase II promoters, 
however pcDNA3 contains the CMV-IE promoter and pTriEx1.1 contains a hybrid 
promoter consisting of a CMV immediate early enhancer fused to the chicken β-actin 
promoter (CAG). pTriEx1.1 also contains a 258 bp intron. Both the CAG promoter and 
the intron could have contributed to the high levels of A238L gene expression achieved 
using pTriEx1.1 alone. Composite CMV-IE and B-actin promoters have been shown to 
drive higher levels of gene expression than the wild type CMV-IE promoter in several 
other studies (Niwa et al., 1991; Sawicki et al., 1998). 
 
Intron-containing genes can exhibit dramatically different expression profiles,  
compared to the same gene with the intron removed, when expressed in mammalian 
systems (Buchman & Berg, 1988). Introns and the act of their removal by the 
spliceosome can effect gene expression at many levels, including transcription, 
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polyadenylation, mRNA export, translation efficiency and the rate of mRNA decay (Le 
Hir et al., 2003). Thus introns and the WPRE have similar roles, in that they can both 
facilitate mRNA processing and nuclear export. Previous work has shown that the 
WPRE can compensate for the lack of an intron in the expression of β-globulin using a 
retroviral vector (Schambach et al., 2000). Thus there may be considerable overlap in 
function between these elements. It is, therefore, highly likely that the presence of an 
intron within pTriEx1.1 contributed, in part, to the high level of A238L expression 
achieved using the pTriEx1.1 expression vector in the absence of the WPRE.  
 
Expression of A238L using pTriEx1.1 was further enhanced by the addition of the 
WPRE, indicating an additive effect between the WPRE and intron. Synergy between 
introns and the WPRE has been reported in several studies, where the WPRE has been 
demonstrated to enhance the expression of both spliced mRNA and unspliced mRNA 
(Callendret et al., 2007; Popa et al., 2002; Schambach et al., 2000; Zufferey et al., 
1999). WPRE RNA and spliced mRNAs use different factors for nuclear export, CRM-1 
and TAP respectively, which could explain the ability of these two elements to act in 
synergy to enhance the level of A238L expression (Stewart, 2007). 
 
Overall the TriEx1.1 expression vector containing the WPRE was considered to be most 
suitable for the generation of recombinant baculovirus as this plasmid produced the 
highest levels of A238L gene expression. In addition, recombinant baculovirus 
containing the target gene under the control of the CAG promoter have been shown 
previously to achieve gene transfer and expression in porcine cells (Shoji et al., 1997).  
3.3.2 A238L gene transfer 
 
Several reports have shown that baculoviruses are useful tools for gene delivery into a 
number of mammalian cell lines, including porcine kidney cells (Kost & Condreay, 
2002). The A238L gene cloned in the pTriEx1.1 vector with the WPRE was used to 
construct a recombinant baculovirus and the ability of this virus to delivery foreign 
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genes into immortalised and primary porcine alveolar macrophage cells was tested. 
Western blot analysis of lysates from cells inoculated with this recombinant baculovirus 
demonstrated efficient transduction of primary porcine alveolar macrophages and IPAM 
cells, an observation which has not previously been published. High levels of cell 
transfection of approximately 85 % and 90 % were observed in the immortalised cell 
line following inoculation with m.o.i.s of 50 and 100 respectively. These results are 
consistent with another study demonstrating that baculovirus can deliver genes to 90-100 
% of cells at an m.o.i of 100 (Shoji et al., 1997). This study also observed no visible 
CPE in cells inoculated with bacuovirus, even at m.o.i.s of 100, a result which is 
consistent with our findings. Unfortunately, it was not possible to obtain an exact 
measure of the transfection efficiency of the recombinant baculovirus in PPAM. 
However, it was not considered necessary to pursue these experiments further because 
the IPAM immortalised porcine alveolar macrophage cell line was selected for the future 
microarray experiments instead.  Use of this cell line should produce more reproducible 
and statistically significant results by reducing the variability likely from using primary 
cells. 
 
The level of A238L protein expressed in IPAM immortalised porcine cells transduced 
with the recombinant baculovirus was higher than in Vero cells infected with the 
BA71V ASFV isolate. However, for the purpose of this study, high levels A238L 
expression were preferable as the experimental approach was to produce excess A238L 
in order to characterise the full range of potential functions of this protein 
 
3.3.3 Conclusion  
 
The data presented in this chapter provide a valuable insight into the possible 
mechanisms responsible for low levels of A238L expression produced using the 
expression vector pcDNA3. The results demonstrated that RNA elements involved in the 
postranscriptional processing and export of mRNA are a key requirement for the 
expression of A238L using mammalian systems. These observations offer a useful 
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approach for optimising the expression of other ASFV genes which exhibit low levels of 
expression using similar systems.  
 
In addition, this chapter also presents a novel approach for the delivery of ASFV genes 
to both primary and immortalised porcine macrophage cells which has the advantage of 





Optimisation of the microarray experimental design 
 
4.1 Introduction 
One of the main aims of this thesis was to investigate the overall effect of A238L on 
host macrophage gene transcription by using a porcine microarray.  Microarray 
experiments are costly and time consuming to perform and this limits the number of 
experimental conditions that can be examined. Therefore it was necessary to optimise 
and carefully select the experimental conditions prior to carrying out the analysis.  
A238L is predicted to inhibit gene expression associated with activated immunological 
signal transduction pathways as discussed previously. This protein has been shown to 
inhibit the transcriptional activation of several genes involved in the host immune 
response to infection, including COX-2, TNF-α, inducible nitric oxide synthases (iNOS) 
and IL-8 (Granja et al., 2004b; Granja et al., 2006d; Powell et al., 1996). Although the 
exact mechanism of this inhibition has not been fully established, previous work has 
shown that A238L inhibits the activity of three cellular proteins which are key regulators 
of signal transduction and gene transcription. These proteins are: the cellular 
transcription factor NF-κB; calcineurin (CaN) a serine/threonine protein phosphatase 
and the transcriptional co-activator p300/CBP (Granja et al., 2006d; Miskin et al., 1998; 
Powell et al., 1996; Revilla et al., 1998). The plan was to investigate the effect of A238L 
on host gene transcription in IPAM cells which had been treated with lipopolysaccharide 
(LPS), phorbol 12-myristate 13-acetate (PMA) and ionomycin, compounds which 
activate signalling pathways involving these transcriptional regulators. LPS activates 
several intracellular pathways via Toll-like receptor 4 including the IκB kinase (IKK)-
NF-κB pathway and three mitogen-activated protein kinase (MAPK) pathways: 
extracellular signal-regulated kinases (ERK) 1 and 2, c-Jun N-terminal kinase (JNK) and 
p38 (Guha & Mackman, 2001).  PMA activates Protein Kinase C and ionomycin is a 
calcium ionophore which increases intracellular levels of calcium, resulting in activation 
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of CaN. Together PMA and ionomycin mimic antigenic stimulation of leukocytes 
resulting in the transcription of NFAT dependent cytokine and immune response genes 
(Acuto & Cantrell, 2000; Rao et al., 1997).  
Regulation of gene expression is a dynamic process and gene expression profiles can 
change significantly over short periods of time in response to stimulation. Therefore, 
selection of the most appropriate conditions and time points to carry out microarray 
analysis following cell activation is an important consideration in order to produce 
informative data and biologically relevant results. The use of immortalised cell lines and 
artificial gene delivery systems (described in chapter 3) to infer the possible functions of 
A238L in host macrophages has both advantages and disadvantages.  It is possible that 
IPAM cells may behave in an unpredicted manner in response to artificial gene delivery 
and stimulation. Therefore as a preliminary experiment it would be useful to gain a 
general overview of the activation state and gene expression profiles produced in IPAM 
cells without stimulation as well as in response to the experimental conditions alone. 
This would allow a more complete interpretation of how A238L may act within this 
system to alter gene expression. There were two main objectives for the experiments 
described in this chapter. The first objective was to optimise the microarray 
experimental design. This included the selection of an appropriate time point following 
A238L gene delivery to stimulate the cells and the selection of appropriate time points 
following stimulation to analyse gene transcription using microarrays. The second 
objective was to characterise the effect of baculovirus gene delivery followed by cell 
stimulation on resting IPAM cells in the absence of A238L gene expression.  
 
4.2 Results 
4.2.1 Optimisation of the microarray experimental design. 
4.2.1.1 Expression of A238L in baculovirus transfected cell lines. 
The previous chapter describes the development of a recombinant baculovirus vector 
capable of transferring the A238L gene to an immortalised porcine alveolar macrophage 
cell line, IPAM, at a high level of transfection efficiency. To determine the amount of 
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A238L protein present in IPAM cells following gene delivery using the baculovirus 
vector, Bac-SV5A238L, a time course experiment was carried out. IPAM cells were 
treated with Bac-SV5A238L at an m.o.i. of 50. At various time points post-infection 
cells lysates were harvested, separated using SDS/PAGE and then blotted onto a 
nitrocellulose membrane. The membrane was then probed for the presence of SV5-
A238L using anti-Pk antibodies and these were detected using HRP conjugated protein 
A. The blot was then stripped and re-probed with antibodies against α - tubulin to 
confirm that comparable levels of protein were loaded in each sample.  
From Figure 4.1 it can be seen that SV5A238L was detected at a low level from as early 
as 4 hrs post-infection with Bac-SV5A238L. By 12 hrs post-infection relatively strong 
levels of SV5A238L could be detected. Therefore 12 hours post Bac-SV5A238L 
mediated gene delivery was selected as an appropriate time point to stimulate IPAM 
cells with LPS, PMA and ionomycin.    
 
4.2.1.2 Expression of immune response genes following LPS, PMA and ionomycin  
treatment of IPAM cells. 
 
Following activation macrophages initiate a rapid transcriptional programme to 
modulate the hosts immune response. Proinflammatory response genes are activated 
immediately and these proteins can act to regulate subsequent gene expression. For 
example IkB-ζ , an immediate early (IE) LPS response gene has been shown to be 
expressed 30 min following LPS treatment of peritoneal macrophages and is essential 
for the expression of IL-6. Transcription of IL-6 follows IkB-ζ mRNA transcription by 
60 min (Yamamoto et al., 2004). A238L is expressed early during ASFV infection and 
the A238L protein can be detected as early as 2 hrs post-infection (Tait et al., 2000). 
Therefore A238L has the potential to regulate host macrophage gene expression during 




early time points were selected, following IPAM activation, to investigate the effects of 
A238L on host gene transcription using microarray analysis. It was intended that the 
first time point would reflect changes in immediate gene expression, directly dependent 
on expression of A238L, and the second time point would reflect subsequent secondary 
changes in gene expression that occurred as a consequence of the expression of 
immediate early genes.  
 
To select these time points total RNA was collect from PMA, LPS and ionomycin 
stimulated and mock-stimulated IPAM cells at 0, 15, 30, 60, 120, 240 min post- 
stimulation. Concentrations of PMA, LPS and ionomycin used have been reported 
previously (Miskin et al., 2000a; Powell et al., 1996). mRNA from both stimulated and 
mock-stimulated  samples was reverse transcribed into cDNA using an oligonucleotide 
dT primer and the resulting cDNAs were then analyzed using semi-quantitative PCR to 
compare the relative levels of mRNA expression of selected genes between stimulated 
and mock-stimulated IPAM cells over time. Total RNA samples were treated with 
DNAse prior to reverse transcription to remove any DNA contamination. In addition, 
control samples, processed in the absence of reverse transcriptase enzyme, were 
analysed from selected samples to act as negative controls. 
 
Genes selected for investigation were: TNF-α, IL-8, COX-2, which have previously 
been shown to be regulated by A238L expression (Granja et al., 2004b; Powell et al., 
1996; Revilla et al., 1998) ; IkB-ζ  which is an immediate early LPS response gene and 
IL-6, which is a secondary LPS response gene dependent on IkB-ζ gene expression 
(Yamamoto et al., 2004). IkB-ζ and IL-6 were selected as indicators for immediate and 
secondary phase gene transcription. β-actin was also examined as a housekeeping gene 
which is constituitively expressed. 
 
From the results presented in Figure 4.2 it can be see that β-actin was present at similar 
levels in all of the samples tested, indicating equal RNA loading between samples. PCR 





all of the samples tested, however relative levels of PCR-product varied between 
stimulated and mock-stimulated cells for a number of the genes tested.  
TNF-α, COX-2 and IL-8 all showed an increase in the amount of mRNA detected in 
stimulated samples compared to mock-stimulated cells at 60, 120 and 240 minuets post- 
stimulation. The levels of IL-6 mRNA did appear slightly raised in stimulated samples 
compared to mock-stimulated controls at 60 and 120 minuets, returning to the level in 
mock-stimulated samples at 240 min. However, the difference was less pronounced than 
that seen for TNF-α, COX-2 and IL-8. No difference in the levels of IkB-ζ mRNA could 
be detected between stimulated and mock-stimulated samples for any of the time points 
tested using this assay. This was unexpected as previous work has demonstrated that 
IkBζ mRNA induction precedes and is required for induction of IL-6 expression 
(Yamamoto et al., 2004).  
Due to the small number of genes tested it is difficult to gain an accurate overview of the 
expression profile of IPAM cells in response to stimulation. However, the results clearly 
demonstrate that early/immediate gene expression associated with LPS/PMA and 
ionomycin stimulation can be detected from 60 minuets following treatment. All of the 
genes tested exhibited low levels of expression even in the absence of LPS, PMA and 
ionomycin treatment indicating that pathways associated with the expression of these 
genes may be constitutively activated in IPAM cells. No changes in the expression 
profile of the selected genes could be detected at 4 hrs compared to the other time points 
tested, which is undoubtedly due to the small number of genes examined.  On the basis 
of these results and previously published data, which demonstrated a significant 
difference in the gene expression profile of whole blood leukocytes at 4 hrs post LPS 
stimulation compared to earlier time points (Boldrick et al., 2002; Calvano et al., 2005), 
1 hr and 4 hr time points post LPS, PMA and ionomycin stimulation were selected for 
analysis in microarray experiments.  
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4.2.2 Microarray analysis of the effect of cell stimulation and baculovirus 
treatment on gene transcription profiles in IPAM cells 
4.2.2.1 Microarray analysis 
Two porcine microarrays were available for this study. A cDNA microarray containing 
2,880 genes, known as Pig 3K Immune cDNA and an oligonucleotide array containing 
the Operon Sus scrofa (pig) v1.0 and Sus scrofa (pig) extension Array-Ready Oligo 
SetsTM. The Pig 3K Immune cDNA is specifically targeted at investigating genes 
associated with the immune response (Zhang et al., 2006b). The Operon Sus scrofa (pig) 
v1.0 and Sus scrofa (pig) extension Array-Ready Oligo SetsTM, consists of 13,297, 70-
mer oligonucleotides representing all known Sus scrofa gene sequences with a hit to 
human, mouse, or pig gene transcripts and a number of sequences containing a 3’ 
expressed sequence Tag (EST) (Operon). Genes present on the Pig 3K Immune cDNA 
but not detected in the 
To examine the effect of baculovirus treatment in combination with cell stimulation on 
untreated IPAM cells in the absence of A238L gene expression, gene expression profiles 
between cells treated with the control baculovirus vector (Bac-WPRE) and stimulated 
with LPS, PMA and Ionomycin (C) were compared directly against a reference pool of 
RNA collected from non-stimulated IPAM cells (CR) (Figure 4.3). This experiment was 
carried out in parallel with the experiment described in chapter 5. Three independent 
experiments were carried out. IPAM cells were treated with control baculovirus not 
expressing the A238L gene (Bac-WPRE) at an m.o.i. 50. 12 hours following baculovirus 
treatment the cells were stimulated with LPS, PMA and Ionomycin. At 1 and 4 hours 
post-stimulation total RNA was isolatedand mRNA was amplified to produce antisense 
RNA. 
Operon oligonucleotide sets were also included on this array. The 
Operon array was selected for this investigation as it contained a larger and more diverse 
set of probes not restricted to a specific cellular response, and therefore more appropriate 
to investigate the global effect of A238L on host cell transcription. 
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Figure 4.3 Schematic representation of the microarray experimental 
design used investigate the effect of baculovirus treatment, and LPS, 
PMA and ionomycin stimulated on untreated IPAM cells. Panel A) 
Experimental procedure: IPAM cells were infected with Bac-WPRE (control) 
at an moi 50. 12 hours following baculovirus treatment the cells were 
stimulated with LPS (100µg/ml), PMA (100 nM) and Ionomycin (4 µM). 1 hr 
(T1) and 4 hrs (T4) following stimulation total RNA was harvested, amplified 
and labeled with either Cy3 or Cy5 fluoresent dyes. The horizontal arrow 
represents the time line post baculovirus treatment. Panel B) Microarray 
experimental design. Control samples were compared indirectly against a 
common reference pool of un-stimulation IPAM RNA. Amplified mRNA from 
each sample and the common reference was labeled with either Cy3 or Cy5 
fluoresent dyes. Each sample was then co-hybridised onto a separate 
porcine oligo arrays (operon) against the common reference sample in the 
opposite channel. Three biological replicates were carried out for each 
experimental condition, with a dye swap for each biological replicate. 
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Equal quantities of test and control samples, labeled with either Cy3 or Cy5 were 
combined and co-hybridised onto the Operon Sus scrofa (pig) v1.0 and Sus scrofa (pig) 
extension OligoTM microarray (Operon). Two hybridisations were carried out for each 
comparison, with the dye assignments reversed in the second hybridisation to account 
for labeling bias between dyes. Images of the hybridised arrays were obtained by laser 
confocal scanning. Raw image files were processed to extract feature information and 
remove background noise and artifacts using BlueFuse for microarrays software. 
Processed data files were then analysed using software tools from the TM4 microarray 
software suite; Microarray Data Analysis System (MIDAS) and Multiexperiment 
Veiwer (MeV) (Saeed et al., 2006). Prior to statistical analysis the total data set was 
filtered to remove poor quality features. This resulted in a final data set from 10146 
oligonucleotides out of an original total of 13657 unique oligonucleotides. 
Significant Analysis of Microarrays (SAM) analysis was used to identify differentially 
regulated genes. This is a statistical method specifically adapted to analyse large 
amounts of data present in microarray data sets (Tusher et al., 2001).  
 
One and four hour data sets were analysed independently using a one class SAM 
analysis. The results from this analysis are presented in Figure 4.5 and 4.6. At 1 hr post-
stimulation a total of 1277 (13%) unique oligonucleotides were identified as hybridising 
to RNAs that were significantly differentially regulated by baculovirus and LPS, PMA 
and ionomycin treatment, 11.12 of these oligonucleotides were estimated to be falsely 
significant (FDR 0.89%). 918 (9%) of these oligonucleotides hybridised to RNAs that 
were predicted to be significantly up-regulated and 359 (4%) oligonucleotides 
hybridised to RNAs that were predicted to be significantly down-regulated. Therefore at 
this time point a greater proportion of the oligonucleotides hybridised to RNAs that were 
significantly up-regulated. At 4hr post stimulation 797 (8%) oligonucleotides were 
identified as hybridising to RNAs that were significantly differentially regulated, 21 of 
these were estimated to be falsely significant (FDR 2.67%). 69 (1%) of these 
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oligonucleotides were shown to be hybridised to RNAs that were significantly up-
regulated, the remaining 728 (7%) oligonucleotides were hybridised to RNAs that were 
significantly down-regulated. Therefore the majority of the oligonucleotides that were 
identified as hybridising to RNAs that were significantly differentially regulated at 4 hrs, 
hybridised to RNAs that were significantly down-regulated, in direct contrast to the 
results presented for the 1 hr time point. This indicates a suppression of differentially 
regulated gene transcription at 4 hrs post LPS, PMA and ionomycin treatment. 
 
To examine the effect of baculovirus, LPS, PMA and ionomycin treatment  on untreated 
IPAM cells, across both time points, the lists of oligonucleotides identified as 
differentially regulated by BacWPRE, LPS, PMA and ionomycin treatment (compared 
to untreated IPAM cells) at both 1 and 4 hrs were combined. This resulted in a final list 
of 1757 unique oligonucleotides that hybridised to differentially regulated RNAs at 
either or both 1 and 4 hrs post-stimulation. 952 (55 %) of these oligonucleotides 
hybridised to RNAs that were differentially regulated at 1 hr post-stimulation but not at 
4 hrs, 306 (17 %) oligonucleotides intersected both time points and therefore hybridised 
to RNAs that were differentially regulated at both 1 and 4 hrs post-stimulation and 488 
(27 %) oligonucleotides hybridised to RNAs differentially regulated at 4 hrs post-
stimulation only. These results are represented as a Venn diagram in Figure 4.7. 
Individual oligonucleotides within each of these groups were then sorted into categories 







their regulation profiles. This resulted in the formation of a total of 8 separate clusters 
exhibiting different expression profiles. Graphical representation of the expression 
profiles of these clusters are presented in Figure 4.8. Cluster 1 contained 296 (16.8%) 
oligonucleotides that hybridised to RNAs that are significantly down-regulated at 1 hr 
post-stimulation returning to normal levels at 4 hrs post-stimulation. Cluster 2 contained 
656 (37.5 %) oligonucleotides that hybridised to RNAs that were significantly up-
regulated at 1 hr post stimulation but not significantly altered at 4 hrs post-stimulation. 
Cluster 3 contained 36 (2 %) oligonucleotides that hybridised to RNAs that were 
significantly down-regulated at 1 hr post -stimulation but up regulated at 4 hrs post-
stimulation. Cluster 4 contained 23 (1.3 %) oligonucleotides that hybridised to RNAs 
that were significantly down-regulated at both  1 and 4 hrs post-stimulation. Cluster 5 
contained 16 (1 %) oligonucleotides that hybridised to RNAs that were significantly up-
regulated at both 1 and 4 hrs post-stimulation. Cluster 6 contained 239 (13.6 %) 
oligonucleotides that hybridised to RNAs that were significantly up-regulated at 1 hr 
post-stimulation but down-regulated at 4 hrs post stimulation. Cluster 7 contained 21 
(1.2 %) oligonucleotides that hybridised to RNAs that are not significantly regulated at 1 
hr post-stimulation but significantly up-regulated at 4 hr post-stimulation and Cluster 8 
contained 467 (26.6 %) oligonucleotides that that are not significantly regulated at 1 hr 
post-stimulation but are significantly down-regulated at 4 hr post-stimulation.   
 
Overall these results demonstrate that baculovirus treatment followed by LPS, PMA and 
inomycin stimulation leads to a profound and rapid effect on the gene expression profile 
of IPAM cells. The majority of oligonucleotides hybridised to RNAs that did not 
significantly alter during the conditions tested. The majority of the remaining 
oligonucleotides hybridised to differentially regulated RNAs that were significantly up-
regulated at 1 hr post-stimulation and/or significantly down regulated at 4 hrs post 
stimulation, indicating that strong negative regulation of gene transcription occurs 
following the initial activation phase. A relatively small proportion of the 
oligonucleotides that hybridised to differentially regulated RNAs hybridised to RNAs 
that were differentially regulated at both time points (17 %). Significantly, the majority 
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of these oligonucleotides (13.6 %) hybridised to RNAs  that were up-regulated at 1hr but 
down regulated at 4hrs post-stimulation, consistent with the overall expression profile 
exhibited by these cells. 
 
4.2.2.2 Functional classification of differentially-regulated genes 
 
Annotation was available for 1273 of the 1721 oligonucleotides which hybridised to 
differentially regulated RNAs. A number of genes were targeted by several different 
oligonucleotides, therefore, after editing to remove redundancy, a final list of 971 
annotated genes was produced. A total gene list of differentially regulated genes along 
with their expression profiles can be found at Appendix 2.  
 
Due to the large number of genes identified as differentially regulated by the test 
conditions, the gene lists were analyzed using the Database for Annotation, Visualisation 
and Intergrated Discovery (DAVID) 2008 (Dennis et al., 2003) to identify significantly 
enriched terms associated with biological processes and signaling networks.  Using this 
approach, Gene-GO term enrichment analysis and KEGG pathway analysis was used to 
identify and cluster functionally related genes according to their biological 
processes/molecular function and relevant signaling networks respectively. GO 
annotations, designated by the gene ontology consortium, provide a controlled 
vocabulary to describe the attributes of a gene product in any organism. This is based on 
the concept that a large proportion of the genes involved in core biological functions are 
shared by all eukaryotes. Genes are characterised using three structured vocabularies (or 
ontologies): molecular function, biological process and cellular component (Consortium, 
2006; Harris et al., 2004). KEGG PATHWAY is a knowledge base for the systematic 
analysis of gene functions linking genomic information with higher order functional 
information. It provides graphical information on cellular processes such as metabolism, 
signal transduction and the cell cycle (Kanehisa et al., 2008).  
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Figure 4.8 Overview of the expression profiles of oligos identified as 
hybridising to RNAs differential regulated by Bac-WPRE, PMA, LPS and 
ionomycin treatment. Expression graphs of individual clusters of oligos
exhibiting different expression profiles. The number within each graph 
represents the cluster identifier followed by the number of oligos present 
within this cluster in brackets. The x-axis is centred (y=0) on the y axis and 
represents each biological replicate at 1 and 4 hrs post stimulation. The y 
axis represents the mean expression levels of all the oligos in the cluster 
(log2). Error bars represent the standard deviation of expression within the 
cluster.
C 1hr
1 ( 296) 2 ( 656)
Intercept
3 ( 36) 4 ( 23)
6 ( 239)5 (16)
C 4hr
8 ( 467)7 ( 21)
Biological replicate 1 2 3 1 2 3
1 hr C 4 hr C
1 2 3 1 2 3
1 hr C 4 hr C
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A summary of the results obtained for Gene GO term enrichment analysis is presented in 
Table 4.1. From this Table it can be seen that similar biological themes were represented 
at both 1 and 4 hrs following LPS, PMA and ionomycin treatment. At 1 hr these themes 
were generally associated with up-regulated genes and at 4 hrs with down-regulated 
genes. A summary of genes associated with several of the major biological themes 
identified by GO term analysis, along with their expression profiles is presented in Table 
4.2. 
 
Macrophages are phagocytic cells that act through direct cell to cell contact or through 
the secretion of a wide array of immunoregulatory products. As a consequence of this, a 
considerable amount of energy is devoted to the synthesis and processing of proteins 
with immunomodulatory functions and the molecules involved in their production. 
Overall the most significantly enriched biological themes included; intracellular 
macromolecule transport; chromosomal organisation and biogenesis; intracellular signal 
transduction and genes associated with the regulation of cell proliferation and apoptosis. 
A considerable number of regulated genes were involved in protein biosynthesis, 
ranging from the manipulation of chromatin structure (to allow access of transcription 
factors) to the processing and movement of nanset polypeptide chains through the 
secretary pathway.  Proteins involved in endocytosis, phagocytosis, cell adhesion and 
communication, and immune response genes were also enriched. This is consistent with 
the biological function of monocytic cells. 
 
Immune response genes  
A number of inflammatory response genes were identified as differentially regulated 
following baculovirus, LPS, PMA and ionomycin treatment and included chemokines, 
cytokines, cytokine receptors and interferon inducible proteins. These genes included   
granulocyte macrophage-colony stimulating factor (GM-CSF), IL-1α, IL-6, macrophage 
inflammatory protein MIP-2α and IL- 2 receptor, gamma (IL-2R γ) and interferon 
(alpha, beta and omega) receptor (IFNR1). IFN inducible genes included interferon-
induced protein 44 and guanylate binding protein 2 (GBP-2). 
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Intracellular transport 37 23 6 56 
Intracellular protein transport 29 14  50 
Protein nuclear transport 13   19 
Secretary pathway 7 6  12 
Endocytosis 12 4  3 
Cytoskeleton-dependent transport 4 3  3 
RNA transport 9  3 13 
Chromosomal organisation and biogenesis 31 5  32 
Chromatin and nucleosome assembly 24   26 
Nucleotide biosynthesis process 10 8  15 
Purine 4   8 
RNA 3   6 
Protein biosynthesis     
Amino acid synthesis 7   11 
tRNA synthesis and metabolic process 5   5 
Translation 21   26 
Intracellular signalling cascades 71   66 
Regulation of the cell cycle 34 24 6 52 
Regulation of programmed cell death 22 4 6 30 
Mitosis 9 5  11 
Lipid biosynthetic process 8    
Membrane lipid biosynthesis 5 15   
Fatty acid metabolism  4   
Immune cell differentiation 7   8 
Acute inflammatory response    4 
Cell matrix adhesion 7    
Angiogenesis 5   9 
Wound healing/blood coagulation 3   3 
Regulation of cell migration 5   8 
Cell projection morphogenesis 2  5 7 
     
 
 Table 4.1 Numbers of genes associated with significantly enriched biological 
themes in baculovirus treated IPAM cells at 1 and 4 hrs post LPS, PMA and 
ionomycin treatment. Go term enrichment analysis using DAVID functional annotation 
software (EASE Score p <=0.1) was used to identify biological enriched themes within 
annotated gene lists of differentially regulated genes at both 1 (1 hr S) and 4 hrs (4 hr S) 
post LPS, PMA and ionomycine treatment. The results represent the number of differential 
regulated genes associated with each biological term for the conditions listed. Results 


















A number of genes usually up regulated following either LPS or PMA/ionomycin 
treatment were not found in the final gene list (Appendix 2). These genes included TNF-
α, IFN-α, IL-8 and IL-2. To determine if these genes were present on the porcine 
oligonucleotide array, the gene names were cross referenced with the Pig Genome Oligo 
Set and Extension V1.0 gene list. Oligonucleotide ID’s, were available for TNF-α, IFN-
α and IL-2, however no oligonucleotides specific for IL-8 could be detected. From the 
original data files it was found that all of  the oligonucleotides specific to TNF-α had 
been eliminated prior to analysis due to poor quality data. Oligonucleotides specific for 
IFN-α and IL-2 were present in the final data set, however any changes in their 
expression levels were not considered to be statistically significant using SAM analysis.  
Surprising IL-1α, GM-CSF, IL-2 R γ and  IFNR1  were all d own-regulated at 1 hr 
following LPS, PMA and ionomycin treatment,  whereas the IFN inducible genes were 
up-regulated. This may indicate the targeted inhibition of signalling pathways associated 
with the expression of these genes at 1 hr post-stimulation. The ccaat/enhancer binding 
protein C/EBP-β gene, an important transcriptional activator in the regulation of 
inflammatory response genes such as IL-6 and CD18 antigen, was also down-regulated 
at 1 hr following stimulation. 
 
Signal transduction 
Go-term and KEGG pathway enrichment analysis identified significant enrichment for 
genes associated with the Janus kinase/signal transducers and activators of transcription 
(JAK/STAT), Mitogen Activated Protein Kinase (MAPK) and NF-кB signalling 
pathways across both time points post-stimulation. The MAPK and NF-κB are directly 
activated by LPS (Guha & Mackman, 2001). The JAK-STAT signalling pathway 
regulates the cellular response to cytokines and growth factors and can be activated by 
immediate response genes, such as IFN-α and IL-1-α, which are expressed in response to 
LPS treatment.   
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Several differentially-regulated genes involved in signal transduction are common to a 
number of cellular pathways. For example, phosphatidylinositol 3-kinase (PI3K), AKT, 
IKKB, CaN, and NF-κB, in particular, are associated with T-cell receptor, B cell 
receptor and the Toll-like receptor signalling pathways. This highlights the complexity 
and the considerable cross-talk between signal transduction pathways within the cell.  
 
GO term and KEGG pathway enrichment analysis did not detect a specific enrichment 
for genes associated with calcium signalling. However proteins regulated by NFAT, NF-
κB and CREB, transcription factors activated by calcium mobilisation (Dolmetsch RE, 
et al., 1997) were present in the final gene list and a number of genes directly associated 
with calcium signalling were identified (Table 4.2). These include: Inositol 1,4,5-
trisphosphate receptor type 3, a secondary messenger that mediates the release of 
intracellular calcium from the endoplasmic reticulum membrane; calmodulin 1, which is 
activated through calcium binding and mediates the control of a large number of 
enzymes; the calcium/calmodulin-dependent serine protein kinase 1(CASK 1) and CaN, 
both of which were up-regulated at 1 hr following baculovirus, LPS, PMA and 
ionomycin treatment.  
 
MAPK pathway 
Several proteins associated with the MAPK pathway were regulated by baculovirus, 
LPS, PMA and ionomycin treatment at both time points (Table 4.2). These included 
upstream activators: MAP2K3 which catalyses the phophorylation of  p38; MAP3K2 
which acts upstream of ERK and MAP3K3, which is involved in directly regulates the 
stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase 
(ERK) pathways by activating SEK and MEK1/2 respectively. Down stream targets of 
the MAPK pathway are: c-jun, MAP kinase-activated protein kinase2 (MAPKAPK2) 
and MAPK interacting kinase 1(MKNK1). The c-jun  transcription factor is activated by 
JNK. MAPKAPK2 is phosphorylated by p38 and is known to be involved in many 
cellular processes including stress and inflammatory responses and MAPK interacting 
kinase 1 is activated by p38 and ERK and may play a role in the response to 
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environmental stress. In addition genes encoding negative regulators of MAPK were 
also differentially regulated: dual specific phosphatases DUSP1, DUSP6 and DUSP10. 
These proteins de-phosphorylate activated MAPKs, thus suppresing their activity. 
DUSP1 and DUSP 6 specifically de-phosphorylate ERK and DUSP 10 de-
phosphorylates p38 and JNK.  
 
With the exception of growth arrest and DNA damage protein, GADD45 β, the majority 
of genes associated with this pathway were either up-regulated 1 hr following LPS, 
PMA and ionomycin and down regulated at 4 hrs, or down regulated at 4 hrs alone 
(Table 4.2). Many genes involved in the regulation of this pathway are auto-regulated 
and include transcription factors such as c-Jun and DUSPs. The results indicate a strong 
activation of this pathway 1 hr following treatment followed by a general suppression at 
4 hrs. 
 
NF-κB pathway  
Differentially-regulated genes belonging to the NF-κB signal transduction pathway 
included: IкB kinase beta (IкBKβ) wh ich  is a comp onent of the IκB kin ase complex, 
p50/p105 and p52/100 which are members of the NF-κB family, and IкBα a cellular 
inhibitor of NF-кB. IкBKβ and p50/p 100 were up-regulated at 1 hr following 
stimulation and down-regulated at 4 hrs. p52/100 was down regulated at 4 hrs only and 
IкBα was d own reg ulated  at bo th 1  and  4  hrs. Similarly to the MAPK p athway, the 
transcription of a number genes involved in the NF-κB pathway are NF-κB dependent, 
these include IкBα, p50/p105 and p52/p100. Other NF -κB dependent genes include: IL-
1α, GADD45 β, uPAR and GM-CSF and ICAM (HL Pahl, 1999). Interestingly the 
majority of these genes were found to be down-regulated at 1 hr following baculovirus, 
LPS, PMA and ionomycin treatment. This could indicate targeted suppression of genes 
associated with this pathway at 1 hr following treatment. 
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Overall GO term and KEGG pathway enrichment analysis of the annotated gene lists 
demonstrated that IPAM cells express proteins consistent with the physiological 
processes and immunological signalling pathways which are involved in the 
monocyte/macrophage activation response (Burke B, 2002). However the expression 
profile exhibited by these genes was not typical of LPS, PMA and ionomycin stimulated 
primary blood derived leukocytes (Bjorkbacka et al., 2004; Boldrick et al., 2002; 
Calvano et al., 2005).  
 
4.3 Discussion 
Microarray experiments are expensive and time consuming to carry out, limiting the 
number of conditions that can be investigated in any one experiment. The aim of this 
chapter was to optimise the microarray experimental design and, in addition, 
characterise the effect of gene delivery using baculovirus and subsequent LPS, PMA and 
ionomycin stimulation on IPAM cell gene expression in the absence of A238L gene 
expression. This was a means to enhance interpretation of the effect of A238L on 
activated IPAM gene expression and also to asses the suitability of these cells for 
carrying out investigations into the effects of A238L on host gene transcription. 
3.3.1 Optimisation of the microarray experimental design 
Semi-quantitative RT-PCR was used to identify suitable time points, early in the pro-
inflammatory signalling cascade, that would be suitable for microarray analysis. Using 
this approach a number of early immune response genes, TNF-α, IL-8 and COX-2 were 
shown to be induced 60 min following stimulation. This demonstrates that the IPAM 
cells respond to LPS, PMA and ionomycin stimulation. Notably all of the genes tested 
were expressed at background levels in un-treated IPAM cells, which suggests that 
signalling pathways associated with the expression of these genes are constitutively-
activated in IPAM cells. Two additional LPS response genes were selected to represent 
early and second phase gene induction, IκB-ζ and  IL-6 respectively. Other work has 
demonstrated that IκB-ζ is essential for IL-6 gene expression, thus IκB-ζ expression 
precedes that of IL-6 (Yamamoto et al., 2004). However, this was not found to be the 
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case in IPAM cells. IL-6 gene expression appeared to be slightly raised in stimulated 
cells at 60 and 90 min post-treatment, however there was no observable increase in IκB-
ζ mRNA, and th is remain ed  constant throu g hout the time cou rse.  Prev iou s work  has 
demonstrated that, although IκB-ζ is required for IL-6 gene expression, other factors are 
involved in IκB-ζ mediated gene transduction. IκB-ζ preferentially binds to the NF-κB 
p50 subunit (Yamazaki et al., 2001) and investigations using NF-κB p50 deficient cells 
demonstrated that p50 is required for IκB-ζ induced gene expression (Motoyama et al., 
2005). As IκB-ζ appears to be constitutively expressed within IPAM cells and therefore 
available to participate in IL-6 induced gene expression, it could be that alteration in the 
cellular concentration and or subcellular localisation of NF-κB p50 is responsible for the 
observed increase in IL-6 mRNA as opposed to a direct increase in IκB-ζ mRNA. 
Due to the small number of genes examined in this analysis it was not possible to detect 
a secondary change in the expression profile of IPAM cells for the time points tested (0-
240 Minuets). However several studies examining the global effects of LPS and 
PMA/ionomycin have reported significant changes in gene expression profiles at 4 hrs 
post-stimulation compared to earlier time points supporting the selection of 1 and 4 hrs 
post-stimulation for microarray analysis (Bjorkbacka et al., 2004; Boldrick et al., 2002; 
Calvano et al., 2005).  
 
4.3.2 Microarray analysis of the effect of cell stimulation and baculovirus 
treatment on gene transcription profiles in IPAM cells 
 
Microarray analysis of the gene expression profile of IPAM cells treated with 
baculovirus followed by LPS, PMA and ionomycin stimulation demonstrated both the 
up-regulation and repression of genes at both 1 and 4 hrs following stimulation. The 
overall trend within the data set demonstrated a significant up-regulation of genes at 1 hr 
post-stimulation followed by significant repression 4 hrs post-stimulation. The rapid 
suppression of gene expression as early as 4 hrs following LPS or PMA and ionomycin 
is not consistent with other studies investigating the effect of these compounds on host 
cell gene transcription (Boldrick et al., 2002; Calvano et al., 2005; Feske et al., 2001; 
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Macian et al., 2002). These studes did demonstrate some down-regulation of gene 
expression in response to endotoxin and PMA/ionomycin treatment at early time points 
post-treatment. However, this response is typically accompanied by a significant up-
regulation of other genes, whose expression profiles peaked at 4-9 hrs returning to 
baseline by 24 hrs (Calvano et al., 2005).  
 
Functional analysis of the differentially regulated gene sets identified similar biological 
categories at both 1 and 4 hrs following LPS, PMA and ionomycin treatment. Many of 
these categories were typical of monocyte/macrophage function as phagocytic and active 
secretory cells, demonstrating that IPAM cells can respond appropriately to activation. 
Biological themes included proteins associated with phagocytosis and cell projection 
morphogenesis (indicative of pseudopodia formation), proteins involved in the secretary 
pathway, cell adhesion and migration molecules, immune response genes and genes 
involved in the coagulation and complement pathway. The majority of these categories 
were up regulated at 1 hr followed by down regulation at 4 hrs, indicating a generalised 
non-specific suppression of gene transcription in baculovirus treated cells at 4 hrs 
following LPS, PMA and ionomycin treatment. 
 
Genes involved in signal transduction were also significantly enriched within the 
differentially-regulated gene list and included members of the MAPK, NF-κB and 
JAK/STAT pathways. MAPK and NF-κB signalling pathways are both activated 
through LPS treatment and many genes associated with these pathways are auto-
regulated. These results indicate regulation of these pathways in the treated IPAM cells. 
The majority of MAPK genes were up-regulated at 1 hr and down-regulated at 4 hrs. 
JAK 1 and STAT3, components of the JAK/STAT pathway and a number of 
components of the calcium signalling pathway (CaN, CASK) were also up-regulated at 1 
hr following treatment. In contrast transcription of several genes dependent on NF-κB, 
were down-regulated at 1 hr following stimulation including IкB-α, IL-1α, GADD45 β, 
uPAR, GM-CSF and ICAM (HL Pahl, 1999). This suggests targeted inhibition of genes 
associated with this pathway at 1 hr following cell stimulation.  
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Down-regulation of some immune response genes, in treated compared to un-treated 
IPAM cells, indicates that signalling pathways associated with the expression of these 
genes are constitutively activated in untreated IPAM cells. This result is consistent with 
the RT-PCR results presented in section 4.2.1.2, which showed background levels of 
TNF-α, IL-8, COX-2 and IL-6 in untreated, control IPAM cells.  
 
Overall microarray analysis demonstrated that IPAM cells pre-treated with baculovirus 
demonstrated a marked increase in gene expression at 1 hr following stimulation with 
LPS, PMA and ionomycin, followed by a rapid generalised suppression of gene 
expression at 4 hrs following treatment. Functional analysis of annotated genes also 
suggested targeted inhibition of some NF-kB dependent genes at 1 hr following 
stimulation. 
 
One possible explanation for this atypical response to LPS, PMA and ionomycin 
treatment could be due to pre-treatment of the cells with recombinant baculovirus.  A 
number of studies have reported that treatment of mammalian cells with the live 
baculovirus can stimulate an antiviral effect in mammalian cells. Abe et al., 2003, 
demonstrated that intranasal inoculation with the baculovirus Autographa californica 
nuclear polyhedrosis virus (AcNPV) induced a strong innate immune response in mice 
and that AcNPV conferred protection from a lethal challenge of influenza A and B virus. 
This study also demonstrated that baculovirus induced the secretion of the inflammatory 
cytokines TNF-α, IL-6 and IL-12 in RAW164.7 cells (a murine macrophage cell line). 
Gronowski et al also reported that AcNPV stimulated IFN production in both human and 
mouse cells in vitro and in vivo (Gronowski et al., 1999). Prior exposure of cells to LPS 
induces a transient state of cellular hyporesponsiveness to subsequent LPS stimulation. 
This is known as endotoxin tolerance. This tolerance results in the selective suppression 
of many proinflammatory cytokines including TNF-α, IL-1β, IL-6 and IL-12 (Schade et 
al 1999). Therefore it could be that the failure to up-regulate the expression of 
proinflammatory cytokines, in addition to the rapid suppression of gene transcription 4 
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hrs following stimulation, is due to prior sensitisation of stimulated cells with 
baculovirus.  
 
From the results presented in this chapter it is not clear what mechanisms are responsible 
for the partially unexpected expression profile exhibited by IPAM cells in response to 
baculovirus treatment and LPS, PMA and ionomycin stimulation. It is likely that both 
the mechanism of gene delivery combined with inherent properties of the IPAM cells 
contributed to this response. Nevertheless, the results presented in this chapter have 
allowed the selection of appropriate conditions for the microarray experimental design. 
Overall the genes differentially regulated in IPAM cells following baculovirus treatment 
and LPS, PMA and ionomycin stimulation were consistent with biological processes 
associated with macrophage activation, providing support for the use of these cells to 
investigate the effect of A238L. However some anomalies in the response of these cells 
to LPS, PMA and ionomycin were detected. Prior knowledge of these anomalies provide 
a distinct advantage in interpreting the effects of A238L within these cells.  
In conclusion, the results presented in this chapter demonstrate that IPAM cells treated 
with baculovirus respond rapidly to LPS, PMA and ionomycine, with a significant 
change in gene expression at 1 hr following treatment. The nature of this response and 
expression profile of individual genes changed significantly between 1 and 4 hrs 
following LPS, PMA and ionomycine treatment. Comparison between these results and 
other work investigating the effect of LPS, PMA and ionomycine on primary and 
immortalised cells indicate that IPAM cells treated with baculovirus do not produce a 
typical expression profile in response to these compounds. This could be due to the 
effect of baculovirus treatement prior to stimulation, inherent properties of the IPAM 
cells or a combination of both. The lack of similarity between IPAM cells compared to 
primary monocytes suggests that the results obtained from baculovirus infected IPAM 
cells are not representive of the potential effect of A238L in primary porcine alveolar 
macrophage. Therfore although interpretation of the results presented in chapter 5 as a 
whole to obtain a greater understanding into the mechanism of A238L action is valid, 
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the effect of A238L on the expression of individual IPAM proteins may not be 




Inhibition of host gene expression assessed by expression of the 




The previous chapter describes the optimization of the microarray experimental design 
to investigate the effect of A238L on host macrophage gene transcription at early time 
points following cell activation. In addition it describes the effect of the experimental 
conditions on IPAM cells alone in the absence of A238L gene expression.  
 
The results presented in this chapter describe the effect of A238L on gene transcription 
in these cells, with the aim of providing a greater understanding of the mechanism of 




5.2.1 Microarray data analysis 
 
To examine the effect of A238L on gene transcription changes caused by LPS, PMA and 
ionomycin treatment of IPAM cells gene expression profiles were compared between 
stimulated cells treated either with baculovirus expressing A238L (BacSV5A238L) or 
control baculovirus (BacWPRE) not expressing the A238L gene using a porcine 
oligonucleotide micorarray (Operon). Two time points post-stimulation were examined 
and 3 independent experiments were carried out. Gene expression profiles were 
compared between stimulated IPAM cells treated with test and control baculovirus 
indirectly using a common reference sample. This reference RNA consisted of a pool of 
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RNA from control untreated IPAM cells. The design for this microarray experiment is 
shown in Figure 5.1. Using this approach it was possible to carry out additional analysis 
on the data set to investigate the effect of baculovirus treatment followed by LPS, PMA, 
and ionomycin on IPAM cells (presented in chapter 4).  IPAM cells were treated with 
BacSV5A238L or BacWPRE at an m.o.i. 50. 12 hours following baculovirus treatment 
the cells were stimulation with LPS, PMA and ionomycin. Total RNA was harvested at 
1 and 4 hours post-stimulation of cells for both the test and control samples. To expand 
the amount of RNA harvested and produce enough RNA sample material for all of the 
hybridizations the mRNAs from these samples and the common reference sample were 
amplified to produce antisense RNA. Amplified RNA was then labeled with either Cy3 
or Cy5 dyes respectively and co-hybridised onto the porcine oligonucleotide arrays 
(Operon). A more detailed description of these procedures is presented in Chapter 2 
(section 2.7). Two hybridisations were carried out for each comparison, with the dye 
assignments reversed in the second hybridisation to account for labeling bias between 
dyes. Images of the hybridised arrays were obtained by laser confocal scanning and 
TIGR sofware was then used to normalize the data sets and identify oligonucleotides 
which hybridised to differentially regulated RNAs. Prior to statistical analysis, the total 
data set was filtered to remove poor quality spots and this identified a final data set of 
10146 unique oligonucleotides. 
 
1 and 4 hr data sets were analyzed independently using a two class paired Significant 
Analysis of Microarrays (SAM) analysis (δ = 0.498). The results from this analysis are 
presented in Figuress 5.2 and 5.3. At 1 hr post-stimulation a total of 214 (2 %) unique 
oligonucleotides were identified as hybridizing to RNAs that were significantly 
differentially regulated by A238L gene expression; 19.98 of these targets were estimated 
to be falsely significant (FDR 9.34 %). Only 2 of these targets hybridized to RNAs that 
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Figure 5.1 Schematic representation of the microarray experimental 
design used investigate the effect of A238L on stimulated IPAM cells.
Panel A) Experimental procedure: IPAM cells were infected with Bac-
SV5A238L (A238L) or Bac-WPRE (control) at an moi 50. 12 hours following 
baculovirus treatment the cells were stimulated with LPS (100µg/ml), PMA 
(100 nM) and Ionomycin (4 µM). 1 hr (T1) and 4 hrs (T4) following 
stimulation total RNA was harvested, amplified and labeled with either Cy3 or 
Cy5 fluoresent dyes. The horizontal arrow represents the time line post 
baculovirus treatment. Panel B) Microarray experimental design. Test and 
control samples were compared indirectly against a common reference pool 
of un-stimulation IPAM RNA. Amplified mRNA from each sample and the 
common reference was labeled with either Cy3 or Cy5 fluoresent dyes. Each 
sample was then co-hybridised onto a separate porcine oligo arrays (operon) 
against the common reference sample in the opposite channel. Three 
biological replicates were carried out for each experimental condition, with a 




down-regulated (see Figure 5.2). At 4hr post-stimulation 89 (1 %) of targets were 
identified as differentially regulated, 20.35 of these were estimated to be falsely 
significant (FDR 22.86 %) (Figure 5.3). All of these oligonucleotides were shown to 
hybridise to RNAs that were significantly down-regulated. It is notable that the number 
of genes identified as differentially regulated at 4 hrs is less than half the number at 1 hr. 
In addition, it is estimated that approximately 23 % of these genes may be falsely 
significant as opposed to only around 10 % at 1 hr post stimulation.  It is therefore 
possible that the reduced number of genes identified as differentially regulated by 
A238L at 4 hrs is a result of high background present on the microarray slides at this 
time point, rather than of biological significance. 
 
To examine the effect of A238L on baculovirus, LPS, PMA and ionomycin treated 
IPAM cells, across both time points, the lists of oligonucleotides identified as 
differentially regulated between BacA238L and BacWPRE treated IPAM cells at 1 and 
4 hrs following LPS, PMA and ionomycin treatment were combined. This resulted in a 
final list of 294 unique oligonucleotides that hybridized to differentially regulated RNAs 
at either or both 1 and 4 hrs post-stimulation. 182 unique oligonucleotides hybridized to 
RNAs that were differentially regulated at 1 hr only, 25 to RNAs that were differentially 
regulated at both 1 and 4 hrs post-stimulation and 62 to RNAs that were differentially 
regulated at 4 hrs only. These results are presented as a Venn diagram in Figure 5.4. As 
stated previously, with the exception of 2 oligonucleotides which hybridized to 
differentially regulated RNAs at 1 hr post-stimulation, all of the remaining 
oligonucleotides hybridized to RNAs that were down-regulated in cells expressing 
A238L. Overall the number of oligonucleotides differentially regulated by A238L is 
relatively small, suggesting a specific targeted effect on host macrophage gene 
transcription, rather than generalized shut-off of host gene transcription. This is 
consistent with the predicted function of A238L as an inhibitor of transcription 









5.2.2 Functional classification of differentially-regulated genes 
 
Annotation was available for 144 of the 294 oligonucleotides that hybridised to 
differentially regulated RNA. This annotation was obtained from the Pig Genome Oligo 
Set and Extension V1.0 gene list last updated in 2004 (OMAD Release: 04/13/04). All 
of the probes present in this array were designed from information present in The 
Institute of Genome Research (TIGR) Gene Index Database SsGI Release 5.0 
(http://www.tigr.org/tdb/tgi/ssgi). The majority of the oligonucleotides were designed 
from sequences with a hit to a known human, mouse, or pig gene transcript (10,665 out 
of 13297). However a proportion of the genes (2632 out of 13297) were designed from 
tentative consensus sequences (TC’s) which represented mRNA transcripts without 
homology to other known genes. Therefore, unlike similar mouse and human arrays, 
there is a significant lack of annotation available for many of the individual 
oligonucleotides spotted onto the porcine array. Annotation was available for less than 
half of the unique oligonucleotide ID’s found to hybridise to RNAs differentially 
regulated by A238L, therefore many genes of interest were potentially excluded from 
the final data set. After editing to remove redundancy between genes targeted by a 
number of different oligonucleotides, a final list of 137 annotated genes was produced. 
This list included a large number of genes which have not previously been shown to be 
regulated by A238L expression.  
 
Several genes, which have been shown previously to be down-regulated by A238L gene 
expression, were not identified as differentially-regulated in this analysis. These genes 
included TNF-α, IL-8, iNOS, COX-2 and IFN-α (Granja et al., 2006a; Granja et al., 
2004a; Granja et al., 2008a; Granja et al., 2006c; Powell et al., 1996). To determine if 
these genes were present on the porcine oligonucleotide array, the gene names were 
cross referenced with the Pig Genome Oligo Set and Extension V1.0 gene list. 
Oligonucleotide ID’s, were available for TNF-α, IFN-α and iNOS, however no 
oligonucleotides specific for COX-2 and IL-8 could be detected. From the original data 
files it was found that all of the oligonucleotides specific to TNF-α had been eliminated 
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prior to analysis due to poor quality data. Oligos specific for IFN-α and iNOS were 
present in the final data set, and although down-regulation of these genes was observed 
in cells expressing A238L this was not found to be statistically significant using SAM 
analysis.  
 
To assist in the functional characterization of genes identified as differentially- regulated 
by A238L, gene GO term enrichment analysis was used to highlight the most relevant 
biological classifications associated with this gene list (Harris et al., 2004). The DAVID 
functional annotation tool was used to carry out this analysis and also to identify any 
clusters of genes common to cell signaling networks defined using KEGG pathways 
(Kanehisa et al., 2008). A detailed description of these terms along with the DAVID 
software is presented in chapter 4. Using this approach several functionally-related 
classes of genes were identified. Genes not clustered using this method were manually 
placed into functionally related categories based on their GO-term annotation. The 
results from this analysis are presented in Tabless 5.1, 5.2, 5.3 and 5.4. Table 5.1 shows 
a summary of the main biological themes along with the number of genes associated 
with each category. Tables 5.2, 5.3 and 5.4 contain a list of the annotated genes down-
regulated by A238L along with there expression profiles. These genes are clustered in 
Table 5.1 according to their most relevant biological category. Table 5.2 includes genes 
which were significantly regulated at 1 hr post-stimulation only. Table 5.3 includes 
genes that are regulated by A238L at both 1 and 4 hrs post-stimulation and Table 5. 4 
shows genes down-regulated by A238L at 4 hrs only. From comparison of Tables 5.2, 
5.3 and 5.4 with data presented in Chapter 4, it can be seen that a large proportion of 
genes regulated by A238L were not shown to be up or down-regulated by control 
baculovirus treatment and cell stimulation. Only 25 of the 137 annotated genes down 
regulated by A38L were significantly regulated in control baculovirus treated and 
stimulated cells. This demonstrates that the majority of genes regulated by A238L are 
constitutively expressed in unstimulated IPAM cells. Tables 5.2, 5.3 and 5. 4 also show 
that the relative difference in gene expression between test and control samples varied 
from Log2 0.48 to Log2 2.23, which is equivalent to a 1.4 – 4.7 fold change in gene 
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expression. This is similar to the range in expression level of differentially-regulated 
genes observed between un-stimulated and stimulated IPAM cells as shown in chapter 4.  
 
Overall the majority of genes differentially regulated by A238L were those that are 
rapidly induced in response to stimulation or physiological stress (such as immune 
activation or DNA damage). From Table 5.1 it can be seen that the genes down-
regulated by A238L cover a diverse range of biological categories. A significant number 
of genes down-regulated by A238L were associated with the immune response, response 
to stimulation and apoptosis. Proteins involved in intracellular signal transduction, 
transcription factors and cell surface/secreted proteins were also well represented. Other 
groups included genes involved in RNA processing, intracellular transport and amino 
acid metabolism.  
 
Down-regulated immune response genes included the cytokines IL-1-α, GM-CSF, 
Monocyte chemotractant protein 1 (MCP 1), CD83 which is involved in antigen 
presentation, four acute phase genes involved in the coagulation cascade (urokinase 
plasminogen activator receptor (uPAR), alpha – 2-macroglobulin, coagulation factor II 
receptor-like 1 and protein S alpha) and nuclear localized factor 2 (NLF2). NLF2 
belongs to a novel family of nuclear factors which are rapidly induced by pro-
inflammatory cytokines (Warton et al., 2004). Interferon-inducible genes associated 
with the JAK/STAT pathway were also identified: Interferon-induced protein 44-like 
(IFI44L), IFN regulatory factor 1, Interferon-induced protein with tetratricopeptide 
repeats 1 and PML-1. PML-1 is clustered with genes involved in apoptosis (Der et al., 
1998). None of these genes have previously been shown to be regulated by A238L gene 
expression. The expression profile of these genes and also the A238L regulated genes 
involved in apoptosis (disscused below) are presented in Table 5.5. 
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GO: Biological Response Time post stimulation
Table 5.1 Functional Classes of A238L down regulated genes. Go term 
enrichment analysis using DAVID functional annotation software was used 
to identify biological enriched themes within annotated gene list. Genes not 
clustered using this method were manually placed into categories based on 
their GO-term annotation. The results represent the number of differential 




        
        
        
Accession no. Description       
        
        
A238L up regulated genes       
        
Extracellular matrix protein       
NM_080645 collagen, type XII, alpha 1 (COL12A1)   -0.78  (-1.14, -0.41) 0.26 (-0.14, 0.66) -1.04 
        
A238L down regulated genes       
        
Immune response genes       
177872 Alpha-2-macroglobulin   1.34 (1.21, 1.46) 0.60  (0.52, 0.68) 0.74 
NM_006820 Interferon-induced protein 44-like (IFI44L)   0.92  (0.77, 1.06) 0.16 (-0.02, 0.34) 0.76 
P09914 Interferon-induced protein with tetratricopeptide repeats 1 (NS) 0.01  (-0.47, 0.49) -1.56 (-1.97, -1.15) 1.57 
Q08353 I-kappa-B-alpha   -1.04  (-1.14, -0.94) -2.07 (-2.47, -1.68) 1.03 
Q29118 Granulocyte-macrophage colony-stimulating factor   -1.21  (-1.57, -0.86) -2.00 (-2.37, -1.63) 0.79 
P18430 Interleukin-1 alpha precursor    -0.57  (-1.86, 0.72) -2.22 (-2.82, -1.61) 1.65 
NM_001993 Homo sapiens coagulation factor III  (NS) -0.42  (-0.60, -0.25) -1.54 (-2.10, -0.98) 1.12 
Q01151 CD83 antigen precursor    -0.47  (-0.98, 0.03) -1.12 (-1.65, -0.59) 0.65 
Response to stimulus       
NM_014685 Homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member 1 (HERPUD1) 
(NS) 0.75  (0.62, 0.89) -0.7  (-1.20, -0.19) 0.82 
NM_005347 Heat shock protein 72kDa    0.73  (0.60, 0.87) -0.38  (-0.48, -0.29)  1.11 
11559490 VDUP1 (NS) -0.09  (-0.35, 0.16) -0.61 (-0.93, -0.29) 0.52 
P47974 TIS11 primary response gene (NS) 0.28 (0.16, 0.40) -0.56 (-0.77, -0.35) 0.84 
13177685 Immediate early protein (NS) -0.40  (-0.72, -0.07) -1.46 (-1.73, -1.19) 1.06 
NM_001007595 Nuclear localized factor 2 (NLF2) (NS) -0.18  (-0.50, 0.14) -1.23 (-1.55, -0.92) 1.05 
Apoptosis        
NM_033240 Promyelocytic leukemia (PML) (NS) 0.33  (-0.16, 0.82) -0.75  (-0.93, -0.56) 1.08 
BC031549 CDC-like kinase 1   0.90  (0.74, 1.07) 0.14 (-0.33, 0.62) 0.76 
NM_002312 DNA ligase IV (NS) 0.84  (0.65, 1.03) 0.26 (-0.25, 0.78) 0.58 
O75293 Growth arrest and DNA-damage-inducible protein GADD45 
beta  
  -0.78  (-0.81, -0.75) -1.39 (-1.48, -1.30) 0.61 
P24522 Growth arrest and DNA-damage-inducible protein GADD45 
alpha  
(NS) -0.16  (-0.34, 0.01) -0.89 (-1.19, -0.60) 0.73 
NM_030952 SNF1-like kinase kinase (NUAK2) (NS) 0.26 (0.03, 0.50) -0.70 (-1.25, -0.15) 0.96 
Cell cycle rgulation       
Q9UQL6 Histone deacetylase 5   0.61  (0.49, 0.74) -0.08  (-0.66, 0.51) 0.69 
NM_005611 Retinoblastoma-like 2 (p130) (NS) 0.43 (0.13, 0.73) -0.73  (-1.10, -0.36) 1.16 
3075509 Serum-inducible kinase (Snk/Plk2)   0.59 (0.37, 0.81) -0.05  (-0.24, 0.15) 0.64 
P21274 Bone morphogenetic protein 2 precursor (BMP-2)   0.41 (0.27, 0.55) -0.47  (-0.76, -0.17)  0.88 
U14603 Protein-tyrosine phosphatase type IV   0.65 (0.18, 1.12) -0.06  (-0.23, 0.11) 0.71 
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Accession Description       
        
A41236 Placental growth factor  (NS) -0.06  (-0.61, 0.49) -0.87 (-1.74, 0.00) 0.81 
Intracellular signal transduction       
NM_018014 B-cell CLL/lymphoma 11A  (NS) -0.01  (-0.09, 0.07) -0.63 (-1.02, -0.24) 0.62 
NM_001894 Casein kinase 1, epsilon  (NS) -0.02  (-0.16, 0.13) -0.68 (-1.07, -0.29) 0.66 
AB125644 PKB/Akt-binding protein (NS) 0.03  (-0.15, 0.21) -0.46 (-0.61, -0.31) 0.49 
P01121 Transforming protein RhoB (H6) (NS) 0.17  (-0.12, 0.47) -2.01 (-2.68, -1.35) 2.18 
BC003562 Dual specificity phosphatase 6 (DUSP6)   0.49  (0.34, 0.65) -0.36  (-0.69, -0.02) 0.85 
BC006823 Protein phosphatase 2 (regulatory subunit B) (NS) 0.30  (0.15, 0.45) -0.26 (-0.43, -0.09) 0.56 
NP_275869 Rho-kinase beta (NS) -0.11  (-0.40, 0.17) -0.70 (-0.94, -0.45) 0.59 
23386514 Ras SF1  (NS) -0.18  (-0.24, -0.13) -0.76 (-0.97, -0.54) 0.58 
NM_018201 TBC1 domain family, member 13  (NS) 0.31  (0.28, 0.34) -0.57 (-1.40, 0.27) 0.88 
Transcription factors / transcription regulation       
NM_012446 Single-stranded DNA-binding protein 2 (NS) 0.18 (0.11, 0.26) -0.36 (-0.56, -0.16) 0.54 
O14896 Interferon regulatory factor 6 (IRF-6) (NS) 0.00  (-0.07, 0.08) -0.64 (-0.77, -0.51) 0.64 
O18896 Transcription factor SOX-9 (NS) -0.05  (-0.65, 0.55) -1.10 (-2.31, 0.12)  1.05 
Q01580 Heparin-binding EGF-like growth factor    -0.5  (-0.72, -0.27) -1.43 (-1.67, -1.19) 0.93 
M92844 Zinc finger transcriptional regulator (GOS24) (NS) -0.35  (-0.55, -0.14) -1.40 (-1.74, -1.06) 1.05 
P17275 Transcription factor jun-B (NS) -0.31  (-0.48, -0.14) -1.22 (-1.71, -0.73) 0.91 
NP_277037 POU domain region; homolog of mouse brn-3 (Oct-1) (NS) 0.62  (0.24, 1.01) -0.08  (-0.90, 0.74)  0.70 
4581531 c-Fos protein   -0.59  (-1.10, -0.08) -2.82 (-3.57, -2.06) 2.23 
P56432 Proto-oncogene c-jun (NS) -0.23  (-0.59, 0.13) -1.61 (-2.07, -1.15) 1.38 
28798059 Interferon regulatory factor 1 (NS) -0.11  (-0.39, 0.17) -1.02 (-1.35, -0.70) 0.91 
Q29031 c-myc (NS) 0.81  (0.70, 0.92) 0.29 (0.21, 0.38) 0.52 
AF454942  HMG-box transcription factor BBX  (NS) 0.23  (0.07, 0.39) -0.36 (-0.86, 0.14) 0.59 
NM_004089 TSC22 domain family, member 3  (NS) 0.29 (-0.06, 0.64) -0.63 (-1.34, 0.08) 0.92 
Cell surface/secreated proteins       
21954715 Matrix Gla protein (NS?) 1.37 (1.10, 1.64) 0.52 (0.34, 0.70) 0.85 
BC015028 Nephroblastoma overexpressed gene  (NS?) 1.15 (1.08, 1.22) 0.41 (0.23, 0.58) 0.74 
1890128 Folate binding protein  (NS) 1.28 (0.91, 1.65) 0.48  (0.15, 0.81) 0.80 
4097833 Connective tissue growth factor (CTGF)   0.62 (0.44, 0.81) -0.53  (-0.75, -0.31) 1.15 
O00622 CYR61 protein precursor  (NS) -0.28  (-0.37, -0.18) -1.60 (-1.86, -1.35) 1.32 
904141 Protein S (NS) 0.51 (0.43, 0.60) -0.03  (-0.17, 0.11) 0.54 
Q92692 CD112 antigen   0.67  (0.48, 0.85) 0.08  (-0.22, 0.38) 0.59 
P17690 Beta-2-glycoprotein I precursor (Apolipoprotein H)    0.70  (0.52, 0.89) 0.01  (-0.15, 0.18) 0.69 
Q99574 Neuroserpin precursor (Protease inhibitor 12) (NS) 0.74 (0.42, 1.06) 0.26 (-0.13, 0.64) 0.48 
Extracellular matrix protein       
NM_000093 collagen, type V, alpha 1 (COL5A1) (NS) 0.45  (0.24, 0.65) -0.24  (-0.47, 0.00) 0.69 
NM_000055 Butyrylcholinesterase  (NS) 0.02 (-0.15, 0.18) -0.53 (-0.89, -0.17) 0.55 
NM_007037 ADAM metallopeptidase motif  8 (ADAMTS8) (NS) -0.17  (-0.90, 0.56) -0.94 (-2.17, 0.29) 0.77 
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Accession Description       
        
Cell migration        
NM_002356 Myristoylated alanine-rich C-kinase substrate    -0.69  (-0.84, -0.54) -1.32 (-1.54, -1.09) 0.63 
2467300 Phosphatidic acid phosphatase 2b (NS) 0.38  (-0.39, 1.15) -0.43  (-0.80, -0.06) 0.81 
RNA processing       
NM_021133 Ribonuclease L (2',5'-oligoisoadenylate synthetase-
dependent) (RNASEL) 
(NS) 0.30  (0.11, 0.50) -0.48 (-1.19, 0.22) 0.78 
NM_001533 Heterogeneous nuclear ribonucleoprotein L (HNRPL) (NS) 0.31  (0.14, 0.49) -0.25 (-0.34, -0.17) 0.56 
NM_020307 Cyclin L1 (CCNL1) (NS) 0.18 (0.03, 0.33) -0.51 (-0.77, -0.24) 0.69 
O94913 Pre-mRNA cleavage complex II protein Pcf11 (NS) 0.22  (-0.10, 0.55) -0.88 (-1.27, -0.48) 1.10 
NM_018146 RNA methyltransferase like 1 (RNMTL1) (NS) 0.26 (0.10, 0.42) -0.37 (-0.54, -0.19) 0.63 
Protein metabolism       
AY496012 Propionyl-coA carboxylase B (PCCB)  (NS) -0.22  (-0.45, 0.01) -0.93 (-1.55, -0.31) 0.71 
JE0172 Ribonuclease T2 (NS) 0.39  (0.10, 0.68) -0.23  (-0.66, 0.20) 0.62 
S52084 Ribosomal protein L22 (NS) 0.32 (0.12, 0.52) -0.24 (-0.36, -0.11) 0.56 
Vesicle mediated / protein transport       
BC007458 Karyopherin alpha 4 (Import alpha 3) (NS) 0.68  (0.30, 1.06) 0.12 (-0.22, 0.46) 0.56 
11321325 Lin-7b  (NS) 0.13 (-0.65, 0.91) -0.88 (-1.40, -0.35) 1.01 
Q9NP90 Ras-related protein Rab-9B (Rab-9L) (NS) 0.04  (-1.48, 1.57) -0.75 (-2.73, 1.24) 0.79 
Macromolecule transport       
NM_005502 ATP-binding cassette, sub-family A, member 1    0.54 (0.43, 0.65) -0.23  (-0.42, -0.05) 0.77 
Intracellular transport       
NM_144996  ADP-ribosylation factor-like 2 protein-like protein    0.55 (0.36, 0.74) -0.05  (-0.38, 0.28) 0.60 
Ion 
Transporter 
       
9501803 Potassium channel interacting protein 1 (NS) 0.17 (-0.09, 0.44) -0.64 (-1.17, -0.11) 0.81 
AJ619991 Small calcium-binding mitochondrial carrier 2 (NS) -0.18  (-0.40, 0.03) -0.95 (-1.04, -0.86) 0.77 
Q96NB2 Sideroflexin 2  (NS) 0.67 (-0.68, 2.01)* -0.78  (-1.37, -0.18) 1.45 
Virus protein        
14530213 Gag protein[Porcine endogenous retrovirus M16]   0.46  (0.34, 0.65) -0.17  (-0.33, -0.01) 0.63 
Unknown function / Hypothetic proteins       
BC009624 Myeloid/lymphoid or mixed-lineage leukemia  (NS) -0.11  (-0.54, 0.32) -0.83 (-1.03, -0.63) 0.72 
NM_017948 Nucleolar protein 8 (NOL8) (NS) 0.20 (-0.11, 0.52) -0.39 (-0.81, 0.04) 0.59 
BC044777 Thioredoxin domain containing 13 (NS) 0.71 (0.32, 1.09) 0.19 (-0.10, 0.48) 0.52 
15128489 Vascular endothelial cell specific protein (NS) 0.57  (0.34, 0.80) -0.34  (-0.91, 0.23) 0.91 
DQ323403 Paternally expressed 10 (Peg10)    1.10 (0.82, 1.39) 0.50  (0.11, 0.90) 0.60 
NM_030938 Transmembrane protein 49  (NS) 0.26 (0.20, 0.33) -0.47 (-0.74, -0.21) 0.73 
AF308819 Nuclear receptor-interacting factor  (NS) 0.29  (0.14, 0.43) -0.20 (-0.40, 0.00) 0.49 
P53804 Tetratricopeptide repeat protein 3 (NS) 0.55 (0.46, 0.64) 0.05  (-0.20, 0.29) 0.50 
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Table 5.2 IPAM cells treated with either recombinant baculovirus expressing the 
A238L gene (Test) or control baculovirus (Control), were stimulated with LPS 
(100µg/ml). PMA (100 nM) and Ionomycine (4 µM). Total RNA was harvested at 
both 1 and 4 hrs post stimulation. mRNA was then amplified and labelled with 
either Cy3 or Cy5 dyes. Samples from control and test treatment conditions 
were hybridised to separate arrays with a common reference sample in the 
second channel. Data sets were analysed using TIGR software and genes 
differentially regulated by A238L were identified using a using a two class paired 
Significant Analysis of Microarrays (SAM) analysis ( δ = 0.498). Annotated 
genes that are regulated by A238L at one hour post stimulation only are 
presented in this Table. The data presented is the log ratio of the experimental 
sample to the common reference. Mean values from 3 individual experiments 
are followed by the 95% confidence interval within brackets. The difference 
between these two values is presented for both 1 and 4 hrs as a log ratio (logs 
are taken to base 2, so a value of 1 represents a 2-fold change in gene 
expression between the test and control sample). Genes that had not previously 
been shown to be significantly up or down regulated by treatment with LPS, 
PMA and ionomycine (Chapter 4, Tables 1, 2 and 3), are indicated by the 
presence of the letters NS (Not Stimulated) in brackets. Accession No. are taken 













Genes involved in mediating programmed cell death in response to cellular stress, 
including DNA damage, were also shown to be down-regulated by A238L. This group 
contained both pro and anti-apoptotic genes. GADD45beta, SNF1-like kinase kinase 
(NUAK2) and baculoviral IAP repeat-containing 3(BIRC3)  are all NF-κB regulated 
anti-apoptotic proteins (Legembre et al., 2004; Wang et al., 1998; Zhang et al., 2006a), 
whereas  GADD45 alpha, Promyeloytic Leukemia (PML-1) and Caspase 3 are pro-
apoptotic. Unlike A238L regulated anti-apoptotic genes, the regulation of these pro-
apoptotic genes is associated with a number of different transcription factors. C-jun is 
one of the transcription factors involved in the transcriptional activation of GADD45 α, 
STAT 1 and IFR 1 are involved in transcriptional activation of caspase 3 expression and  
IFN regulatory factor 3 induces PML transcription (Chen et al., 2001a; Earnshaw et al., 
1999; Kim et al., 2007).  
 
Proportionally (36/137) the largest number of genes regulated by A238L were involved 
in intracellular signal transduction and transcription (Table 5.1). These categories 
included a significant number of genes directly involved in regulating the NF-кB and the 
MAPK signaling cascade. The expression profile of selected genes belonging to these 
categories is presented in Table 5.6. These genes are disscussed in more detail below. 
 
PML, IκB-α, Programmed cell death 11 protein and B cell lymphoma/leukemia 10 all 
target NF-κB regulated transcription. Programmed cell death 11 protein and Bcl10 both 
positively regulate the IKK leading to the phosphorylation and subsequent degradation 
of IκB-α, thereby allowing NF-κB to translocate to the nucleus and initiate gene 
transcription (Dennis et al., 2003; Yeh et al., 2006). In contrast IκB-α binds to and 
inhibits the activity of the p50/p65 NF-kB heterodimer retaining it in a predominantly 
cytoplasmic location. B cell lymphoma/leukemia 10 and IκB-α are both up-regulated by 
NF-κB, however Bcl10 requires additional modification to be functionally active 
(Carlotti et al., 2000; Yeh et al., 2006). IκB α provides a negative feedback mechanism  
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 for this pathway and prevents the uncontrolled transcription of NF-κB-regulated genes. 
Inhibition of NF-κB activation would be expected to result in down-regulation of genes 
that are activated by NF-κB. Other down-regulated genes involved in suppression of NF-
κB mediated gene transcription are TSC22D3 (GILZ), a transcription factor regulator 
involved in the anti-inflammatory effects of IL-10 and glucocorticoids in macrophages 
and the pro-apoptotic protein PML. Both of these proteins have been shown to bind to 
the p65 subunit of NF-κB suppressing NF-κB -mediated gene transcription (Berrebi et 
al., 2003; Wu et al., 2003). PML is thought to induce apoptosis through repression of the 
NF-κB survival pathway, by direct interaction and inhibition of Rel A/p65. Unlike IκBα 
these proteins are not induced by NF-κB. 
 
A significant number of genes involved in regulating the Mitogen Activated Protein 
Kinase (MAPK) signaling pathway were also differentially regulated by A238L as 
shown in Tablesss 5.2, 5.3 and 5.4. In addition to the GO-term analysis, KEGG pathway 
enrichment analysis also identified significant enrichment for genes associated with the 
MAPK signalling pathway. This pathway is involved in regulating cell cycle 
progression, differentiation and programmed cell death. The MAPK signaling pathway 
comprises of a 3 component protein cascade: MAP kinase, kinase, kinase (MAP3K), 
which phosphorylates and activates a dual specific protein kinase (MAP2K) which in 
turn activates a MAP Kinase.  Once activated MAPKs phosphorylate numerous 
substrate proteins including transcription factors and phospholipases. Three major 
MAPK pathways that have been identified in mammals: MAPK/ERK, SAPK/JNK and 
p38/MAPK. A238L regulated genes are associated with the MAPK/ERK, SAPK/JNK 
and p38/MAPK pathways, all three of which are involved in transcriptional activation of 
genes involved in the innate immune response (Dong et al., 2002). A238L regulated 
genes include activators, inhibitors and downstream targets of ERK, JNK and MAPK. 
Figure 5.5 represents a simplified overview of these three MAPK pathways and their 























Figure 5.5 Schematic representation of the MAP Kinase signaling cascade This 
pathway consists of a 3 component protein cascade. Upstream activators, including 
ligation of the TLR and cytokine receptors, lead to the phophoralation and activation of 
MAP kinase, kinase, kinase (MAPKKK), which phosphorylates and activates a dual 
specific protein kinase (MAPKK) which in turn activates a MAP Kinase (MAPK).  Once 
activated MAPK’s phosphorylate numerous substrate proteins including transcription 
factors leading to gene transcription. 3 major MAPK pathways are represented: 
extracellular signal-regulated kinase (ERK), c-jun NH2-terminal kinase (JNK) and p38. 
These pathways are auto-regulated by dual-specific phosphatases (DUSP) which 
dephosphorylate and inactivated MAPK providing a critical negative feedback 
mechanism. Arrows represent direct interaction and activation of the target protein and 
blunt ended lines represent direct inhibition. A238L down regulated proteins are 
identified by coloured oblongs: genes down regulated at 1 hr only are red, 1 and 4 hrs
are orange and genes down regulated at 4 hrs only are grey. Transcription of all of the 
A238L regulated genes is subject to auto-regulation of the MAPK signaling cascades. 
ATF 2, activating transcription factor 2; ELK 1, ets-like protein 1; MEF-2C, myocyte
enhancer factor 2C. Adapted from Salojin et al 2007.












The activation of the mitogen-activated protein kinases, ERK, JNK and p38 is regulated 
through the reversible, dual phosphorylation of threonine and tyrosine residues within a 
conserved Thr-X-Tyr motif. The phosphorylation status of these enzymes is altered 
through the activity of Mitogen Activated Protein Kinase Kinases (MAP2K) and a 
family of dual-specificity tyrosine phosphatases (DUSP) (also known as MAPK 
phosphatases (MKP)). These enzymes activate and suppress the activity of MAPK 
signalling pathways respectively. The expression of three DUSP genes was down-
regulated by A238L: DUSP1 (MKP-1), DUSP6 (MKP-3) and DUSP10 (MKP-5). These 
proteins are important negative-feedback regulators of MAPK signal transduction. 
DUSP6 gene transcription is dependent on ERK activation; following expression, 
DUSP6 dephosphorylates ERK inhibiting its activity (Ekerot et al., 2008; Reffas & 
Schlegel, 2000). DUSP 10 binds to and inactivates p38 and SAPK/JNK and DUSP1 
plays a critical role in the negative regulation of p38 MAPK and JNK in response to 
stress to promote cell survival (Wadgaonkar et al., 2004; Wu & Bennett, 2005). DUSP 1 
and DUSP10 gene expression is dependent on ATF 2, which is phosphorylated and  
activated by JNK (Teng et al., 2007). The transcription factors AP1 and CREB have also 
been implicated in DUSP1 gene expression (Furst et al., 2008). One activator of JNK, 
MAPKK7, was also down-regulated by A238L (Tournier et al., 2001). 
 
Several transcription factors which are activated by MAPK, and were shown to be 
down-regulated by A238L, are also subject to feedback regulation (c-Jun, c-fos and 
JunB). ERK activation leads to the rapid and transient induction of c-fos mRNA 
transcription by acting on the transcription factors constitutively bound to the c-fos 
promoter (Janknecht & Hunter, 1997). ERK then phosphorylates newly synthesised c-
fos increasing its transcriptional activity (Murphy et al., 2002). This dual mechanism of 
control is also involved in the control of c-jun by JNKs. The c-jun promoter contains 
several c-jun sites, therefore phosphorylation of c-jun by JNK enhances its 
transcriptional activity leading to an increase in its expression. c-jun is also involved in 
the transcription of GADD45α. This protein activates MKK4, an upstream kinase of 
JNK (Zhang et al., 2006a). GADD45 beta and HSP72, also regulate MAPK signal 
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transduction, however these genes function by blocking JNK activity. GADD45 beta 
associates with the JNK N-terminal kinase MKK7, inhibiting its catalytic activity (Papa 
et al., 2007) and HSP72 binds directly to JNK, blocking its activity, (Park et al., 2001). 
HSP72 has also been implicated in suppressing ERK activation by protecting DUSP and 
suppressing MEK1/2 activity (Yaglom et al., 2003). 
 
Nearly all of the biological categories described above contain genes with directly 
opposing function. In some cases the explanation for this is clear since down-regulation 
of activators of transcription is predicted to also down-regulate targets for these factors, 
including negative feedback regulators of these pathways.  The ability of A238L to 
down-regulate so many genes with opposing functions is most likely to be the result of 
A238L targeting the activity of one or several common features involved in regulating 
the transcription of these genes.  
 
Overall the regulation of genes suppressed by A238L was associated with several 
different signal transduction pathways and transcription factors. Genes induced by NF-
κB, MAPK and JAK/STAT pathways are all present in Tablesss 5.2, 5.3 and 5.4. A large 
number of NF-κB dependent genes were present including IL-1α, GADD45 β, NF2, 
NUAK2, IκBα, coagulation factor 3 and uPAR (Monaco et al., 2004; Warton et al., 
2004). NFAT dependent genes, regulated through CaN activation, were also identified 
within the gene lists and include MKP-1, GM-CSF and EGR-2 (Rao et al., 1997). 
Several other transcription factors are involved in the transcription of genes down-
regulated by A238L. These transcription factors are listed below with the A238L-
regulated genes shown in brackets: STAT1 (IRF-1, caspase 3), CREB, (Heparin-binding 
EGF-like growth factor (HERPUD1), Cyr61, GADD45a, DUSP 1, JunB) (Abramovitch 
et al., 2004), c-Jun (Alpha-2-macroglobulin, c-jun, GADD45a, DUSP 1 and DUSP 10), 
STAT 3 (Alpha-2-macroglobulin ), ATF2 (DUSP1, DUSP 10) and IRF3 (PML). The 
transcription of many of the A238L regulated genes can be associated with more than 
one transcription factor. For example the expression of GM-CSF is dependent on 
cooperative binding between NFAT and the AP-1 heterodimer, Fos-Jun. 
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The ability of A238L to down-regulate NF-κB and NFAT dependent gene expression is 
not unexpected and has been described previously in Chapter 1. However the ability of 
A238L to regulate so many genes associated with such a diverse range of transcription 
factors has not previously been reported. Interestingly all of the transcription factors 
described above have been shown to interact with the transcriptional co-activators 
CBP/P300 (Garcia-Rodriguez & Rao, 1998; Janknecht & Hunter, 1996; Yoneyama et 
al., 1998). This identifies a common link between these factors, and indicates that 
A238L may target CBP/P300 to inhibit gene transcription. This observation supports 
recent work demonstrating that A238L interacts with and inhibits CBP/P300 function 




A238L is known to inhibit the activity of several cellular proteins involved in gene 
transcription including NF-κB, CaN and most recently, p300. Therefore A238L has the 
potential to effect the transcription of a large number of cellular genes. Previous work on 
A238L has been limited to investigating the effect of this protein on individual immune 
response genes and specific transcription factors. The aim of this chapter was to examine 
the global effect of A238L on host macrophage gene expression. 
 
Differential gene expression between an immortalised porcine macrophage cell line 
expressing A238L and control cells was compared using a porcine oligonucleotide 
microarray. This microarray was produced using the Array-Ready Oligo Sets™ for the 
Pig Genome, version 1.0 and the Pig Genome Oligo extension Set, Version 1.0. An 
additional set of 360 oligonucleotides specific for genes present on the Pig 3K Immune 
cDNA (Zhang F et al 2006), but not identified within the Operon Oligonucleotide sets 
were also produced by Operon and included on this array. This array contains 13,657 
oligonucleotides representing all currently known Sus scrofa gene sequences with a hit 
to human, mouse, or pig gene transcripts and a number of sequences containing a 3’ 
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expressed sequence Tag (EST). Using this approach it was possible to investigate the 
effect of A238L in its natural host species and target cell type. 
 
The results presented in this chapter demonstrated that A238L was a potent inhibitor of 
gene transcription, targeting many genes associated with the inducible response to 
cellular stress. A238L was shown to differentially regulate the expression of porcine 
mRNAs targeted by a total of 294 unique oligonucleotides over two time points 
following cell stimulation. Cells were treated with LPS, PMA and ionomycin to activate 
NF-кB, PKC and  CaN d ep end ent signallin g  pathways resp ectively. Th is d ata set 
translated to a final gene list of 132 unique annotated genes. A large proportion of these 
annotated genes were found to be inducible in response to cell stimulation, and a number 
of genes were associated with NF-кB, MAPK and NFAT transcription activation 
consistent with LPS, PMA and ionomycin treatment. However, surprisingly, 
comparisons between this data set and the results presented in chapter 4 demonstrated 
that the majority of genes regulated by A238L in IPAM cells were not found to be up-
regulated by baculovirus, LPS, PMA and ionomycin treatment. This result indicates that 
genes associated with these pathways are constitutively activated in IPAM cells, and is 
consistent with other data presented in chapter 4 demonstrating the presence of NF-кB 
and NFAT regulated gene transcripts, TNF α, COX-2 and IL-8, in un-treated IPAM 
cells. 
 
With the exception of two oligonucleotides, which were found to be up-regulated by 
A238L expression at 1 hr post-stimulation, all of the remaining 292 oligonucleotides 
were down-regulated. This result clearly demonstrates that A238L has a fundamental 
role in the suppression of host gene expression. Only one of the two oligonucleotides 
found to be up-regulated by A238L was annotated, and is predicted to be specific for the 
extra cellular matrix protein collegen, type Xii, alpha. Considering the relatively small 
number of oligonucleotides that hybridise to RNAs up-regulated by A238L, it is quite 
possible that the identification of these 2 oligonucleotides is due to statistical error since 
approximately 10 % of the oligonucleotides identified as being significantly regulated by 
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A238L at 1 hr post-stimulation are predicted to be falsely significant. Overall the 
number of oligonucleotides identified as differentially regulated between A238L 
expressing and control samples is relatively small number compared to the total number 
of oligonucleotides analysed (292 out of 10146),  indicating that A238L does not 
mediate a general “switch–off” of host gene transcription but is targeted to a specific 
sub-set of genes. This is consistent with previous work on A238L which demonstrated 
that A238L specifically inhibits the expression of TNF-α and IFN-α gene transcripts, but 
not TGF-β suggesting a specific inhibition of target genes (Powell et al., 1996). In 
addition, A238L has been shown to inhibit the transcriptional activity of  NFAT and NF-
кB reporter constructs, but not Sp-1 reporter constructs (Tait et al., 2000)Granja et al., 
2008).  
 
The majority of target oligonucleotides which hybridised to mRNAs differentially-
regulated by A238L expression were transiently down-regulated at only one of the two 
time points examined. Only a relatively small group of 25 RNAs hybridising to unique 
oligonucleotide ID’s were found to be regulated at both time points post-stimulation. 
Similarly, the results presented in chapter 4 (examining the effect of baculovirus 
treatment and cell stimulation on IPAM cells) also found that the majority of 
differentially-regulated genes were specific to either 1 or 4 hrs post-stimulation, 
reflecting the rapid ability of cells to adapt to environmental changes through altering 
their pattern of gene expression within the cell. Recent work carried out in our 
laboratory using a porcine cDNA to examine the effect of ASFV infection on primary 
host macrophage gene expression at both early and late times post infection, 
demonstrated marked differences in the regulation of host genes between these time 
points (Zhang et al., 2006b).Together these results indicate that the inhibition of host 
macrophage gene transcription by A238L at different time points during ASFV infection 
is likely to be of different biological consequence. 
 
The final gene list of 137 unique annotated genes regulated by A238L gene expression 
contained genes with a wide range of cellular functions.  Biological characterization of 
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these genes indicated that a significant proportion of these genes were associated with 
the cells response to stimulation and/or physiological stress. Central themes included 
immune response genes, immediate early genes that response to growth factors and 
genes associated with regulating cell mediated cell death and progression through the 
cell cycle in response to physiological stress such as DNA damage. Genes involved in 
modulating intracellular signaling cascades were also common. Some were associated 
with regulating NF-kB activity. However the majority were associated with modulating 
the MAPK signaling cascades. MAPK signaling pathways are important mediators of 
transcriptional responses to extracellular signals and are involved in many cellular 
processes including growth, differentiation, apoptosis and the immune response. Most of 
the genes regulated by A238L are associated with ERK, JNK and p38 MAPK pathways. 
ERK is mainly activated by growth factors and hormones and is associated with cell 
proliferation and differentiation while JNK and p38 are activated by environmental 
stress and pro-inflammatory cytokines. JNK activation is associated with apoptosis 
(Baichwal & Baeuerle, 1997). Significantly ERK, JNK and p38 are all involved in 
regulating the innate immune response to infection (Dong et al., 2002).The ability of 
A238L to regulate genes induced by the MAPK and the NF-κB pathway, which are both 
associated with regulating the inflammatory response, apoptosis and the cell cycle, could 
explain the high number of A238L down-regulated genes associated with these 
physiological processes.  
 
Several of the genes regulated by A238L exhibited directly opposing biological 
functions. This was particularly apparent for A238L regulated genes involved in 
apoptosis and NF-кB and MAPK pathway regulation. The MAPK pathway is known to 
induce the expression of both negative and positive regulators of MAPK signal 
transduction leading to the auto-regulation of this pathway. Therefore this result is most 
likely to be due to A238L targeting the activity of one or several common features 
involved in the transcription of these genes rather than of biological significance. In 
addition, the experimental approach, which involved the over-expression of A238L in an 
attempt to identify all of the potential effects of A238L on host cell gene transcription 
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may also contribute to these results. It is probable that A238L exhibits a more specific 
effect during ASFV infection. 
 
It was interesting to note, that all of  the A238L regulated anti-apoptotic genes, 
GADD45 beta, SNF1-like kinase kinase (NUAK2) and baculoviral IAP repeat-
containing 3 (BIRC3) are dependent on NF-κB mediated gene transcription (Legembre 
et al., 2004; Wang et al., 1998; Zhang et al., 2005). NF-κB plays an important role 
inhibiting cell death through the expression of anti-apoptotic genes (Baichwal & 
Baeuerle, 1997). Indeed PML a pro-apoptotic gene, also regulated by A238L, induces 
apoptosis through the direct inhibition of NF-κB function. A238L is a known inhibitor 
of NF-κB mediated gene transcription, therefore the down-regulation of these anti-
apoptotic genes could be predicted. ASFV encodes two proteins involved in inhibiting 
apoptosis: A224L and A179L. A224L is an IAP homologue that binds to and inhibits the 
activity of caspase 3 (Nogal et al., 2001) and A179L is a viral Bcl-2 homologue which 
inhibits Bid induced apoptosis (Galindo et al., 2008).   Therefore it could be that in 
addition to inhibiting apoptosis induced through activation of the host immune response 
these proteins also function to counteract the pro-apoptotic effects of A238L. 
Interestingly, A238L also has the potential to inhibit apoptosis through inhibition of 
CaN. CaN dephosphorylates the pro-apoptotic Bcl-2 family protein BAD leading to its 
activation (Wang et al., 1999). CaN inhibition by A238L could therefore inhibit 
apoptosis induced by BAD. Although viruses are required to inhibit apoptosis at early 
times during infection in order to replicate, at later times post-infection induction of 
apoptosis may possibly be an advantage for virus spread.  
 
 
The results presented in this chapter demonstrate that A238L is able to suppress the 
expression of a large number of genes, regulated by wide range of transcription factors 
in addition to NFAT and NF-kB. All of the transcription factors identified interact with 
the transcription co-activator CBP/P300. In addition, recent work on A238L has 
proposed that A238L inhibits transcriptional activation mediated by NF-kB, NFAT and 
c-jun via a common mechanism involving the transcriptional co-activator CBP/P300 
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(Granja et al., 2006a; Granja et al., 2008a; Granja et al., 2006c).  Together these results 
provide strong evidence for the role of A238L as a potent inhibitor of gene expression 









Previous work carried out in our laboratory has shown that the A238L protein fused to a 
14 aa N-terminal Pk epitopetag is present in the both the nucleus and cytoplasm of 
infected cells at late times post-infection with ASFV (Bowick, 2004). In addition, recent 
work has demonstrated that A238L can be found in both the cytoplasm and nucleus of 
ASFV infected porcine alveolar macrophages and in Jurkat T cells stably expressing 
A238L (Granja et al., 2006a). Together these data suggests that A238L may function 
within both the cytoplasm and nucleus of infected cells. However, a detailed study into 
the nuclear translocation of A238L has not been carried out. 
 
The control of the subcellular localisation of proteins through regulation of their 
nuclear/cytoplamic transport can have a significant impact on protein function. Indeed 
many transcription factors, including NF-κB and NFAT are partially regulated through 
altering their subcellular localisation within the cell (Ghosh & Karin, 2002; Rao et al., 
1997). The aim of this chapter is to explore the mechanisms involved in the nuclear 
transport of A238L and to establish if A238L is retained in the nucleus or is actively 




6.2.1 A238L is exported from the nucleus by a CRM-1 mediated pathway. 
 
The active transport of molecules out of the nucleus typically involves interaction with 
carrier proteins, called exportins. CRM-1, also known as exportin-1, is a well 
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characterised nuclear export factor responsible for the export of numerous cellular and 
viral proteins. To investigate if A238L is exported from the nucleus via the CRM-1 
pathway, the sub-cellular localisation of A238L was examined in the presence of 
Leptomycin B (LMB). LMB a specific inhibitor of the CRM-1 dependent nuclear export 
pathway and binds directly to CRM-1 inhibiting its interaction with target proteins 
(Kudo et al., 1998).  
 
Levels of A238L expressed in Vero cells infected with the recombinant ASFV , 
Sv5GaL, which contains an SV5 Pk-tagged A238L gene (Miskin et al., 1998) were low 
and difficult to detect using immunofluorescence microscopy (section 3.2.7). Therefore 
to produce detectable levels of A238L, Vero cells were transfected with a plasmid 
containing Pk-tagged A238L gene under the control of the A238L promoter (pFlanks-
SV5A238L) and then infected with the ASFV isolate BA71V. This plasmid has been 
described previously (Miskin et al., 1998). At 3 hrs prior to fixation the cells were 
treated with LMB or were untreated, in either the presence or absence of PMA and LPS. 
Cells transfected with a plasmid containing Pk-tagged IκB-α were used as a positive 
control for LMB: IκB-α contains a CRM-1 dependent nuclear export signal and has 
previously been shown to accumulate exclusively in the nucleus in the presence of LMB 
(Huang et al., 2000). These cells were treated with PMA/LPS to activate NF-κB and 
enhance IκB-α nuclear import. Due to the predicted similarity between A238L and 
cellular IκB-α (Revilla et al., 1998) the effect of PMA and LPS treatment on A238L was 
also examined. At 8 and 16 hrs post-infection the cells were fixed, permeabilised and 
stained with an antibody specific to the Pktag followed by a fluorescently labelled 
secondary antibody. Cells were then examined using confocal microscopy and the sub-
cellular localisation of A238L determined.  
 
As shown in Figure 6.1 (a), in cells stimulated with PMA/LPS, in the presence of LMB 
all of the IκB-α was present in the nucleus as expected. In the absence of LMB, although 
most of the IκB-α was in the nucleus, a small amount was present in the cytoplasm. This  
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is consistent with the nuclear export of IκB-α via the CRM-1 mediated pathway, and 
shows that the LMB is functionally active. 
 
 In ASFV infected cells expressing A238L under the control of its own promoter, A238L 
exhibited a distribution which could be characterised into three distinct patterns of sub-
cellular localisation. These were either: preferentially nuclear, a uniform distribution 
throughout the cytoplasm and nucleus, or preferentially cytoplasmic (see Figure 6.1 (b)). 
One hundred cells were scored for the above three cellular distributions for each 
experimental condition and in three independent experiments. To avoid bias a number of 
slides were analyzed blind and the results were verified by an impartial research 
scientist. In the presence of LMB, at both 8 and 16 hrs post-infection, there was a 
significant increase in the number of cells exhibiting a predominantly nuclear 
localization compared to in the absence of LMB (approximately 50 % compared to less 
than 10 %) (Figure 6.2). This demonstrates that at least a proportion of the nuclear 
A238L is exported to the cytoplasm using the CRM-1 nuclear export pathway. In the 
cells treated with LMB, although A238L was predominantly present in the nucleus in 
more cells, nevertheless in approximately half of the cells treated with LMB A238L 
exhibited an even distribution of A238L throughout the nucleus and cytoplasm. Possibly 
a proportion of A238L is either not imported into the nucleus and remains in the 
cytoplasm, or if it is imported into the nucleus and it is then exported using a CRM-1 
independent nuclear export pathway.  
 
No difference was observed in the distribution of A238L in PMA and LPS treated cells 
compared to untreated cells. This result could indicate that, unlike IκB-α,  the subcellular 
distribution of A238L is not dependent on NF-κB activation. However, this result is not 
conclusive as infection of cells with ASFV, even in the absence of LPS and PMA 
treatment, is likely to activate several cell signaling pathways including NF-κB (Powell 
et al., 1996). The results from these experiments demonstrate that A238L is actively 






6.2.2 Nuclear import of A238L occurs by an energy dependent process. 
 
Following translation, proteins are imported into the nucleus through the nuclear pore 
complex. This process can occur by either active transport or passive diffusion. The 
diffusion exclusion limit of the nuclear pore complex is approximately 60 kDa, therefore 
passive diffusion of proteins can only occur if the molecular weight is below this limit. 
Since both forms of A238L are less than 60 kDa in size and could therefore enter the 
nucleus by diffusion, an additional experiment was carried out to determine if A238L is 
actively imported into the nucleus. This involved comparison of the sub-cellular 
localisation of A238L at 37 °C and 4 °C. At 4 °C all active transport processes are 
blocked, whereas the rate of diffusion is reduced but not inhibited. In addition, to 
determine if the nuclear pool of A238L resulted from import of existing cytoplasmic 
A238L or if new synthesis of A238L protein was required for transport into the nucleus, 
cells were also treated with cycloheximide to prevent de-novo protein synthesis.  From 
Figure 6.3 it can be seen that in the majority of cells incubated at 4 oC, A238L was 
observed to be evenly distributed between the nucleus and cytoplasm, in both the 
presence and absence of LMB, demonstrating that A238L is able to passively diffuse 
between the cytoplasm and nucleus.  However, when cells were incubated at 37 oC, the 
results were dramatically different: A238L exhibited a predominantly nuclear 
localisation in almost 50 % of the cells examined. This suggests that although passive 
diffusion may play a role in the nuclear accumulation of A238L, an additional active 
nuclear transport process is involved.  
 
No significant difference in the distribution of A238L between cells treated with 
cycloheximide compared to untreated cells was detected (Figure 6.3). This demonstrates 
that new protein synthesis was not necessary for the nuclear accumulation of A238L and  





Figure 6.3 Movement of A238L is energy dependent. ASFV infected Vero 
cells expressing PK-tagged A238L under the control of it’s promoter were 
treated with CHX (100 µg/ml) or were left untreated. 3 hrs prior to fixation the 
cells were treated with or without LMB (40 nM) and incubated at either 37oC 
or 4oC. PK-tagged A238L was detected by indirect immunofluorescence and 
imaged using confocal microscopy. The percent of cells exhibiting either N, 
N/C or C phenotype was determined for each condition tested. Data 
represents an average of 3 independent experiments (+ SD). Panel (a) shows 


































6.2.3 The role of putative nuclear localisation signals in A238L nuclear 
translocation 
 
Most proteins that are actively transported between the nucleus and cytoplasm contain 
specific sequences required for interaction with the cellular import and export apparatus. 
Nuclear localization (NLS) signals typically consist of short mono or bi-partite stretches 
of amino acids that are highly enriched in basic residues. Typical nuclear export signals 
(NES) consist of short leucine rich motifs. Sequence analysis of  A238L using PSORT 
(Horton, 2006), a computer program which predicts possible sub-cellular localisation 
motifs, identified two putative NLSs. These NLSs consist of a single short stretch of 
amino acids, highly enriched in basic residues. One of these (NLS-1) is located close to 
the N-terminus of A238L towards the C-terminal end of the first ankrin repeat domain 
and includes amino acids 80 to 86 (PHRRDKD). The second (NLS-2) includes amino 
acids 202 to 206, and is located close to the C-terminus within the PxIxITxC/S 
calcinurin binding domain. NLS-2 comprises of two short overlapping NLS sequences 
(KKKPK). Mapping these motifs onto a  predicted structure of A238L, generated by Dr 
David Chapman, suggests that both  NLS-1 and NLS-2 are located on exposed sites at 
the surface of the A238L protein and therefore have the potential to be to be functionally 
active (Figure 6.4). No typical nuclear export signals were identified using this program. 
This suggests that A238L may contain atypical CRM-1 nuclear export sites or is 
potentially exported in association with another protein. 
 
To determine if the predicted nuclear localisation signals NLS1 and NLS2 were 
involved in the nuclear localisation of A238L, the sub-cellular localisation of A238L 
proteins containing mutations within either or both NLS1 and NLS2 was examined. 
 
Plasmids expressing Pk-tagged A238L under the control of its own promoter and 







NLS 1 (aa 80 - 86)
PHRRDKD






Ank 1 Ank 2 Ank 3 Ank 4NH2 COOH
Figure 6.4 Schematic representation of A238L. Panel (A) represents the 
A238L protein which is 238 aa in length. A238L is predicted to encode four 
ankrin repeat domains (Ank) (represented by solid black bars) and two 
putative NLS, 1 and 2 (represented by three red stripes). A238L also 
contains a CaN binding motif located at the C-terminus and depicted in red. 
Diagram is not to scale. Panel (B) is the aa sequence of the predicted NLS1 
and NLS2. Panel (C) is a 3 dimensional model of the predicted structure of 
the A238L protein based on it’s similarity with IkBa. NLS1 and NLS2 are 
shown in yellow. This diagram is courtesy of Dr D. Chapman, Institute of 
Animal Health.
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(Miskin et al., 2000b). Due to the predicted location of NLS-2, within the CaN binding 
domain of A238L, some of these plasmids also contain mutations within the NLS-2. 
Plasmids W13-A238L and B19-A238L contain detrimental mutations within the 
predicted NLS-2. Plasmid W20-A238L contains a P to S mutation within NLS-2 
however this is not predicted to disrupt NLS-2. W13-A238L and W20-A238L proteins 
do not bind to CaN whereas WT-A238L and B19-A238L proteins are CaN binding 
(Table 6.1). 
 
A plasmid containing mutations within NLS-1 has also been produced previously 
(Chapman, unpublished). This plasmid (pcDNA3-A238L 84-88) encodes four valines at 
amino acid residues 84 to 88, instead of the wild type sequence, DKDG. Analysis of this 
mutant sequence using PSORT failed to identify the presence of a NLS at amino acids 
80 to 86. Therefore the mutation of the amino acid residues 84, 85 and 86 within NLS 1 
was considered to be sufficient to inactivate this NLS. To examine the effect of this 
mutation on the sub-celluar localisation of A238L in ASFV infected cells this mutant 
form of the A238L protein was cloned under the control of its own promoter and fused 
to the Pk epitope tag (pFlanks-WT-NLS-1).  
 
To generate this plasmid the N-terminal 310 bp fragment of A238L 84-88 was amplified 
by PCR from pcDNA3-A238L 84-88, using forward and reverse primers containing an 
Xho I site and EcoN I site respectively. These sites are compatible with an Xho I site 
present at the start codon of A238L and an endogenous EcoN I restriction site present 
within the A238L gene. The resulting PCR product was then gel purified, digested with 
Xho I and EcoN I restriction enzymes, gel purified again and then ligated into 
compatible restriction sites on pFlanks-SV5A238L to generate pFlanks-WT-NLS-1. 
This cloning strategy is presented in Figure 6.5. To examine the effect of mutation of 
NLS-1 in conjunction with mutation of NLS-2 and/or the CaN binding domain, this 
cloning strategy was repeated to insert the 310 bp N-terminal fragment of A238L 84-88 
into W13-A238L, W20-A238L and B19-A238L. The amino acid sequence of both NLS 
1 and NLS 2 and the CaN binding properties of all of these plasmids are described in  
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Table 6.1 Amino acid sequences of WT A238L and A238L constructs 
containing mutations within the putative nuclear localisation signals 
NLS 1 and NLS 2.Residues identical to the WT A238L sequence are 




(aa 80 – 86 )
NLS 2
(aa 202 – 206)
CaN  Binding
WT A238L P H R R D K D K K K P K Yes
W13 *  *  *  *  *  *  * T  T  T  S  * No
W20 *  *  *  *  *  *  * *  *  *   S  * No
B19 *  *  *  *  *  *  * T  T  T *  * Yes
WT/NLS 1 *  *  *  * V V V *  *  *  *  * Yes
W13/NLS 1 *  *  *  * V V V T  T  T  S  * No
W20/NLS 1 *  *  *  * V V V *  *  *   S  * No
B19/NLS  1 *  *  *  * V V V T  T  T *  * Yes
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1) PCR amplification and 
digestion with Xho1 and Eco N1
pcDNA3 
A238L 84-88













(start) Eco N1 (310)
SV5
Xho 1 
(start) Eco N1 (310)
2) Digestion with Xho1 and Eco N1
3) Ligate
Figure. 6.5 Illustration of the cloning strategy to produce an A238L protein 
containing a non-functional NLS 1. PcDNA3-A238L 84-86 encodes an A238L 
protein which contains a mutated NLS 1.pFlanks-SV5A238L encodes an original 
A238L sequence fused to a pK tag at it’s N-terminus.  NLS are represented as 
vertical bars: red bars indicate a functional NLS and black bars represent a 
disrupted NLS. A238L is represented as a blue rectangle and the SV5 tag is in 
green. The position of restriction sites and the NLSs are shown along with their 
nucteotide postion indicated in brackets.  To produce pFlanks WT-NLS1 a 310 
nucleotide fragment containing the mutated NLS1 was PCR amplified from 
PcDNA3-A238L 84-86, digested with Xho1 and Eco N1 and then ligated into 







SV5 NLS 2 
(606-618)
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Table 6.1. All the plasmids generated were sequenced to confirm the presence of the 
mutated bases. 
 
To investigate the effect of these mutations on the subcellular localisation of A238L, 
ASFV infected Vero cells were transfected with plasmids expressing wild type or 
mutant A238L and examined at 16hrs post-infection by confocal microscopy. 
Observations were recorded in the presence or absence of LMB and this was added 3 hrs 
prior to fixation. The subcellular localisation of A238L was scored for 100 cells in three 
replicate experiments.  The averages of these results for the plasmids tested are shown in 
Figure 6.6 and Figure 6.7. Figure 6.6 shows the effect of mutating NLS-2 on the 
subcellular distribution of A238L and Figure 6.7 shows the effects of mutating both 
NLS-1 and NLS-2. 
 
The effect of disrupting NLS-2 alone was investigated first. NLS-2 is located within the 
A238L CaN binding motif. Therefore the effect inhibiting CaN binding to A238L was 
also investigated. The subcellular distribution of mutant A238Ls in Vero cells 
transfected with pflanks W13-A238L, W20-A238L and B19-A238L was compared to 
WT-A238L. As described previously, W13-A238L and B19-A238L are predicted to 
have a non-functional NLS-2 where as W20-A238L is predicted to encode a functional 
NLS-2. W13-A238L and W20-A238L are non-CaN binding and B19-A238L binds to 
CaN. All of these plasmids contain the wild type NLS-1 sequence. From Figure 6.6  it 
can be seen that both W13-A238L and B19-A238L showed a similar subcellular 
distribution to WT-A238L in both the absence and presence of LMB. This result 
demonstrates that disruption of the NLS 2 motif alone was not sufficient to alter the 
proportion of A238L which accumulates in the nucleus.  This suggests that either a 
different or additional mechanism exists for nuclear import of A238L. Surprisingly cells 
transfected with a plasmid expressing the W20 protein, which has an intact NLS-2 but 
does not bind to CaN, showed a dramatic increase in the number of cells exhibiting a 
predominantly nuclear distribution compared to cells transfected with a plasmid 





distribution, in the presence of LMB, increased from approximately 25 % for those 
transfected with WT-A238L compared to greater than 70 % for cells transfected with 
plasmid expressing W20-A238L. The number of cells showing a nuclear distribution 
was also significantly increased in the absence of LMB: from approximately 2 % for 
WT-A238L to approximately 30 % for W20-A238L. Since W20-A238L contains an 
intact NLS-2 sequence but does not bind to CaN, the data suggest that when A238L does 
not bind to CaN, significantly more A238L protein accumulates in the nucleus. A 
probable explanation for this result could be that the interaction between the WT-A238L 
and CaN masks NLS-2, and this may contribute to the retention of a proportion of 
A238L in the cytoplasm of cells. 
 
The effect of mutating NLS-1 alone, and in combination with NLS-2, on the subcellular 
localisation of A238L was also examined. The subcellular localisation of A238L in the 
presence and absence of LMB was examined for 4 test plasmids which express mutant 
forms of the A238L protein (WT/NLS 1, W13/NLS 1, W20/NLS 1 and B19/NLS 1) and 
compared with WT A238L. All of the test plasmids contain a mutated NLS-1 motif. 
WT/NLS 1 and W20/NLS 1 contain a complete NLS2; WT/NLS1 binds CaN and 
W20/NLS 1 does not bind CaN. W13/NLS-1 and B19/NLS-1 both contain a mutated 
NLS-2; W13/NLS-1 is CaN binding and B19/NLS-1 does not bind CaN.  
 
The results of this experiment are shown in Figure 6.7. WT/NLS-1 showed a similar 
subcellular distribution to WT-A238L, indicating that disruption of NLS 1 alone was not 
sufficient to alter the nuclear accumulation of A238L. Interestingly, disruption of NLS-1 
also failed to affect the subcellular distribution of  W20/NLS-1 which is also non-CaN 
binding, this plasmid showed a similar distribution to its parent W20 (see Figure 6.6). In 
both cases a significant increase was detected in the nuclear accumulation of these 
proteins compared to WT-A238L. In contrast to these results, plasmids W13/NLS-1 and 
B19/NLS-1, which contain mutations within both NLS 1 and NLS2, showed a dramatic 
decrease in the number of cells exhibiting a predominately nuclear distribution. In the 
presence of LMB, less than 15 % of the cells examined showed a predominately nuclear  
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distribution in cells transfected with either W13/NLS-1 or B19/NLS-1, compared to 
greater than 50 % for WT-A238L. In the absence of LMB, in cells transfected with these 
two plasmids a significantly higher proportion of cells exhibited a predominantly 
cytoplasmic distribution of A238L (approximately 50 %) compared to cells transfected 
with WT-A238L (<10 %). Therefore mutation of both of these putative NLS 
significantly reduced the nuclear accumulation of A238L. However, mutation of both 
NLS 1 and NLS 2 did not completely abolish the nuclear accumulation of A238L. Cells 
transfected with either W13/NLS-1 or B19/NLS-1 showed a difference in the number of 
cells exhibiting a nuclear and cytoplasmic distribution (N/C) between LMB treated 
(approximately 80 %) and untreated cells (< 60 %). These results suggest that, in 
addition to nuclear import mediated by NLS-1 and NLS-2, another mechanism may 
facilitate the nuclear localisation of A238L. It is possible that passive diffusion may 
contribute to the nuclear presence of A238, however this process is not effected by LMB 
treatment and therefore does not account for these results.  
 
Taken together these results indicate that both NLS-1 and NLS-2 play a significant role 
in the nuclear localisation of A238L, and appear to act independently since loss of one 
NLS is compensated  for by the presence of the other.  
 
6.2.4 The cellular protein p65 is not involved in the nuclear export of A238L  
 
No typical nuclear export signals (NES) were identified on the A238L protein using the 
PSORT prediction program. The possibility that A238L may be exported in conjunction 
with another cellular protein, the p65 subunit of NF-κB, was examined. P65 has been 
shown to contain a functional NES and is exported from the nucleus by a CRM-1 
dependent pathway (Harhaj & Sun, 1999). In addition, A238L has previously been 
shown to co-precipitate with the p65 subunit of NF-κB demonstrating that the two 
proteins are in a complex together (Revilla et al., 1998; Tait et al., 2000). To investigate 
the effect of p65 on the cytoplasmic/nuclear shuttling of A238L, a mouse embryonic 
fibroblast (MEF) cell line, homozygous negative for the p65 subunit of NF-κB (p65 -/-) 
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was obtained from Professor Ron Hay at the University of St. Andrews. The unaltered 
original MEF cell line (p65 +/+) was also provided as a control.   
 
MEF cells are not susceptible to infection with ASFV, therefore MEF p65 -/- and p65 
+/+ cells were transfected with a plasmid expressing Pk-tagged A238L under the control 
of a mammalian cell active promoter. The cells were treated with or without LPS and 
PMA in the presence or absence of LMB 3 hrs prior to fixation. Cells transfected with 
Pk-tagged IkB-α and stimulated with LPS and PMA were used as a positive controls. 
Cells were fixed, permeabilized and stained with anti-Pk followed by a fluorescently 
labeled secondary antibody. At 16 hrs post-transfection the subcellular distribution of 
A238L was examined. Although the subcellular distribution of A238L did alter in 
response to LMB treatment, no difference could be detected between p65 -/- and control 
(p65 +/+) MEF (Figure 6.8). Treatment of cells with LPS and PMA, to activate NF-kB 
and induce the nuclear translocation of p65, also had no effect on the subcellular 
localization of A238L. These results show that p65 is not required for nuclear import or 
export of A238L. This suggests that A238L uses an alternative mechanism for nuclear 
export. From comparisons with Figure 6.2 and 6.3 it can be seen that A238L exhibits a 
different subcellular distribution profile in MEF p65 -/- and p65 +/+ cells compared to 
Vero cells. In MEF cells A238L exhibited a predominantly N/C and C distribution 
whereas in Vero cells the distribution was predominantly N and N/C with only a small 
proportion of cells exhibiting an exclusively cytoplasmic distribution. This could be due 
to difference in the efficiency or concentration of proteins associated with the nuclear 
import pathways between these cells. 
 
6.2.5 Expression of A238L does not inhibit the nuclear translocation of p65. 
 
NF-κB mediated gene expression can be regulated by several mechanisms including its 
subcellular localization within the cell. Previous work has suggested than A238L may 
inhibit NF-κB mediated gene transcription by retaining NF-κB in  the cytoplasm of 




the p65 sub-unit of NF-κB in cytoplasm of ASFV infected cell at 8 hrs post infection 
(Tait et al., 2000). These authors reported that A238L could not be detected in the 
nucleus at this time point post-infection (Tait et al., 2000) although other studies have 
detected A238L in the nucleus at early times (Bowick 2004, Silk et al., 2007). To 
investigate this possibility, the subcellular distribution and nuclear translocation of the 
p65 subunit of NF-κB was examined in ASFV infected cells using indirect 
immunofluorescence. Vero cells were infected with either the ASFV isolate BA71V, 
which expresses the wild type A238L protein, or a recombinant BA71V isolate from 
which the A238L gene has been deleted (vIKGAL) (Miskin et al 1998). 3 hrs prior to 
fixation the cells were treated with PMA/LPS in the presence or absence of LMB. PMA 
and LPS were used to enhance the nuclear translocation of NF-κB. Cells were fixed, 
permeabilized and stained at 8 hrs post-infection. Cells were treated with antibodies 
against endogenous p65 and an antibody specific for the ASFV early protein p30 (to 
identify ASFV infected cells). These antibodies were detected using Alexa 568-
conjugated goat anti-rabbit IgG secondary antibody and Alexa 488-conjugated goat anti-
mouse IgG respectively.  Cells were then examined using confocal microscopy.  
 
Figure 6.9 shows representative images of three independent experiments.  ASFV 
infected cells were identified by staining for anti-p30 as detected by green staining, 
endogenous p65 was detected by an antibody specific for p65 and is shown as red 
staining and the nucleus and virus factories were detected by DAPI staining of DNA as 
shown in blue. P65 was detected in the nucleus of cells treated both in the presence and 
absence of LMB. As expected, treatment of cells with LMB resulted in an almost 
exclusive nuclear localisation of p65. In the absence of LMB an increase in the amount 
of cytoplasmic p65 was observed, demonstrating that p65 is exported from the nucleus 
to the cytoplasm by a CRM-1 mediated pathway. No difference could be seen in the 
amount of p65 in the nucleus of cells infected with either BA71V or ViKGal compared 
to uninfected cells. This suggests that nuclear translocation of p65 is not inhibited in 
cells infected with ASFV. Comparisons between cells infected with BA71V or vIKGal 




viruses, indicating that A238L does not alter the subcellular distribution of cellular p65 
or inhibits the nuclear export of of this protein. These results suggest that A238L uses an 




Previous work on A238L has shown that this protein can be detected in both the nucleus 
and cytoplasm of infected cells. However a detailed study of the movement of A238L 
within ASFV infected cells has not previously been carried out.  
 
The data presented in this chapter shows that A238L is actively imported into the 
nucleus by an energy dependent process and is then exported utilising the CRM-1 
pathway. LMB induced nuclear accumulation of A238L was insensitive to the protein 
synthesis inhibitor cycloheximide, demonstrating that new protein synthesis is not 
required for A238L nuclear import and that A238L is transported into the nucleus from a 
pre-existing cytoplasmic pool. Interestingly, even in the presence of LMB, A238L was 
not exclusively located in the nucleus and could be detected in the cytoplasm of infected 
cells. This suggests that either a proportion of A238L remains in the cytoplasm and is 
not imported into the nucleus (possibly through its interaction with CaN) or 
alternatively, that A238L can also be exported from the nucleus by a CRM-1 
independent nuclear export pathway. 
 
To identify possible sequences responsible for the nucleocytoplasmic shuttling of 
A238L, sequence analysis was performed. This analysis identified the presence of 2 
classical NLS (NLS-1 and NLS-2). However no typical NES could be identified. 
Comparisons between the sub-cellular distributions of A238L mutants containing site-
directed mutations within either NLS-1 or NLS-2 with WT-A238L, failed to identify 
differences in the nuclear import of A238L. However, mutation of both NLS- and NLS-
2 together resulted in a significant reduction in the nuclear accumulation of A238L. This 
suggests that both of these sites are functional and exhibit redundancy, since mutation of 
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one site is compensated for by the presence of the other. Several proteins have been 
reported to contain multiple signals for nuclear import. These include the human 
immunodeficiency virus type 1 protein Vpr, the Adenovirus core protein pVII and the 
Epstein-Barr virus nuclear antigen 3A, the later has been shown to contain six functional 
localisation signals (Buck et al., 2006; Sherman et al., 2001; Wodrich et al., 2006). It is 
not fully understood why proteins contain multiple NLS, however many of these 
proteins have multiple binding partners which could potentially mask one or several of 
the functional NLS. The presence of multiple, separate NLS would be an effective 
strategy to ensure that at least a proportion of the protein is targeted to the nucleus. 
 
The presence of NLS-2 within the CaN binding site of A238L is consistent with this 
theory.  If the CaN binding site in A238L is functional it is possible that binding of 
A238L to CaN, would mask NLS2 and possibly facilitate the retention of the A238L-
CaN complex in the cytoplasm. If this is the case then a second NLS may be essential to 
ensure that an adequate proportion of A238L enters the nucleus either in complex with 
CaN or independently. Examination of the sub-cellular distribution of the A238L mutant 
W20-A238L, which is non-CaN binding, but has an intact NLS2, showed a large 
increase in the nuclear accumulation of A238L particularly in the presence of LMB. 
This would support the hypothesis that binding of A238L to CaN masks NLS-2  and 
could contribute to the retention of A238L in the cytoplasm of infected cells. 
 
Interestingly mutation of both NLS-1 and NLS-2 did not completely prevent the nuclear 
translocation of A238L, suggesting that an additional mechanism could facilitate the 
movement of A238L to the nucleus. Due to the small molecular weight of A238L, 
passive diffusion could be responsible for the nuclear localisation of this protein. 
However, it is also possible that A238L may contain other, non-typical, NLS. A diverse 
range of sequences can act as NLS and new signals are continually identified. Thus 
producing a definitive list of consensus NLS is difficult.  Indeed only two of the six NLS 
detected in the EBV protein, NA3A, were identified by the PSORT sequence analysis 
software (Buck et al., 2006). Ankyrin repeat domains (ARDs) have also been shown to 
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substitute for classical nuclear localisation signals in a number of other proteins, 
including IkB-α and Myxoma Nuclear Factor (MNF), a virulence factor encoded by 
myxoma virus (Camus-Bouclainville et al., 2004; Sachdev et al., 1998). A238L is 
predicted to contain four ARDs (Revilla et al., 1998), which could potentially function 
as additional NLSs. To investigate this further it would be useful to construct a double 
EGFP-A238L fusion protein which is estimated to have a molecular weight of 88 kDa, 
well above the nuclear pore passive diffusion exclusion limit. Using this construct and 
others containing mutations within the predicted NLS-1 and NLS-2 it would be possible 
to prevent the passive diffusion of A238L into the nucleus of cells and establish if other 
non-typical NLS exist.  
 
The nuclear accumulation of A238L in the presence of LMB clearly demonstrates that 
A238L is exported from the nucleus by a CRM-1 mediated mechanism. Although no 
typical NES were identified within A238L, it is possible that A238L contains non-
classical NES or nucleo-cytoplasmic bidirectional signals. Another alternative is that 
A238L is exported from the nucleus in association with another protein using a 
‘piggyback’ mechanism. This strategy is used by the Hepatitis B Virus X protein for 
nuclear import. The X protein interacts directly with IkB-α and this complex is imported 
into the nucleus. Import  requires the presence of the second ARD of IkB-α which is 
involved in  nuclear import of IkB-α following NF-κB activation (Weil et al., 1999). 
CaN is also transported in association with another cellular protein, NFAT (Shibasaki et 
al., 1996). A238L interacts with several cellular proteins. In particular, A238L has been 
suggested to bind to the p65 sub-unit of NF-κB (Tait et al., 2000), which contains a 
functional NES and exhibits CRM-1 dependent nuclear export (Harhaj & Sun, 1999), 
thereby raising the possibility that A238L could be exported in complex with p65. 
However, the results presented in this chapter failed to support this theory since no 
difference was detected in the subcellular distribution of A238L between wild type cells 
and a p65 homozygous negative cell line. This suggests that p65 does not contribute to 
nuclear export of A238L. This result does not exclude the possibility that another 
cellular protein may be involved in CRM-1 mediated nuclear export. 
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In the experiments carried out it was notable that treatment of cells with LMB did not 
result in the exclusive nuclear accumulation of A238L. One possible explanation for this 
is the involvement of an additional nuclear export pathway that is CRM-1 independent. 
Multiple nuclear export strategies have recently been reported for another ASFV protein, 
p37 (Eulalio et al., 2006). This protein contains three independent NES, two of which 
function via the CRM-1 pathway and one via a CRM-1 independent mechanism. 
Therefore, in addition to the presence of multiple NLS for nuclear import, A238L may 
also use multiple strategies for nuclear export. 
 
NF-κB mediated gene transcription is regulated at by several mechanisms, which 
include altering the subcellular localisation NF-κB and also through post translation 
modification (Chen et al., 2002; Ghosh & Karin, 2002). The phophoryalation and 
acetylation of p65 are particularly important in regulating NF-κB transcriptional activity 
within the nucleus. These modifications effect the ability of NF-κB to  interact with  
transcriptional co-activators and also its cellular inhibitor protein IkB-α (Chen & 
Greene, 2004). IkB-α inhibits NF-κB through regulating its subcellular localisation. 
IkBα retains the p65-p50 NF-kB heterodimers in a predominantly cytoplasmic location 
preventing NF-kB from entering the nucleus and binding to its DNA binding site 
(Carlotti et al., 2000). Considering A238L’s homology with IκB-α and  the ab ility of  
A238L to inhibit NF-κB mediated gene expression the effect of A238L on the 
subcellular localisation of p65 was explored. Comparisons between the subcellular 
distribution of endogenous p65 in infected and uninfected cells demonstrated that 
A238L did not alter the subcellular localisation of NF-κB and therefore does not 
function in a similar manner to IκB-α. This is consistent with previous work carried out 
in our laboratory which used Western blotting to demonstrate that A238L did not 
prevent the nuclear accumulation of the NF-κB p50 and p65 subunits in ASFV infected 
cells (Bowick, 2004). Together these results suggest that A238L uses an alternative 




Presence of multiple NLS and the possibility that A238L uses more than one nuclear 
export pathway strongly suggests that nucleo-cytoplasmic shuttling of A238L is a key to 
the mechanism of action of this protein. However, the functional significance of the 
translocation of A238L between the cytoplasm and nucleus is still unclear. It could be 
that the ability of this protein to shuttle between the nucleus and cytoplasm is an 
essential strategy to ensure that adequate A238L is available in both the cytoplasm and 
nucleus to perform the multiple functions associated with this protein. 
 
The data presented in this chapter support a model where by A238L functions both 
within the nucleus and cytoplasm and suggests that binding of CaN to A238L 







The main aim of this thesis was to gain a greater understanding into the mechanism of 
A238L action and to better define the functional consequences of A238L expression 
within host cells. This was achieved through investigating the global effect of A238L 
expression on host macrophage gene expression and also through studies into the 
subcellular localisation of A238L. 
 
7.2 Effect of A238L on host macrophage gene transcription 
 
The global effect of A238L protein on host macrophage gene transcription was 
examined using a porcine oligonucleotide microarray.  Oligonucleotidess present on this 
array were designed from gene clusters derived by sequencing of EST libraries from a 
wide range of porcine tissues and therefore cover target genes with a wide range of 
biological functions (Operon). Using this approach it was possible to investigate the 
effect of A238L expression in its target species by using a cell line derived from porcine 
macrophages, the main target cell of ASFV. To achieve this it was first necessary to 
develop an appropriate gene expression and delivery system suitable for use with 
porcine cells. The development and validation of this approach, which used baculovirus 
to deliver the A238L gene under control of a mammalian gene promoter, is described 
and discussed in detail in chapter 3 and 4. Using this approach the A238L gene was 
transiently expressed in 85 % of cells, thus increasing the chance of detecting its effect 
on host gene transcription.   
 
Previous work has shown that A238L can inhibit NF-кB and NFAT regulated gene 
transcription (Miskin et al., 1998; Powell et al., 1996; Revilla et al., 1998). These 
transcription factors are activated in response to cell stimulation. Therefore test cells 
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were treated with compounds which activate signalling pathways involving these 
transcriptional factors. These compounds were LPS, PMA and ionomycin. LPS activates 
NF-κB and the MAPK pathways (Guha & Mackman, 2001).  Phorbol 12-myristate 13-
acetate (PMA) activates Protein Kinase C and ionomycin is a calcium ionophore which 
increase intracellular levels of calcium, resulting in NFAT activation via CaN. Together 
PMA and ionomycin mimic antigenic stimulation of leukocytes resulting in the 
transcription of NFAT dependent cytokine and immune response genes (Acuto & 
Cantrell, 2000; Rao et al., 1997). 
 
The results presented in chapter 5 describe the effect of A238L on host cell gene 
transcription at 1 and 4 hrs following LPS, PMA and ionomycin treatment. These results 
demonstrated that A238L is a potent inhibitor of host cell gene transcription, down 
regulating the expression of porcine mRNA’s targeted by a total of 292 oligonucleotides 
over both time points. In comparison only two oligonucleotides were found to hybridise 
to mRNA that were significantly up-regulated by A238L expression at 1 hr following 
stimulation. Due to the relatively small number of RNAs up-regulated across both time 
points it was assumed that the identification of these oligonucleotides was due to 
statistical error. Annotation was available for less than half of these oligonucleotides and 
resulted in a final gene list of 132 unique annotated genes. This highlights one of the 
disadvantages of using the porcine oligonucleotide array, as unlike similar mouse and 
human arrays, there is a significant lack of annotation available for many of the 
individual oligonucleotidess spotted onto the porcine array. Therefore many genes of 
interest were potentially excluded from the final data set. 
 
Analysis of the functional classes of genes whose expression was down-regulated by 
A238L identified many genes which are inducible in response to cellular stress. The 
majority of these genes had not previously been shown to be regulated by A238L. 
Significantly, many of these genes were regulated through the NF-κB and MAPK 
pathways, key pathways involved in regulating the cells immune response to infection. 
NF-кB regulates the expression of pro-inflammatory cytokines, chemokines and acute 
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phase proteins that are involved in recruiting inflammatory cells to sites of infection 
(Ghosh et al., 1998). MAPKs are involved in regulating many aspects of immune 
responses, from the initiation phase of innate immunity, the activation of adaptive 
immunity and cell death. In addition, a smaller number of genes were associated with 
the JAK/STAT pathway, which is involved in cytokine signal transduction including the 
IFN response (Dong et al., 2002). This result demonstrates that A238L functions as a 
potent immunosuppressor protein by inhibiting the transcriptional activation of genes 
dependent on these pathways. Genes associated with MAPK pathway were particularly 
enriched. The ability of A238L to regulate genes associated with the MAPK and 
JAK/STAT pathway has not previously been reported. 
 
Comparison between these results and the results presented in chapter 4, describing the 
effect of LPS, PMA and ionomycin treatment on IPAM cells alone, demonstrated that 
nearly all of the A238L regulated genes were not induced in response to stimulation but 
were constitutively expressed in resting IPAM cells. This suggests that pathways 
associated with the regulation of these genes are active in untreated IPAM cells. It is 
therefore possible that specific enrichment for genes associated with the NF-кB and 
MAPK pathway in cells expressing A238L is in part a consequence of the activation 
status of the IPAM cells.  
 
Gene transcription is regulated at several levels and involves the simultaneous 
interaction of multiple different factors, including transcriptional activators, coactivators 
(also known as adaptors) and the basal transcriptional apparatus. Transcription factors 
bind directly to sequence specific DNA elements, whereas coactivators do not bind 
directly to DNA but interact with DNA binding proteins and can act to bridge 
interactions between transcription activators and basal factors. Proteins involved in 
modulating chromatin structure also play a significant role in the regulation of gene 
transcription by influencing the accessibility of DNA control elements to transcription 
factors (Ernst & Smale, 1995). 
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Early work on A238L, described in chapter 1, demonstrated that A238L was able to 
inhibit gene transcription dependent on the cellular transcription factors, NF-кB and 
NFAT (Miskin et al., 1998; Powell et al., 1996; Revilla et al., 1998). This work 
proposed a model whereby A238L exhibited dual functionality inhibiting NF-кB and 
NFAT dependent gene expression by independent mechanisms. A238L was shown to 
co-precipitate with the p65 sub-unit of NF-кB and also prevent p50-p65 hetero-dimers, 
but not p50 homo-dimers, from binding to their DNA binding sites (Revilla et al., 1998). 
This suggested that A238L interacts with p65, either directly or through interaction with 
another protein, to block binding of NF-кB to DNA. In a separate study the C-terminal 
82 amino acids of A238L was shown to bind directly to CaN and inhibit CaN 
phophatase activity (Abrams et al., 2008). CaN dependent pathways, including 
inhibition of NFAT mediated gene expression, are therefore inhibited (Miskin et al., 
1998). CaN acts to de-phosphorylate NFAT and this exposes nuclear localisation signals 
on NFAT resulting in its translocation into the nucleus. A238L was proposed to inhibit 
NFAT mediated gene transcription indirectly by inhibiting CaN-mediated 
dephosphorylation of NFAT therefore preventing its nuclear translocation. However, 
this work did not examine the subcellular localisation or phosphorylation status of 
NFAT in ASFV infected cells or in transfected cells expressing A238L and only 
proposed this model as a potential mechanism of action. 
 
The results presented in Chapter 5 of this thesis demonstrate that A238L is able to 
inhibit gene transcription dependent on several transcription factors in addition to NF-кB 
and NFAT. All of the transcription factors identified interact with the transcription co-
activator CBP/P300. This identifies a common link between these factors, and indicates 
that A238L may target CBP/P300 to inhibit gene transcription. This observation 
supports recent work demonstrating that A238L interacts with and inhibits CBP/P300 
function (Granja et al., 2006a; Granja et al., 2008; Granja et al., 2006b).In these studies 
A238L was shown not to prevent the nuclear translocation of NF-кB or NFAT, bu t 
inhibited NF-кB and NFAT dependent gene transcription through direct interaction and 
inhibition of the transcriptional coactivator CBP/P300. CBP and p300 are large nuclear 
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proteins which play a central role in the integration of multiple signaling events within 
the transcriptional apparatus, exerting their activity through several mechanisms 
(Chakravarti et al., 1996; Chan & La Thangue, 2001; Janknecht & Hunter, 1996). These 
proteins do not bind directly to DNA but interact with a variety of sequence specific 
transcription activators including CREB/ATF, c-jun, c-Fos, NF-kB and NFAT, where 
they act as a scaffold protein, linking these transcription factors to the basal 
transcriptional apparatus. In addition they also have histone acetyltransferase (HAT) 
activity allowing them to influence chromatin structure and have been shown to 
acetylate a number of other cellular proteins including p53 and p65 altering their 
transcriptional activity . In an additional level of complexity the activity of CBP and 
p300 is also regulated through phosphorylation and auto-acetylation (Chan & La 
Thangue, 2001). Through these activities CBP and p300 play a central role in the 
regulation and integration of a multitude of signal transduction pathways, including the 
MAPK, NF-кB and JAK/STAT pathways (Janknecht & Hunter, 1996; Vo & Goodman, 
2001).  
 
CBP/p300 share extensive homology and have several conserved domains: including 
two separate transactivation domains located at the amino and carboxyl-terminal region 
and a central acetyl-transferase domain. A diagram of the arrangement of these domains, 
showing interactions with CBP/p300 binding proteins, is presented in Figure 7.1. The 
amino-terminal and carboxyl-terminal TADs can act independently and simultaneously 
with the transcriptional apparatus to regulated gene transcription (Swope et al., 1996). 
A238L has been shown to specifically bind to the amino-terminal TAD of p300, 
preventing interaction between p300 and transcription factors regulated through this 
domain. However, transcription factors associated with the carboxy-terminal region, 
such as c-fos, are unaffected (Granja et al., 2008b). This domain is essential for the 
transactivation of several transcription factors involved in the immune response 
including NF-kB-p65, STAT 3, IFR 3, NFAT and c-Jun (Garcia-Rodriguez & Rao, 
1998; Janknecht & Hunter, 1996; Yoneyama et al., 1998), providing support for the role 
of this protein in modulating the innate immune response. With the exception of ATF-2, 
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all of the transcription factors involved in the regulation of genes down-regulated by 
A238L were directly associated with the carboxyl-terminal transactivation domain of 
CBP/p300 providing additional and independent support for these results.  
 
Interaction between p300 and A238L was also shown to inhibit the subsequent 
acetylation of the p65 subunit of NF-kB (Granja et al., 2008b ). Acetylation of RelA/p65 
regulates NF-κB activity by enhancing its DNA binding activity and attenuating its 
interaction with IκBα (Chen et al., 2002). Therefore this observation is consistent with 
previous work which demonstrated that A238L is able to prevent p50-p65 heterodimers, 
from binding to their DNA binding sites.  
 
Granja et al (2008) also demonstrated that interaction between p300 and A238L did not 
affect the intrinsic HAT activity of p300, but blocked phosphorylation of a novel serine 
residue within the amino-terminus of p300 by PKC-θ. This inhibition prevented the 
autoacetylation of the amino-terminal TAD reducing the transactivation activity of this 
domain. The activity of CBP/p300 is regulated through post-translation modification, 
including phosphorylation, methylation and autoacetylation (Chawla et al., 1998; Liu et 
al., 1999; Stiehl et al., 2007; Xu et al., 2001). The post translation modification status of 
CBP/P300 has a direct effect on the HAT and transcriptional activities of this molecule 
and also alters the binding preference of this molecule for different transcription factors. 
For example, phosp horylation of CBP b y IKKα at two serine resid u es with in  the 
carboxyl-terminal region of CBP, switches the binding preference of CBP from p53 to 
NF-кB (Huang et al., 2007) and autoacetylation of p300 regulates complex formation 
with p53 (Stiehl et al., 2007). Therefore it could be that by altering the acetylation status 
of p300, A238L acts as a molecular switch diverting CBP/ p300 activity away from 


















Figure 7.1 Organisation of CBP/p300 and it’s interacting proteins.
Panel a) Model of CBP/p300 bridging between sequence specific
transcription factors and components of the basal transcription
machinery. TBP, TATA-box-binding protein; TF11B, transcription factor
11B.( Adapted from Janknecht R et al 1996 nature). Panel b) Schematic
representation of CBP/p300 and its associated binding proteins.
Transcriptional activators (top) and basal transcription factors and HATs
(bottom). Functional domains are indicated: zinc fingers (Zn), CREB-
binding domain (KIK), bromodomain (Bromo), HAT domain and







As yet the role of CaN inhibition by A238L within host cells has not been defined. As 
described above the evidence strongly suggests that A238L acts through the 
transcriptional coactivators CBP/p300 to inhibit gene transcription. However it is 
possible that inhibition of CaN by A238L could contribute to this mechanism. One study 
investigating the effect of A238L on COX-2 expression in a Junkat T-cell line (which 
was shown to be dependent on NFAT elements within the COX-2 promoter), 
demonstrated that A238L did not inhibit the nuclear translocation of NFAT or binding of 
NFAT to its DNA binding site. However, overexpression of a constitutively active 
version of CaN reversed A238L mediated inhibition of the expression of COX-2 (Granja 
et al., 2004b). This suggests that inhibition of CaN by A238L is involved in the 
inhibition of COX-2 expression in these cells by an unknown mechanism.  It could be 
that CaN is in some way involved in the activation of CBP/P300. Direct interaction 
between CaN and CBP/P300 has not been demonstrated. However CaN has been shown 
to act in synergy with protein kinase C to activate the IKKβ in both T lymphocytes and 
mouse peritoneal macrophages (Kim et al., 2004; Trushin et al., 1999). CaN has also 
been shown to preferentially synergise with PKC-θ in Ju rk at T cells, tog ether their 
signals converge on (or upstream of) Rac leading to potent JNK activation (Werlen et 
al., 1998). The regulation of CBP/P300 is complex and involves multiple signalling 
pathways which result in the post translation modification of this protein. Therefore CaN 
could potentialy act at a point upstream in these signalling pathways indirectly affecting 
the activity of CBP/P300.  
 
It is also possible that the ability of A238L to inhibit CaN activity has an alternative role, 
independent of regulation NFAT transcriptional activation. As described in chapter 1 
CaN regulates the activity of several cellular proteins in addition to NFAT. These 
proteins include Elk-1 and BAD. CaN negatively regulates the activity of Elk-1, a 
transcription factor activated by mitogen activated protein kinases (MAPK) (Tian & 
Karin, 1999). Therefore inhibition of CaN could potential lead to an increase in Elk-1 
dependent gene transcription; however no up-regulation of gene expression by A238L 
 204 
was detected in this study. CaN is also responsible for activating the pro-apoptotic 
protein BAD (Wang et al., 1999). Therefore it could be that A238L acts as an anti-
apoptotic protein inhibiting calcium-induced apoptosis through CaN mediated 
dephosphorylation of BAD. 
 
Many other viruses express proteins which modulate CBP/P300 function. These include 
several DNA virus oncoproteins such as the adenovirus E1A protein, the Simian virus 
40 (SV40) large T antigen (TAg) and human papillomavirus E6 (Chakravarti et al., 
1999; Eckner et al., 1996; Thomas & Chiang, 2005). CBP and P300 are important 
negative regulators of cell cycle progression, preventing premature exit from G1 phase 
to S phase (Rajabi et al., 2005). Thus inhibition of CBP/P300 by these virus proteins 
promotes entry into S phase. This can promote virus replication by increasing supply of 
factors required for virus DNA replication. E1A directly represses the HAT activity of  
p300/CBP and blocks p53 acetylation (Chakravarti et al., 1999). Simian virus Large T 
antigen alters the phosphorylation status of CBP/P300 and inhibits E2 transcription 
which is associated with a cysteine and histidine rich domain in the carboxy-terminus of 
CBP/P300 and E6 inhibits the p300-mediated acteylation of p53, inhibiting p53 
dependent transcription (Eckner et al., 1996; Thomas & Chiang, 2005). All of these 
proteins target the activation of carboxy-terminal interacting transcription factors, such 
as p53 or E2F, and can alter the HAT activity of P300/CBP promoting the malignant 
transformation of infected cells. In contrast to these viral oncogenic proteins, A238L has 
been shown to interact with the amino – terminal region of p300 consistent with an 
alternative role for this protein in regulating the host immune response. Retroviruses also 
express proteins which manipulate CPB/P300. The Tax protein from human T cell 
leukemia virus recruits CBP/P300 in conjunction with cellular CREB to conserved CRE-
containing elements within the HTLV promoter. Together these proteins act as potent 
activators of viral transcription (Geiger et al., 2008). 
 
The results described in chapter 5 indicate the broad effect of A238L expression on host 
gene transcription. In this experiment A238L was over-expressed to indicate all of the 
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potential roles of this protein on host cell transcription. These results demonstrated that 
A238L can inhibit transcription of a diverse range of genes associated with several 
cellular processes. Studies in mice deficient in p300 or CBP have demonstrated that 
these molecules are in limiting supply within the cell and competition for CBP/P300 by 
different transcription factors can lead to negative interference between different 
signalling pathways (Janknecht & Hunter, 1999). Therefore it is probable that A238L 
exhibits a more specific effect during ASFV infection targeting a distinct subset of 
ASFV activated cellular genes. Future work comparing differential gene expression 
between A238L deletion mutant ASFV and wild type ASFV using the porcine 
microarray described in this study would help to resolve this question and could also 
provide an indication of functional redundancy between A238L and other ASFV genes. 
Considering the potential for A238L to exhibit different properties at different times 
during the ASFV infectious cycle, it would also be beneficial to look at differences in 
the host cell gene transcription at several different time points during ASFV infection.  
 
7.3 Mechanisms involved in the subcellular localisation of A238L 
 
The second aim of this thesis was to carry out further investigation into the mechanisms 
involved in the sub-cellular localisation of A238L to gain a better understanding of how 
this protein functions.  
 
7.3.1 A238L is actively shuttled between the nucleus and cytoplasm 
Previous work on A238L has demonstrated that this protein is present in both the 
nucleus and cytoplasm of ASFV infected cells (Bowick, 2004). Other work has also 
showed that A238L is present in the nucleus and cytoplasm of transiently transfected 
Vero cells and a human T-cell line expressing A238L (Granja et al., 2004b; Granja et 
al., 2006d). The results presented in chapter 6 demonstrated that A238L was located in 
both the nucleus and cytoplasm of ASFV infected cells and that a proportion of this 
cytoplasmic pool was actively imported into the nucleus and exported by the CRM-1 
dependent pathway. This suggests that A238L consists of two populations within the 
 206 
cell: molecules that are actively imported and exported from the nucleus and molecules 
that are retained in the cytoplasm. Previous work on A238L has shown that A238L 
consists of 2 molecular weight forms consisting of 32 kDa and 28 kDa (Tait et al., 
2000). Western blotting analysis of nuclear and cytoplasmic fraction of ASFV infected 
cell lysates demonstrated that both forms of A238L can be detected in the cytoplasm of 
infected cells throughout infection with the 32 kDa higher molecular mass form of 
A238L accumulating predominantly in the nucleus at later times post-infection (Bowick, 
2004; Silk et al., 2007). Treatment of infected cells with cytosine arabinoside, an 
inhibitor of ASFV DNA replication and late virus gene expression did not alter the 
cellular levels of A238L indicating that A238L is synthesised early during ASFV 
infection and that late gene expression is not required for the nuclear accumulation of 
A238L (Bowick, 2004).  
The difference between the two forms of A238L has not been defined but is thought to 
be due to post-translational modification of A238L (Tait et al., 2000). Possible 
explanations for accumulation of the 32 kDa form of A238L in the nucleus could be that 
the modification to the protein takes place in the nucleus or that this modification is 
required for nuclear translocation of the protein. Previous data has shown that A238L, 
co-localises and associates with CBP/P300 in the nucleus of both Vero cells and 
stimulated T-cells. Together this data could suggest that, particularly at late times post 
infection, the 32 kDa form of A238L preferentially functions within the nucleus to 
inhibit CBP/P300 action. It could be that this higher molecular mass 32 kDa form of 
A238L shuttles between the nucleus and cytoplasm, explaining the presence of both 
forms of A238L in the cytoplasm of infected cells.  
Events responsible for the predominant nuclear accumulation of A238L at late time 
points post infection demonstrated by Bowick 2004 have not been established. The 
results presented in chapter 6 did not detect a significant difference between the 
subcellular distribution of A238L between 8 and 16 hrs post ASFV infection. However 
this work is not directly comparable to Bowick (2004). The approach used in chapter 6 
involved transfecting cells with a plasmid expressing A238L under the control of its own 
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promoter and then infecting the cells with ASFV to activate gene transcription. This 
approach leads to the over expression of A238L in ASFV infected cells and was 
necessary to produce detectable levels of A238L for immunofluorescence analysis. 
Possibly over expression of A238L may lead to the presence of this protein in the 
nucleus at earlier time points during ASFV infection. The results presented in chapter 6 
also demonstrated that A238L nuclear import and export was not dependent on cell 
pathways activated through PMA, LPS or ionomycin treatment in ASFV infected cells. 
This observation is inconsistent with recent work which demonstrated that A238L was 
localised preferentially in the cytoplasm of un-stimulated T cells and, after treatment 
with PMA/Ionomycin translocated to the nucleus (Granja et al., 2008). A similar 
observation was demonstrated in Vero cells (Granja et al., 2006b). Unlike the 
experiments carried out in chapter 6 these studies did not examine the subcellular 
localization of A238L in the presence of LMB, which blocks nuclear export of A238L. 
Bowick (2004) demonstrated that A238L predominantly accumulated in the nucleus at 
late times post-infection, however low levels of A238L could be detected within the 
nucleus from 3 hrs post-infection. Possibly A238L continually shuttles between the 
nucleus and cytoplasm in un-stimulated cells and is only retained in the nucleus 
following PMA/ionomycin treatment or ASFV activation of a cellular pathway at late 
times points following ASFV infection. Immunoprecipitation studies (Granja et al., 
2008), indicated that A238L preferentially interacts with p300 following 
PMA/ionomycin treatment. P300 activity is regulated through phosphorylation by many 
different kinases including PKC (Goodman & Smolik, 2000). PMA/ionomycin treatment 
leads to the activation of several PKC isotypes including PKC-θ. Therefore one possible 
explanation for these results could be that post-translational modification of p300 
induced by PMA/ionomycin treatment or pathways activated by ASFV infection 
increases the binding efficiency between A238L and P300, leading to the nuclear 
retention of A238L. 
Sequence analysis of A238L identified the presence of two putative nuclear localisation 
signals (NLS-1 and NLS-2). NLS-2 was located within the CaN docking motif. Both of 
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theses signals were found to be functionally active and exhibit functional redundancy. 
CaN is not thought to contain specific NLSs and instead is thought to shuttle into the 
nucleus in a complex with other proteins such as NFAT (Crabtree & Olson, 2002). 
Mutation of the A238L CaN motif alone in the presence of an intact NLS-2, resulted in a 
dramatic increase in the nuclear localisation of A238L.  This suggests that binding of 
A238L to CaN masks NLS-2 contributing to the cytoplasmic retention of A238L. 
Therefore if it could be that if the higher molecular weight form interacts in the nucleus 
with CBP/P300, the lower 28 kDa form of A238L is held in the cytoplasm in complex 
with CaN. A representation of this model is presented in Figure 7.2.  
A significant amount of further work is required to establish if this model is correct. As 
described above the difference between the two forms of A238L has not been 
established, but is thought to be due to post-translation modification (Tait et al., 2000).  
CBP/P300 is known to acetylate several proteins including histones (Chan HM and La 
thang NB 2001). Therefore considering the interaction between A238L and CBP/P300 it 
is possible that this PTM could be due to acetylation. Two-dimensional gel 
electrophoresis (2DE) followed by Post-Source Decay Matrix-Assisted Laser 
Desorption/Ionization Mass Spectrometry (PSD-MALDI-MS) has recently revealed that 
the ASFV protein pE120R, essential for virus transport from assembly sites to plasma 
membranes, is acetylated at the N-terminal Ala residue during infection (Alfonso et al., 
2007). This approach could also be used to establish the nature and location of any PTM 
present on the A238L protein. This information could then be used to investigate the 
affinity of each form of A238L for p300 and CaN. Further investigation into the 
localization of CaN within ASFV infected and A238L transfected cells would also help 
to establish if the above model is correct.  
 
7.4 Role of A238L during ASFV infection 
 
Despite the ability of A238L to regulate the expression of many genes involved in the 
host’s immune response, deletion of the A238L gene from ASFV field isolates does not  
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Figure 7.2 Schematic representation of the mechanism of A238L action.
A238L  protein is proposed to consist of two populations: one set of molecules that are 
actively shuttling between the nucleus and cytoplasm and use CRM-1 mediated nuclear 
export and a second group that are retained in the cytoplasm through interaction with 
the cellular protein CaN. CaN is thought to mask a nuclear localisation signal (NLS) 
located within the CaN binding domain of A238L there by contributing to the cytoplasmic
retention of A238L. Once in the nucleus A238L interacts with and inhibits gene 
transcription through direct binding and inhibition of the transcriptional co-activator 
CBP/P300. Experiments suggests that the 32 kDa form of A238L (dark green) shuttles 
between nucleus and cytoplasm and the 28 kDa form of A238L (light green) is located 
preferential in the cytoplasm. Experimental evidence providing support for this model is 
published in Granjer et 2008, Silk et al 2007, Abrams et al 2007 and Miskin et al 2000.
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affect the pathogenesis of this disease or reduce ASFV replication in cell culture (Neilan 
et al., 1997; Salguero et al., 2008). A recent study comparing pathogenesis in pigs 
infected with a highly virulent isolate of ASFV (E-70) and an A238L E-70 deletion 
mutant demonstrated that TNF-α mRNA expression was enhanced in PBMC taken from 
pigs inoculated with the A238L deletion isolate compared to the wild type isolate. This 
indicates that A238L can inhibit pro-inflammatory gene expression in vivo in infected 
domestic pigs. However no significant differences in clinical symptoms and disease 
pathology were observed (Salguero et al., 2008). Although this result seems surprising 
there are several possible explanations. First of all the effect of deleting A238L on 
secretion of proinflammatory cytokines has not been measured in vivo. Gene expression 
is regulated at several different levels and changes in transcription level may not lead to 
the same effect at the functional level. Other ASFV genes may also compensate for the 
loss of A238L to reduce proinflammatory gene expression. 
 
It is also possible that A238L may have an essential role in the natural hosts of ASFV, 
warthogs and Ornithodoros ticks. The IKK, MAPK and JAK/STAT signalling pathways 
are ancient evolutionarily conserved pathways and have been identified in invertebrates 
(Arbouzova & Zeidler, 2006; Bantignies et al., 2002; Govind, 1999; Sluss et al., 1996). 
Functional homologues of CBP and CaN are also present in invertebrates (Bantignies et 
al., 2002). It is therefore reasonable to propose that A238L may function in the tick 
vector. Therefore it would be interesting to investigate the replication and pathogenesis 
of A238L deletion mutants and wild type isolates in its tick vector, to establish the role 




The results presented in this thesis provide compelling evidence for the role of A238L as 
a potent inhibitor of gene transcription through inhibition of the transcriptional co-
activator CBP/P300 and demonstrates that A238L is able to suppress a number of 
immunological signalling pathways through this action.  
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The results also provide evidence that A238L functions within both the cytoplasm and 
nucleus of ASFV infected cells and suggest that a sub-population of A238L may be 
retained in the cytoplasm through interaction with CaN. These results combined with 
recent publications exploring the mechanism of A238L action (Abrams et al., 2008; 
Granja et al., 2008; Silk et al., 2007) support a model where A238L acts within the 
cytoplasm of infected cells at early times post infection potentially inhibiting CaN, and 
is retained in the nucleus at late time points post infection to inhibit CBP/P300 action.  
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This study examined nuclear and cytoplasmic shuttling of the African swine fever virus (ASFV)
A238L protein, which is an inhibitor of NF-kB and of calcineurin phosphatase. The results showed
that the protein was present in both the nucleus and the cytoplasm in ASFV-infected cells and that
the higher molecular mass 32 kDa form of the A238L protein was the predominant nuclear
form, which accumulated later in infection. In contrast, both the 28 and 32 kDa forms of the A238L
protein were present in the cytoplasm. The A238L protein was actively imported into the nucleus
and exported by a CRM1-mediated pathway, although a pool of the protein remained in the
cytoplasm and did not enter the nucleus. By using a recombinant ASFV from which the A238L gene
had been deleted, it was shown that expression of A238L did not inhibit nuclear import of the NF-kB
p50 or p65 subunit and did not inhibit nuclear export of p65 by a CRM1-mediated pathway. The
results were consistent with a model in which A238L functions within both the nucleus and the
cytoplasm.
INTRODUCTION
African swine fever virus (ASFV) is a large cytoplasmic DNA
virus that replicates primarily in macrophages in vivo and in
macrophages and endothelial cells in vitro. ASFV causes an
acute haemorrhagic fever in domestic pigs but inapparent
infections in its natural hosts – warthogs, bushpigs and ticks
of the species Ornithodoros moubata and Ornithodoros
erraticus. In these hosts, and in domestic pigs, which recover
from infection with less-virulent isolates, the virus can
persist over long periods. The virus genome varies from
about 170 to 192 kbp and encodes between 160 and 175
proteins. ASFV shares similarities in replication strategy
with poxviruses but is classified in a separate family, the
Asfarviridae (Dixon et al., 2005). Estimates indicate that
about 90 poxvirus proteins are required for virus replication
in cells, suggesting that ASFV may require a similar number
(Upton et al., 2003). Other virus-encoded proteins include
several with roles in evading host defence systems (Dixon
et al., 2004).
One of these, the A238L protein, functions by several
different mechanisms to interfere with signalling pathways
in infected macrophages. The first functions demonstrated
for A238L were inhibition of NF-kB activation and
inhibition of calcineurin phosphatase activity. As a
consequence, calcineurin-activated pathways, such as
activation of the NFAT (nuclear factor of activated T cells)
transcription factor are inhibited. More recently A238L has
been shown to inhibit TNF-a expression through a CREB-
binding protein (CBP)/p300 transcriptional co-activators
pathway (Granja et al., 2004b; Miskin et al., 1998, 2000;
Powell et al., 1996; Revilla et al., 1998). By interfering with
the activation of several different host factors, A238L is
predicted to inhibit transcriptional activation of a broad
spectrum of host response genes. So far, A238L expression
has been shown to inhibit transcription of the COX-2 gene
and production of prostaglandins and to inhibit transcrip-
tional activation of the TNF-a gene. This could reduce the
inflammatory response to ASFV and help prevent virus
elimination (Granja et al., 2006). Interestingly, deletion of
the A238L gene from the genome of a virulent ASFV isolate
did not reduce the virulence of the virus for domestic pigs
(Neilan et al., 1997), suggesting either that the pathways
inhibited by A238L do not play a critical role in virus
pathogenesis or that the virus encodes other complementary
genes. which may compensate for the loss of A238L.
Mapping of the domain in the A238L protein required to
bind to calcineurin has identified a 14 aa peptide located
between residues 200 and 213, which binds with high affinity
to calcineurin but does not inhibit its phosphatase activity. A3These authors contributed equally to this work.
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critical motif in this peptide, PxIxITxC/S, is similar to
calcineurin-docking motifs in the NFAT substrate and other
cellular inhibitors of calcineurin (Aubareda et al., 2006;
Martinez-Martinez & Redondo, 2004). A purified recombi-
nant peptide containing the C-terminal 82 aa of A238L
alone was sufficient to act as a potent inhibitor of calcineurin
(C. C. Abrams, R. Silk, D. Chapman & L. K. Dixon et al.,
unpublished results; Miskin et al., 2000).
The A238L protein contains ankyrin repeats in the centre of
the protein, which most closely resemble those in the IkBa
protein, which acts as an inhibitor of NF-kB activation. This
data suggests that, like IkB proteins, A238L may bind
directly to NF-kB, inhibiting its activity. Further support for
this model comes from experiments showing that expres-
sion of A238L inhibits NF-kB-dependent gene transcription
and that A238L is co-precipitated from cell extracts with the
p65 subunit of NF-kB (Revilla et al., 1998). Moreover,
addition of A238L recombinant protein to nuclear extracts
from activated cells showed that A238L inhibited binding of
p65/p50 NF-kB heterodimers to kB-binding sequences and
displaced preformed complexes from these sequences.
Together, these data suggest that A238L can act as a
homologue of IkBa. However, a direct interaction between
A238L and p65 has not been demonstrated and it remains
possible that A238L acts by a different mechanism to inhibit
NF-kB. It has also been shown that A238L is recruited into a
complex with p65 only after signal-induced degradation of
IkB, suggesting that A238L does not displace IkB from a
complex with NF-kB but instead is incorporated into a
complex after degradation of IkB (Tait et al., 2000). Two
different forms of the A238L protein have been detected
with molecular masses of 28 and 32 kDa; these two forms
are thought to result from post-translational modification,
but the nature of the modification has not been defined. The
32 kDa form of A238L has been shown to co-precipitate
with p65 (Tait et al., 2000).
The IkB family of proteins consists of at least seven members
(IkBa, IkBb, IkBe, p105, p100, IkBf and Bcl-3), which
contain a central domain with five to seven ankyrin repeats.
These act by several mechanisms to inhibit the activity of
NF-kB (Hayden & Ghosh, 2004; Israel, 2000). The crystal
structures of IkBa and IkBa bound to NF-kB p65/p50
heterodimers show that the ankyrin repeats of IkB make
multiple contacts with NF-kB to block both the DNA-
binding site and the nuclear localization signal (NLS) of p65
(Huxford et al., 1998; Jacobs & Harrison, 1998; Malek et al.,
2001, 2003). However, the exposed NLS on the p50 subunit
coupled with a nuclear export signal (NES) present on both
IkBa and p65 result in constant nuclear–cytoplasmic
shuttling of NF-kB/IkB complexes, although the steady-
state localization is in the cytoplasm (Huang et al., 2000;
Johnson et al., 1999). Signal-induced degradation of IkB
alters the dynamics of this shuttling, leading to nuclear
accumulation of NF-kB and activation of NF-kB-dependent
gene transcription. Transcription of IkB genes is activated
by NF-kB and this provides a negative feedback loop to
regulate NF-kB activation. Newly synthesized IkB enters the
nucleus forming a complex with NF-kB, which leads to its
displacement from target DNA sequences and export from
the nucleus (Huang & Miyamoto, 2001; Israel, 2000).
Although previous data have suggested that A238L may
function within the nucleus, one study showed that, at 8 h
post-infection (p.i.), A238L was found exclusively in the
cytoplasm in a complex with NF-kB. This suggested that
A238L may inhibit NF-kB activity by retaining the complex
in the cytoplasm (Tait et al., 2000). However, detailed
studies of the nuclear–cytoplasmic shuttling of A238L
throughout a time course of infection have not been carried
out. In this study, we showed that A238L is actively
transported into the nucleus, with larger amounts present at
late times p.i. We also demonstrated that a proportion of
A238L is exported from the nucleus by a CRM1-mediated
pathway. In addition, we showed that A238L does not
inhibit nuclear import or export of p65.
METHODS
Viruses and cells. African green monkey (Cercopithecus aethiops)
kidney (Vero) cells were maintained in Dulbecco’s modified Eagle’s
medium containing 25 mM HEPES and supplemented with 2 mM
glutamine, 50 U penicillin ml21, 50 mg streptomycin ml21 and 5 %
bovine fetal calf serum (FCS; PAA Laboratories GmbH).
ASFV strains were the BA71V tissue-culture-adapted ASFV isolate and
recombinants of this isolate, which either had the simian virus 5 (SV5)
Pk epitope tag (V5 tag) fused to the 59 end of the A238L gene (SV5Gal)
or had the coding region of A238L deleted (vIKGal). These viruses
contained the b-galactosidase gene under the control of the ASFV p72
promoter inserted at the site of recombination (Miskin et al., 1998).
Virus infection. Cells were washed and virus was added at an
m.o.i. of 5 in serum-free medium. After incubation for 1.5 h at
37 uC, virus was removed. Cells were then washed twice and cultured
in medium with FCS for various lengths of time as indicated.
Preparation of cell extracts. Cells were washed in PBS, harvested
by scraping and pelleted by centrifugation. To prepare nuclear and
cytoplasmic fractions, cells were resuspended in 200 ml pre-chilled
fractionation buffer [150 mM Tris/HCl (pH 8.8), 10 mM KCl,
1 mM EDTA, 0.2 % NP-40, 10 % glycerol, 1 mM PMSF, 1 mg small
protease inhibitors (leupeptin, pepstatin, antipain and chymostatin)
ml21] and incubated on ice for 10 min. The suspension was then
centrifuged for 5 min at 13 200 r.p.m. in a benchtop centrifuge to
pellet the nuclei. The supernatant was removed and added to 200 ml
SDS-PAGE sample buffer [100 mM Tris/HCl (pH 6.8), 4 % SDS,
0.2 % bromophenol blue, 20 % glycerol, 100 mM dithiothreitol]. The
nuclear pellet was then harvested in 50 ml SDS-PAGE sample buffer
and the DNA sheared by repeated passage through a 21-gauge
needle. To prepare total extracts, cell pellets were resuspended in
SDS-PAGE sample buffer and the DNA sheared as described above.
To confirm that fractions were not cross-contaminated, parallel
blots were probed with antibody against histone H1 as a nuclear
marker or against a-tubulin as a cytoplasmic marker.
Western blotting. Proteins were separated by SDS-PAGE electro-
phoresis and transferred to nitrocellulose membranes. Membranes
were blocked in blocking solution [3 % milk powder in PBS with
0.1 % Tween 20) at 4 uC overnight or at room temperature for 3 h.
Membranes were incubated with antibodies in blocking solution for
1 h at room temperature and then washed in PBS plus 0.05 %
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Tween 20, before incubation with HRP-conjugated protein A
(ab7456-1, diluted 1 : 2000; Abcam). Bound antibodies were detected
by enhanced chemiluminescence (ECL). Digital images of gels were
collected using a Bio-Rad GS-710 densitometer.
Indirect immunofluorescence. Cells were grown on glass cover-
slips to approximately 90 % confluence and then transfected for 4 h
using Lipofectamine 2000 (Invitrogen). Following transfection, cells
were washed in serum-free medium and then, where appropriate,
infected with ASFV following the above protocol. At the appropriate
times p.i., the coverslips were washed with PBS, fixed in 4 % paraf-
ormaldehyde for 30 min and permeabilized for internal staining
with PBS containing 0.2 % Triton X-100 (Sigma) for 15 min. Cells
were blocked in PBS containing 3 % BSA (Sigma) for 1 h and then
incubated with primary antibody diluted in PBS/3 % BSA. V5-
tagged proteins were detected with mouse anti-Pk tag (diluted
1 : 100; Serotec) and p65 was detected using anti-p65 (sc-372, diluted
1 : 200; Santa-Cruz). After 30 min, the cells were washed three times
in PBS plus 0.2 % Tween 20 (Sigma) and then incubated with sec-
ondary antibodies diluted 1 : 300 in PBS/3 % BSA for 30 min.
Primary mouse antibodies were detected using Alexa 488-conjugated
goat anti-mouse IgG and rabbit polyclonal serum was detected using
Alexa 568-conjugated goat anti-rabbit IgG secondary antibody
(Molecular Probes). Cells were washed twice in PBS/0.2 % Tween
and three times in PBS. The coverslips were mounted onto slides
with Vectashield containing DAPI (Vector Laboratories). The cells
were visualized using a Leica TCS SP2 confocal laser scanning
microscope. Data were collected sequentially to prevent cross-talk
between detection channels and were analysed using LCS (Leica
Confocal Software). The images shown are representative of three
independent experiments.
RESULTS
A238L accumulates in the nucleus at late times
p.i.
The subcellular localization of the 28 and 32 kDa forms of
the A238L protein at various times p.i. was investigated. To
do this, Vero cells were infected with a recombinant ASFV
(SV5Gal) in which the wild-type A238L gene had been
replaced with an A238L gene containing the Pk tag from SV5
fused to the 59 end. This fusion has previously been shown
not to affect either function of A238L (Miskin et al., 1998).
At various times p.i., cell extracts were separated into
nuclear and cytoplasmic fractions. These fractions were
separated by SDS-PAGE, blotted onto nitrocellulose
membranes and probed with an antibody against the Pk
tag to detect the A238L protein. As shown in Fig. 1(a), both
the 28 and 32 kDa forms of the A238L protein were detected
early in infection (3 or 4 h p.i.). At early times, most of the
A238L protein was present in the cytoplasm, although
overexposure of the gels showed that small amounts of
A238L could be detected in the nucleus from 3 h p.i.
(Fig. 1b). Increasing amounts of A238L could be detected in
the nuclear fraction from 16 h p.i., reaching a maximum at
16–24 h p.i. Slightly more of the 28 kDa form of A238L was
detected at early times p.i. compared with the 32 kDa form,
but from 16 h p.i. onwards, the 32 kDa form of the protein
was the main form detected, particularly in the nuclear
fraction. The protein detected in the nucleus at late times p.i.
ran slightly more slowly than the form detected in the
cytoplasm, raising the possibility that it had been modified
further. Parallel infected cultures were incubated for 16 h in
the presence of cytosine arabinoside, an inhibitor of virus
DNA replication and late virus gene expression. Similar
amounts of both forms of the A238L protein were detected
in the nuclear and cytoplasmic fractions compared with
cultures incubated without cytosine arabinoside (Fig. 1c).
This showed that most of the A238L protein was synthesized
early in infection and that late virus gene expression was not
required for nuclear accumulation of A238L or for the
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Fig. 1. Localization of the A238L protein in different subcellular fractions during ASFV infection. (a) Vero cells were infected
with SV5Gal. At various times after infection, cells were harvested and separated into nuclear and cytoplasmic fractions.
Proteins from each fraction were separated by SDS-PAGE, transferred to nitrocellulose membranes and probed with anti-Pk
tag antibodies followed by HRP-conjugated anti-mouse secondary antibodies. Bound antibodies were detected by ECL. The
time (h p.i.) at which extracts were harvested is indicated. (b) Overexposure of extracts harvested 3 h p.i. (c) Extracts
harvested from cells at 16 h p.i. in the presence (+) or absence (”) of cytosine arabinoside. N, Nuclear fraction; C,
cytoplasmic fraction.
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A238L is exported from the nucleus by a
CRM1-mediated pathway
To investigate whether A238L was exported from or retained
in the nucleus, the subcellular localization of A238L was
examined in the presence of leptomycin B (LMB), a specific
inhibitor of the CRM1-dependent nuclear export pathway
(Huang et al., 2000). Levels of A238L detected in infected
cells by immunofluorescence were low and difficult to
quantify. Therefore, we transfected Vero cells with a plasmid
containing a Pk-tagged A238L gene under the control of the
A238L promoter. Cells were then infected with ASFV isolate
BA71V. Three hours prior to fixation, cells were treated or
not with LMB in the presence or absence of PMA and LPS.
Cells transfected with a plasmid containing Pk-tagged IkBa
were used as a positive control for LMB: IkBa contains a
CRM1-dependent NES and has previously been shown to
accumulate exclusively in the nucleus in the presence of
LMB (Huang et al., 2000). These cells were treated with
PMA/LPS to activate NF-kB and enhance IkB nuclear
import. At 8 and 16 h p.i., cell cultures were fixed,
permeabilized and stained with an antibody specific to the
Pk tag, followed by a fluorescently labelled secondary
antibody. Cells were then examined using confocal micro-
scopy and the subcellular localization of A238L was
determined.
As shown in Fig. 2(a), in cells stimulated with PMA/LPS in
the presence of LMB, all of the IkB was present in the
nucleus as expected. In the absence of LMB, although most
IkB was in the nucleus, a detectable amount was present in
the cytoplasm. This is consistent with the nuclear export of
IkB via the CRM1-mediated pathway and showed that the
LMB was functionally active.
In ASFV-infected cells expressing A238L under the control
of its own promoter, A238L exhibited a distribution that
could be characterized into three distinct patterns of
subcellular localization: preferentially nuclear, a uniform
distribution throughout the cytoplasm and nucleus, or
preferentially cytoplasmic [see Fig. 2b(i)]. One hundred cells
were scored for these three cellular distributions under each
experimental condition and in three independent experi-
ments. In the presence of LMB, at both 8 and 16 h p.i., there
was a significant increase in the number of cells exhibiting
a predominantly nuclear localization compared with in
the absence of LMB (~50 % compared with <10 %)
[Fig. 2b(ii)]. This demonstrated that at least a proportion of
the nuclear A238L was exported to the cytoplasm using the
CRM1-dependent nuclear export pathway. In cells treated
with LMB, A238L was predominantly present in the nucleus
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Fig. 2. A238L is exported from the nucleus by a CRM1-
mediated pathway. (a) Vero cells were transfected for 16 h
with a plasmid expressing Pk-tagged IkBa. Three hours prior to
fixation, cells were treated with LPS (10 mg ml”1) and PMA
(100 nM) in the presence or absence of LMB (40 nM). (b)
BA71V-infected Vero cells expressing Pk-tagged A238L under
the control of its own promoter. Three hours prior to fixation,
cells were treated with or without LPS and PMA in the pre-
sence or absence of LMB, as above. At 8 or 16 h p.i., cells
were fixed and stained. In both (a) and (b), Pk-tagged proteins
were detected with anti-Pk antibody, followed by Alexa 488-
conjugated goat anti-mouse IgG secondary antibody, and
imaged using confocal microscopy. The subcellular localization
of Pk-tagged A238L was characterized as preferentially nuclear
(N), both nuclear and cytoplasmic (N/C) or preferentially cyto-
plasmic (C). Representative images are shown (i). For each
condition tested, 100 cells were counted and the percentages
of cells exhibiting N, N/C and C distributions were determined.
Cells were examined in the absence (ii) or presence (iii) of
PMA/LPS, with or without LMB as indicated. Data presented is
the mean (±SD) of three independent experiments. Bars,
10 mm.
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treated with LMB, A238L exhibited an even distribution of
A238L throughout the nucleus and cytoplasm. It is possible
that a proportion of A238L was either not imported into the
nucleus and remained in the cytoplasm, or, if it was imported
into the nucleus and then exported, a CRM1-independent
nuclear export pathway may have been involved.
Infection of cells is likely to activate a number of signalling
pathways and this probably explains why no difference was
observed in the distribution of A238L in PMA/LPS-treated
cells compared with untreated cells. The Western blot results
shown in Fig. 1 indicated that at 9 h p.i. most A238L was in
the cytoplasm. In contrast, the results from the immuno-
fluorescence experiments shown in Fig. 2 suggested that
similar amounts of A238L were present in the nucleus at 8
compared with 16 h p.i. One possible explanation is that
protein expression was higher from the plasmid transfected
into infected cells in the immunofluorescence experiments.
The complex interactions of A238L with components of the
NF-kB and calcineurin signalling pathways and with nuclear
import and export machinery mean that altering expression
levels of A238L may alter its distribution. Nevertheless, our
key conclusion regarding the nuclear export of A238L
remained valid.
Nuclear import of A238L occurs by
an energy-dependent process
Both forms of A238L are less than 60 kDa, which is the
diffusion exclusion limit of the nuclear pore complex. To
determine whether A238L is imported into the nucleus by an
active process, cells were treated with cycloheximide to
block protein synthesis and then incubated at 37 or 4 uC. At
4 uC, all active transport processes are blocked, whereas
diffusion is unaffected. In the majority of cells at 4 uC, A238L
was found to be evenly distributed between the nucleus and
cytoplasm, both in the presence and absence of LMB.
However, when cells were incubated at 37 uC, the results
were dramatically different and A238L exhibited a pre-
dominantly nuclear localization in almost 50 % of the cells
examined (Fig. 3). This suggested that, although passive
diffusion may play a role in the nuclear import of A238L, an
additional active nuclear transport process is involved.
This comparison also showed that there was no significant
difference in the distribution of A238L in cells treated with
cycloheximide compared with untreated cells (see Fig. 3).
As inhibition of protein synthesis did not prevent the
nuclear accumulation of A238L, we concluded that a pool of
pre-existing cytoplasmic A238L was imported into the
nucleus.
Expression of A238L does not inhibit nuclear
translocation of NF-kB
To investigate whether expression of A238L inhibited
nuclear translocation of NF-kB, we compared nuclear
translocation of the p65 and p50 subunits of NF-kB in cells
infected with ASFV BA71V isolate expressing the Pk-tagged
A238L gene (SV5Gal) or a recombinant BA71V isolate from
which the A238L gene had been deleted (vIKGal). Deletion
of the A238L gene has been shown previously not to affect
virus replication in cells and, as demonstrated in Fig. 4(b),
the patterns of virus protein synthesis were not significantly
different during a time course of infection with these viruses.
To determine whether the total cellular pool of the p65 and
p50 proteins was altered following infection with SV5Gal or
vIKGal virus, total cell extracts were separated by SDS-
PAGE, blotted and probed with antibody against p65 or p50.
No change was detected in the total cellular pool of p50
during infection with either virus (Fig. 4a). In contrast, an
increase in the amount of p65 was detected at 3 h p.i. Total
amounts of p65 decreased at 6 and 9 h p.i. but increased
again at 12 and 18 h p.i. These results suggested that
regulation of the total cellular pool of p65 may contribute to
regulation of NF-kB activity during ASFV infection.
However, similar changes in amounts of p65 were observed
in cells infected with both wild-type BA71V and the deletion
mutant lacking A238L, suggesting that A238L expression
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Fig. 3. Movement of A238L is energy-dependent. ASFV-
infected Vero cells expressing Pk-tagged A238L under the
control of its promoter were treated with cycloheximide (CHX;
100 mg ml”1) (a) or were left untreated (b). Three hours prior
to fixation, cells were treated with or without LMB (40 nM) and
incubated at either 37 or 4 6C. Pk-tagged A238L was detected
by indirect immunofluorescence. The percentages of cells exhi-
biting the N, N/C and C phenotypes were determined for each
condition tested. Data represent the mean of three independent
experiments (±SD).
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At various times after infection, cells were fractionated into
nuclear and cytoplasmic extracts and these were separated
by SDS-PAGE, blotted onto nitrocellulose membranes and
probed with antibodies that recognized either the p50 or the
p65 NF-kB subunit. Fig. 5(a) shows that in cells infected
with SV5Gal, which expressed A238L, the p65 subunit of
NF-kB was detected in both nuclear and cytoplasmic
fractions throughout infection. Larger amounts were
detected in the nucleus at late times (16–24 h p.i.). At
early times, the p50 subunit was detected almost exclusively
in the cytoplasm but was detected in both nuclear and
cytoplasmic fractions at late times (16–24 h p.i.). Fig. 5(b)
shows the distribution of the p65 and p50 subunits following
infection with the vIKGal ASFV A238L deletion mutant.
There was no significant difference in the distribution of p65
and p50 between the nucleus and cytoplasm when results
were compared with those from cells infected with virus
expressing A238L. At 16 and 24 h p.i., an additional 55 kDa
form of p65 was detected in the nucleus. The appearance of
this band is consistent with cleavage of p65 late in infection
by caspase-3 (Kang et al., 2001), which has been shown to be
induced in ASFV-infected cells (Nogal et al., 2001).
Fig. 6 shows cells that were infected with ASFV and stained
with antibodies against an early ASFV protein, p30 (green),
and the p65 subunit of NF-kB (red); nuclei are shown in
blue. Translocation of p65 to the nucleus was observed in
cells that were stained with the anti-p30 antibody. There was
no difference in the amount of p65 in the nucleus of
uninfected cells that did not show positive staining with the
anti-p30 antibody, demonstrating that nuclear translocation
of p65 was not inhibited in cells infected with ASFV. To
determine whether expression of A238L inhibited nuclear
export of p65, we compared localization of p65 in cells
infected with BA71V or vIKGal ASFV in the presence and
absence of LMB. The results showed that, as expected,
treatment of cells with LMB resulted in an increase in the
percentage of cells showing a predominantly nuclear
localization of p65. In the absence of LMB, an increase in
the amount of cytoplasmic p65 was observed, showing that
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Fig. 4. Expression of the p50 and p65 subunits of NF-kB at
different times after infection with recombinant ASFV either
expressing A238L (SV5Gal) or with the A238L gene deleted
(vIKGal). Vero cells were infected with the SV5Gal or vIKGal
recombinant strains of ASFV isolate BA71V. At different times
p.i., total cell extracts were harvested, separated by SDS-PAGE
and blotted onto nitrocellulose membranes. Blots were probed
with antibodies against the p65 or p50 subunits of NF-kB or
against a-tubulin (a), or with hyperimmune serum from an
ASFV-infected pig (b). Appropriate HRP-conjugated secondary
antibodies were used and bound antibodies were detected by
ECL. The positions of the major capsid protein, p72, and of
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Fig. 5. Localization of the p50 and p65 subunits of NF-kB at different times after infection with recombinant ASFV either
expressing A238L (SV5Gal) or with the A238L gene deleted (vIKGal). Vero cells were infected with the SV5Gal (a) or vIKGal
(b) recombinant strains of the ASFV BA71V isolate. At different times p.i., cells were harvested and separated into nuclear and
cytoplasmic fractions. These were separated by SDS-PAGE and blotted onto nitrocellulose membranes. Blots were probed
with antibodies against the p65 or p50 subunit of NF-kB, or with an antibody against histone H1 as a control for the
fractionation. After reaction with an appropriate secondary antibody, bound antibodies were detected by ECL. The time (h p.i.)
at which extracts were harvested is indicated. N, nuclear fraction; C, cytoplasmic fraction. Lane M, mock-infected cells.
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CRM1-mediated pathway. No difference was observed in
the cells infected with the two viruses, demonstrating that
A238L does not inhibit nuclear export of p65.
DISCUSSION
The A238L protein of ASFV inhibits activation of the NF-kB
transcription factor and the phosphatase activity of
calcineurin. In addition, A238L has been shown to inhibit
transcription from the TNF-a promoter by a mechanism
involving the CBP/p300 transcriptional co-activators. The
A238L protein thus has the potential to act as a potent
immunosuppressant by inhibiting transcriptional activation
of the many immune response genes regulated by these
factors (Miskin et al., 1998, 2000; Powell et al., 1996; Revilla
et al., 1998). Evidence to date has shown that, in a T-cell line,
A238L inhibition of cyclo-oxygenase 2 (COX2) gene
transcription is dependent on an NFAT element within
the gene promoter and involves inhibition of the p300
transcriptional co-activator (Granja et al., 2004a). Similarly,
inhibition of TNF-a expression has been shown to involve
inhibition of CBP/p300 function (Granja et al., 2006). The
NF-kB and NFAT pathways are targeted by other viruses
(Bowie et al., 2004; Camus-Bouclainville et al., 2004; Li et al.,
2004; Scott et al., 2001), although A238L is the only protein
known to combine both of these functions in a single
protein.
Little is known of the detailed mechanism by which A238L
functions. Previous work has suggested that the protein may
function in both the cytoplasm and the nucleus (Granja
et al., 2006; Revilla et al., 1998; Tait et al., 2000), but a
detailed study of the location and cytoplasmic nuclear
shuttling of A238L during ASFV infection has not previously
been carried out.
The similarity between the ankyrin repeats of A238L and
those of members of the IkB family suggests that A238L may
make direct contact via these ankyrin repeats with NF-kB
subunits. The observation that A238L can be co-precipitated
with the NF-kB p65 subunit supports this hypothesis,
although direct contact between A238L and p65 has not
been demonstrated. IkB proteins contain between five and
seven ankyrin repeats, and crystallographic structures of
IkBa and IkBb in complex with p65/p50 NF-kB hetero-
dimers show that the IkB ankyrin repeats make multiple
contacts with NF-kB, blocking both the NLS and DNA-
binding domain on the p65 subunit (Huxford et al., 1998;
Jacobs & Harrison, 1998; Malek et al., 1998, 2003). In
contrast, A238L contains only four ankyrin repeats, and
protein structure modelling (D. Chapman & L. K. Dixon,
unpublished data), based on the structure of IkB in complex
with NF-kB, suggests that A238L may block the DNA-
binding site but not the nuclear localization signal on p65,
and vice versa.
In this study, we have shown that A238L is imported into the
nucleus by an active process in virus-infected cells. Western
blotting of nuclear and cytoplasmic cell extracts suggested
that the 32 kDa higher molecular mass form of A238L
predominantly accumulated in the nucleus at later times
post-infection. Previous data has shown that this form of the
protein is co-precipitated with the NF-kB p65 subunit,
suggesting that, particularly at late times p.i., A238L
functions within the nucleus to inhibit NF-kB. The
difference between the two forms of A238L has been








Fig. 6. p65 nuclear import and export is not inhibited in ASFV-
infected cells. Vero cells were fixed 8 h after infection with
BA71V (a) or vIKGal isolates (b). Three hours prior to fixation,
cells were stimulated with PMA (100 nM) and LPS
(10 mg ml”1) in the presence or absence of LMB. Cells were
incubated with an antibody against cellular p65 (red) and with
an antibody specific for the early viral protein p30 (green). DNA
was labelled with DAPI (blue). Bars, 10 mm.
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protein, although the nature of the modification has not
been defined (Tait et al., 2000). Possible explanations for
accumulation of the 32 kDa form of A238L in the nucleus
are that the modification to the protein takes place in the
nucleus or that this modification is required for nuclear
translocation of the protein. NLSs on A238L have not been
defined to date. However, sequence analysis of A238L using
PSORT (Horton et al., 2006), which predicts possible
subcellular localization sites, has identified two putative
NLSs. These consist of single, short stretches of amino acids
highly enriched in basic residues. One of these is located at
the N terminus towards the tail end of the first ankyrin
repeat domain and the second is located at the C terminus
within the PxIxITxC/S calcineurin-binding domain. A
proportion of the A238L protein is also present in the
cytoplasm. We showed a greater nuclear accumulation of
A238L in cells when LMB was added to inhibit CRM1-
mediated nuclear export. Thus, we concluded that A238L is
exported actively from the nucleus by a CRM1-mediated
pathway. No NESs were identified and it is not known
whether A238L interacts directly with the nuclear export
pathways or translocates in association with another protein
that contains a NES.
Our experiments indicated that the cytoplasmic A238L
protein comprises both molecules that do not enter the
nucleus and molecules that are actively exported from the
nucleus. If the higher molecular mass 32 kDa form of A238L
shuttles between the nucleus and cytoplasm, this could
explain why both forms are present in the cytoplasm. The
28 kDa form of A238L is not co-precipitated with p65,
suggesting that this may be the form of the protein that
binds to and inhibits calcineurin (Tait et al., 2000). If the
predicted NLS within the calcineurin-docking motif in the
A238L protein is functional, then this would be masked
when A238L binds to calcineurin. Hence, this A238L–
calcineurin complex would be predicted to remain in the
cytoplasm. Calcineurin is not thought to contain specific
NLSs and instead is thought to shuttle into the nucleus in a
complex with other proteins such as NFAT (Crabtree &
Olson, 2002).
Our data also showed that expression of A238L did not
inhibit nuclear translocation of the NF-kB p50 and p65
subunits. This is consistent with a model whereby A238L
may act within the nucleus to inhibit binding of NF-kB to
DNA. Previous experiments have shown that recombinant
A238L, when added to nuclear extracts from stimulated
cells, inhibits binding of NF-kB to kB enhancer sequences
and can also displace preformed NF-kB transcription
complexes from DNA (Revilla et al., 1998).
p65 can be exported from the nucleus either using NESs
contained in the p65 protein or as part of a complex with IkB
utilizing export signals on IkB (Huang et al., 2000). Our data
showed that A238L did not inhibit nuclear export of p65,
although we did not define the form in which p65 is
exported in ASFV-infected cells.
Accumulating evidence suggests that IkB proteins play
critical roles within the nucleus in regulating NF-kB-
dependent gene transcription. IkBf acts within the nucleus
and can either inhibit or activate NF-kB transcriptional
activity. IkBf binds to the p50 subunit of NF-kB in both p50/
p50 and p50/p65 NF-kB dimers. Transcription of the IkBf
gene has been shown to be activated in response to IL-1 and
signalling through Toll-like receptors. Evidence from IkBf-
deficient cells shows that IkBf is required for transcriptional
activation of IL-6 and a number of other immune response
genes (Yamamoto et al., 2004; Yamazaki et al., 2001).
Evidence to date suggests that A238L acts as an inhibitor of
NF-kB-dependent gene transcription. However, we cannot
exclude the possibility that A238L may also have some role
in activating gene transcription. This may be revealed by
global transcription profiling.
As both NF-kB and calcineurin are important targets for
immunomodulatory drugs, there is considerable interest in
defining how a single protein can mediate inhibition of both
of these pathways. Understanding how the two functions of
A238L are regulated is also important for understanding its
role during ASFV infection.
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Abstract
The African swine fever virus A238L protein inhibits calcineurin phosphatase activity and activation of NF-κB and p300 co-activator. An 82
amino acid domain containing residues 157 to 238 at the C-terminus of A238L was expressed in E. coli and purified. This purified A238L
fragment acted as a potent inhibitor of calcineurin phosphatase in vitro with an IC50 of approximately 70 nM. Two putative nuclear localisation
signals were identified between residues 80 to 86 (NLS-1) and between residues 203 to 207 overlapping with the N-terminus of the calcineurin
docking motif (NLS-2). Mutation of these motifs independently did not reduce nuclear localisation compared to the wild type A238L protein,
whereas mutation of both motifs significantly reduced nuclear localisation of A238L. Mutation of the calcineurin docking motif resulted in a
dramatic increase in the nuclear localisation of A238L provided an intact NLS was present. We propose that binding of calcineurin to A238L
masks NLS-2 contributing to the cytoplasmic retention of A238L.
Crown Copyright © 2008 Published by Elsevier Inc. All rights reserved.Keywords: African swine fever virus; Calcineurin phosphatase inhibitor; NF-κB inhibitor; Immune evasion; Macrophage; Nuclear localisationIntroduction
African swine fever virus (ASFV) is a large, cytoplasmic
DNA virus and is the only member of the Asfarviridae family.
The virus encodes between 156 and 167 ORFs, many of which
are not essential for virus replication in cells but have important
roles in virus/host interactions. These include a number
encoding proteins which inhibit host defence pathways (Dixon
et al., 2005). One of these, the A238L protein, has been reported
to inhibit signalling pathways in infected cells by three diffe-
rent mechanisms; inhibition of NF-κB activation, inhibition of
the activity of calcineurin (CaN) phosphatase (now known as
protein phosphatase 3C or PP3C) resulting in inhibition of
pathways dependent on CaN including activation of NFAT
transcription factor (Hogan et al., 2003) and inhibition of the
transcriptional co-activator p300 (Granja et al., 2004, 2006b;
Miskin et al., 1998; Powell et al., 1996; Revilla et al., 1998).⁎ Corresponding author. Institute for Animal Health Pirbright Laboratory, Ash
Road, Pirbright, Surrey GU24 0NF, UK. Fax: +44 1483 232448.
E-mail address: linda.dixon@bbsrc.ac.uk (L.K. Dixon).
0042-6822/$ - see front matter. Crown Copyright © 2008 Published by Elsevier In
doi:10.1016/j.virol.2008.01.005A238L is predicted to act as a potent immunosuppressive pro-
tein by inhibiting transcriptional activation of the broad range of
immunomodulatory genes dependent on these pathways. So
far reports have shown that A238L is involved in inhibiting
transcription from the TNF-α, cycloxygenase-2 and inducible
nitric oxide synthase genes which results in reduced production
of inflammatory mediators NO, prostaglandins and TNF-α from
infected cells (Granja et al., 2006a, 2004, 2006b; Miskin et al.,
1998; Powell et al., 1996; Revilla et al., 1998). The A238L
gene is conserved in all ASFV isolates analysed. Deletion of the
A238L gene from the genome of a virulent isolate did not reduce
virus virulence in pigs (Neilan et al., 1997), possibly other genes
may compensate for the loss of A238L. The A238L protein is
238 amino acids long and contains a central region encoding 4
ankyrin-like repeats, an N-terminal domain of unknown func-
tion and a C-terminal domain which contains a docking motif
involved in binding to CaN (Miskin et al., 2000; Neilan et al.,
1997; Revilla et al., 1998). The ankyrin repeats in the A238L
protein resemble those in the IκBα inhibitor of NF-κB acti-
vation. In resting cells NF-κB is present in a complex with IκB
inhibitor proteins (Wietek and O’Neill, 2007). Activation by ac. All rights reserved.
Fig. 1. Inhibition of CaN phosphatase activity by the A238L157–238 fragment.
Panel a) shows proteins purified from E. coli strain BL21 which were
transformed with either pET32a vector alone or pET32a containing A238L
fragment encoding residues 157 to 238. Protein expression was induced by
addition of IPTG and the His-tagged proteins were purified from extracts
by nickel affinity chromatography. Purified proteins were separated by SDS-
PAGE and blotted onto PVDF membranes. The His-tagged proteins were
detected using ant-His antibodies followed by HRP-conjugated Protein A.
Bound antibodies were detected by enhanced chemiluminescence. Lane 1 shows
the Trx protein tag purified from bacteria transformed with pET32a vector and
lane 2 shows the Trx-A238L157–238 fusion protein purified from bacteria
transformed with the vector containing the A238L insert. The position of
molecular weight markers run in parallel is indicated. In Panel b) the effect
of varying concentrations of these proteins on CaN phosphatase activity is
shown. The concentration (nM) of either the Trx-A238L157–238 fusion protein
or the Trx protein alone added to each reaction is indicated on the X-axis.
The CaN phosphatase activity measured in cpm of [32P] released from a
phosphorylated substrate peptide is indicated on the y-axis. Data from a re-
presentative experiment is shown and represents means from 3 replicates.
Standard deviation error bars are shown.
478 C.C. Abrams et al. / Virology 374 (2008) 477–486variety of stimuli leads to phosphorylation dependent ubiquiti-
nylation of IκB and degradation by the proteasome. Nuclear
localisation signals on NF-κB are exposed resulting in its trans-
location into the nucleus and activation of genes containing the
NF-κB binding sites in the promoter. The similarity between the
ankyrin repeats in A238L and those in IκB suggested that A238L
may act as a homologue of IκB to inhibit the stimulus induced
activation of NF-κB that occurs following virus infection. This
was supported by experiments which demonstrated that expres-
sion of A238L inhibits transcriptional activation of an NF-κB
dependent luciferase reporter gene (Powell et al., 1996; Revilla
et al., 1998). The A238L protein was shown, by co-precipitation,
to be present in a complex with the p65 subunit of NF-κB,
although, direct interaction between A238L and the p65 subunit
of NF-κB has not been demonstrated (Revilla et al., 1998; Tait
et al., 2000). In one study A238L was shown to be predominantly
localised in the cytoplasm at 8 h post-infection (Tait et al., 2000).
However, our data showed that the A238L protein is present in
both the cytoplasm and nucleus of cells and accumulates in the
nucleus at later times post-infection (from 10 to 18 hpi). A238L
was shown to be actively imported into the nucleus and exported
by a CRM-1 dependent pathway (Silk et al., 2007). Two forms of
the A238L protein are expressed during infection, a 28 kDa and
32 kDa form. These are thought to differ by post-translational
modification, although the nature of themodification has not been
defined (Tait et al., 2000). The higher molecular weight form
accumulates in the nucleus and is preferentially co-precipitated
with the p65 subunit of NF-κB (Tait et al., 2000). Expression of
A238L does not inhibit nuclear accumulation of NF-κB p50
or p65 subunits. Recombinant A238L added to nuclear extracts
inhibits binding of NF-κB to its binding elements in gene
promoters in electromobility shift assays and displaced prebound
NF-κB from DNA (Revilla et al., 1998). These data provide
support for a model whereby A238L acts in the nucleus to inhi-
bit NF-κB activation.
Evidence that A238L acts by modulating the function of the
transcriptional co-activator CREB binding protein/p300 comes
from studies using cell lines expressing A238L. In a Jurkat
T cell line A238L inhibited expression from the TNF-α pro-
moter by modulating NF-κB, NFAT and c-Jun transactivation
by a mechanism that involves CREB binding protein/p300
function (Granja et al., 2006a). A238L inhibition of transcrip-
tion from the cyclooxygenase-2 promoter depended on NFAT
elements within the promoter and was reversed by a cons-
titutively active CaN. This suggested that inhibition of CaN was
involved in this process. However, the data showed that binding
of NFAT to DNA was not inhibited, but that transactivation of
p300 by a GAL4/NFAT fusion protein was inhibited (Granja
et al., 2004). LPS and IFN-γ stimulated transcription of the
inducible nitric oxide synthase (iNOS) gene promoter was
inhibited in the RAW 264.7 mouse macrophage cell line ex-
pressing A238L. In this study A238L was shown to inhibit p65
and p300 interaction and inhibited p65/rel A and p300 bind-
ing to distal NF-κB sequence in the iNOS promoter. In these
experiments A238L also abrogated p300 transactivation me-
diated by a GAL4 p300 fusion protein. These results also
suggest that A238L acts within the nucleus possibly by inter-fering with the activation of the transcriptional co-activator
CREB binding protein/p300 (Granja et al., 2006b). The mode of
A238L action may depend on the stimulus delivered, cell and
promoter type.
Fig. 2. Domains and mutant forms of A238L used in studies of its subcellular localisation. Panel a) schematically illustrates the structure of A238L illustrating the
position of the ankyrin repeats (Ank1 to 4), predicted NLS (NLS-1 and -2), CaN binding domain (CaN bd) and CaN inhibitory domains. Panel b) shows the sequence
of the CaN inhibitory domain including residues 157 to 238 from the A238L protein of the BA71V strain and the Malawi LIL20/1 strain. Panel c) shows the sequence
of the NLS-1, NLS-2 and CaN binding domain from the wild type A238L and mutant forms used in these studies. The ability of the expressed proteins to bind to CaN
as determined previously is indicated by ‘Yes’ or ‘No’.
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which A238L functions. In particular little is known about func-
tional domains within the A238L protein. A peptide containing the
motifwhich is essential for binding ofA238L toCaNdid not inhibit
phosphatase activity, suggesting that additional sequences from
A238L are required for this inhibition (Miskin et al., 2000). Here
we demonstrate that the C-terminal 82 amino acid domain of
A238L effectively inhibits CaN phosphatase activity. Previously
we showed that the A238L protein is actively imported into the
nucleus and exported by a CRM-1 dependent pathway. Here we
evaluate the role of two putative nuclear localisation signals (NLS)
in the nuclear translocation of A238L. Our results show that mu-
tation of either NLS alone does not alter the nuclear accumulation
of A238L but that mutation of both significantly reduces nuclear
import. In addition we show that mutating the CaN docking motif
of A238L results in increased accumulation into the nucleus
providing an intact NLS is present. Thus binding of A238L to CaN
may result in increased retention of A238L in the cytoplasm.
Results
A238L calcineurin phosphatase inhibitory domain
Our previous data identified critical residues that are required for
binding to CaN, PxIxITxC/S within the sequence PKIIITGC atresidues 206 to 213 close to the C-terminus of A238L. A 14 amino
acid peptide containing residues 200 to 213, which included these
residues, bound with high affinity to CaN but did not inhibit its
phosphatase activity (Miskin et al., 2000). This suggested that other
residues from A238L or possibly another protein, are required to
inhibit CaN. In order to identify this domain, we cloned the 3′ end
of the A238L gene encoding the C-terminal 82 amino acids from
residues 157 to 238 in the bacterial expression vector pET32a. The
A238L sequenceswere fused downstream from the 100 amino acid
Trx tag from the thioredoxin gene. Polyhistidine tags were also
present in frame with the A238L fragment. The plasmid was
transformed into E. coli strain BL21 and, following induction of
expression, a protein of molecular weight 27 kDa was detected in
extracts from bacteria transformed with the plasmid expressing
157–238-A238L-polyhistidine. This protein was not detected in
extracts from bacteria transformed with the vector plasmid alone,
instead an additional protein of 17 kDa was detected following
induction of expression. These proteins were detected by western
blotting using an antibody which binds to the polyhistidine tag,
confirming that they were the proteins expressed from the pET32a
vector (see Fig. 1a). The 157–238-A238L-Trx fusion protein and
the Trx tag expressed from the vector alone were purified byNickel
affinity chromatography and the amount of protein quantified.
Varying concentrations of this purified A238L-polyhistidine fusion
protein, ranging between 60 nM to 720 nM, were added to in vitro
Fig. 3. Effect of mutating NLS-2 and the CaN binding domain on the subcellular distribution of A238L. Vero cells were transfected with plasmids expressing
different versions of PK-taggedA238L under the control of theA238L promoter and infectedwithASFVBA71VVIKGal strain. After incubation for 13 h cells were treated
with or without LMB (40 nM) 3 h prior to fixation. Permeabilised cells were incubated with antibodies against the PK-tag to detect the A238L proteins, followed by Alexa
Fluor 488 conjugated goat anti-mouse IgG secondary antibody and imaged using confocal microscopy. Panel a) shows representative images of the subcellular localisation
of PK-tagged A238L. This was characterised as either, preferentially nuclear (N), both nuclear and cytoplasmic (N/C) or preferentially cytoplasmic (C). Panel b) shows
images from control experiments inwhich a plasmid expressing IκB fused to the PK-tagwas transfected into cells and thesewere either treated or untreatedwith LMB.Panel
c) shows the percentage of cells exhibiting predominantly nuclear (N), predominantly cytoplasmic (C), or nuclear and cytoplasmic (N/C) distributions for each A238L
constructed and tested and under each condition. Data represents 3 independent experiments for which 100 cells were counted for each treatment. Means and standard
deviation error bars are shown. The properties of each plasmid tested are shown beneath the graph. A cross (+) represents a functional CaN binding site, NLS-1 and NLS-2
and a bar (−) represents non-functional motifs.
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inhibit the release of [32 P] from a phosphorylated substrate of CaN
was measured in reactions containing 100 nM concentration of
CaN (Fig. 1b). This showed that the 157–238-A238L-polyhistidine
protein inhibited CaN in a dose dependent manner varying from
45% inhibition at 60 nM concentration to 80% at 150 nM andmore
than 90% at 720 nM. The IC50 was estimated to be 70 nM. In
contrast, no inhibition was observed when comparable amounts of
control Trx tag protein purified from bacteria transformed with the
pET32a vector without insert was added to the CaN phosphatase
assays. A similar percentage inhibition was observed when either
the CaN autoinhibitory peptide or cyclosporine A, cyclophilin
complexes were added to reactions (data not shown). These results
show that theC-terminal domain ofA238L containing residues 157and 238 alone is a very effective inhibitor of CaN phosphatase and
that no additional proteins are required. The estimated IC50 is
comparable to that reported for other inhibitors of CaN including
carabin, cyclosporine A/cyclophilin complexes and calcipressin.
Attempts were made to further define the domain of A238L re-
quired to inhibit CaN phosphatase by subcloning a fragment con-
taining residues 157 to 213 and testing in in vitro assays using the
same strategy. The results showed this fragment did not inhibit CaN
even at concentrations up to 600 nM (data not shown). A peptide
was synthesised which contained residues 191 to 220 fromA238L.
Thiswas tested for its ability to inhibit CaNphosphatase activity but
no inhibition was observed even at concentrations up to 600 nM
(data not shown). Although no inhibition of CaN activity was
observed with these fragments of A238L, we cannot exclude the
481C.C. Abrams et al. / Virology 374 (2008) 477–486possibility that this was because the fragments did not fold in their
native format.
Sequences involved in the nuclear localisation of A238L
Previous data had suggested that A238L is present both in
the cytoplasm and in the nucleus and that a proportion of the
protein is actively transported into the nucleus and exported by
a CRM-1 dependent pathway (Silk et al., 2007). In order to
define signals in A238L that may be involved in nuclear
localisation and to determine if interaction with CaN may af-
fect the localisation of A238L, we observed the subcellular
localisation of a series of mutants of the A238L protein by
confocal microscopy. Analysis of the A238L protein sequence
using the PSORT programme (Horton et al., 2006), which
predicts putative nuclear localisation signals (NLS), identified
two (see Fig. 2). These NLSs consist of short stretches of amino
acids, highly enriched in basic residues. One of these (NLS-1)
is located close to the N-terminus of A238L near the C-terminus
of the first ankyrin repeat domain and includes amino acids 80
to 86 (PHRRDKD). The second (NLS-2), which includes the
sequence KKKPK between amino acids 202 to 206, is loca-
ted close to the C-terminus adjacent to and overlapping the
PxIxITxC/S CaN binding domain. Mapping the NLS-1 motif
onto the model of the predicted structure of A238L, suggests
it is on the surface of the A238L protein. The NLS-2 sequence
is also predicted to be located on the surface since it overlaps the
CaN binding site.
To determine if the predicted signals NLS-1 and NLS-2
are involved in the nuclear localisation of A238L, mutations
were generated in each of these sites separately and in both sites
(Fig. 2). The subcellular localisation of the expressed A238L
proteins was examined by confocal microscopy by using anti-
bodies against the PK-epitope tag fused at the N-terminus of
the gene. Plasmids expressing A238L under the control of the
A238L promoter and containing mutations within the CaN
binding motif have been described previously (Miskin et al.,
2000). Plasmids W13-A238L and B19-A238L contain muta-
tions within the predicted NLS-2. Although plasmidW20-A238L
contains a P to S mutation, this is not predicted to disrupt NLS-2.
The proteins W20-A238L and W13-A238L do not bind to
CaN whereas the WT-A238L and B19-A238L proteins bind
CaN (Fig. 2) (Miskin et al., 2000).
An additional plasmid was constructed which had muta-
tions within the predicted NLS-1. This plasmid (pcDNA3-
A238L 84–88) encodes 5 G residues at amino acid positions 84–
88, instead of the wild type sequence, DKDGN. This was
predicted by the PSORT programme to inactivate the NLS-1
sequence present between residues 80–86. This mutant form of
the A238L protein was cloned under control of its own promoter
and fused to the PK-epitope tag (pFlanks-WT-NLS-1). A 310 bp
N-terminal fragment of A238L containing these mutations in
NLS-1, was inserted into the plasmids described above which
contain mutations within the predicted NLS-2 and CaN bind-
ing domain. The amino acid sequence of the regions including
NLS-1 and NLS-2 and the CaN binding properties of all of these
plasmids are described in Fig. 2.The effect of disrupting NLS-2 was first examined by trans-
fection of plasmids expressing wild type and mutant A238L
proteins under control of their own promoter into ASFV-infected
Vero cells. The subcellular distribution of A238L was examined
at late times post-infection by confocal microscopy in both the
presence and absence of leptomycin B (LMB) to inhibit CRM-1
mediated nuclear export (Fig. 3a and b). All of these plasmids
encode an intact NLS-1. Plasmids pFlanks-W13-A238L and
B19-A238L contain mutations which are predicted to disrupt
NLS-2; W13-A238L encodes a protein which does not bind
CaN and B19-A238L binds to CaN. As mentioned above, the
P to S mutation in plasmidW20-A238L does not disrupt NLS-2,
but the expressed protein does not bind to CaN. The distribution
of A238L was scored as predominantly nuclear, predominantly
cytoplasmic or distributed between the nucleus and cytoplasm.
Three independent experiments were performed and distribu-
tions were scored in 100 cells for each treatment (see Fig. 3.).
Both W13-A238L and B19-A238L showed a similar sub-
cellular distribution to wild type A238L in both the absence
and presence of LMB (Fig. 3c). This showed that disruption of
the NLS-2 motif alone was not sufficient to alter or prevent the
nuclear accumulation of A238L. Surprisingly, in cells trans-
fected with the plasmid expressing W20-A238L, which has an
intact NLS-2 but disrupted CaN binding motif, a dramatic
increase in the number of cells exhibiting a predominantly
nuclear distribution was observed compared to the wild type
protein, both in untreated cells and cells treated with LMB. This
observation was particularly dramatic in cells treated with LMB
since the proportion of cells showing a nuclear distribution of
A238L increased from approximately 25% for wild type A238L
to greater than 70% for W20-A238L. The number of cells
showing a predominantly nuclear distribution was also sig-
nificantly increased in the absence of LMB: from approximately
2% for wild type A238L to approximately 30% forW20-A238L.
Since disruption of the CaN binding site significantly increases
the nuclear accumulation of A238L a likely hypothesis is that the
interaction between wild type A238L and CaN masks NLS-2,
contributing to the retention of a proportion of A238L in the
cytoplasm of ASFV-infected cells. The difference observed
between untreated cells and those treated with LMB confirm our
previous results (Silk et al., 2007) and indicate that a proportion
of A238L is exported from the nucleus by a CRM-1 mediated
pathway.
The effect of mutating NLS-1 alone, and in combination
with NLS-2, was also examined. The subcellular localisation of
A238L in the presence and absence of LMB was examined
following transfection of 4 plasmids expressing forms of A238L
which all had mutations in NLS-1 (A238L-NLS-1, W13-
A238L-NLS-1, W20-A238L-NLS-1 and B19-A238L-NLS-1).
A238L-NLS-1 does not contain mutations in NLS-2 and, al-
though W20-A238L-NLS-1 has a mutation of the P to S residue
(see Fig. 2), this is not predicted to interfere with the function of
NLS-2. WT-A238L-NLS-1 and B19-A238L-NLS-1 bind CaN
whereas W20-A238L-NLS-1 and W13-A238L-NLS-1 do not
bind CaN. W13-A238L-NLS-1 and B19-A238L-NLS-1 both
contain a disrupted NLS-2; W13-A238L-NLS-1 does not bind
CaN whereas B19-A238L-NLS-1 does bind CaN. As shown
Fig. 4. Effect of mutating NLS-1, NLS-2 and the CaN binding domain on the subcellular distribution of A238L. Vero cells were transfected with plasmids expressing
different versions of PK-tagged A238L under the control of its promoter and infected with ASFV BA71V vIKGal strain. After incubation for 13 h cells were treated
with or without LMB (40 nM) 3 h prior to fixation. Permeabilised cells were incubated with antibodies against the PK-tag to detect the A238L proteins, followed by
Alexa Fluor 488 conjugated secondary antibody. A238L was detected by indirect immunofluorescence. Cells were imaged using confocal microscopy. The percent of
cells exhibiting predominantly nuclear (N), predominantly cytoplasmic (C), or nuclear and cytoplasmic (N/C) distributions was determined for each A238L
constructed and tested and under each condition. Data represents 3 independent experiments for which 100 cells were counted for each treatment. Means and standard
deviation error bars are shown. The properties of each plasmid tested are shown beneath the graph. A cross (+) represents a functional CaN binding site, NLS-1 and
NLS-2 and a bar (−) represents non-functional motifs.
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similar subcellular distribution to wild type A238L, indicating
that disruption of NLS-1 alone was not sufficient to alter the
nuclear accumulation of A238L. The protein expressed from
plasmidW20-A238L-NLS-1 showed a similar distribution to that
expressed from the parental W20 plasmid, (see Figs. 3c and 4)
and, as discussed above, a significant increase was detected in the
nuclear accumulation of these A238L proteins compared to WT
A238L. This supports our hypothesis that disruption of the CaN
binding domain results in increased nuclear accumulation of
A238L, provided that a functional NLS is present.
In contrast to these results, when cells were transfected
with plasmids expressingW13-A238L-NLS-1 and B19-A238L-
NLS-1, which contain mutations within both NLS-1 and NLS-2,
a dramatic decrease in the number of cells exhibiting a pre-
dominately nuclear distribution was observed. In the presence
of LMB, less than 15% of the cells examined showed a pre-
dominately nuclear distribution for both W13-NLS-1-A238L and
B19-NLS-1-A238L, compared to greater than 50% for WT-
A238L. In the absence of LMB a significantly higher proportion of
cells transfectedwithW13-A238L-NLS-1 andB19-A238L-NLS-1
exhibited a predominantly cytoplasmic distribution (approxi-
mately 50%) compared to those transfected with a plasmid
expressing WT-A238L (b10%). Therefore mutation of both
NLS-1 and NLS-2 together significantly reduced the nuclear
accumulation of A238L, although nuclear translocation of
A238L was not completely abolished. This suggests that, in
addition to NLS-1 and NLS-2, another mechanism may operate
to facilitate the nuclear localisation of A238L. Taken toge-
ther these results indicate that both of these NLS play a sig-
nificant role in the nuclear localisation of A238L, and appear toact independently with one compensating for the loss of the
other.
Mutation of residues within the A238L ankyrin repeats does not
alter the ability to inhibit NF-κB dependent gene expression
The mechanism by which A238L inhibits NF-κB activity has
not been defined. Although A238L has been shown to be co-
precipitated from cells with the p65 subunit of NF-κB (Revilla
et al., 1998; Tait et al., 2000), direct interaction of these proteins
has not been demonstrated. However, the presence of ankyrin
repeats in A238L suggests that these may make direct contact
with NF-κB, as has been reported for IκB. Determination of the
structure of IκB in complex with NF-κB (Huxford et al., 1998)
showed that non-contacting amino acids play a role in the
formation of this complex. The most important of these residues
are found within 20 Å of residues Asn 202 and Ser 203 of the
P65 subunit of NF-κB (Huxford et al., 1998). The structure of
the central domain of A238L containing the ankyrin repeats was
modelled using the DeepView software and the structure of
IκBα as substrate. Comparison of this model of A238L with
that of IκBα identified those residues on A238L which were
predicted to be within a 20 Å radius of the 202 and 203 residues
of p65 and potentially to make contact with p65. These included
two groups of residues between 84 to 88 and 121 to 125 which
were highly conserved in the A238L sequences from all ASFV
isolates. These residues are located within the ankyrin repeats
and are predicted to be solvent exposed on the loop structures.
To determine if mutation of these residues altered the ability
of A238L to inhibit NF-κB dependent gene transcription, three
mutant forms of A238L were tested. The residues 84 to 88
Fig. 5. Effect of mutations in A238L protein on inhibition of NF-κB activation.
Sequences encoding residues 84–88 and 121–125 of A238L were mutated as
shown in panel a). Plasmids expressing A238L proteins containing these
mutations were co-transfected into LPK15a cells with a plasmid expressing the
luciferase reporter gene under control of an NF-κB dependent element. Cells
were stimulated with PMA, LPS and ionomycin and after 4 h extracts were
prepared and tested for luciferase activity. The plasmid transfected is indicated
on the x-axis. The y-axis indicates luciferase activity as a percentage of that
observed in stimulated cells transfected with vector alone and also shows the
percentage inhibition of this activity. Results from a typical experiment
including triplicate samples are shown in panel b). Mean and standard deviation
error bars are shown.
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residues to Gs was described above (A238L-NLS-1). Two ad-
ditional mutant forms of A238L were constructed. One of these
had mutated sequences encoding residues 121 to 125 to either
G or S (A238L 121_125). The third mutant (A238L 84+121)
combined both sets of mutations in residues 84 to 88 and 121 to
125. To test the effect of these mutant forms of A238L on
activation of NF-κB dependent transcription, the plasmids ex-
pressing mutant forms or wild type A238L were co-transfected
into PK15a cells with an NF-κB dependent luciferase reporter
construct. Cells were stimulated with PMA, LPS and ionomycin
to activate NF-κB and the level of activation assayed by mea-
suring luciferase activity in cell extracts. The expression of
wild type A238L inhibited the activation of NF-κB depen-
dent gene transcription by 78% compared to stimulated cells
(Fig. 5) whereas expression of A238L-NLS-1 inhibited NF-κB
activation by 68% and expression of A238L 121_125 inhibited
NF-κB activation by 69%. Expression of the A238L mutant,
A238L 84+121, which combined both of these mutations, also
inhibited NF-κB activation by 69%. Therefore mutation of these
groups of residues both individually and combined had a com-
paratively small effect on the ability of A238L to inhibit NF-κB
activation.Discussion
A238L is the only protein known to combine the functions of
inhibiting both CaN phosphatase activity and activation of NF-κB.
The importance of these pathways as targets for immunosup-
pressive drugs means that there is considerable interest in defi-
ning the molecular mechanisms by which these dual functions
of A238L are mediated and the functional consequences. Pre-
viously a CaNdockingmotif of sequence PKIIITGCwas identified
in the C-terminal domain of A238L. This domain contains critical
residues PxIxITxC/S required for binding of A238L to CaN. A 14
amino acid peptide, including this motif and adjacent residues,
bound to CaNwith high affinity (Kd 600 nM) but did not inhibit its
phosphatase activity, suggesting that additional residues were
required for inhibition. These might be either from A238L or
another protein which might associate with A238L (Miskin et al.,
2000a). Here we show that an 82 amino acid C-terminal domain of
A238L very effectively inhibits CaN phosphatase activity at low
concentrations (IC50 is approximately 70 nM) indicating that this
fragment binds to CaN with high affinity to inhibit its phosphatase
activity.
The CaN docking motif in A238L closely resembles those in
substrate proteins of CaN including NFAT 1–4 (Aramburu et al.,
1998, 1999) and the yeast transcription factor Crz1 (Roy et al.,
2007) as well as cellular inhibitors of CaN including members
of the calcipressin family and cabin/cain (Aubareda et al., 2006;
Liu, 2003; Martinez-Martinez and Redondo, 2004; Sun et al.,
1998).
Although all of these proteins share the conserved residues
PxIxIT in their CaN docking sequence, other residues both in the
core motif and surrounding residues differ considerably. There is
strong evidence supporting a model whereby the sequence of
these other residues in the docking motif determines the affinity
of binding to CaN. A random screening approach identified
the peptide containing core residues PVIVIT which bound to
CaN with higher affinity than the docking peptide identified in
NFAT (PRIEIT) (Aramburu et al., 1998, 1999). Replacement of
the CaN docking motif in the CaN substrates NFAT and the
yeast Crz1 protein with the PVIVIT sequence resulted in their
constitutive dephosphorylation and activation (Aramburu et al.,
1998; Roy et al., 2007). In the NFAT protein a second site
involved in binding to CaN has been identified and it is propo-
sed that this is a lower affinity interaction which is brought
into contact with CaN following initial binding to the PRIEIT
sequence. This brings the hyperphosphorylated residues on
NFAT in contact with the active site following displacement of
the autoinhibitory peptide of CaN (Garcia-Cozar et al., 1998;
Park et al., 2000). The structure of the PVIVIT peptide in
complex with CaN has recently been solved by NMR. These
results showed that the PVIVIT peptide binds as a β-strand on
the edge of aβ-sheet of CaN. The side chains of the core residues
PxIxIT make extensive interactions with conserved residues in
CaN. Non-conserved residues are solvent exposed and sequence
variations can modulate the Kd of the interaction (between 1 μM
to 1 mM) (Li et al., 2007; Takeuchi et al., 2007). We showed
previously that a 14 amino acid residue peptide containing the
docking motif from A238L competed more strongly for binding
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supporting the hypothesis that A238L may bind to CaN via this
docking motif with higher affinity than NFAT (Miskin et al.,
2000). We propose that this interaction brings additional resi-
dues from A238L into contact with CaN, resulting in inhibition
of phosphatase activity, possibly by blocking access to the active
site. Other possibilities such as conformational changes in CaN
induced by the binding cannot be excluded. Our demonstration
that a purified recombinant protein containing the C-terminal 82
amino acids of A238L inhibits CaN phosphatase activity very
effectively with an IC50 comparable to other defined CaN in-
hibitors (IC50 in the nM range) shows that no other proteins are
required for the inhibition. We have not further defined the
sequences in A238L required for inhibiting CaN. There is no
obvious sequence similarity with the second site in NFAT (Cn B)
that is required for binding to CaN or with inhibitory domains
from the defined CaN endogenous inhibitors (Hogan et al.,
2003). Sequence comparison of A238L proteins from 9 different
isolates show that these share between 75 and 100% identity
(Neilan et al., 1997) and residues in the C-terminal domain are
very well conserved.
Previous data has shown that A238L is present in both the
cytoplasm and nucleus of cells and that a proportion is active-
ly imported into the nucleus and exported by a CRM-1 mediated
pathway (Silk et al., 2007). Here we have examined the role of
two predicted NLS signals, one located within the first anky-
rin repeat and the other immediately adjacent to the CaN docking
motif. We showed that mutation of each of these independently
did not significantly alter the nuclear accumulation of A238L
when compared to the wild type A238L. However, when both
of these putative NLS were mutated, nuclear accumulation
of A238L was significantly reduced compared to mutation of
either NLS alone or the wild type A238L. This suggests that
both of these putative NLS are involved in nuclear import of
A238L and that one can compensate for loss of the other.
Mutation of the CaN docking motif, which is adjacent to and
partially overlaps with the NLS-2, resulted in a dramatic increase
in nuclear accumulation of A238L when the NLS-2 signal was
intact. In contrast expression of mutant A238L, with both a
disrupted CaN docking motif and NLS-2 signal did not result
in any increased nuclear accumulation compared to wild type
A238L. An attractive hypothesis is that binding of CaN to
A238L masks this NLS-2 and this contributes to retention of
A238L in the cytoplasm. In this case theNLS-1, which is close to
the N-terminus of A238L and distant from the CaN binding
domain, may be exposed and direct nuclear translocation of
A238L. We observed increased nuclear accumulation of the
higher molecular weight form of A238L at late times post-
infection compared to early times (Silk et al., 2007). This form of
A238L was shown to be preferentially co-precipitated with the
p65 subunit of NF-κB suggesting it may function primarily to
inhibit NF-κB activity. Possibly post-translational modification
of A238L may disrupt its binding to CaN exposing NLS-2 and
enhancing the nuclear localisation of this modified form of
A238L. Binding of CaN to the lower molecular weight form
of A238L may enhance cytoplasmic retention of this form of
the protein.The detailed mechanism by which A238L inhibits NF-κB
activation remains unclear. AlthoughA238L can be co-precipitated
with the p65 subunit of NF-κB, direct interaction between the
proteins has not been demonstrated. Herewe havemutated residues
of A238L predicted to be important for interaction with p65 and
shown that there was no dramatic effect of these mutations on the
ability of A238L to inhibit NF-κB activation.
No other proteins have been described which have the dual
functions of inhibiting both CaN and NF-κB pathways. However
endogenous inhibitors of CaN combined with other pathways
have been described. One such endogenous inhibitor is the
ubiquitously expressed Cabin 1/cain CaN protein. This consists
of more than 2200 amino acids and contains functional domains
in addition to the CaN inhibitory domain. A region containing
multiple ligands for SH3 domains is required for binding of Cabin
1/cain to amphiphysin, a component of a protein complex res-
ponsible for calcium dependent synaptic vesicle release. A model
was proposed in which Cabin 1/cain serves as a negative regula-
tor of CaN and neurotransmitter endocytosis. In addition to its
function as a negative regulator of CaN, Cabin 1/cain was shown
to act as a transcriptional repressor of the myocyte enhancing
factor (MEF)-2 family of transcription factors. This may provide a
mechanism to integrate regulation of both CaN dependent and
MEF2 pathways. An endogenous inhibitor of CaN, named
Carabin, has recently been identified, which also inhibits the Ras
signalling pathway through its intrinsic Ras GTPase-activating
protein (GAP) activity. Expression of this inhibitor is induced
through the T cell signalling pathway. As a negative feedback
inhibitor of the CaN signalling pathway that also mediates cross-
talk between CaN and Ras, Carabin may provide a mechanism
for feedback regulation of pathways including T cell activation
(Pan et al., 2007). Evidence suggests that the main role of the
A238L protein is to inhibit the activation of host defence path-
ways dependent on CaN and NF-κB which occurs in response to
virus infection. Targeting of these pathways by A238L em-
phasises their importance in regulating the host's defences in
infected macrophages.
CaN and NF-κB pathways are important targets for im-
munosuppressive drugs. Understanding how A238L inhibits
both pathways will provide new leads for drug discovery. Here
we have identified a short domain of 82 amino acids which acts
as a potent inhibitor of CaN.
Materials and methods
Viruses and cells
The Vero cell-adapted ASFV strain BA71V with the A238L
gene deleted, vIKGAL, has been described previously (Miskin
et al., 1998). Vero cells were used for infections with ASFV.
Vero cells and PK15a (Gilpin et al., 2003) cells were used for
transfections.
Construction of plasmids
The fragments of A238L encoding residues 157 to 238 and
157 to 213 from the Malawi LIL 20/1 isolate were amplified by
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the 5′ and 3′ ends respectively. These fragments were digested
with Bam HI and Hind III and cloned into the pET32a vector
(Novagen), which had been digested with the same enzymes.
Sequences encoding residues 84 to 88 and 121 to 125 of
A238L were mutated using the Stratagene quick change sys-
tem. The respective fragments were amplified by PCR from







introduce the following mutations, residues 84 to 88 change
from DKDGN to GGGGG and residues 121–125 are changed
from NFNGM to GSGGG, respectively.
The plasmids pFlanks-A238L, pFlanks-W13-A238L, pFlanks-
W20-A238L, and pFlanks-B19-A238L have been described
previously (Miskin et al., 2000). These contain upstream promoter
sequences of the A238L gene and either the wild type A238L gene
from Malawi LIL 20/1 isolate or forms of the gene containing
mutations in the CaN docking motif as described previously
(Miskin et al., 2000). The PK-tag is fused at the N-terminus of the
A238L gene in all plasmids. The plasmids pFlanks-WT-A238L-
NLS-1, pFlanks-W13-A238L-NLS-1, pFlanks-W20-A238L-
NLS-1, and pFlanks-B19-A238L-NLS-1 were constructed by in-
serting a fragment containing the mutated version of the predicted
NLS-1 site into plasmids pFlanks-A238L, pFlanks-W13-A238L,
pFlanks-W20-A238L, and pFlanks-B19-A238L. This was ac-
hieved by PCR amplification of a fragment encoding amino acids 1
to 103 from the pcDNA3-A238L84–88 plasmid using forward and
reverse primers containing an Xho1 site and EcoN1 site res-
pectively. The resulting PCR product was digested with Xho1 and
EcoN1 and ligated into the appropriate backbone plasmid from
which the same fragment had been removed by digestion. The
sequence of all plasmids was confirmed. The NF-κB dependent
luciferase reporter plasmid was a gift from Prof. Ron Hay, Uni-
versity of Dundee and was used previously to measure the effect
of A238L.
Expression and purification of proteins from E. coli
The pET32a vector containing fragments from A238L and
the vector without insert, were transformed into E. coli strain
BL21 and cultures incubated at 37 °C. Expression of the proteins
was induced by addition of IPTG and 2 h after induction bacteria
were pelleted and lysed by suspension in buffer containing
50 mM Tris pH 8.0, 1 mM DTT, 10 mM imidazole, 300 mM
NaCl, 0.1% NP40 and a mixture of protease inhibitors (Sigma),
followed by sonication for 5 bursts of 30 s. The expressed
proteins were purified using His Trap columns (GEHealthcare)
according to the manufacturer's instructions. Purified proteins
were stored at −80 °C in aliquots. The amount of protein present
was determined using the Protein Assay Kit (Biorad) and by
comparison with a known amount of protein markers run on
SDS-PAGE and detected by silver staining. Proteins sampleswere separated by SDS-PAGE and either detected by silver
staining or blotted onto Hybond C membranes (GE Health care)
and detected with anti-His antibody (GE Healthcare) followed
by secondary antibodies. Bound antibodies were detected by
enhanced chemiluminescence.
CaN phosphatase assays
Purified CaN (100 nM Sigma) and calmodulin (600 nm
Sigma) were incubated for 30 min. with 32P-labelled RII phos-
phopeptide in 60 μl reactions containing 12 mM Tris–HCl
(pH 7.5), 3.5 mMMgCl2, 17 mM CaCl2, 8 mM 2-mercaptoetha-
nol, and 58 μg/ml bovine serum albumin. CaN phosphatase
activity was measured by release of [32P]-phosphate from the RII
phosphopeptide (Fruman et al., 1996). Where indicated recombi-
nant proteins were added to the reactions.
Infection and transfection
Vero cells or PK15a cells were seeded into 35 mm wells of a
6 well plate at a density of 1×106 and incubated at 37 °C, 5%
CO2, for 24 h. Vero cells were infected with ASFV for 2 h then
transfected with 5 μg of plasmid DNA using lipofectin or
lipofectamine according to the manufacturer's recommenda-
tions (Invitrogen). After transfection for 5 h at 37 °C, 5% CO2,
the transfection reagent was replaced with 3 ml of antibiotic free
DMEM and incubated for further periods as indicated.
SDS-PAGE gel electrophoresis and Western blotting
Protein samples were prepared in SDS-PAGE sample load-
ing buffer and heated at 90 °C for 5 min to denature the pro-
tein sample. Proteins were resolved at 100 V on 12.5% Tricine
SDS-PAGE gels. Where appropriate a small aliquot of the pro-
tein sample was removed for quantification prior to the ad-
dition of loading buffer. Gels were either silver stained or
transferred to PVDF membrane, 0.2 μm, for Western blot ana-
lysis. Western blots were probed with anti-His antibody (GE
Healthcare) at a dilution of 1/1000 followed by HRP-conjuga-
ted Protein A. Bound antibodies were detected by enhanced
chemiluminescence.
Confocal microscopy
Cell monolayers were grown on 22×22 mm glass cover slips
in 35 mm wells and fixed for 20 min in PBSe containing 4%
paraformaldehyde. The cells were permeabilised in 1% Triton
X-100 in PBSe for 15 min then incubated in 0.5% BSA in PBSe
for 30 min to inhibit non-specific antibody binding. They were
incubated with primary antibody diluted in 0.5% BSA/PBSe for
1 h and after washing in secondary antibody diluted in 0.5%
BSA/PBSe for 1 h. After washing cells were mounted onto glass
slides using VectaShield mounting medium with Dapi (Vector
Laboratories). The cells were visualised using Leica TCS SP2
confocal microscopy. The primary antibody used was mouse
anti-PK-tag (Serotec) 20 μg/ml and the secondary antibody was
Alexa Fluor 488 goat anti-mouse 10 μg/ml.
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PK15a cells were transfected with either a NF-κB luciferase
expression plasmid or both the NF-κB luciferase expression plas-
mid and an A238L expression plasmid, as previously described.
After incubation for 18 h post-transfection cells were stimulated by
the addition of 100 nM Phorbol 12-myristate 13-acetate (PMA),
10 μg/ml Lipopolysacharide (LPS) and 4 nM Ionomycin for 4 h to
induce NF-κB activity. The cells were then harvested using the
Promega (USA) Luciferase assay system according to the manu-
facturer's instructions. Sample measurement was performed using
a BioOrbit 1253 luminometer (Turku, Finland) according to the
instructions provided by Promega.
Protein modelling
The structure of A238L was modelled using the DeepView
software package (Guex and Peitsch, 1997). Themodel of A238L
is based upon the atomic coordinates from the crystal structure of
IκB, as these two proteins share significant homology within the
region of the ankyrin repeats. As the significant homology only
encompasses the central region of A238L, the model lacks the
first 52 amino acids from the N-terminus and last 55 amino acids
from the C-terminus.
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Genes differentially regulated by baculovirus, LPS, PMA and 
ionomycin treatment. 
APPENDIX 2 Genes differentialy regulated by baculovirus, LPS, PMA and ionomycin treatment
1 hour 4 hours
Accession No. Description Average CI -ve CI +ve Average CI -ve CI +ve
Genes up regulated by baculovirus treatment followed by LPS, PMA and ionomycin stimulation at 1 hr post stimulation
NM_020858 sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D (SEM 1.88 ( 1.52 , 2.24 )
NM_003246 thrombospondin 1 (THBS1), mRNA 1.63 ( 1.19 , 2.07 )
NM_020747 zinc finger protein 608 (ZNF608), mRNA 1.37 ( 1.02 , 1.72 )
NM_000014 alpha-2-macroglobulin (A2M), mRNA 1.34 ( 1.21 , 1.46 )
NM_014622 loss of heterozygosity, 11, chromosomal region 2, gene A (LOH11CR2A), transcript vari 1.31 ( 1 , 1.62 )
NM_000856 guanylate cyclase 1, soluble, alpha 3 (GUCY1A3), mRNA 1.29 ( 1.19 , 1.38 )
NM_002224 inositol 1,4,5-triphosphate receptor, type 3 (ITPR3), mRNA 1.26 ( 1.22 , 1.29 )
NM_004183 vitelliform macular dystrophy (Best disease, bestrophin) (VMD2), mRNA 1.25 ( 0.75 , 1.75 )
NM_003931 WAS protein family, member 1 (WASF1), mRNA 1.21 ( 0.7 , 1.73 )
NM_002885 RAP1, GTPase activating protein 1 (RAP1GA1), mRNA 1.2 ( 1.07 , 1.34 )
NM_002603 phosphodiesterase 7A (PDE7A), transcript variant 1, mRNA 1.19 ( 0.38 , 2.01 )
NM_002356 myristoylated alanine-rich protein kinase C substrate (MARCKS), mRNA 1.18 ( 0.84 , 1.52 )
NM_005447 peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor (PAMCI), mRNA 1.14 ( 0.68 , 1.6 )
NM_003243 transforming growth factor, beta receptor III (betaglycan, 300kDa) (TGFBR3), mRNA 1.11 ( 0.81 , 1.41 )
NM_020732 AT rich interactive domain 1B (SWI1-like) (ARID1B), transcript variant 2, mRNA 1.1 ( 0.86 , 1.33 )
NM_006887 zinc finger protein 36, C3H type-like 2 (ZFP36L2), mRNA 1.09 ( 0.79 , 1.39 )
NM_181673 O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptid 1.07 ( 0.76 , 1.38 )
NM_018243 septin 11 (SEPT11), mRNA 1.06 ( 0.51 , 1.61 )
NM_014606 hect domain and RLD 3 (HERC3), mRNA 1.06 ( 0.82 , 1.29 )
NM_004910 phosphatidylinositol transfer protein, membrane-associated 1 (PITPNM1), mRNA 1.06 ( 0.74 , 1.38 )
NM_020918 glycerol-3-phosphate acyltransferase, mitochondrial (GPAM), mRNA 1.05 ( 0.74 , 1.36 )
NM_032772 zinc finger protein 503 (ZNF503), mRNA 1.04 ( 0.62 , 1.47 )
NM_020770 cingulin (CGN), mRNA 1.04 ( 0.77 , 1.32 )
NM_001006665 ribosomal protein S6 kinase, 90kDa, polypeptide 1 (RPS6KA1), transcript variant 2, mR 1.03 ( 0.72 , 1.35 )
NM_021070 latent transforming growth factor beta binding protein 3 (LTBP3), mRNA 1.02 ( 0.8 , 1.24 )
NM_006044 histone deacetylase 6 (HDAC6), mRNA 1.01 ( 0.88 , 1.13 )
NM_033632 F-box and WD-40 domain protein 7 (archipelago homolog, Drosophila) (FBXW7), transcrip 1 ( 0.54 , 1.46 )
NM_001005404 yippee-like 2 (Drosophila) (YPEL2), mRNA 0.99 ( 0.72 , 1.26 )
NM_006079 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 (CI 0.99 ( 0.61 , 1.37 )
NM_002589 BH-protocadherin (brain-heart) (PCDH7), transcript variant a, mRNA 0.99 ( 0.86 , 1.11 )
NM_000293 phosphorylase kinase, beta (PHKB), mRNA 0.98 ( 0.75 , 1.22 )
NM_145175 NSE1 (NSE1), mRNA 0.98 ( 0.68 , 1.28 )
NM_006469 influenza virus NS1A binding protein (IVNS1ABP), transcript variant 1, mRNA 0.97 ( 0.84 , 1.11 )
NM_024613 pleckstrin homology domain containing, family F (with FYVE domain) member 2 (PLEKHF2) 0.97 ( 0.53 , 1.4 )
NM_138615 DEAH (Asp-Glu-Ala-His) box polypeptide 30 (DHX30), transcript variant 1, mRNA 0.95 ( 0.7 , 1.2 )
NM_021056 tuberous sclerosis 2 (TSC2), transcript variant 3, mRNA 0.95 ( 0.82 , 1.07 )
NM_145341 programmed cell death 4 (neoplastic transformation inhibitor) (PDCD4), transcript var 0.94 ( 0.69 , 1.19 )
NM_002166 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2), mRNA 0.93 ( 0.85 , 1.01 )
NM_004926 zinc finger protein 36, C3H type-like 1 (ZFP36L1), mRNA 0.92 ( 0.57 , 1.28 )
NM_014452 tumor necrosis factor receptor superfamily, member 21 (TNFRSF21), mRNA 0.92 ( 0.66 , 1.18 )
NM_006820 interferon-induced protein 44 (IFI44L), mRNA 0.92 ( 0.77 , 1.06 )
NM_144729 dual specificity phosphatase 10 (DUSP10), transcript variant 3, mRNA 0.92 ( 0.59 , 1.24 )
NM_000455 serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA 0.91 ( 0.52 , 1.3 )
NM_004071 CDC-like kinase 1 (CLK1), mRNA 0.9 ( 0.74 , 1.07 )
NM_033104 stonin 2 (STN2), mRNA 0.89 ( 0.55 , 1.24 )
NM_206943 latent transforming growth factor beta binding protein 1 (LTBP1), transcript variant 0.89 ( 0.44 , 1.34 )
NM_013392 nuclear receptor binding protein (NRBP), mRNA 0.89 ( 0.62 , 1.16 )
NM_032457 BH-protocadherin (brain-heart) (PCDH7), transcript variant c, mRNA 0.89 ( 0.76 , 1.01 )
NM_020801 arrestin domain containing 3 (ARRDC3), mRNA 0.88 ( 0.3 , 1.46 )
NM_133635 protein O-fucosyltransferase 2 (POFUT2), transcript variant 3, mRNA 0.88 ( 0.62 , 1.14 )
NM_173694 ATPase, Class VI, type 11C (ATP11C), mRNA 0.87 ( 0.76 , 0.99 )
NM_012235 SREBP cleavage-activating protein (SCAP), mRNA 0.87 ( 0.58 , 1.16 )
NM_015246 mahogunin, ring finger 1 (MGRN1), mRNA 0.86 ( 0.72 , 1.01 )
NM_172060 eyes absent homolog 1 (Drosophila) (EYA1), transcript variant 1, mRNA 0.86 ( 0.41 , 1.31 )
NM_001418 eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2), mRNA 0.86 ( 0.5 , 1.22 )
NM_020654 SUMO1/sentrin specific protease 7 (SENP7), mRNA 0.86 ( 0.61 , 1.11 )
NM_005966 NGFI-A binding protein 1 (EGR1 binding protein 1) (NAB1), mRNA 0.85 ( 0.81 , 0.88 )
NM_018364 round spermatid basic protein 1 (RSBN1), mRNA 0.84 ( 0.59 , 1.1 )
NM_198501 FLJ42461 protein (FLJ42461), mRNA 0.84 ( 0.34 , 1.34 )
NM_003688 calcium/calmodulin-dependent serine protein kinase (MAGUK family) (CASK), mRNA 0.83 ( 0.54 , 1.12 )
NM_018490 leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4), mRNA 0.83 ( 0.37 , 1.3 )
NM_012199 eukaryotic translation initiation factor 2C, 1 (EIF2C1), mRNA 0.82 ( 0.49 , 1.16 )
NM_001627 activated leukocyte cell adhesion molecule (ALCAM), mRNA 0.82 ( 0.66 , 0.98 )
NM_000340 solute carrier family 2 (facilitated glucose transporter), member 2 (SLC2A2), mRNA 0.82 ( 0.4 , 1.24 )
NM_000259 myosin VA (heavy polypeptide 12, myoxin) (MYO5A), mRNA 0.82 ( 0.66 , 0.98 )
NM_002821 PTK7 protein tyrosine kinase 7 (PTK7), transcript variant PTK7-1, mRNA 0.81 ( 0.72 , 0.9 )
NM_002569 furin (paired basic amino acid cleaving enzyme) (FURIN), mRNA 0.8 ( 0.74 , 0.85 )
NM_001287 chloride channel 7 (CLCN7), mRNA 0.8 ( 0.64 , 0.95 )
NM_017641 kinesin family member 21A (KIF21A), mRNA 0.79 ( 0.09 , 1.5 )
NM_053064 guanine nucleotide binding protein (G protein), gamma 2 (GNG2), mRNA 0.79 ( 0.65 , 0.94 )
NM_152754 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3 0.79 ( 0.55 , 1.03 )
NM_016275 selenoprotein T (SELT), mRNA 0.79 ( 0.62 , 0.95 )
NM_014707 histone deacetylase 9 (HDAC9), transcript variant 3, mRNA 0.79 ( 0.57 , 1 )
NM_016061 yippee-like 5 (Drosophila) (YPEL5), mRNA 0.79 ( 0.48 , 1.09 )
NM_000341 solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activa 0.79 ( -0.15 , 1.72 )
NM_080685 protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosp 0.78 ( 0.71 , 0.85 )
NM_007191 WNT inhibitory factor 1 (WIF1), mRNA 0.78 ( 0.23 , 1.33 )
NM_198968 DAZ interacting protein 1 (DZIP1), mRNA 0.78 ( -0.06 , 1.61 )
NM_004162 RAB5A, member RAS oncogene family (RAB5A), mRNA 0.78 ( 0.69 , 0.86 )
NM_015662 selective LIM binding factor, rat homolog (SLB), mRNA 0.77 ( 0.47 , 1.08 )
NM_005630 solute carrier organic anion transporter family, member 2A1 (SLCO2A1), mRNA 0.77 ( 0.64 , 0.9 )
NM_005581 Lutheran blood group (Auberger b antigen included) (LU), mRNA 0.77 ( 0.55 , 0.99 )
NM_013291 cleavage and polyadenylation specific factor 1, 160kDa (CPSF1), mRNA 0.77 ( 0.53 , 1.01 )
NM_032547 short coiled-coil protein (SCOC), mRNA 0.77 ( 0.44 , 1.1 )
NM_002291 laminin, beta 1 (LAMB1), mRNA 0.77 ( 0.22 , 1.31 )
NM_170662 Cas-Br-M (murine) ecotropic retroviral transforming sequence b (CBLB), mRNA 0.77 ( 0.45 , 1.09 )
NM_145740 glutathione S-transferase A1 (GSTA1), mRNA 0.77 ( 0.58 , 0.96 )
NM_030791 sphingosine-1-phosphate phosphatase 1 (SGPP1), mRNA 0.77 ( 0.47 , 1.06 )
NM_002971 special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold-associat 0.77 ( 0.71 , 0.82 )
NM_016824 adducin 3 (gamma) (ADD3), transcript variant 1, mRNA 0.76 ( 0.62 , 0.9 )
NM_002111 huntingtin (Huntington disease) (HD), mRNA 0.76 ( 0.54 , 0.98 )
NM_003020 secretory granule, neuroendocrine protein 1 (7B2 protein) (SGNE1), mRNA 0.76 ( 0.59 , 0.93 )
NM_007222 zinc fingers and homeoboxes 1 (ZHX1), mRNA 0.76 ( 0.59 , 0.92 )
NM_016357 epithelial protein lost in neoplasm beta (EPLIN), mRNA 0.76 ( 0.45 , 1.07 )
NM_080792 protein tyrosine phosphatase, non-receptor type substrate 1 (PTPNS1), mRNA 0.76 ( 0.33 , 1.18 )
NM_000166 gap junction protein, beta 1, 32kDa (connexin 32, Charcot-Marie-Tooth neuropathy, X-l 0.76 ( 0.65 , 0.86 )
NM_022171 T-cell leukemia translocation altered gene (TCTA), mRNA 0.75 ( 0.71 , 0.79 )
NM_001256 cell division cycle 27 (CDC27), mRNA 0.75 ( 0.5 , 0.99 )
NM_002210 integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) (ITGAV), mR 0.75 ( 0.49 , 1.01 )
NM_006648 protein kinase, lysine deficient 2 (PRKWNK2), mRNA 0.75 ( 0.05 , 1.44 )
NM_001343 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) (DAB2), mRNA 0.75 ( 0.6 , 0.89 )
NM_004225 malignant fibrous histiocytoma amplified sequence 1 (MFHAS1), mRNA 0.74 ( 0.38 , 1.11 )
NM_006835 cyclin I (CCNI), mRNA 0.74 ( 0.66 , 0.83 )
NM_021005 nuclear receptor subfamily 2, group F, member 2 (NR2F2), mRNA 0.74 ( 0.6 , 0.88 )
NM_015640 PAI-1 mRNA-binding protein (PAI-RBP1), mRNA 0.74 ( 0.69 , 0.79 )
NM_003128 spectrin, beta, non-erythrocytic 1 (SPTBN1), transcript variant 1, mRNA 0.74 ( 0.64 , 0.83 )
NM_001418 eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2), mRNA 0.73 ( 0.64 , 0.82 )
NM_130839 ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman s 0.73 ( 0.66 , 0.8 )
NM_153280 ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing) 0.73 ( 0.67 , 0.78 )
NM_000110 dihydropyrimidine dehydrogenase (DPYD), mRNA 0.73 ( 0.55 , 0.9 )
NM_025188 tripartite motif-containing 45 (TRIM45), mRNA 0.72 ( 0.45 , 1 )
NM_014729 thymus high mobility group box protein TOX (TOX), mRNA 0.72 ( 0.05 , 1.4 )
NM_013231 fibronectin leucine rich transmembrane protein 2 (FLRT2), mRNA 0.72 ( 0.43 , 1.01 )
NM_006614 cell adhesion molecule with homology to L1CAM (close homolog of L1) (CHL1), mRNA 0.72 ( 0.16 , 1.29 )
NM_000362 tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) 0.72 ( 0.59 , 0.85 )
NM_052886 mal, T-cell differentiation protein 2 (MAL2), mRNA 0.72 ( 0.56 , 0.88 )
NM_032995 Rho guanine nucleotide exchange factor (GEF) 4 (ARHGEF4), transcript variant 2, mRNA 0.72 ( 0.51 , 0.92 )
NM_198576 agrin (AGRN), mRNA 0.72 ( 0.46 , 0.97 )
NM_003601 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily 0.72 ( 0.47 , 0.96 )
NM_015964 brain specific protein (CGI-38), mRNA 0.72 ( 0.11 , 1.32 )
NM_002979 sterol carrier protein 2 (SCP2), transcript variant 1, mRNA 0.71 ( 0.37 , 1.06 )
NM_022157 Ras-related GTP binding C (RRAGC), mRNA 0.71 ( 0.32 , 1.1 )
NM_032383 Hermansky-Pudlak syndrome 3 (HPS3), mRNA 0.71 ( 0.49 , 0.92 )
NM_148169 F-box protein 17 (FBXO17), transcript variant 1, mRNA 0.7 ( 0.06 , 1.35 )
NM_000042 apolipoprotein H (beta-2-glycoprotein I) (APOH), mRNA 0.7 ( 0.52 , 0.89 )
NM_199462 receptor interacting protein kinase 5 (RIPK5), transcript variant 2, mRNA 0.7 ( 0.14 , 1.26 )
NM_173853 keratinocyte associated protein 3 (KRTCAP3), mRNA 0.7 ( 0.58 , 0.81 )
NM_002959 sortilin 1 (SORT1), mRNA 0.7 ( 0.43 , 0.96 )
NM_052932 pro-oncosis receptor inducing membrane injury gene (PORIMIN), mRNA 0.7 ( 0.49 , 0.9 )
NM_212472 protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguish 0.69 ( 0.54 , 0.85 )
NM_015141 glycerol-3-phosphate dehydrogenase 1-like (GPD1L), mRNA 0.69 ( 0.55 , 0.84 )
NM_004723 rho/rac guanine nucleotide exchange factor (GEF) 2 (ARHGEF2), mRNA 0.69 ( 0.53 , 0.86 )
NM_020861 zinc finger and BTB domain containing 2 (ZBTB2), mRNA 0.69 ( 0.49 , 0.89 )
NM_005924 mesenchyme homeo box 2 (growth arrest-specific homeo box) (MEOX2), mRNA 0.69 ( 0.5 , 0.88 )
NM_207035 NPD014 protein (NPD014), transcript variant 1, mRNA 0.69 ( 0.56 , 0.82 )
NM_012089 ATP-binding cassette, sub-family B (MDR/TAP), member 10 (ABCB10), nuclear gene encodi 0.69 ( 0.3 , 1.08 )
NM_000186 complement factor H (CFH), mRNA 0.69 ( 0.52 , 0.85 )
NM_016596 histone deacetylase 7A (HDAC7A), transcript variant 2, mRNA 0.68 ( 0.64 , 0.73 )
NM_003640 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associa 0.68 ( 0.55 , 0.81 )
NM_139321 attractin (ATRN), transcript variant 1, mRNA 0.68 ( 0.51 , 0.85 )
NM_000314 phosphatase and tensin homolog (mutated in multiple advanced cancers 1) (PTEN), mRNA 0.68 ( 0.53 , 0.83 )
NM_003972 BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolo 0.67 ( 0.31 , 1.04 )
NM_005197 checkpoint suppressor 1 (CHES1), mRNA 0.67 ( 0.27 , 1.07 )
NM_006275 splicing factor, arginine/serine-rich 6 (SFRS6), mRNA 0.67 ( 0.56 , 0.78 )
NM_002856 poliovirus receptor-related 2 (herpesvirus entry mediator B) (PVRL2), mRNA 0.67 ( 0.48 , 0.85 )
NM_002227 Janus kinase 1 (a protein tyrosine kinase) (JAK1), mRNA 0.67 ( 0.47 , 0.86 )
NM_207040 transcription factor 12 (HTF4, helix-loop-helix transcription factors 4) (TCF12), tra 0.67 ( 0.35 , 0.99 )
NM_020169 latexin (LXN), mRNA 0.67 ( 0.11 , 1.23 )
NM_021913 AXL receptor tyrosine kinase (AXL), transcript variant 1, mRNA 0.67 ( 0.27 , 1.06 )
NM_032451 spire homolog 2 (Drosophila) (SPIRE2), mRNA 0.66 ( 0.46 , 0.86 )
NM_000945 protein phosphatase 3 (formerly 2B), regulatory subunit B, 19kDa, alpha isoform (calc 0.66 ( 0.52 , 0.81 )
NM_021906 ubiquitin specific protease 9, X-linked (fat facets-like, Drosophila) (USP9X), transc 0.66 ( 0.3 , 1.02 )
NM_003629 phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) (PIK3R3), mRNA 0.66 ( 0.35 , 0.97 )
NM_024658 importin 4 (IPO4), mRNA 0.66 ( 0.5 , 0.82 )
NM_145906 RIO kinase 3 (yeast) (RIOK3), transcript variant 2, mRNA 0.66 ( 0.41 , 0.91 )
NM_006664 chemokine (C-C motif) ligand 27 (CCL27), mRNA 0.66 ( 0.53 , 0.78 )
NM_001846 collagen, type IV, alpha 2 (COL4A2), mRNA 0.66 ( 0.63 , 0.68 )
NM_016235 G protein-coupled receptor, family C, group 5, member B (GPRC5B), mRNA 0.66 ( 0.5 , 0.81 )
NM_177414 phosphatidic acid phosphatase type 2B (PPAP2B), transcript variant 2, mRNA 0.66 ( 0.24 , 1.07 )
NM_012406 PR domain containing 4 (PRDM4), mRNA 0.66 ( 0.57 , 0.74 )
NM_006243 protein phosphatase 2, regulatory subunit B (B56), alpha isoform (PPP2R5A), mRNA 0.65 ( 0.41 , 0.89 )
NM_003479 protein tyrosine phosphatase type IVA, member 2 (PTP4A2), transcript variant 1, mRNA 0.65 ( 0.18 , 1.12 )
NM_000927 ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1), mRNA 0.65 ( 0.57 , 0.73 )
NM_138730 high mobility group nucleosomal binding domain 3 (HMGN3), transcript variant 2, mRNA 0.65 ( 0.42 , 0.87 )
NM_018085 importin 9 (IPO9), mRNA 0.64 ( 0.26 , 1.03 )
NM_020166 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) (MCCC1), mRNA 0.64 ( 0.44 , 0.85 )
NM_004438 EPH receptor A4 (EPHA4), mRNA 0.64 ( 0.43 , 0.86 )
NM_003635 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 (NDST2), mRNA 0.64 ( 0.4 , 0.89 )
NM_001690 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A (ATP6V1A), mRNA 0.64 ( 0.44 , 0.84 )
NM_001005502 carboxypeptidase M (CPM), transcript variant 3, mRNA 0.64 ( -0.18 , 1.46 )
NM_005967 NGFI-A binding protein 2 (EGR1 binding protein 2) (NAB2), mRNA 0.64 ( 0.45 , 0.83 )
NM_016035 coenzyme Q4 homolog (yeast) (COQ4), mRNA 0.64 ( 0.13 , 1.15 )
NM_199368 transient receptor potential cation channel, subfamily C, member 4 associated protein 0.64 ( 0.57 , 0.71 )
NM_001001560 golgi associated, gamma adaptin ear containing, ARF binding protein 1 (GGA1), transcr 0.63 ( 0.4 , 0.87 )
NM_014454 sestrin 1 (SESN1), mRNA 0.63 ( 0.56 , 0.7 )
NM_001418 eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2), mRNA 0.63 ( 0.54 , 0.71 )
NM_000084 chloride channel 5 (nephrolithiasis 2, X-linked, Dent disease) (CLCN5), mRNA 0.63 ( 0.42 , 0.84 )
NM_198976 TH1-like (Drosophila) (TH1L), transcript variant 1, mRNA 0.63 ( 0.47 , 0.78 )
NM_181524 phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) (PIK3R1), transcript vari 0.62 ( 0.48 , 0.77 )
NM_001901 connective tissue growth factor (CTGF), mRNA 0.62 ( 0.44 , 0.81 )
NM_015518 DKFZP434C131 protein (DKFZP434C131), mRNA 0.62 ( 0.47 , 0.78 )
NM_000038 adenomatosis polyposis coli (APC), mRNA 0.62 ( 0.24 , 1.01 )
NM_012287 centaurin, beta 2 (CENTB2), mRNA 0.62 ( 0.35 , 0.9 )
NM_012414 rab3 GTPase-activating protein, non-catalytic subunit (150kD) (RAB3-GAP150), mRNA 0.62 ( 0.45 , 0.8 )
NM_003128 spectrin, beta, non-erythrocytic 1 (SPTBN1), transcript variant 1, mRNA 0.62 ( 0.45 , 0.79 )
NM_000689 aldehyde dehydrogenase 1 family, member A1 (ALDH1A1), mRNA 0.62 ( 0.45 , 0.79 )
NM_005313 glucose regulated protein, 58kDa (GRP58), mRNA 0.62 ( 0.46 , 0.78 )
NM_004776 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 (B4GALT5), mRNA 0.62 ( 0.36 , 0.87 )
NM_002703 phosphoribosyl pyrophosphate amidotransferase (PPAT), mRNA 0.62 ( 0.36 , 0.88 )
NM_014014 activating signal cointegrator 1 complex subunit 3-like 1 (ASCC3L1), mRNA 0.62 ( 0.44 , 0.79 )
NM_020385 XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis) (XPMC2H), mRNA 0.62 ( 0.54 , 0.69 )
NM_005474 histone deacetylase 5 (HDAC5), transcript variant 1, mRNA 0.61 ( 0.49 , 0.74 )
NM_001008493 enabled homolog (Drosophila) (ENAH), transcript variant 1, mRNA 0.61 ( 0.25 , 0.98 )
NM_203372 acyl-CoA synthetase long-chain family member 3 (ACSL3), transcript variant 2, mRNA 0.61 ( 0.55 , 0.68 )
NM_194298 solute carrier family 16 (monocarboxylic acid transporters), member 9 (SLC16A9), mRNA 0.61 ( 0.5 , 0.73 )
NM_014633 SH2 domain binding protein 1 (tetratricopeptide repeat containing) (SH2BP1), mRNA 0.61 ( 0.29 , 0.93 )
NM_004521 kinesin family member 5B (KIF5B), mRNA 0.61 ( 0.39 , 0.83 )
NM_004529 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); transloca 0.61 ( 0.33 , 0.89 )
NM_002291 laminin, beta 1 (LAMB1), mRNA 0.61 ( 0.39 , 0.82 )
NM_006378 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplas 0.6 ( 0.51 , 0.7 )
NM_022776 oxysterol binding protein-like 11 (OSBPL11), mRNA 0.6 ( 0.55 , 0.65 )
NM_006805 heterogeneous nuclear ribonucleoprotein A0 (HNRPA0), mRNA 0.6 ( 0.46 , 0.74 )
NM_145059 fucokinase (FUK), mRNA 0.6 ( 0.2 , 0.99 )
NM_018303 SEC5-like 1 (S. cerevisiae) (SEC5L1), mRNA 0.6 ( 0.41 , 0.78 )
NM_006622 polo-like kinase 2 (Drosophila) (PLK2), mRNA 0.59 ( 0.37 , 0.81 )
NM_000903 NAD(P)H dehydrogenase, quinone 1 (NQO1), mRNA 0.59 ( 0.38 , 0.8 )
NM_006751 sperm specific antigen 2 (SSFA2), mRNA 0.59 ( 0.34 , 0.84 )
NM_002687 pinin, desmosome associated protein (PNN), mRNA 0.59 ( 0.44 , 0.74 )
NM_013449 bromodomain adjacent to zinc finger domain, 2A (BAZ2A), mRNA 0.59 ( 0.43 , 0.75 )
NM_145720 tigger transposable element derived 4 (TIGD4), mRNA 0.58 ( 0.4 , 0.77 )
NM_033140 caldesmon 1 (CALD1), transcript variant 5, mRNA 0.58 ( 0.52 , 0.65 )
NM_207297 muscleblind-like (Drosophila) (MBNL1), transcript variant 7, mRNA 0.58 ( 0.38 , 0.78 )
NM_212482 fibronectin 1 (FN1), transcript variant 1, mRNA 0.58 ( 0.52 , 0.65 )
NM_006243 protein phosphatase 2, regulatory subunit B (B56), alpha isoform (PPP2R5A), mRNA 0.58 ( 0.44 , 0.73 )
NM_003565 unc-51-like kinase 1 (C. elegans) (ULK1), mRNA 0.58 ( 0.32 , 0.85 )
NM_002293 laminin, gamma 1 (formerly LAMB2) (LAMC1), mRNA 0.58 ( 0.31 , 0.85 )
NM_002568 poly(A) binding protein, cytoplasmic 1 (PABPC1), mRNA 0.58 ( 0.56 , 0.6 )
NM_000263 N-acetylglucosaminidase, alpha- (Sanfilippo disease IIIB) (NAGLU), mRNA 0.58 ( 0.16 , 0.99 )
NM_004157 protein kinase, cAMP-dependent, regulatory, type II, alpha (PRKAR2A), mRNA 0.58 ( 0.34 , 0.82 )
NM_013374 programmed cell death 6 interacting protein (PDCD6IP), mRNA 0.58 ( 0.43 , 0.73 )
NM_016357 epithelial protein lost in neoplasm beta (EPLIN), mRNA 0.57 ( 0.26 , 0.89 )
NM_017436 alpha 1,4-galactosyltransferase (A4GALT), mRNA 0.57 ( 0.13 , 1.02 )
NM_004656 BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) (BAP1), mRNA 0.57 ( 0.41 , 0.74 )
NM_004449 v-ets erythroblastosis virus E26 oncogene like (avian) (ERG), transcript variant 2, m 0.57 ( 0.34 , 0.8 )
NM_003506 frizzled homolog 6 (Drosophila) (FZD6), mRNA 0.57 ( 0.46 , 0.68 )
NM_000790 dopa decarboxylase (aromatic L-amino acid decarboxylase) (DDC), mRNA 0.57 ( 0.22 , 0.92 )
NM_003635 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 (NDST2), mRNA 0.57 ( 0.35 , 0.79 )
NM_003861 WD repeat domain 22 (WDR22), mRNA 0.57 ( 0.49 , 0.66 )
NM_003070 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily 0.57 ( 0.16 , 0.98 )
NM_001007553 upstream of NRAS (UNR), transcript variant 1, mRNA 0.57 ( 0.44 , 0.7 )
NM_005316 general transcription factor IIH, polypeptide 1 (62kD subunit) (GTF2H1), mRNA 0.57 ( 0.29 , 0.85 )
NM_022575 vacuolar protein sorting 16 (yeast) (VPS16), transcript variant 1, mRNA 0.57 ( 0.34 , 0.8 )
NM_025160 WD repeat domain 26 (WDR26), mRNA 0.57 ( 0.28 , 0.86 )
NM_001304 carboxypeptidase D (CPD), mRNA 0.57 ( 0.27 , 0.86 )
NM_006357 ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog, yeast) (UBE2E3), transcript varia 0.57 ( 0.46 , 0.67 )
NM_000722 calcium channel, voltage-dependent, alpha 2/delta subunit 1 (CACNA2D1), mRNA 0.57 ( 0.33 , 0.8 )
NM_014862 aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2), mRNA 0.57 ( 0.32 , 0.81 )
NM_004667 hect domain and RLD 2 (HERC2), mRNA 0.57 ( 0.34 , 0.79 )
NM_058172 anthrax toxin receptor 2 (ANTXR2), mRNA 0.56 ( 0.34 , 0.79 )
NM_014892 RNA binding motif protein 16 (RBM16), mRNA 0.56 ( 0.36 , 0.77 )
NM_016322 RAB14, member RAS oncogene family (RAB14), mRNA 0.56 ( 0.45 , 0.68 )
NM_015200 SCC-112 protein (SCC-112), mRNA 0.56 ( 0.5 , 0.62 )
NM_018482 development and differentiation enhancing factor 1 (DDEF1), mRNA 0.56 ( 0.25 , 0.87 )
NM_025132 WD repeat domain 19 (WDR19), mRNA 0.56 ( 0.08 , 1.04 )
NM_006887 zinc finger protein 36, C3H type-like 2 (ZFP36L2), mRNA 0.56 ( 0.14 , 0.98 )
NM_173561 unc-5 homolog C (C. elegans)-like (UNC5CL), mRNA 0.56 ( 0.52 , 0.59 )
NM_015885 pre-mRNA cleavage complex II protein Pcf11 (PCF11), mRNA 0.56 ( 0.27 , 0.84 )
NM_024085 APG9 autophagy 9-like 1 (S. cerevisiae) (APG9L1), mRNA 0.56 ( 0.17 , 0.94 )
NM_005847 solute carrier family 23 (nucleobase transporters), member 1 (SLC23A1), transcript va 0.56 ( 0.4 , 0.71 )
NM_001618 poly (ADP-ribose) polymerase family, member 1 (PARP1), mRNA 0.55 ( 0.35 , 0.76 )
NM_020150 SAR1a gene homolog 1 (S. cerevisiae) (SARA1), mRNA 0.55 ( 0.4 , 0.71 )
NM_003385 visinin-like 1 (VSNL1), mRNA 0.55 ( 0.35 , 0.75 )
NM_014727 myeloid/lymphoid or mixed-lineage leukemia 4 (MLL4), mRNA 0.55 ( 0.45 , 0.65 )
NM_020132 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3), mRNA 0.55 ( 0.52 , 0.58 )
NM_138729 suppression of tumorigenicity 7 like (ST7L), transcript variant 4, mRNA 0.55 ( 0.25 , 0.85 )
NM_006763 BTG family, member 2 (BTG2), mRNA 0.55 ( 0.25 , 0.85 )
NM_014991 WD repeat and FYVE domain containing 3 (WDFY3), transcript variant 1, mRNA 0.55 ( 0.21 , 0.89 )
NM_144996 ADP-ribosylation factor-like 2-like 1 (ARL2L1), transcript variant 2, mRNA 0.55 ( 0.36 , 0.74 )
NM_181354 oxidation resistance 1 (OXR1), mRNA 0.55 ( 0.4 , 0.69 )
NM_006565 CCCTC-binding factor (zinc finger protein) (CTCF), mRNA 0.55 ( 0.28 , 0.82 )
NM_006822 RAB40B, member RAS oncogene family (RAB40B), mRNA 0.54 ( 0.36 , 0.73 )
NM_172218 sperm associated antigen 1 (SPAG1), transcript variant 2, mRNA 0.54 ( 0.43 , 0.66 )
NM_033271 BTB (POZ) domain containing 6 (BTBD6), mRNA 0.54 ( 0.18 , 0.91 )
NM_019610 similar to RNA binding motif protein, X-linked (LOC494115), mRNA 0.54 ( 0.31 , 0.77 )
NM_000359 transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamylt 0.54 ( 0.39 , 0.7 )
NM_025109 myosin head domain containing 1 (MYOHD1), mRNA 0.54 ( 0.47 , 0.61 )
NM_015989 cysteine sulfinic acid decarboxylase (CSAD), mRNA 0.54 ( 0.09 , 0.99 )
NM_021962 active BCR-related gene (ABR), transcript variant 1, mRNA 0.54 ( 0.51 , 0.57 )
NM_014947 forkhead box J3 (FOXJ3), mRNA 0.54 ( 0.44 , 0.63 )
NM_005502 ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1), mRNA 0.54 ( 0.43 , 0.65 )
NM_003216 thyrotrophic embryonic factor (TEF), mRNA 0.54 ( 0.47 , 0.6 )
NM_005271 glutamate dehydrogenase 1 (GLUD1), mRNA 0.54 ( 0.39 , 0.69 )
NM_024712 engulfment and cell motility 3 (ced-12 homolog, C. elegans) (ELMO3), mRNA 0.54 ( 0.22 , 0.85 )
NM_005077 transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) (TLE1), mRNA 0.54 ( 0.38 , 0.69 )
NM_004124 glia maturation factor, beta (GMFB), mRNA 0.53 ( 0.38 , 0.69 )
NM_017761 proline-rich nuclear receptor coactivator 2 (PNRC2), mRNA 0.53 ( 0.43 , 0.63 )
NM_004705 protein-kinase, interferon-inducible double stranded RNA dependent inhibitor, repress 0.53 ( 0.46 , 0.61 )
NM_002271 RAN binding protein 5 (RANBP5), mRNA 0.53 ( 0.41 , 0.66 )
NM_002945 replication protein A1, 70kDa (RPA1), mRNA 0.53 ( 0.38 , 0.68 )
NM_018847 kelch-like 9 (Drosophila) (KLHL9), mRNA 0.53 ( 0.47 , 0.59 )
NM_006016 CD164 antigen, sialomucin (CD164), mRNA 0.53 ( 0.32 , 0.75 )
NM_000176 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) (NR3C1), mR 0.53 ( 0.18 , 0.89 )
NM_020440 prostaglandin F2 receptor negative regulator (PTGFRN), mRNA 0.53 ( 0.44 , 0.63 )
NM_014735 PHD finger protein 16 (PHF16), mRNA 0.53 ( 0.18 , 0.88 )
NM_003922 hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like 0.53 ( 0.42 , 0.64 )
NM_001987 ets variant gene 6 (TEL oncogene) (ETV6), mRNA 0.53 ( 0.15 , 0.91 )
NM_032409 PTEN induced putative kinase 1 (PINK1), mRNA 0.53 ( 0.24 , 0.81 )
NM_004120 guanylate binding protein 2, interferon-inducible (GBP2), mRNA 0.53 ( 0.29 , 0.77 )
NM_012330 MYST histone acetyltransferase (monocytic leukemia) 4 (MYST4), mRNA 0.53 ( 0.43 , 0.63 )
NM_020383 X-prolyl aminopeptidase (aminopeptidase P) 1, soluble (XPNPEP1), mRNA 0.53 ( 0.44 , 0.62 )
NM_018695 erbb2 interacting protein (ERBB2IP), transcript variant 2, mRNA 0.53 ( 0.38 , 0.67 )
NM_021009 ubiquitin C (UBC), mRNA 0.53 ( 0.36 , 0.69 )
NM_020899 zinc finger and BTB domain containing 4 (ZBTB4), mRNA 0.53 ( 0.19 , 0.86 )
NM_017922 PRP39 pre-mRNA processing factor 39 homolog (yeast) (PRPF39), mRNA 0.52 ( 0.34 , 0.71 )
NM_017944 ubiquitin specific protease 47 (USP47), mRNA 0.52 ( 0.16 , 0.89 )
NM_016081 palladin (KIAA0992), mRNA 0.52 ( 0.36 , 0.69 )
NM_005595 nuclear factor I/A (NFIA), mRNA 0.52 ( 0.37 , 0.68 )
NM_183381 ring finger protein 13 (RNF13), transcript variant 4, mRNA 0.52 ( 0.12 , 0.93 )
NM_005766 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived) (FARP1), 0.52 ( 0.24 , 0.8 )
NM_020773 TBC1 domain family, member 14 (TBC1D14), mRNA 0.52 ( 0.29 , 0.75 )
NM_014950 zinc finger and BTB domain containing 1 (ZBTB1), mRNA 0.52 ( 0.43 , 0.61 )
NM_025238 BTB (POZ) domain containing 1 (BTBD1), mRNA 0.52 ( 0.35 , 0.69 )
NM_020965 membrane-associated guanylate kinase-related (MAGI-3) (MAGI-3), mRNA 0.52 ( 0.41 , 0.63 )
NM_138973 beta-site APP-cleaving enzyme 1 (BACE1), transcript variant d, mRNA 0.52 ( 0.45 , 0.59 )
NM_004170 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, sys 0.52 ( 0.41 , 0.63 )
NM_205842 NCK-associated protein 1 (NCKAP1), transcript variant 2, mRNA 0.52 ( 0.42 , 0.61 )
NM_014038 basic leucine zipper and W2 domains 2 (BZW2), mRNA 0.52 ( 0.39 , 0.65 )
NM_003982 solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 (SLC7A 0.52 ( 0.3 , 0.74 )
NM_015153 PHD finger protein 3 (PHF3), mRNA 0.52 ( 0.39 , 0.64 )
NM_014604 Tax1 (human T-cell leukemia virus type I) binding protein 3 (TAX1BP3), mRNA 0.51 ( 0.08 , 0.95 )
NM_014314 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 (DDX58), mRNA 0.51 ( 0.39 , 0.64 )
NM_002647 phosphoinositide-3-kinase, class 3 (PIK3C3), mRNA 0.51 ( 0.21 , 0.82 )
NM_147233 nuclear receptor coactivator 1 (NCOA1), transcript variant 3, mRNA 0.51 ( 0.32 , 0.71 )
NM_019063 echinoderm microtubule associated protein like 4 (EML4), mRNA 0.51 ( 0.23 , 0.8 )
NM_002065 glutamate-ammonia ligase (glutamine synthase) (GLUL), mRNA 0.51 ( 0.37 , 0.66 )
NM_019023 protein arginine N-methyltransferase 7 (PRMT7), mRNA 0.51 ( 0.35 , 0.68 )
NM_005445 chondroitin sulfate proteoglycan 6 (bamacan) (CSPG6), mRNA 0.51 ( 0.4 , 0.62 )
NM_004396 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5), mRNA 0.51 ( 0.44 , 0.58 )
NM_001396 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A), transcrip 0.51 ( 0.21 , 0.81 )
NM_001753 caveolin 1, caveolae protein, 22kDa (CAV1), mRNA 0.51 ( 0.2 , 0.82 )
NM_201281 myotubularin related protein 2 (MTMR2), transcript variant 3, mRNA 0.51 ( 0.24 , 0.77 )
NM_001568 eukaryotic translation initiation factor 3, subunit 6 48kDa (EIF3S6), mRNA 0.51 ( 0.32 , 0.69 )
NM_003816 a disintegrin and metalloproteinase domain 9 (meltrin gamma) (ADAM9), transcript vari 0.51 ( 0.3 , 0.71 )
NM_003036 v-ski sarcoma viral oncogene homolog (avian) (SKI), mRNA 0.51 ( 0.31 , 0.7 )
NM_007214 SEC63-like (S. cerevisiae) (SEC63), mRNA 0.51 ( 0.29 , 0.72 )
NM_025230 WD repeat domain 23 (WDR23), transcript variant 1, mRNA 0.5 ( 0.42 , 0.59 )
NM_080546 CDW92 antigen (CDW92), mRNA 0.5 ( 0.33 , 0.68 )
NM_152493 FLJ25476 protein (FLJ25476), mRNA 0.5 ( 0.46 , 0.55 )
NM_001280 cold inducible RNA binding protein (CIRBP), mRNA 0.5 ( 0.23 , 0.77 )
NM_022470 p53 target zinc finger protein (WIG1), transcript variant 1, mRNA 0.5 ( 0.17 , 0.83 )
NM_004393 dystroglycan 1 (dystrophin-associated glycoprotein 1) (DAG1), mRNA 0.5 ( 0.24 , 0.76 )
NM_004476 folate hydrolase (prostate-specific membrane antigen) 1 (FOLH1), mRNA 0.5 ( 0.26 , 0.74 )
NM_015393 DKFZP564O0823 protein (DKFZP564O0823), mRNA 0.5 ( 0.36 , 0.63 )
NM_020142 NADH:ubiquinone oxidoreductase MLRQ subunit homolog (LOC56901), mRNA 0.5 ( 0.36 , 0.63 )
NM_006646 WAS protein family, member 3 (WASF3), mRNA 0.49 ( 0.12 , 0.87 )
NM_006022 transforming growth factor beta 1 induced transcript 4 (TGFB1I4), transcript variant 0.49 ( 0.22 , 0.77 )
NM_031466 Tularik gene 1 (T1), mRNA 0.49 ( 0.24 , 0.74 )
NM_014045 low density lipoprotein receptor-related protein 10 (LRP10), mRNA 0.49 ( 0.4 , 0.58 )
NM_139276 signal transducer and activator of transcription 3 (acute-phase response factor) (STA 0.49 ( 0.31 , 0.67 )
NM_016733 LIM domain kinase 2 (LIMK2), transcript variant 2b, mRNA 0.49 ( 0.21 , 0.76 )
NM_000480 adenosine monophosphate deaminase (isoform E) (AMPD3), mRNA 0.49 ( 0.44 , 0.53 )
NM_213618 suppression of tumorigenicity 5 (ST5), transcript variant 3, mRNA 0.49 ( 0.35 , 0.62 )
NM_006633 IQ motif containing GTPase activating protein 2 (IQGAP2), mRNA 0.48 ( 0.38 , 0.59 )
NM_177453 progestin and adipoQ receptor family member III (PAQR3), mRNA 0.48 ( 0.24 , 0.73 )
NM_017709 family with sequence similarity 46, member C (FAM46C), mRNA 0.48 ( 0.36 , 0.6 )
NM_003056 solute carrier family 19 (folate transporter), member 1 (SLC19A1), transcript variant 0.48 ( 0.36 , 0.6 )
NM_032121 implantation-associated protein (DKFZp564K142), mRNA 0.48 ( 0.41 , 0.55 )
NM_153427 paired-like homeodomain transcription factor 2 (PITX2), transcript variant 1, mRNA 0.48 ( 0.33 , 0.62 )
NM_013995 lysosomal-associated membrane protein 2 (LAMP2), transcript variant LAMP2B, mRNA 0.48 ( 0.26 , 0.7 )
NM_004360 cadherin 1, type 1, E-cadherin (epithelial) (CDH1), mRNA 0.48 ( 0.27 , 0.68 )
NM_021079 N-myristoyltransferase 1 (NMT1), mRNA 0.48 ( 0.31 , 0.64 )
NM_003200 transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47) (TCF3), 0.48 ( 0.42 , 0.53 )
NM_020474 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (G 0.48 ( 0.26 , 0.69 )
NM_201274 myosin phosphatase-Rho interacting protein (M-RIP), mRNA 0.48 ( 0.43 , 0.52 )
NM_031454 selenoprotein O (SELO), mRNA 0.47 ( 0.41 , 0.54 )
NM_020126 sphingosine kinase 2 (SPHK2), mRNA 0.47 ( 0.3 , 0.65 )
NM_145690 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypept 0.47 ( 0.42 , 0.52 )
NM_001961 eukaryotic translation elongation factor 2 (EEF2), mRNA 0.47 ( 0.36 , 0.58 )
NM_002959 sortilin 1 (SORT1), mRNA 0.47 ( 0.38 , 0.57 )
NM_178822 immunoglobulin superfamily, member 10 (IGSF10), mRNA 0.47 ( 0.38 , 0.56 )
NM_175629 DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A), transcript variant 1, mRNA 0.47 ( 0.19 , 0.75 )
NM_007085 follistatin-like 1 (FSTL1), mRNA 0.47 ( 0.26 , 0.67 )
NM_007043 HIV-1 rev binding protein 2 (HRB2), mRNA 0.47 ( 0.46 , 0.48 )
NM_145324 oxysterol binding protein-like 3 (OSBPL3), transcript variant 6, mRNA 0.47 ( 0.39 , 0.54 )
NM_015575 trinucleotide repeat containing 15 (TNRC15), mRNA 0.47 ( 0.43 , 0.5 )
NM_024525 tetratricopeptide repeat domain 13 (TTC13), mRNA 0.47 ( 0.23 , 0.7 )
NM_006454 MAX dimerization protein 4 (MXD4), mRNA 0.47 ( 0.33 , 0.6 )
NM_022830 RNA binding motif protein 21 (RBM21), mRNA 0.46 ( 0.35 , 0.57 )
NM_100264 WW domain containing adaptor with coiled-coil (WAC), transcript variant 2, mRNA 0.46 ( 0.42 , 0.5 )
NM_002499 neogenin homolog 1 (chicken) (NEO1), mRNA 0.46 ( 0.33 , 0.6 )
NM_022763 factor for adipocyte differentiation 104 (FAD104), mRNA 0.46 ( 0.42 , 0.51 )
NM_004579 mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2), mRNA 0.46 ( 0.19 , 0.74 )
NM_018023 YEATS domain containing 2 (YEATS2), mRNA 0.46 ( 0.38 , 0.55 )
NM_199320 PHD finger protein 17 (PHF17), transcript variant L, mRNA 0.46 ( 0.18 , 0.74 )
NM_014282 hyaluronan binding protein 4 (HABP4), mRNA 0.46 ( 0.39 , 0.53 )
NM_033625 ribosomal protein L34 (RPL34), transcript variant 2, mRNA 0.46 ( 0.19 , 0.73 )
NM_021943 testis expressed sequence 27 (TEX27), mRNA 0.46 ( 0.2 , 0.72 )
NM_181349 SMAD specific E3 ubiquitin protein ligase 1 (SMURF1), transcript variant 2, mRNA 0.46 ( 0.3 , 0.62 )
NM_001033 ribonucleotide reductase M1 polypeptide (RRM1), mRNA 0.46 ( 0.39 , 0.52 )
NM_181443 BTB (POZ) domain containing 3 (BTBD3), transcript variant 2, mRNA 0.46 ( 0.23 , 0.68 )
NM_002844 protein tyrosine phosphatase, receptor type, K (PTPRK), mRNA 0.45 ( 0.22 , 0.69 )
NM_005234 nuclear receptor subfamily 2, group F, member 6 (NR2F6), mRNA 0.45 ( 0.26 , 0.64 )
NM_016289 calcium binding protein 39 (CAB39), mRNA 0.45 ( 0.36 , 0.54 )
NM_005271 glutamate dehydrogenase 1 (GLUD1), mRNA 0.45 ( 0.37 , 0.54 )
NM_005271 glutamate dehydrogenase 1 (GLUD1), mRNA 0.45 ( 0.23 , 0.67 )
NM_000158 glucan (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, 0.45 ( 0.34 , 0.57 )
NM_018230 nucleoporin 133kDa (NUP133), mRNA 0.45 ( 0.31 , 0.6 )
NM_201525 G protein-coupled receptor 56 (GPR56), transcript variant 3, mRNA 0.45 ( 0.29 , 0.61 )
NM_031483 itchy homolog E3 ubiquitin protein ligase (mouse) (ITCH), mRNA 0.45 ( 0.39 , 0.51 )
NM_032293 GTPase activating Rap/RanGAP domain-like 3 (GARNL3), mRNA 0.45 ( 0.29 , 0.61 )
NM_152850 phosphatidylinositol glycan, class O (PIGO), transcript variant 2, mRNA 0.45 ( 0.3 , 0.6 )
NM_020141 protein x 013 (AD-020), mRNA 0.45 ( 0.39 , 0.51 )
NM_000093 collagen, type V, alpha 1 (COL5A1), mRNA 0.45 ( 0.24 , 0.65 )
NM_020830 WD repeat and FYVE domain containing 1 (WDFY1), mRNA 0.45 ( 0.36 , 0.53 )
NM_004064 cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B), mRNA 0.44 ( 0.29 , 0.6 )
NM_003849 succinate-CoA ligase, GDP-forming, alpha subunit (SUCLG1), mRNA 0.44 ( 0.26 , 0.63 )
NM_004613 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) (TGM2 0.44 ( 0.23 , 0.65 )
NM_013239 protein phosphatase 2A 48 kDa regulatory subunit (PR48), transcript variant 1, mRNA 0.44 ( 0.29 , 0.6 )
NM_012199 eukaryotic translation initiation factor 2C, 1 (EIF2C1), mRNA 0.44 ( 0.25 , 0.63 )
NM_024580 elongation factor Tu GTP binding domain containing 1 (EFTUD1), mRNA 0.44 ( 0.26 , 0.62 )
NM_018844 B-cell receptor-associated protein 29 (BCAP29), transcript variant 2, mRNA 0.44 ( 0.22 , 0.66 )
NM_015000 serine/threonine kinase 38 like (STK38L), mRNA 0.44 ( 0.26 , 0.61 )
NM_005027 phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) (PIK3R2), mRNA 0.44 ( 0.33 , 0.55 )
NM_003684 MAP kinase interacting serine/threonine kinase 1 (MKNK1), mRNA 0.44 ( 0.34 , 0.53 )
NM_003023 SH3-domain binding protein 2 (SH3BP2), mRNA 0.44 ( 0.31 , 0.57 )
NM_013354 CCR4-NOT transcription complex, subunit 7 (CNOT7), transcript variant 1, mRNA 0.44 ( 0.24 , 0.63 )
NM_004945 dynamin 2 (DNM2), transcript variant 3, mRNA 0.43 ( 0.31 , 0.56 )
NM_001068 topoisomerase (DNA) II beta 180kDa (TOP2B), mRNA 0.43 ( 0.24 , 0.62 )
NM_014646 lipin 2 (LPIN2), mRNA 0.43 ( 0.25 , 0.61 )
NM_002693 polymerase (DNA directed), gamma (POLG), mRNA 0.43 ( 0.35 , 0.51 )
NM_015392 neural proliferation, differentiation and control, 1 (NPDC1), mRNA 0.43 ( 0.35 , 0.5 )
NM_003861 WD repeat domain 22 (WDR22), mRNA 0.43 ( 0.3 , 0.55 )
NM_001004106 G protein-coupled receptor kinase 6 (GRK6), transcript variant 1, mRNA 0.43 ( 0.25 , 0.61 )
NM_003932 suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein) (ST13) 0.43 ( 0.32 , 0.53 )
NM_004768 splicing factor, arginine/serine-rich 11 (SFRS11), mRNA 0.42 ( 0.31 , 0.54 )
NM_003980 microtubule-associated protein 7 (MAP7), mRNA 0.42 ( 0.31 , 0.53 )
NM_001007553 upstream of NRAS (UNR), transcript variant 1, mRNA 0.42 ( 0.34 , 0.5 )
NM_002899 retinol binding protein 1, cellular (RBP1), mRNA 0.42 ( 0.34 , 0.5 )
NM_015954 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) (DERA), mRNA 0.42 ( 0.26 , 0.57 )
NM_005080 X-box binding protein 1 (XBP1), mRNA 0.41 ( 0.33 , 0.5 )
NM_001200 bone morphogenetic protein 2 (BMP2), mRNA 0.41 ( 0.27 , 0.55 )
NM_002556 oxysterol binding protein (OSBP), mRNA 0.41 ( 0.27 , 0.55 )
NM_020441 coronin, actin binding protein, 1B (CORO1B), mRNA 0.41 ( 0.35 , 0.47 )
NM_138319 proprotein convertase subtilisin/kexin type 6 (PCSK6), transcript variant 2, mRNA 0.4 ( 0.35 , 0.45 )
NM_002856 poliovirus receptor-related 2 (herpesvirus entry mediator B) (PVRL2), mRNA 0.4 ( 0.3 , 0.5 )
NM_022771 TBC1 domain family, member 15 (TBC1D15), mRNA 0.4 ( 0.34 , 0.45 )
NM_148923 cytochrome b-5 (CYB5), transcript variant 1, mRNA 0.39 ( 0.34 , 0.44 )
NM_001287 chloride channel 7 (CLCN7), mRNA 0.38 ( 0.37 , 0.39 )
Genes down regulated by baculovirus treatment followed by LPS, PMA and ionomycin stimulation at 1 hr post stimulation
NM_012145 deoxythymidylate kinase (thymidylate kinase) (DTYMK), mRNA -0.45 ( -0.48 , -0.42 )
NM_018686 cytidine monophosphate N-acetylneuraminic acid synthetase (CMAS), mRNA -0.45 ( -0.5 , -0.39 )
NM_033550 TP53 regulating kinase (TP53RK), mRNA -0.46 ( -0.53 , -0.38 )
NM_000113 torsin family 1, member A (torsin A) (TOR1A), mRNA -0.46 ( -0.52 , -0.4 )
NM_012155 echinoderm microtubule associated protein like 2 (EML2), mRNA -0.46 ( -0.55 , -0.37 )
NM_001305 claudin 4 (CLDN4), mRNA -0.46 ( -0.52 , -0.41 )
NM_018412 suppression of tumorigenicity 7 (ST7), transcript variant a, mRNA -0.46 ( -0.55 , -0.38 )
NM_012100 aspartyl aminopeptidase (DNPEP), mRNA -0.47 ( -0.48 , -0.45 )
NM_002319 leucine-rich repeats and calponin homology (CH) domain containing 4 (LRCH4), mRNA -0.47 ( -0.5 , -0.43 )
NM_007170 testis-specific kinase 2 (TESK2), mRNA -0.47 ( -0.55 , -0.39 )
NM_198954 nudix (nucleoside diphosphate linked moiety X)-type motif 1 (NUDT1), transcript varia -0.47 ( -0.51 , -0.43 )
NM_001013 ribosomal protein S9 (RPS9), mRNA -0.47 ( -0.52 , -0.42 )
NM_006854 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 (KDELR2), m -0.47 ( -0.58 , -0.36 )
NR_002163 olfactory receptor, family 7, subfamily E, member 37 pseudogene (OR7E37P) on chromoso -0.47 ( -0.59 , -0.36 )
NM_018367 phytoceramidase, alkaline (PHCA), mRNA -0.47 ( -0.51 , -0.44 )
NM_001249 ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5), mRNA -0.47 ( -0.56 , -0.39 )
NM_005488 target of myb1 (chicken) (TOM1), mRNA -0.47 ( -0.56 , -0.39 )
NM_001050 somatostatin receptor 2 (SSTR2), mRNA -0.48 ( -0.54 , -0.41 )
NM_007322 RAN binding protein 3 (RANBP3), transcript variant RANBP3-d, mRNA -0.48 ( -0.56 , -0.39 )
NM_002479 myogenin (myogenic factor 4) (MYOG), mRNA -0.48 ( -0.62 , -0.34 )
NM_014725 START domain containing 8 (STARD8), mRNA -0.48 ( -0.61 , -0.35 )
NM_152359 carnitine palmitoyltransferase 1C (CPT1C), mRNA -0.48 ( -0.59 , -0.37 )
NM_177543 phosphatidic acid phosphatase type 2C (PPAP2C), transcript variant 3, mRNA -0.48 ( -0.55 , -0.41 )
NM_001122 adipose differentiation-related protein (ADFP), mRNA -0.48 ( -0.6 , -0.37 )
NM_000599 insulin-like growth factor binding protein 5 (IGFBP5), mRNA -0.48 ( -0.5 , -0.46 )
NM_013304 zinc finger, DHHC domain containing 1 (ZDHHC1), mRNA -0.48 ( -0.56 , -0.41 )
NM_006854 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 (KDELR2), m -0.48 ( -0.58 , -0.39 )
NM_005626 splicing factor, arginine/serine-rich 4 (SFRS4), mRNA -0.49 ( -0.58 , -0.41 )
NM_005318 H1 histone family, member 0 (H1F0), mRNA -0.49 ( -0.61 , -0.37 )
NM_025080 asparaginase like 1 (ASRGL1), mRNA -0.49 ( -0.56 , -0.43 )
NM_014224 pepsinogen 5, group I (pepsinogen A) (PGA5), mRNA -0.5 ( -0.66 , -0.33 )
NM_002234 potassium voltage-gated channel, shaker-related subfamily, member 5 (KCNA5), mRNA -0.5 ( -0.66 , -0.33 )
NM_005681 TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 48kDa (TAF1A), -0.5 ( -0.68 , -0.32 )
NM_005105 RNA binding motif protein 8A (RBM8A), mRNA -0.5 ( -0.64 , -0.36 )
NM_017634 potassium channel tetramerisation domain containing 9 (KCTD9), mRNA -0.5 ( -0.59 , -0.41 )
NM_001658 ADP-ribosylation factor 1 (ARF1), mRNA -0.5 ( -0.63 , -0.38 )
NM_005386 neuronatin (NNAT), transcript variant 1, mRNA -0.5 ( -0.65 , -0.36 )
NM_004368 calponin 2 (CNN2), transcript variant 1, mRNA -0.5 ( -0.66 , -0.35 )
NM_005721 ARP3 actin-related protein 3 homolog (yeast) (ACTR3), mRNA -0.51 ( -0.67 , -0.34 )
NM_001361 dihydroorotate dehydrogenase (DHODH), nuclear gene encoding mitochondrial protein, mR -0.51 ( -0.72 , -0.3 )
NM_022164 lipocalin 7 (LCN7), mRNA -0.51 ( -0.54 , -0.48 )
NM_000145 follicle stimulating hormone receptor (FSHR), transcript variant 1, mRNA -0.51 ( -0.62 , -0.4 )
NM_013964 neuregulin 1 (NRG1), transcript variant HRG-alpha, mRNA -0.51 ( -0.56 , -0.46 )
NM_006155 neural precursor cell expressed, developmentally down-regulated 5 (NEDD5), transcript -0.51 ( -0.7 , -0.32 )
NM_001678 ATPase, Na+/K+ transporting, beta 2 polypeptide (ATP1B2), mRNA -0.51 ( -0.67 , -0.36 )
NM_003258 thymidine kinase 1, soluble (TK1), mRNA -0.51 ( -0.62 , -0.41 )
NM_032682 forkhead box P1 (FOXP1), mRNA -0.51 ( -0.6 , -0.43 )
NM_001069 tubulin, beta 2 (TUBB2), mRNA -0.52 ( -0.68 , -0.35 )
NM_002999 syndecan 4 (amphiglycan, ryudocan) (SDC4), mRNA -0.52 ( -0.65 , -0.38 )
NM_002773 protease, serine, 8 (prostasin) (PRSS8), mRNA -0.52 ( -0.67 , -0.37 )
NM_006843 serine dehydratase (SDS), mRNA -0.52 ( -0.61 , -0.42 )
NM_003896 sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synt -0.52 ( -0.67 , -0.37 )
NM_003132 spermidine synthase (SRM), mRNA -0.52 ( -0.54 , -0.5 )
NM_018463 uncharacterized hematopoietic stem/progenitor cells protein MDS028 (MDS028), mRNA -0.52 ( -0.6 , -0.44 )
NM_206914 hepatocellularcarcinoma-associated antigen HCA557a (DKFZP586D0919), transcript varian -0.52 ( -0.73 , -0.31 )
NM_013328 pyrroline-5-carboxylate reductase family, member 2 (PYCR2), mRNA -0.52 ( -0.76 , -0.29 )
NM_020676 abhydrolase domain containing 6 (ABHD6), mRNA -0.52 ( -0.65 , -0.39 )
NM_002373 microtubule-associated protein 1A (MAP1A), mRNA -0.52 ( -0.7 , -0.35 )
NM_000206 interleukin 2 receptor, gamma (severe combined immunodeficiency) (IL2RG), mRNA -0.52 ( -0.75 , -0.29 )
NM_000629 interferon (alpha, beta and omega) receptor 1 (IFNAR1), mRNA -0.53 ( -0.78 , -0.27 )
NM_004742 BAI1-associated protein 1 (BAIAP1), mRNA -0.53 ( -0.55 , -0.5 )
NM_003029 SHC (Src homology 2 domain containing) transforming protein 1 (SHC1), transcript vari -0.53 ( -0.7 , -0.36 )
NM_033308 ATP-binding cassette, sub-family A (ABC1), member 7 (ABCA7), transcript variant 2, mR -0.53 ( -0.79 , -0.26 )
NM_016042 exosome component 3 (EXOSC3), transcript variant 1, mRNA -0.53 ( -0.63 , -0.43 )
NM_024632 Sin3A associated protein p30-like (SAP30L), mRNA -0.53 ( -0.63 , -0.43 )
NM_006662 Snf2-related CBP activator protein (SRCAP), mRNA -0.53 ( -0.73 , -0.34 )
NM_021626 serine carboxypeptidase 1 (SCPEP1), mRNA -0.53 ( -0.58 , -0.49 )
NM_014476 PDZ and LIM domain 3 (PDLIM3), mRNA -0.53 ( -0.79 , -0.28 )
NM_207411 HARL2754 (UNQ2754), mRNA -0.53 ( -0.74 , -0.33 )
NM_005202 collagen, type VIII, alpha 2 (COL8A2), mRNA -0.54 ( -0.63 , -0.44 )
NM_138352 atherin (LOC90378), mRNA -0.54 ( -0.77 , -0.31 )
NM_019110 zinc finger protein 307 (ZNF307), mRNA -0.54 ( -0.7 , -0.38 )
NM_000486 aquaporin 2 (collecting duct) (AQP2), mRNA -0.54 ( -0.58 , -0.51 )
NM_001895 casein kinase 2, alpha 1 polypeptide (CSNK2A1), transcript variant 2, mRNA -0.55 ( -0.66 , -0.43 )
NM_004767 G-protein coupled receptor 37 like 1 (GPR37L1), mRNA -0.55 ( -0.82 , -0.27 )
NM_001824 creatine kinase, muscle (CKM), mRNA -0.55 ( -0.74 , -0.35 )
NM_003142 Sjogren syndrome antigen B (autoantigen La) (SSB), mRNA -0.55 ( -0.68 , -0.42 )
NM_213646 tryptophanyl-tRNA synthetase (WARS), transcript variant 4, mRNA -0.55 ( -0.64 , -0.45 )
NM_031299 cell division cycle associated 3 (CDCA3), mRNA -0.55 ( -0.59 , -0.52 )
NM_004094 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa (EIF2S1), mRNA -0.55 ( -0.65 , -0.46 )
NM_004161 RAB1A, member RAS oncogene family (RAB1A), mRNA -0.55 ( -0.64 , -0.47 )
NM_032311 polymerase (DNA-directed), delta interacting protein 3 (POLDIP3), transcript variant -0.55 ( -0.7 , -0.41 )
NM_012080 haloacid dehalogenase-like hydrolase domain containing 1A (HDHD1A), mRNA -0.55 ( -0.75 , -0.36 )
NM_001866 cytochrome c oxidase subunit VIIb (COX7B), nuclear gene encoding mitochondrial protei -0.56 ( -0.76 , -0.35 )
NM_006319 CDP-diacylglycerol--inositol 3-phosphatidyltransferase (phosphatidylinositol synthase -0.56 ( -0.73 , -0.39 )
NM_017634 potassium channel tetramerisation domain containing 9 (KCTD9), mRNA -0.56 ( -0.64 , -0.48 )
NM_052944 solute carrier family 5 (sodium/glucose cotransporter), member 11 (SLC5A11), mRNA -0.56 ( -0.73 , -0.39 )
NM_016320 nucleoporin 98kDa (NUP98), transcript variant 1, mRNA -0.56 ( -0.86 , -0.26 )
NM_031443 cerebral cavernous malformation 2 (CCM2), mRNA -0.56 ( -0.68 , -0.44 )
NM_019116 similar to ubiquitin binding protein (UBPH), mRNA -0.56 ( -0.71 , -0.41 )
NM_144564 solute carrier family 39 (zinc transporter), member 3 (SLC39A3), transcript variant 1 -0.56 ( -0.79 , -0.34 )
NM_021078 GCN5 general control of amino-acid synthesis 5-like 2 (yeast) (GCN5L2), mRNA -0.56 ( -0.68 , -0.44 )
NM_000107 damage-specific DNA binding protein 2, 48kDa (DDB2), mRNA -0.56 ( -0.89 , -0.24 )
NM_016282 adenylate kinase 3 like 1 (AK3L1), mRNA -0.56 ( -0.88 , -0.25 )
NM_170691 G elongation factor, mitochondrial 2 (GFM2), nuclear gene encoding mitochondrial prot -0.57 ( -0.72 , -0.41 )
NM_004886 amyloid beta (A4) precursor protein-binding, family A, member 3 (X11-like 2) (APBA3), -0.57 ( -0.78 , -0.36 )
NM_153684 nucleoporin 50kDa (NUP50), transcript variant 1, mRNA -0.57 ( -0.82 , -0.32 )
NM_053017 ADP-ribosyltransferase 5 (ART5), mRNA -0.57 ( -0.66 , -0.49 )
NM_001129 AE binding protein 1 (AEBP1), mRNA -0.57 ( -0.87 , -0.28 )
NM_004577 phosphoserine phosphatase (PSPH), mRNA -0.58 ( -0.88 , -0.27 )
NM_003279 troponin C2, fast (TNNC2), mRNA -0.58 ( -0.93 , -0.23 )
NM_018297 N-glycanase 1 (NGLY1), mRNA -0.58 ( -0.72 , -0.44 )
NM_199204 dehydrogenase/reductase (SDR family) member 9 (DHRS9), transcript variant 2, mRNA -0.58 ( -0.89 , -0.27 )
NM_004435 endonuclease G (ENDOG), nuclear gene encoding mitochondrial protein, mRNA -0.58 ( -0.62 , -0.54 )
NM_006412 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase -0.58 ( -0.87 , -0.29 )
NM_017955 cell division cycle associated 4 (CDCA4), transcript variant 1, mRNA -0.58 ( -0.64 , -0.53 )
NM_001003794 monoglyceride lipase (MGLL), transcript variant 2, mRNA -0.58 ( -0.69 , -0.47 )
NM_016020 transcription factor B1, mitochondrial (TFB1M), mRNA -0.59 ( -0.65 , -0.52 )
NM_000098 carnitine palmitoyltransferase II (CPT2), nuclear gene encoding mitochondrial protein -0.59 ( -0.79 , -0.39 )
NM_012137 dimethylarginine dimethylaminohydrolase 1 (DDAH1), mRNA -0.59 ( -0.73 , -0.44 )
NM_000858 guanylate kinase 1 (GUK1), mRNA -0.59 ( -0.71 , -0.47 )
NM_024102 MEP50 protein (MEP50), mRNA -0.59 ( -0.88 , -0.3 )
NM_014578 ras homolog gene family, member D (RHOD), mRNA -0.59 ( -0.69 , -0.5 )
NM_000943 peptidylprolyl isomerase C (cyclophilin C) (PPIC), mRNA -0.59 ( -0.74 , -0.45 )
NM_030984 thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) (TBXAS1), -0.6 ( -0.92 , -0.27 )
NM_006182 discoidin domain receptor family, member 2 (DDR2), mRNA -0.6 ( -0.91 , -0.28 )
NM_024417 ferredoxin reductase (FDXR), nuclear gene encoding mitochondrial protein, transcript -0.6 ( -0.76 , -0.44 )
NM_014341 mitochondrial carrier homolog 1 (C. elegans) (MTCH1), nuclear gene encoding mitochond -0.6 ( -0.76 , -0.44 )
NM_004553 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa (NADH-coenzyme Q reductase) (N -0.6 ( -0.82 , -0.38 )
NM_016319 COP9 constitutive photomorphogenic homolog subunit 7A (Arabidopsis) (COPS7A), mRNA -0.6 ( -0.88 , -0.33 )
NM_000022 adenosine deaminase (ADA), mRNA -0.61 ( -0.75 , -0.46 )
NM_006268 D4, zinc and double PHD fingers family 2 (DPF2), mRNA -0.61 ( -0.85 , -0.36 )
NM_005489 SH2 domain containing 3C (SH2D3C), mRNA -0.61 ( -1.08 , -0.13 )
NM_014020 LR8 protein (LR8), mRNA -0.61 ( -0.7 , -0.52 )
NM_020189 e(y)2 protein (e(y)2), mRNA -0.61 ( -0.97 , -0.25 )
NM_006449 CDC42 effector protein (Rho GTPase binding) 3 (CDC42EP3), mRNA -0.61 ( -0.73 , -0.5 )
NM_020137 GRIP1 associated protein 1 (GRIPAP1), transcript variant 1, mRNA -0.62 ( -1.01 , -0.23 )
NM_002710 protein phosphatase 1, catalytic subunit, gamma isoform (PPP1CC), mRNA -0.63 ( -0.68 , -0.57 )
NM_181798 potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1), transcript var -0.63 ( -0.87 , -0.38 )
NM_002659 plasminogen activator, urokinase receptor (PLAUR), transcript variant 1, mRNA -0.63 ( -0.93 , -0.33 )
NM_022473 zinc finger protein 106 homolog (mouse) (ZFP106), mRNA -0.63 ( -0.69 , -0.56 )
NM_005070 solute carrier family 4, anion exchanger, member 3 (SLC4A3), mRNA -0.63 ( -0.99 , -0.26 )
NM_006745 sterol-C4-methyl oxidase-like (SC4MOL), mRNA -0.63 ( -0.7 , -0.56 )
NM_015219 exocyst complex component 7 (EXOC7), mRNA -0.63 ( -0.8 , -0.47 )
NM_020133 1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid acyltransferase -0.64 ( -0.84 , -0.43 )
NM_000766 cytochrome P450, family 2, subfamily A, polypeptide 13 (CYP2A13), mRNA -0.64 ( -0.98 , -0.29 )
NM_004967 integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II) (IBSP), mRNA -0.64 ( -1.1 , -0.18 )
NM_182926 kinectin 1 (kinesin receptor) (KTN1), mRNA -0.64 ( -0.89 , -0.38 )
NM_017436 alpha 1,4-galactosyltransferase (A4GALT), mRNA -0.64 ( -0.78 , -0.51 )
NM_012154 eukaryotic translation initiation factor 2C, 2 (EIF2C2), mRNA -0.65 ( -0.76 , -0.54 )
NM_014176 HSPC150 protein similar to ubiquitin-conjugating enzyme (HSPC150), mRNA -0.65 ( -0.86 , -0.44 )
NM_002823 prothymosin, alpha (gene sequence 28) (PTMA), mRNA -0.65 ( -1.08 , -0.22 )
NM_181745 G protein-coupled receptor 120 (GPR120), mRNA -0.66 ( -0.82 , -0.5 )
NM_021932 likely ortholog of mouse synembryn (RIC-8), mRNA -0.66 ( -0.84 , -0.48 )
NM_006256 protein kinase N2 (PKN2), mRNA -0.66 ( -0.96 , -0.37 )
NM_005147 DnaJ (Hsp40) homolog, subfamily A, member 3 (DNAJA3), mRNA -0.66 ( -0.93 , -0.4 )
NM_007188 ATP-binding cassette, sub-family B (MDR/TAP), member 8 (ABCB8), nuclear gene encoding -0.67 ( -0.74 , -0.6 )
NM_005195 CCAAT/enhancer binding protein (C/EBP), delta (CEBPD), mRNA -0.68 ( -1.35 , -0.02 )
NM_012214 mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isoenzym -0.68 ( -0.76 , -0.61 )
NM_001219 calumenin (CALU), mRNA -0.68 ( -0.78 , -0.59 )
NM_181597 uridine phosphorylase 1 (UPP1), transcript variant 2, mRNA -0.69 ( -0.79 , -0.58 )
NM_001798 cyclin-dependent kinase 2 (CDK2), transcript variant 1, mRNA -0.69 ( -0.87 , -0.51 )
NM_002532 nucleoporin 88kDa (NUP88), mRNA -0.7 ( -0.93 , -0.47 )
NM_001785 cytidine deaminase (CDA), mRNA -0.71 ( -1 , -0.41 )
NM_014474 sphingomyelin phosphodiesterase, acid-like 3B (SMPDL3B), mRNA -0.71 ( -0.95 , -0.47 )
NM_006744 retinol binding protein 4, plasma (RBP4), mRNA -0.74 ( -0.89 , -0.58 )
NM_021127 phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1), mRNA -0.74 ( -0.84 , -0.64 )
NM_002689 polymerase (DNA-directed), alpha (70kD) (POLA2), mRNA -0.74 ( -0.93 , -0.56 )
NM_003943 genethonin 1 (GENX-3414), mRNA -0.74 ( -0.92 , -0.56 )
NM_005550 kinesin family member C3 (KIFC3), mRNA -0.74 ( -0.85 , -0.64 )
NM_003380 vimentin (VIM), mRNA -0.75 ( -0.85 , -0.64 )
NM_182665 Ras association (RalGDS/AF-6) domain family 5 (RASSF5), transcript variant 3, mRNA -0.75 ( -1.18 , -0.33 )
NM_001003689 l(3)mbt-like 2 (Drosophila) (L3MBTL2), transcript variant 2, mRNA -0.77 ( -0.9 , -0.64 )
NM_001423 epithelial membrane protein 1 (EMP1), mRNA -0.77 ( -0.93 , -0.62 )
NM_015675 growth arrest and DNA-damage-inducible, beta (GADD45B), mRNA -0.78 ( -0.81 , -0.75 )
NM_005114 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (HS3ST1), mRNA -0.78 ( -1.49 , -0.06 )
NM_017775 tetratricopeptide repeat domain 19 (TTC19), mRNA -0.8 ( -1.52 , -0.08 )
NM_012385 p8 protein (candidate of metastasis 1) (P8), mRNA -0.8 ( -0.87 , -0.73 )
NM_018264 radical S-adenosyl methionine and flavodoxin domains 1 (RSAFD1), mRNA -0.81 ( -1.23 , -0.38 )
NM_001126 adenylosuccinate synthase (ADSS), mRNA -0.81 ( -0.94 , -0.68 )
NM_018103 leucine rich repeat containing 5 (LRRC5), mRNA -0.82 ( -1.16 , -0.49 )
NM_013322 sorting nexin 10 (SNX10), mRNA -0.83 ( -0.92 , -0.74 )
NM_001008222 zinc finger, DHHC domain containing 9 (ZDHHC9), transcript variant 2, mRNA -0.84 ( -1.17 , -0.51 )
NM_015847 methyl-CpG binding domain protein 1 (MBD1), transcript variant PCM1, mRNA -0.86 ( -1 , -0.71 )
NM_022078 G patch domain containing 3 (GPATC3), mRNA -0.87 ( -0.92 , -0.82 )
NM_002466 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 (MYBL2), mRNA -0.87 ( -1.26 , -0.49 )
NM_206918 degenerative spermatocyte homolog 2, lipid desaturase (Drosophila) (DEGS2), mRNA -0.9 ( -1.16 , -0.64 )
NM_001444 fatty acid binding protein 5 (psoriasis-associated) (FABP5), mRNA -0.91 ( -1.17 , -0.64 )
NM_006493 ceroid-lipofuscinosis, neuronal 5 (CLN5), mRNA -0.91 ( -1.01 , -0.81 )
NM_005562 laminin, gamma 2 (LAMC2), transcript variant 1, mRNA -0.95 ( -1.09 , -0.8 )
NM_002076 glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) (GNS), mRNA -0.95 ( -1.2 , -0.71 )
NM_016225 Rhesus blood group, D antigen (RHD), transcript variant 2, mRNA -1 ( -1.59 , -0.4 )
NM_005882 macrophage erythroblast attacher (MAEA), mRNA -1.02 ( -1.31 , -0.74 )
NM_000024 adrenergic, beta-2-, receptor, surface (ADRB2), mRNA -1.04 ( -1.33 , -0.75 )
NM_014889 pitrilysin metalloproteinase 1 (PITRM1), mRNA -1.06 ( -1.61 , -0.52 )
NM_001110 a disintegrin and metalloproteinase domain 10 (ADAM10), mRNA -1.15 ( -1.45 , -0.84 )
NM_017921 nuclear protein localization 4 (NPL4), mRNA -1.2 ( -1.56 , -0.84 )
NM_000210 integrin, alpha 6 (ITGA6), mRNA -1.27 ( -1.52 , -1.02 )
NM_006659 tubulin, gamma complex associated protein 2 (TUBGCP2), mRNA -1.27 ( -2.22 , -0.33 )
NM_012486 presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, mRNA -1.36 ( -1.53 , -1.18 )
Genes Up regulated at 1 and 4 hrs
NM_000803 folate receptor 2 (fetal) (FOLR2), mRNA 1.28 ( 0.91 , 1.65 ) 1.89 ( 1.49 , 2.3 )
NM_000900 matrix Gla protein (MGP), mRNA 1.37 ( 1.1 , 1.64 ) 1.61 ( 1.4 , 1.8 )
NM_005025 serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1 (SERPINI1), mRNA 0.74 ( 0.42 , 1.06 ) 1.38 ( 1.11 , 1.7 )
NM_004772 chromosome 5 open reading frame 13 (C5orf13), mRNA 0.95 ( 0.49 , 1.41 ) 1.25 ( 0.88 , 1.6 )
NM_002514 nephroblastoma overexpressed gene (NOV), mRNA 1.15 ( 1.08 , 1.22 ) 1.22 ( 0.79 , 1.7 )
NM_006988 a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 1 (AD  1.63 ( 1.36 , 1.89 ) 1.14 ( 0.66 , 1.6 )
NM_004337 chromosome 8 open reading frame 1 (C8orf1), mRNA 0.66 ( 0.53 , 0.79 ) 1.01 ( 0.74 , 1.3 )
NM_152556 hypothetical protein FLJ31818 (FLJ31818), mRNA 0.78 ( 0.75 , 0.82 ) 0.97 ( 0.43 , 1.5 )
NM_001889 crystallin, zeta (quinone reductase) (CRYZ), mRNA 0.68 ( 0.61 , 0.76 ) 0.91 ( 0.44 , 1.4 )
NM_025243 solute carrier family 19, member 3 (SLC19A3), mRNA 0.7 ( 0.19 , 1.21 ) 0.87 ( 0.42 , 1.3 )
NM_006237 POU domain, class 4, transcription factor 1 (POU4F1), mRNA 0.62 ( 0.24 , 1.01 ) 0.83 ( 0.55 , 1.1 )
NM_003528 histone 2, H2be (HIST2H2BE), mRNA 0.78 ( 0.47 , 1.09 ) 0.73 ( 0.54 , 0.9 )
NM_000313 protein S (alpha) (PROS1), mRNA 0.51 ( 0.43 , 0.6 ) 0.71 ( 0.53 , 0.9 )
NM_199040 nudix (nucleoside diphosphate linked moiety X)-type motif 4 (NUDT4), transcript variant 2, mR 0.77 ( 0.52 , 1.02 ) 0.65 ( 0.55 , 0.8 )
Genes Up regulated at 1 hr and down regulated at 4 hrs
NM_007361 nidogen 2 (osteonidogen) (NID2), mRNA 0.51 ( 0.25 , 0.77 ) -0.42 ( -0.5 , -0.3 )
NM_144967 hypothetical protein FLJ30058 (FLJ30058), mRNA 0.46 ( 0.28 , 0.65 ) -0.42 ( -0.5 , -0.3 )
NR_001564 X (inactive)-specific transcript (XIST) on chromosome X 0.83 ( 0.2 , 1.45 ) -0.42 ( -0.5 , -0.3 )
NM_139207 nucleosome assembly protein 1-like 1 (NAP1L1), transcript variant 1, mRNA 0.84 ( 0.62 , 1.05 ) -0.43 ( -0.6 , -0.3 )
NM_002467 c-myc, mRNA 0.81 ( 0.7 , 0.92 ) -0.45 ( -0.6 , -0.3 )
NM_175066 DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 (DDX51), mRNA 0.48 ( 0.33 , 0.62 ) -0.45 ( -0.5 , -0.4 )
NM_017458 major vault protein (MVP), transcript variant 1, mRNA 0.51 ( 0.38 , 0.65 ) -0.45 ( -0.6 , -0.3 )
NM_000404 galactosidase, beta 1 (GLB1), transcript variant 1 0.52 ( 0.33 , 0.7 ) -0.46 ( -0.6 , -0.3 )
NM_005560 laminin, alpha 5 (LAMA5), mRNA 1.33 ( 0.85 , 1.8 ) -0.46 ( -0.6 , -0.3 )
NM_012334 myosin X (MYO10), mRNA 0.55 ( 0.36 , 0.74 ) -0.46 ( -0.6 , -0.4 )
NM_018082 polymerase (RNA) III (DNA directed) polypeptide B (POLR3B), mRNA 0.45 ( 0.23 , 0.66 ) -0.47 ( -0.6 , -0.3 )
NM_139124 mitogen-activated protein kinase 8 interacting protein 2 (MAPK8IP2), transcript variant 3, mRN 0.55 ( 0.39 , 0.72 ) -0.47 ( -0.6 , -0.3 )
NM_018834 matrin 3 (MATR3), mRNA 0.91 ( 0.78 , 1.03 ) -0.47 ( -0.6 , -0.3 )
NM_014787 DnaJ (Hsp40) homolog, subfamily C, member 6 (DNAJC6), mRNA 0.48 ( 0.37 , 0.6 ) -0.47 ( -0.7 , -0.3 )
NM_001005273 chromodomain helicase DNA binding protein 3 (CHD3), transcript variant 1, mRNA 0.59 ( 0.28 , 0.89 ) -0.48 ( -0.7 , -0.2 )
NM_018060 mitochondrial isoleucine tRNA synthetase (FLJ10326), mRNA 0.5 ( 0.43 , 0.58 ) -0.48 ( -0.6 , -0.4 )
NM_001046 solute carrier family 12 (sodium/potassium/chloride transporters), member 2 (SLC12A2), mRN 0.48 ( 0.21 , 0.74 ) -0.48 ( -0.7 , -0.3 )
NM_020117 leucyl-tRNA synthetase (LARS), mRNA 0.43 ( 0.33 , 0.53 ) -0.48 ( -0.7 , -0.3 )
NM_003758 eukaryotic translation initiation factor 3, subunit 1 alpha, 35kDa (EIF3S1), mRNA 0.43 ( 0.3 , 0.56 ) -0.49 ( -0.7 , -0.2 )
NM_002940 ATP-binding cassette, sub-family E (OABP), member 1 (ABCE1), mRNA 0.52 ( 0.36 , 0.69 ) -0.49 ( -0.5 , -0.5 )
NM_032208 anthrax toxin receptor 1 (ANTXR1), transcript variant 1, mRNA 0.97 ( 0.57 , 1.37 ) -0.49 ( -0.7 , -0.3 )
NM_153051 myotubularin related protein 3 (MTMR3), transcript variant 2, mRNA 0.4 ( 0.36 , 0.45 ) -0.49 ( -0.7 , -0.3 )
NM_004910 phosphatidylinositol transfer protein, membrane-associated 1 (PITPNM1), mRNA 0.5 ( 0.24 , 0.76 ) -0.5 ( -0.6 , -0.4 )
NM_004739 metastasis associated 1 family, member 2 (MTA2), mRNA 0.48 ( 0.37 , 0.59 ) -0.51 ( -0.8 , -0.3 )
NM_002267 karyopherin alpha 3 (importin alpha 4) (KPNA3), mRNA 0.54 ( 0.06 , 1.02 ) -0.51 ( -0.7 , -0.3 )
NM_022763 factor for adipocyte differentiation 104 (FAD104), mRNA 0.42 ( 0.29 , 0.56 ) -0.51 ( -0.8 , -0.3 )
NM_014969 WD repeat domain 47 (WDR47), mRNA 0.94 ( 0.7 , 1.18 ) -0.51 ( -0.8 , -0.3 )
NM_003501 acyl-Coenzyme A oxidase 3, pristanoyl (ACOX3), mRNA 1.24 ( 0.4 , 2.07 ) -0.51 ( -0.8 , -0.2 )
NM_002748 mitogen-activated protein kinase 6 (MAPK6), mRNA 0.86 ( 0.57 , 1.15 ) -0.53 ( -0.7 , -0.3 )
NM_003998 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) (NFKB1), mRNA 0.65 ( 0.5 , 0.8 ) -0.53 ( -0.7 , -0.3 )
M14636 glycogen phosphorylase mRNA, complete cds 0.55 ( 0.43 , 0.67 ) -0.53 ( -0.9 , -0.2 )
NM_015705 RUN and TBC1 domain containing 3 (RUTBC3), mRNA 0.45 ( 0.35 , 0.56 ) -0.53 ( -0.8 , -0.3 )
NM_005940 matrix metalloproteinase 11 (stromelysin 3) (MMP11), mRNA 0.42 ( 0.29 , 0.56 ) -0.53 ( -0.8 , -0.2 )
BC003562 dual specificity phosphatase 6, mRNA 0.66 ( 0.5 , 0.81 ) -0.54 ( -0.9 , -0.2 )
NM_018699 PR domain containing 5 (PRDM5), mRNA 0.71 ( 0.47 , 0.95 ) -0.54 ( -0.9 , -0.2 )
NM_021078 GCN5 general control of amino-acid synthesis 5-like 2 (yeast) (GCN5L2), mRNA 0.45 ( 0.33 , 0.56 ) -0.55 ( -0.6 , -0.5 )
NM_014743 KIAA0232 gene product (KIAA0232), mRNA 0.57 ( 0.15 , 1 ) -0.55 ( -0.9 , -0.2 )
NM_173172 nuclear receptor subfamily 4, group A, member 2 (NR4A2), transcript variant 3, mRNA 0.68 ( 0.42 , 0.94 ) -0.55 ( -0.7 , -0.4 )
XM_114611 omo sapiens hypothetical protein KIAA1833 (KIAA1833), mRNA 0.84 ( 0.57 , 1.11 ) -0.55 ( -0.9 , -0.2 )
NM_147171 A kinase (PRKA) anchor protein (yotiao) 9 (AKAP9), transcript variant 1, mRNA 0.43 ( 0.35 , 0.52 ) -0.56 ( -0.7 , -0.5 )
NM_018981 DnaJ (Hsp40) homolog, subfamily C, member 10 (DNAJC10), mRNA 0.51 ( 0.23 , 0.79 ) -0.56 ( -0.8 , -0.3 )
NM_020718 ubiquitin specific protease 31 (USP31), mRNA 0.6 ( 0.45 , 0.75 ) -0.56 ( -0.6 , -0.5 )
NM_018569 chromosome 4 open reading frame 16 (C4orf16), mRNA 0.59 ( 0.42 , 0.76 ) -0.56 ( -0.6 , -0.5 )
NM_002342 lymphotoxin beta receptor (TNFR superfamily, member 3) (LTBR), mRNA 0.38 ( 0.34 , 0.43 ) -0.56 ( -0.8 , -0.4 )
NM_198531 ATPase, Class II, type 9B (ATP9B), mRNA 0.6 ( 0.47 , 0.72 ) -0.57 ( -0.8 , -0.3 )
NM_177423 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin),       0.68 ( 0.66 , 0.71 ) -0.57 ( -0.7 , -0.5 )
NM_015534 zinc finger, ZZ domain containing 3 (ZZZ3), mRNA 0.69 ( 0.34 , 1.05 ) -0.58 ( -0.9 , -0.3 )
NM_014423 ALL1 fused gene from 5q31 (AF5Q31), mRNA 1.12 ( 0.73 , 1.52 ) -0.58 ( -0.8 , -0.4 )
NM_030580 zinc finger protein 34 (KOX 32) (ZNF34), mRNA 0.46 ( 0.44 , 0.48 ) -0.58 ( -1.1 , -0.1 )
NM_004747 discs, large homolog 5 (Drosophila) (DLG5), mRNA 0.57 ( 0.34 , 0.8 ) -0.58 ( -0.9 , -0.3 )
NM_015434 DKFZP434B168 protein (DKFZP434B168), mRNA 0.42 ( 0.35 , 0.5 ) -0.58 ( -0.7 , -0.5 )
NM_032870 chromosome 6 open reading frame 111 (C6orf111), mRNA 0.58 ( 0.49 , 0.68 ) -0.58 ( -0.8 , -0.4 )
NM_015173 TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 (TBC1D1), mRNA 0.65 ( 0.45 , 0.85 ) -0.59 ( -0.9 , -0.3 )
NM_144997 folliculin (FLCN), transcript variant 1, mRNA 0.47 ( 0.2 , 0.73 ) -0.59 ( -0.7 , -0.5 )
NM_018156 vacuolar protein sorting 13D (yeast) (VPS13D), transcript variant 2, mRNA 0.65 ( 0.54 , 0.75 ) -0.6 ( -0.7 , -0.5 )
NM_006775 quaking homolog, KH domain RNA binding (mouse) (QKI), transcript variant 1, mRNA 0.73 ( 0.67 , 0.79 ) -0.6 ( -0.9 , -0.3 )
NM_198597 SEC24 related gene family, member C (S. cerevisiae) (SEC24C), transcript variant 2, mRNA 0.48 ( 0.26 , 0.7 ) -0.6 ( -1 , -0.2 )
NM_003685 KH-type splicing regulatory protein (FUSE binding protein 2) (KHSRP), mRNA 0.46 ( 0.23 , 0.69 ) -0.6 ( -0.8 , -0.4 )
NM_006715 mannosidase, alpha, class 2C, member 1 (MAN2C1), mRNA 0.54 ( 0.27 , 0.81 ) -0.6 ( -0.9 , -0.3 )
NM_019020 TBC1 domain family, member 16 (TBC1D16), mRNA 1.17 ( 0.68 , 1.66 ) -0.61 ( -1 , -0.2 )
NM_002444 moesin (MSN), mRNA 0.46 ( 0.21 , 0.7 ) -0.61 ( -0.9 , -0.3 )
NM_015049 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 3 (ALS2CR3), mRNA 0.5 ( 0.44 , 0.57 ) -0.61 ( -0.8 , -0.4 )
NM_022652 dual specificity phosphatase 6 (DUSP6), transcript variant 2, mRNA 1.11 ( 0.94 , 1.28 ) -0.62 ( -0.9 , -0.4 )
NM_017694 FLJ20160 protein (FLJ20160), mRNA 0.49 ( 0.44 , 0.54 ) -0.62 ( -0.8 , -0.4 )
NM_004819 symplekin (SYMPK), mRNA 0.66 ( 0.25 , 1.06 ) -0.63 ( -1 , -0.3 )
NM_020410 ATPase type 13A (ATP13A), mRNA 0.6 ( 0.53 , 0.67 ) -0.63 ( -0.9 , -0.3 )
NM_016272 transducer of ERBB2, 2 (TOB2), mRNA 0.74 ( 0.57 , 0.91 ) -0.63 ( -1.1 , -0.2 )
NM_001001894 tetratricopeptide repeat domain 3 (TTC3), transcript variant 2, mRNA 0.55 ( 0.46 , 0.64 ) -0.63 ( -1 , -0.3 )
NM_005124 nucleoporin 153kDa (NUP153), mRNA 0.62 ( 0.34 , 0.89 ) -0.63 ( -1 , -0.3 )
NM_016343 centromere protein F, 350/400ka (mitosin) (CENPF), mRNA 0.72 ( -0.06 , 1.5 ) -0.63 ( -1.1 , -0.2 )
NM_006788 ralA binding protein 1 (RALBP1), mRNA 0.44 ( 0.21 , 0.68 ) -0.63 ( -0.9 , -0.4 )
NM_022553 vacuolar protein sorting 52 (yeast) (VPS52), transcript variant 2, mRNA 0.68 ( 0.55 , 0.81 ) -0.63 ( -0.7 , -0.5 )
NM_014666 enthoprotin (ENTH), mRNA 0.56 ( 0.37 , 0.74 ) -0.64 ( -0.9 , -0.4 )
NM_005596 nuclear factor I/B (NFIB), mRNA 0.42 ( 0.27 , 0.58 ) -0.64 ( -0.7 , -0.6 )
NM_004846 eukaryotic translation initiation factor 4E member 2 (EIF4E2), mRNA 0.76 ( 0.44 , 1.07 ) -0.65 ( -1.2 , -0.1 )
NM_003760 eukaryotic translation initiation factor 4 gamma, 3 (EIF4G3), mRNA 0.62 ( 0.4 , 0.83 ) -0.65 ( -1.2 , -0.1 )
NM_014640 tubulin tyrosine ligase-like family, member 4 (TTLL4), mRNA 0.43 ( 0.39 , 0.48 ) -0.65 ( -1 , -0.3 )
NM_018125 hypothetical protein FLJ10521 (FLJ10521), mRNA 0.68 ( 0.51 , 0.86 ) -0.65 ( -0.9 , -0.4 )
NM_001556 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (IKBKB), mRNA 0.81 ( 0.66 , 0.96 ) -0.66 ( -1 , -0.3 )
NM_153329 hypothetical protein MGC10204 (MGC10204), mRNA 0.91 ( 0.73 , 1.1 ) -0.66 ( -1.1 , -0.2 )
NM_012102 arginine-glutamic acid dipeptide (RE) repeats (RERE), mRNA 0.48 ( 0.4 , 0.57 ) -0.66 ( -1 , -0.3 )
NM_017721 putative NFkB activating protein (FLJ20241), mRNA 0.59 ( 0.45 , 0.73 ) -0.66 ( -0.9 , -0.4 )
NM_144982 hypothetical protein MGC23401 (MGC23401), mRNA 0.54 ( 0.4 , 0.67 ) -0.67 ( -1 , -0.4 )
NM_012272 Huntingtin interacting protein C (HYPC), mRNA 0.77 ( -0.42 , 1.97 ) -0.67 ( -0.8 , -0.5 )
NM_012297 Ras-GTPase activating protein SH3 domain-binding protein 2 (G3BP2), transcript variant 2, m 0.54 ( 0.19 , 0.89 ) -0.67 ( -1.2 , -0.1 )
NM_007110 telomerase-associated protein 1 (TEP1), mRNA 0.67 ( 0.33 , 1 ) -0.67 ( -1.2 , -0.1 )
XM_371575 omo sapiens formin binding protein 3 (FNBP3), mRNA 0.89 ( 0.72 , 1.05 ) -0.67 ( -1 , -0.4 )
NM_002268 karyopherin alpha 4 (importin alpha 3) (KPNA4), mRNA 0.68 ( 0.3 , 1.06 ) -0.68 ( -1.1 , -0.3 )
NM_002892 AT rich interactive domain 4A (RBP1-like) (ARID4A), transcript variant 1, mRNA 0.46 ( 0.27 , 0.64 ) -0.68 ( -1.1 , -0.3 )
NM_005257 GATA binding protein 6 (GATA6), mRNA 1.19 ( 1.01 , 1.36 ) -0.68 ( -1.3 , -0.1 )
NM_002556 oxysterol binding protein (OSBP), mRNA 0.93 ( 0.79 , 1.07 ) -0.68 ( -1 , -0.4 )
NM_024662 N-acetyltransferase-like protein (FLJ10774), mRNA 0.59 ( 0.39 , 0.8 ) -0.68 ( -0.8 , -0.6 )
NM_003935 topoisomerase (DNA) III beta (TOP3B), mRNA 0.58 ( 0.46 , 0.7 ) -0.69 ( -1 , -0.4 )
NM_015027 KIAA0251 protein (KIAA0251), mRNA 0.65 ( 0.28 , 1.03 ) -0.69 ( -1 , -0.3 )
NM_006387 calcium homeostasis endoplasmic reticulum protein (CHERP), mRNA 0.43 ( 0.29 , 0.58 ) -0.69 ( -1 , -0.4 )
NM_001981 epidermal growth factor receptor pathway substrate 15 (EPS15), mRNA 0.53 ( 0.17 , 0.9 ) -0.7 ( -0.9 , -0.5 )
NM_014925 KIAA1002 protein (KIAA1002), mRNA 0.48 ( 0.33 , 0.63 ) -0.7 ( -1.2 , -0.2 )
NM_018223 checkpoint with forkhead and ring finger domains (CHFR), mRNA 0.46 ( 0.23 , 0.7 ) -0.7 ( -1 , -0.5 )
XM_497119 omo sapiens upstream regulatory element binding protein 1 (UREB1), mRNA 0.5 ( 0.43 , 0.58 ) -0.71 ( -1.2 , -0.3 )
NM_018193 hypothetical protein FLJ10719 (FLJ10719), mRNA 0.49 ( 0.26 , 0.73 ) -0.71 ( -1 , -0.4 )
NM_145110 mitogen-activated protein kinase kinase 3 (MAP2K3), transcript variant C, mRNA 0.57 ( 0.42 , 0.72 ) -0.71 ( -0.7 , -0.7 )
NM_006306 SMC1 structural maintenance of chromosomes 1-like 1 (yeast) (SMC1L1), mRNA 0.52 ( 0.28 , 0.77 ) -0.72 ( -1 , -0.5 )
NM_080669 similar to RIKEN cDNA 1110002C08 gene (MGC9564), mRNA 0.58 ( 0.41 , 0.76 ) -0.72 ( -1.2 , -0.3 )
NM_024811 pre-mRNA cleavage factor I, 59 kDa subunit (FLJ12529), mRNA 0.47 ( 0.21 , 0.72 ) -0.72 ( -0.9 , -0.5 )
NM_017790 regulator of G-protein signalling 3 (RGS3), transcript variant 3, mRNA 0.49 ( 0.21 , 0.76 ) -0.73 ( -0.9 , -0.6 )
NM_014608 cytoplasmic FMR1 interacting protein 1 (CYFIP1), mRNA 0.7 ( 0.48 , 0.92 ) -0.73 ( -1.3 , -0.2 )
NM_006825 cytoskeleton-associated protein 4 (CKAP4), mRNA 0.62 ( 0.53 , 0.71 ) -0.73 ( -0.8 , -0.7 )
NM_002519 nuclear protein, ataxia-telangiectasia locus (NPAT), mRNA 0.48 ( 0.32 , 0.64 ) -0.73 ( -1.1 , -0.4 )
NM_016111 KIAA0683 gene product (KIAA0683), mRNA 0.64 ( 0.41 , 0.86 ) -0.73 ( -0.9 , -0.6 )
NM_006836 GCN1 general control of amino-acid synthesis 1-like 1 (yeast) (GCN1L1), mRNA 0.71 ( 0.6 , 0.81 ) -0.74 ( -1 , -0.5 )
NM_022089 putative ATPase (HSA9947), mRNA 0.67 ( 0.21 , 1.14 ) -0.74 ( -1 , -0.5 )
NM_002885 RAP1, GTPase activating protein 1 (RAP1GA1), mRNA 0.61 ( 0.54 , 0.68 ) -0.75 ( -1.2 , -0.3 )
NM_016111 KIAA0683 gene product (KIAA0683), mRNA 0.63 ( 0.42 , 0.85 ) -0.75 ( -1.3 , -0.2 )
NM_005347 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) (HSPA5), mRNA 1.11 ( 0.83 , 1.38 ) -0.75 ( -1.1 , -0.4 )
NM_020857 vacuolar protein sorting protein 18 (VPS18), mRNA 0.56 ( 0.46 , 0.65 ) -0.75 ( -0.9 , -0.6 )
NM_004526 MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae) (MCM2), mRNA 0.52 ( 0.24 , 0.8 ) -0.75 ( -1.1 , -0.4 )
NM_000152 glucosidase, alpha; acid (Pompe disease, glycogen storage disease type II) (GAA), mRNA 0.78 ( 0.57 , 0.99 ) -0.76 ( -1.2 , -0.3 )
NM_016649 chromosome 20 open reading frame 6 (C20orf6), mRNA 0.75 ( 0.28 , 1.23 ) -0.76 ( -1.1 , -0.4 )
NM_016320 nucleoporin 98kDa (NUP98), transcript variant 1, mRNA 0.67 ( 0.51 , 0.83 ) -0.76 ( -1.2 , -0.3 )
NM_014773 KIAA0141 (KIAA0141), mRNA 0.82 ( 0.8 , 0.83 ) -0.76 ( -1.1 , -0.5 )
NM_015516 likely ortholog of chicken tsukushi (TSK), mRNA 0.73 ( 0.71 , 0.76 ) -0.76 ( -1.3 , -0.2 )
NM_006322 tubulin, gamma complex associated protein 3 (TUBGCP3), mRNA 0.83 ( 0.67 , 0.99 ) -0.77 ( -1.2 , -0.3 )
NM_015047 KIAA0090 protein (KIAA0090), mRNA 0.45 ( 0.25 , 0.66 ) -0.78 ( -1 , -0.6 )
NM_019606 hypothetical protein FLJ20257 (FLJ20257), mRNA 0.64 ( 0.44 , 0.85 ) -0.78 ( -1 , -0.6 )
NM_018085 importin 9 (IPO9), mRNA 0.53 ( 0.5 , 0.56 ) -0.78 ( -1.2 , -0.4 )
NM_198830 ATP citrate lyase (ACLY), transcript variant 2, mRNA 0.57 ( 0.28 , 0.87 ) -0.78 ( -1.1 , -0.5 )
NM_139181 centaurin, delta 2 (CENTD2), transcript variant 1, mRNA 1.05 ( 0.95 , 1.15 ) -0.79 ( -1.5 , -0.1 )
NM_015537 nasal embryonic LHRH factor (NELF), mRNA 0.46 ( 0.31 , 0.62 ) -0.79 ( -1.1 , -0.5 )
NM_001280 cold inducible RNA binding protein (CIRBP), mRNA 0.62 ( 0.31 , 0.94 ) -0.79 ( -1.3 , -0.3 )
XM_496933 omo sapiens similar to FLJ00261 protein (LOC441296), mRNA 0.76 ( 0.51 , 1 ) -0.79 ( -1 , -0.6 )
NM_001961 eukaryotic translation elongation factor 2 (EEF2), mRNA 0.61 ( 0.16 , 1.07 ) -0.79 ( -1.4 , -0.2 )
NM_003029 SHC (Src homology 2 domain containing) transforming protein 1 (SHC1), transcript variant 2, m 0.45 ( 0.33 , 0.57 ) -0.8 ( -1.3 , -0.3 )
NM_006129 bone morphogenetic protein 1 (BMP1), transcript variant BMP1-3, mRNA 0.48 ( 0.36 , 0.61 ) -0.8 ( -1 , -0.6 )
NM_003567 breast cancer anti-estrogen resistance 3 (BCAR3), mRNA 0.59 ( 0.46 , 0.72 ) -0.81 ( -1.1 , -0.5 )
NM_003170 suppressor of Ty 6 homolog (S. cerevisiae) (SUPT6H), mRNA 0.45 ( 0.21 , 0.7 ) -0.81 ( -1.4 , -0.2 )
NM_031965 haspin (GSG2), mRNA 0.4 ( 0.3 , 0.51 ) -0.81 ( -1.2 , -0.4 )
NM_024663 aminopeptidase-like 1 (NPEPL1), mRNA 0.73 ( 0.42 , 1.03 ) -0.81 ( -1.3 , -0.3 )
NM_033200 hypothetical protein BC002942 (BC002942), mRNA 0.76 ( 0.43 , 1.08 ) -0.82 ( -1.2 , -0.5 )
NR_001564 X (inactive)-specific transcript (XIST) on chromosome X 0.94 ( 0.67 , 1.2 ) -0.82 ( -1.1 , -0.6 )
NM_000148 fucosyltransferase 1 (galactoside 2-alpha-L-fucosyltransferase) (FUT1), mRNA 0.86 ( 0.76 , 0.97 ) -0.82 ( -1.3 , -0.3 )
NM_170707 lamin A/C (LMNA), transcript variant 1, mRNA 0.48 ( 0.43 , 0.54 ) -0.82 ( -0.9 , -0.8 )
NM_015335 thyroid hormone receptor associated protein 2 (THRAP2) 0.8 ( 0.6 , 1.01 ) -0.82 ( -1 , -0.6 )
NM_005993 tubulin-specific chaperone d (TBCD), mRNA 0.63 ( 0.43 , 0.82 ) -0.82 ( -1 , -0.6 )
NM_181351 neural cell adhesion molecule 1 (NCAM1), mRNA 0.44 ( 0.26 , 0.63 ) -0.83 ( -1.3 , -0.4 )
NM_002081 glypican 1 (GPC1), mRNA 0.45 ( 0.39 , 0.51 ) -0.83 ( -1.2 , -0.4 )
NM_015631 chromosome 10 open reading frame 61 (C10orf61), mRNA 1.05 ( 1.02 , 1.08 ) -0.83 ( -1.1 , -0.6 )
NM_173555 trypsin domain containing 1 (TYSND1), mRNA 0.69 ( 0.44 , 0.94 ) -0.83 ( -1.2 , -0.5 )
NM_002130 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) (HMGCS1), mRNA 0.46 ( 0.28 , 0.65 ) -0.84 ( -1.1 , -0.6 )
NM_152383 hypothetical protein MGC42174 (MGC42174), mRNA 0.85 ( 0.71 , 0.98 ) -0.84 ( -1.5 , -0.2 )
NM_017758 hypothetical protein FLJ20308 (FLJ20308), mRNA 0.84 ( 0.65 , 1.03 ) -0.85 ( -1.1 , -0.6 )
NM_015425 polymerase (RNA) I polypeptide A, 194kDa (POLR1A), mRNA 0.52 ( 0.48 , 0.57 ) -0.85 ( -1 , -0.7 )
NM_001681 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 (ATP2A2), transcript variant 2, mRN 0.52 ( 0.32 , 0.71 ) -0.86 ( -1 , -0.7 )
XM_496255 KIAA0563-related gene (LOC440472), mRNA 0.6 ( 0.35 , 0.85 ) -0.86 ( -1.3 , -0.4 )
XM_374768 USP6 N-terminal like (USP6NL), mRNA 0.68 ( 0.51 , 0.85 ) -0.86 ( -1.2 , -0.5 )
NM_013432 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 2 (NFKBIL2), m 0.5 ( 0.37 , 0.63 ) -0.86 ( -1.2 , -0.5 )
NM_007055 polymerase (RNA) III (DNA directed) polypeptide A, 155kDa (POLR3A), mRNA 0.56 ( 0.26 , 0.86 ) -0.87 ( -1.3 , -0.5 )
NM_003400 exportin 1 (CRM1 homolog, yeast) (XPO1), mRNA 0.61 ( 0.22 , 1 ) -0.87 ( -1.1 , -0.7 )
NM_014661 family with sequence similarity 53, member B (FAM53B), mRNA 0.44 ( 0.31 , 0.58 ) -0.87 ( -1.5 , -0.3 )
NM_005779 lipoma HMGIC fusion partner-like 2 (LHFPL2), mRNA 1.19 ( 1.11 , 1.26 ) -0.87 ( -1.3 , -0.5 )
NM_020832 KIAA1441 protein (KIAA1441), mRNA 0.54 ( 0.26 , 0.81 ) -0.88 ( -1.3 , -0.4 )
NM_003481 ubiquitin specific protease 5 (isopeptidase T) (USP5), mRNA 0.69 ( 0.52 , 0.85 ) -0.88 ( -1.1 , -0.6 )
NM_024519 hypothetical protein FLJ13725 (FLJ13725), mRNA 0.5 ( 0.29 , 0.71 ) -0.89 ( -1.8 , 0 )
NM_017747 ankyrin repeat and KH domain containing 1 (ANKHD1), transcript variant 1, mRNA 0.57 ( 0.49 , 0.65 ) -0.89 ( -1.3 , -0.5 )
NM_021174 KIAA1967 (KIAA1967), transcript variant 1, mRNA 0.72 ( 0.45 , 0.99 ) -0.9 ( -1.5 , -0.3 )
NM_030792 hypothetical protein PP1665 (PP1665), mRNA 0.63 ( 0.55 , 0.71 ) -0.9 ( -1.2 , -0.6 )
NM_032259 WD repeat domain 24 (WDR24), mRNA 0.73 ( 0.46 , 1.01 ) -0.91 ( -1.3 , -0.5 )
NM_207197 a disintegrin and metalloproteinase domain 15 (metargidin) (ADAM15), transcript variant 6, mR 0.66 ( 0.61 , 0.72 ) -0.91 ( -1.3 , -0.6 )
NM_020461 tubulin, gamma complex associated protein 6 (TUBGCP6), transcript variant 1, mRNA 0.69 ( 0.41 , 0.97 ) -0.92 ( -1.1 , -0.7 )
NM_012305 adaptor-related protein complex 2, alpha 2 subunit (AP2A2), mRNA 0.61 ( 0.43 , 0.79 ) -0.93 ( -1.2 , -0.7 )
NM_002332 low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) (LRP1), mRNA 0.47 ( 0.4 , 0.55 ) -0.93 ( -1.6 , -0.3 )
NM_015329 KIAA0892 (KIAA0892), mRNA 0.55 ( 0.39 , 0.71 ) -0.94 ( -1.4 , -0.5 )
NM_001270 chromodomain helicase DNA binding protein 1 (CHD1), mRNA 0.66 ( 0.07 , 1.24 ) -0.94 ( -1.3 , -0.5 )
NM_001084 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3), mRNA 0.74 ( 0.66 , 0.83 ) -0.95 ( -1.4 , -0.5 )
NM_014918 carbohydrate (chondroitin) synthase 1 (CHSY1), mRNA 0.7 ( 0.49 , 0.91 ) -0.95 ( -1.3 , -0.6 )
NM_005245 FAT tumor suppressor homolog 1 (Drosophila) (FAT), mRNA 0.49 ( 0.41 , 0.57 ) -0.96 ( -1.3 , -0.7 )
NM_004341 carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), m 0.46 ( 0.39 , 0.54 ) -0.97 ( -1.1 , -0.8 )
NM_030628 KIAA1698 protein (KIAA1698), mRNA 0.63 ( 0.49 , 0.78 ) -0.97 ( -1.5 , -0.5 )
NM_206937 ligase IV, DNA, ATP-dependent (LIG4), mRNA 0.84 ( 0.65 , 1.03 ) -0.97 ( -1.2 , -0.8 )
NM_198066 glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1), mRNA 0.44 ( 0.25 , 0.63 ) -0.98 ( -1.2 , -0.7 )
NM_004634 bromodomain and PHD finger containing, 1 (BRPF1), transcript variant 2, mRNA 0.58 ( 0.35 , 0.81 ) -1 ( -1.5 , -0.5 )
NM_014045 low density lipoprotein receptor-related protein 10 (LRP10), mRNA 0.87 ( 0.66 , 1.07 ) -1 ( -1.4 , -0.7 )
NM_005163 v-akt murine thymoma viral oncogene homolog 1 (AKT1), mRNA 0.62 ( 0.57 , 0.66 ) -1.01 ( -1.3 , -0.7 )
NM_004687 myotubularin related protein 4 (MTMR4), mRNA 0.93 ( 0.78 , 1.08 ) -1.02 ( -1.3 , -0.7 )
NM_002663 phospholipase D2 (PLD2), mRNA 0.51 ( 0.33 , 0.69 ) -1.04 ( -1.9 , -0.2 )
NM_006038 spermatogenesis associated 2 (SPATA2), mRNA 0.63 ( 0.21 , 1.06 ) -1.04 ( -1.4 , -0.7 )
NM_033407 dedicator of cytokinesis 7 (DOCK7), mRNA 0.55 ( 0.05 , 1.05 ) -1.04 ( -1.1 , -1 )
NM_138619 golgi associated, gamma adaptin ear containing, ARF binding protein 3 (GGA3), transcript var   0.98 ( 0.57 , 1.39 ) -1.08 ( -1.5 , -0.6 )
NR_001564 X (inactive)-specific transcript (XIST) on chromosome X 0.74 ( 0.4 , 1.08 ) -1.08 ( -1.3 , -0.9 )
NM_004941 DEAH (Asp-Glu-Ala-His) box polypeptide 8 (DHX8), mRNA 1.11 ( 0.95 , 1.26 ) -1.1 ( -1.3 , -0.9 )
NM_012294 Rap guanine nucleotide exchange factor (GEF) 5 (RAPGEF5), mRNA 0.45 ( 0.21 , 0.7 ) -1.13 ( -1.8 , -0.5 )
NM_173602 KIAA1463 protein (KIAA1463), mRNA 0.47 ( 0.25 , 0.69 ) -1.14 ( -1.4 , -0.9 )
NM_006295 valyl-tRNA synthetase 2 (VARS2), mRNA 1.13 ( 0.86 , 1.4 ) -1.14 ( -1.6 , -0.7 )
NM_014287 NODAL modulator 1 (NOMO1), mRNA 0.99 ( 0.78 , 1.2 ) -1.14 ( -1.5 , -0.8 )
NM_004716 proprotein convertase subtilisin/kexin type 7 (PCSK7), mRNA 1.12 ( 1.05 , 1.19 ) -1.16 ( -1.4 , -0.9 )
NM_002447 macrophage stimulating 1 receptor (c-met-related tyrosine kinase) (MST1R), mRNA 0.82 ( 0.66 , 0.98 ) -1.16 ( -1.6 , -0.7 )
NM_134269 smoothelin (SMTN), transcript variant 2, mRNA 0.71 ( 0.63 , 0.78 ) -1.16 ( -1.6 , -0.7 )
NM_002691 polymerase (DNA directed), delta 1, catalytic subunit 125kDa (POLD1), mRNA 0.78 ( 0.47 , 1.09 ) -1.21 ( -1.9 , -0.5 )
NM_004383 c-src tyrosine kinase (CSK), mRNA 0.84 ( 0.55 , 1.12 ) -1.25 ( -2.2 , -0.3 )
NM_004260 RecQ protein-like 4 (RECQL4), mRNA 0.47 ( 0.45 , 0.5 ) -1.3 ( -1.7 , -1 )
NM_024757 euchromatic histone methyltransferase 1 (EHMT1), mRNA 0.69 ( 0.42 , 0.95 ) -1.33 ( -1.9 , -0.7 )
NM_024997 activating transcription factor 7 interacting protein 2 (ATF7IP2), mRNA 1.02 ( 0.46 , 1.59 ) -1.33 ( -1.7 , -1 )
NM_014685 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain membe    0.75 ( 0.62 , 0.89 ) -1.37 ( -1.7 , -1.1 )
NM_000455 serine/threonine kinase 11 (Peutz-Jeghers syndrome) (STK11), mRNA 1.02 ( 0.65 , 1.39 ) -1.39 ( -1.9 , -0.9 )
NM_203346 high density lipoprotein binding protein (vigilin) (HDLBP), mRNA 0.86 ( 0.58 , 1.14 ) -1.41 ( -1.5 , -1.3 )
Genes down regulated at 1 and 4 hrs
NM_006649 UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) (UTP14A), mRNA -2.12 ( -2.24 , -2 ) 1.95 ( 1.13 , 2.8 )
NM_032991 caspase 3, apoptosis-related cysteine protease (CASP3), transcript variant beta, mRNA -1.2 ( -1.37 , -1.03 ) 1.74 ( 0.59 , 2.9 )
NM_018842 insulin receptor tyrosine kinase substrate (LOC55971), mRNA -1.35 ( -1.41 , -1.28 ) 1.48 ( 0.79 , 2.2 )
NM_013366 anaphase promoting complex subunit 2 (ANAPC2), mRNA -1.96 ( -2.33 , -1.59 ) 1.46 ( 1.2 , 1.7 )
NM_004433 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) (ELF3), mRNA -0.99 ( -1.27 , -0.71 ) 1.38 ( 1.15 , 1.6 )
NM_004157 protein kinase, cAMP-dependent, regulatory, type II, alpha (PRKAR2A), mRNA -0.63 ( -0.78 , -0.47 ) 1.35 ( 0.17 , 2.5 )
NM_006764 interferon-related developmental regulator 2 (IFRD2), mRNA -0.77 ( -0.97 , -0.57 ) 1.23 ( 0.27 , 2.2 )
NM_003383 very low density lipoprotein receptor (VLDLR), mRNA -1.43 ( -1.56 , -1.31 ) 1.21 ( 1.04 , 1.4 )
NM_002137 heterogeneous nuclear ribonucleoprotein A2/B1 (HNRPA2B1), transcript variant A2, mRNA -0.9 ( -1.18 , -0.62 ) 1.19 ( 0.65 , 1.7 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.05 ( -1.12 , -0.97 ) 1.13 ( 0.82 , 1.4 )
NM_001005386 ARP2 actin-related protein 2 homolog (yeast) (ACTR2), transcript variant 1, mRNA -0.59 ( -0.68 , -0.5 ) 1.09 ( 0.43 , 1.8 )
NM_001005386 ARP2 actin-related protein 2 homolog (yeast) (ACTR2), transcript variant 1, mRNA -0.78 ( -1.08 , -0.47 ) 1.08 ( 0.58 , 1.6 )
NM_005826 heterogeneous nuclear ribonucleoprotein R (HNRPR), mRNA -0.78 ( -0.97 , -0.6 ) 1.07 ( 0.49 , 1.7 )
NM_003379 villin 2 (ezrin) (VIL2), mRNA -1.52 ( -1.72 , -1.32 ) 1.06 ( 0.71 , 1.4 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.3 ( -1.44 , -1.17 ) 1.06 ( 0.76 , 1.4 )
NM_014570 ADP-ribosylation factor GTPase activating protein 3 (ARFGAP3), mRNA -0.94 ( -1.1 , -0.79 ) 1.04 ( 0.49 , 1.6 )
NM_002298 lymphocyte cytosolic protein 1 (L-plastin) (LCP1), mRNA -1.33 ( -2.04 , -0.63 ) 1.01 ( 0.47 , 1.6 )
NM_001539 DnaJ (Hsp40) homolog, subfamily A, member 1 (DNAJA1), mRNA -0.61 ( -0.79 , -0.44 ) 0.99 ( 0.43 , 1.6 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.01 ( -1.07 , -0.94 ) 0.95 ( 0.71 , 1.2 )
NM_024419 phosphatidylglycerophosphate synthase (PGS1), mRNA -1.3 ( -1.37 , -1.23 ) 0.93 ( 0.43 , 1.4 )
NM_017722 hypothetical protein FLJ20244 (FLJ20244), mRNA -1.07 ( -1.32 , -0.81 ) 0.92 ( 0.41 , 1.4 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.39 ( -1.46 , -1.31 ) 0.89 ( 0.73 , 1.1 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.27 ( -1.35 , -1.18 ) 0.87 ( 0.68 , 1.1 )
NM_007357 component of oligomeric golgi complex 2 (COG2), mRNA -0.66 ( -0.77 , -0.55 ) 0.84 ( 0.44 , 1.3 )
NM_002356 myristoylated alanine-rich protein kinase C substrate (MARCKS), mRNA -0.69 ( -0.84 , -0.54 ) 0.82 ( 0.55 , 1.1 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.43 ( -1.56 , -1.3 ) 0.81 ( 0.42 , 1.2 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.03 ( -1.11 , -0.95 ) 0.79 ( 0.54 , 1 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.13 ( -1.23 , -1.03 ) 0.79 ( 0.47 , 1.1 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -0.96 ( -1.08 , -0.83 ) 0.78 ( 0.41 , 1.1 )
NM_014437 solute carrier family 39 (zinc transporter), member 1 (SLC39A1), mRNA -0.89 ( -1.07 , -0.7 ) 0.74 ( 0.64 , 0.8 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.08 ( -1.25 , -0.91 ) 0.73 ( 0.43 , 1 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -1.36 ( -1.45 , -1.27 ) 0.68 ( 0.46 , 0.9 )
NM_005346 heat shock 70kDa protein 1B (HSPA1B), mRNA -0.49 ( -0.65 , -0.33 ) 0.38 ( 0.23 , 0.5 )
Genes down regulated at 1 and 4 hrs
NM_005345 heat shock 70kDa protein 1A (HSPA1A), mRNA -0.56 ( -0.73 , -0.39 ) -0.21 ( -0.4 , -0 )
NM_005345 heat shock 70kDa protein 1A (HSPA1A), mRNA -0.59 ( -0.67 , -0.5 ) -0.25 ( -0.5 , 0.1 )
NM_002659 plasminogen activator, urokinase receptor (PLAUR) -0.71 ( -0.81 , -0.61 ) -0.52 ( -0.7 , -0.3 )
NM_001270 chromodomain helicase DNA binding protein 1 (CHD1), mRNA -0.52 ( -0.73 , -0.32 ) -0.54 ( -0.7 , -0.4 )
XM_377072 similar to LINE-1 reverse transcriptase homolog (LOC401623), mRNA -1.36 ( -1.77 , -0.94 ) -0.55 ( -1 , -0.2 )
NM_005194 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB), mRNA -0.59 ( -0.96 , -0.22 ) -0.58 ( -0.7 , -0.5 )
NM_203418 Down syndrome critical region gene 1 (DSCR1), transcript variant 3, mRNA -0.86 ( -1.2 , -0.52 ) -0.62 ( -0.8 , -0.5 )
NM_016522 neurotrimin (HNT), mRNA -0.71 ( -1.34 , -0.07 ) -0.63 ( -0.9 , -0.4 )
NM_002659 plasminogen activator, urokinase receptor (PLAUR), transcript variant 1, mRNA -0.79 ( -0.88 , -0.7 ) -0.7 ( -0.9 , -0.5 )
NM_000045 arginase, liver (ARG1), mRNA -1.64 ( -2.33 , -0.96 ) -0.71 ( -1 , -0.4 )
NM_012118 CCR4 carbon catabolite repression 4-like (S. cerevisiae) (CCRN4L), mRNA -0.59 ( -0.71 , -0.47 ) -0.71 ( -1.1 , -0.3 )
NM_020529 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA), m -1.04 ( -1.14 , -0.94 ) -0.76 ( -0.9 , -0.6 )
NM_006216 serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1)     -1.17 ( -1.33 , -1.01 ) -0.8 ( -0.9 , -0.7 )
NM_001008490 Kruppel-like factor 6 (KLF6), transcript variant 1, mRNA -0.56 ( -0.63 , -0.49 ) -0.81 ( -1.1 , -0.5 )
NM_002133 heme oxygenase (decycling) 1 (HMOX1), mRNA -0.81 ( -0.89 , -0.74 ) -0.81 ( -1.4 , -0.2 )
NM_002089 chemokine (C-X-C motif) ligand 2 (CXCL2), mRNA. -1 ( -1.62 , -0.38 ) -0.91 ( -1.1 , -0.8 )
NM_005946 metallothionein 1A (functional) (MT1A), mRNA -0.65 ( -0.92 , -0.39 ) -0.94 ( -1.3 , -0.6 )
BC088358 eukaryotic translation termination factor 1, mRNA -1.08 ( -1.56 , -0.6 ) -1.07 ( -2.4 , 0.3 )
NM_000758 colony stimulating factor 2 (granulocyte-macrophage) (CSF2), mRNA -1.21 ( -1.57 , -0.86 ) -1.11 ( -1.4 , -0.9 )
NM_080645 collagen, type XII, alpha 1 (COL12A1), transcript variant short, mRNA -0.78 ( -1.14 , -0.41 ) -1.13 ( -1.4 , -0.9 )
NM_001550 interferon-related developmental regulator 1 (IFRD1), transcript variant 1, mRNA -0.46 ( -0.5 , -0.41 ) -0.78 ( -1 , -0.5 )
Genes up regulated by baculovirus treatment followed by LPS, PMA and ionomycin stimulation at 4 hrs post stimulation
NM_001001992 ubiquitin specific protease 16 (USP16), transcript variant 2, mRNA 1.63 ( 0.33 , 2.9 )
NM_000341 solute carrier family 3 (cystine, dibasic and neutral amino acid transporters, activator of cystine            1.28 ( 0.55 , 2 )
NM_004396 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (DDX5), mRNA 1.08 ( 0.47 , 1.7 )
NM_002165 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein (ID1), transcript variant 1   0.98 ( 0.9 , 1.1 )
NM_014618 deleted in bladder cancer 1 (DBC1), mRNA 0.94 ( 0.7 , 1.2 )
NM_001359 2,4-dienoyl CoA reductase 1, mitochondrial (DECR1), nuclear gene encoding mitochondrial pr   0.88 ( 0.54 , 1.2 )
NM_004058 calcyphosine (CAPS), transcript variant 1, mRNA 0.87 ( 0.5 , 1.2 )
NM_006406 peroxiredoxin 4 (PRDX4), mRNA 0.77 ( 0.62 , 0.9 )
NM_020899 zinc finger and BTB domain containing 4 (ZBTB4), mRNA 0.76 ( 0.67 , 0.9 )
NM_000055 butyrylcholinesterase (BCHE), mRNA 0.72 ( 0.6 , 0.8 )
NM_000029 angiotensinogen (serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, ant      0.72 ( 0.62 , 0.8 )
NM_018337 zinc finger protein 444 (ZNF444), mRNA 0.7 ( 0.64 , 0.8 )
NM_006953 uroplakin 3A (UPK3A), mRNA 0.65 ( 0.58 , 0.7 )
NM_177925 H2A histone family, member J (H2AFJ), transcript variant 2, mRNA 0.62 ( 0.62 , 0.6 )
Genes down regulated by baculovirus treatment followed by LPS, PMA and ionomycin stimulation at 4 hrs post stim  
NM_000575 interleukin 1, alpha (IL1A), mRNA -1.48 ( -1.7 , -1.2 )
NM_000358 transforming growth factor, beta-induced, 68kDa (TGFBI), mRNA -1.13 ( -2 , -0.3 )
NM_000499 cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), mRNA -1.13 ( -1.4 , -0.9 )
NM_012291 extra spindle poles like 1 (S. cerevisiae) (ESPL1), mRNA -1.1 ( -1.2 , -1 )
NM_032010 microtubule-associated protein 1B (MAP1B), transcript variant 2, mRNA -1.1 ( -1.8 , -0.4 )
NM_002502 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) (NFKB2), mRN  -1.1 ( -1.6 , -0.6 )
NM_007171 protein-O-mannosyltransferase 1 (POMT1), mRNA -1.08 ( -1.8 , -0.4 )
NM_015633 FGFR1 oncogene partner 2 (FGFR1OP2), mRNA -1.07 ( -1.4 , -0.7 )
NM_001986 ets variant gene 4 (E1A enhancer binding protein, E1AF) (ETV4), mRNA -1.06 ( -1.3 , -0.8 )
NM_007353 guanine nucleotide binding protein (G protein) alpha 12 (GNA12), mRNA -1.03 ( -1.4 , -0.7 )
BC113560 IBR domain containing 3, mRNA -1.03 ( -1.5 , -0.6 )
NM_019902 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 (ABCC1), transcript variant 7, mR  -0.99 ( -1.3 , -0.7 )
NM_014674 ER degradation enhancer, mannosidase alpha-like 1 (EDEM1), mRNA -0.99 ( -1.1 , -0.8 )
NM_003376 vascular endothelial growth factor (VEGF), mRNA -0.99 ( -1.3 , -0.7 )
NM_020443 neuron navigator 1 (NAV1), mRNA -0.97 ( -1.5 , -0.5 )
NM_015361 R3H domain (binds single-stranded nucleic acids) containing (R3HDM), mRNA -0.97 ( -1.4 , -0.6 )
NM_001431 erythrocyte membrane protein band 4.1-like 2 (EPB41L2), mRNA -0.96 ( -1.3 , -0.6 )
NM_004670 3'-phosphoadenosine 5'-phosphosulfate synthase 2 (PAPSS2), mRNA -0.95 ( -1.2 , -0.7 )
NM_015355 suppressor of zeste 12 homolog (Drosophila) (SUZ12), mRNA -0.95 ( -1 , -0.9 )
NM_201533 diacylglycerol kinase, zeta 104kDa (DGKZ), transcript variant 3, mRNA -0.92 ( -1.4 , -0.5 )
NM_016936 ubinuclein 1 (UBN1), mRNA -0.91 ( -1.4 , -0.4 )
NM_006845 kinesin family member 2C (KIF2C), mRNA -0.9 ( -1.4 , -0.5 )
NM_000358 transforming growth factor, beta-induced, 68kDa (TGFBI), mRNA -0.9 ( -1.1 , -0.7 )
NM_015120 Alstrom syndrome 1 (ALMS1), mRNA -0.89 ( -1.2 , -0.6 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.87 ( -1.6 , -0.2 )
NM_018069 centrosomal protein 192 kDa (Cep192), transcript variant 2, mRNA -0.87 ( -1.1 , -0.6 )
NM_001423 epithelial membrane protein 1 (EMP1), mRNA -0.87 ( -1.3 , -0.5 )
NM_152829 testis derived transcript (3 LIM domains) (TES), transcript variant 2, mRNA -0.87 ( -1 , -0.7 )
NM_002019 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor re    -0.86 ( -1.2 , -0.5 )
NM_014727 myeloid/lymphoid or mixed-lineage leukemia 4 (MLL4), mRNA -0.86 ( -1.4 , -0.3 )
NM_006453 transducin (beta)-like 3 (TBL3), mRNA -0.86 ( -1.2 , -0.5 )
NM_000419 integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41B) (ITGA2B), mRNA -0.85 ( -1.2 , -0.5 )
NM_017641 kinesin family member 21A (KIF21A), mRNA -0.85 ( -1.1 , -0.6 )
NM_173555 trypsin domain containing 1 (TYSND1), mRNA -0.85 ( -1.1 , -0.6 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.84 ( -1.3 , -0.4 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.84 ( -1.1 , -0.5 )
NM_003580 neutral sphingomyelinase (N-SMase) activation associated factor (NSMAF), mRNA -0.84 ( -1.2 , -0.5 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.83 ( -1.6 , -0.1 )
NM_001521 general transcription factor IIIC, polypeptide 2, beta 110kDa (GTF3C2), mRNA -0.83 ( -1.1 , -0.5 )
NM_021229 netrin 4 (NTN4), mRNA -0.83 ( -1 , -0.7 )
NM_015349 KIAA0240 (KIAA0240), mRNA -0.83 ( -1.4 , -0.3 )
NM_001876 carnitine palmitoyltransferase 1A (liver) (CPT1A), nuclear gene encoding mitochondrial protein   -0.82 ( -1 , -0.6 )
NM_015904 eukaryotic translation initiation factor 5B (EIF5B), mRNA -0.82 ( -1.3 , -0.4 )
NM_006389 hypoxia up-regulated 1 (HYOU1), mRNA -0.81 ( -1.2 , -0.5 )
NM_004867 integral membrane protein 2A (ITM2A), mRNA -0.81 ( -1.3 , -0.3 )
NM_006715 mannosidase, alpha, class 2C, member 1 (MAN2C1), mRNA -0.81 ( -1.1 , -0.5 )
NM_017790 regulator of G-protein signalling 3 (RGS3), transcript variant 3, mRNA -0.81 ( -0.9 , -0.7 )
NM_003557 phosphatidylinositol-4-phosphate 5-kinase, type I, alpha (PIP5K1A), mRNA -0.81 ( -1 , -0.6 )
NM_018201 TBC1 domain family, member 13 (TBC1D13), mRNA -0.8 ( -1.4 , -0.3 )
NM_003028 SHB (Src homology 2 domain containing) adaptor protein B (SHB), mRNA -0.8 ( -1.7 , 0.1 )
NM_001819 chromogranin B (secretogranin 1) (CHGB), mRNA -0.8 ( -1.1 , -0.6 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.8 ( -1.2 , -0.5 )
NM_001605 alanyl-tRNA synthetase (AARS), mRNA -0.79 ( -1 , -0.6 )
NM_015172 HBxAg transactivated protein 2 (XTP2), mRNA -0.79 ( -0.9 , -0.7 )
NM_014649 scaffold attachment factor B2 (SAFB2), mRNA -0.79 ( -1.3 , -0.3 )
NM_172230 synovial apoptosis inhibitor 1, synoviolin (SYVN1), transcript variant 2, mRNA -0.78 ( -1.1 , -0.5 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.78 ( -1 , -0.6 )
NM_006089 sex comb on midleg-like 2 (Drosophila) (SCML2), mRNA -0.78 ( -1.2 , -0.4 )
NM_002627 phosphofructokinase, platelet (PFKP), mRNA -0.77 ( -1.1 , -0.5 )
NM_004941 DEAH (Asp-Glu-Ala-His) box polypeptide 8 (DHX8), mRNA -0.77 ( -1.2 , -0.4 )
NM_019054 family with sequence similarity 35, member A (FAM35A), mRNA -0.77 ( -0.9 , -0.6 )
NM_001006642 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 25 (SLC25A25), nu          -0.77 ( -1 , -0.5 )
NM_016252 baculoviral IAP repeat-containing 6 (apollon) (BIRC6), mRNA -0.77 ( -1 , -0.5 )
NM_152221 casein kinase 1, epsilon (CSNK1E), transcript variant 1, mRNA -0.76 ( -1 , -0.5 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.76 ( -1.3 , -0.3 )
NM_007183 plakophilin 3 (PKP3), mRNA -0.76 ( -1.3 , -0.3 )
NM_014292 chromobox homolog 6 (CBX6), mRNA -0.76 ( -0.9 , -0.6 )
NM_004817 tight junction protein 2 (zona occludens 2) (TJP2), transcript variant 1, mRNA -0.75 ( -1 , -0.6 )
NM_020432 putative homeodomain transcription factor 2 (PHTF2), mRNA -0.75 ( -1 , -0.5 )
NM_203351 mitogen-activated protein kinase kinase kinase 3 (MAP3K3), transcript variant 1, mRNA -0.75 ( -1.3 , -0.2 )
NM_032960 mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), transcript variant 2,  -0.75 ( -1.2 , -0.3 )
NM_033512 TSPY-like 5 (TSPYL5), mRNA -0.75 ( -1.1 , -0.4 )
NM_016076 CGI-146 protein (PNAS-4), mRNA -0.74 ( -0.9 , -0.6 )
NM_017553 homolog of yeast INO80 (INO80), transcript variant 1, mRNA -0.74 ( -1.1 , -0.4 )
NM_005134 protein phosphatase 4, regulatory subunit 1 (PPP4R1), mRNA -0.74 ( -1 , -0.5 )
NM_014786 Rho guanine nucleotide exchange factor (GEF) 17 (ARHGEF17), mRNA -0.74 ( -1.3 , -0.2 )
NM_014611 MDN1, midasin homolog (yeast) (MDN1), mRNA -0.74 ( -0.9 , -0.6 )
NM_018671 smooth muscle cell associated protein-1 (SMAP-1), mRNA -0.73 ( -1.2 , -0.3 )
NM_018201 TBC1 domain family, member 13 (TBC1D13), mRNA -0.73 ( -0.8 , -0.7 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.73 ( -1.2 , -0.3 )
NM_178819 putative lysophosphatidic acid acyltransferase (DKFZp586M1819), mRNA -0.73 ( -0.8 , -0.7 )
NM_004638 HLA-B associated transcript 2 (BAT2), transcript variant 2, mRNA -0.72 ( -1.1 , -0.3 )
NM_033046 rhotekin (RTKN), mRNA -0.72 ( -1 , -0.4 )
NM_000617 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 (SLC11A2)   -0.72 ( -0.9 , -0.6 )
NM_002466 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 (MYBL2), mRNA -0.72 ( -1.1 , -0.3 )
NM_005647 transducin (beta)-like 1X-linked (TBL1X), mRNA -0.72 ( -1.1 , -0.3 )
NM_022070 amplified in breast cancer 1 (ABC1), mRNA -0.72 ( -1.1 , -0.3 )
NM_005700 dipeptidylpeptidase 3 (DPP3), transcript variant 1, mRNA -0.72 ( -0.9 , -0.5 )
NM_017565 family with sequence similarity 20, member A (FAM20A), mRNA -0.72 ( -1.1 , -0.3 )
NM_002359 v-maf musculoaponeurotic fibrosarcoma oncogene homolog G (avian) (MAFG), transcript varia    -0.72 ( -1 , -0.5 )
NM_001457 filamin B, beta (actin binding protein 278) (FLNB), mRNA -0.71 ( -1 , -0.4 )
NM_030884 microtubule-associated protein 4 (MAP4), transcript variant 2, mRNA -0.71 ( -1.4 , -0.1 )
NM_000211 integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage a        -0.71 ( -1.4 , -0.1 )
NM_014631 SH3 multiple domains 1 (SH3MD1), mRNA -0.71 ( -1.4 , -0.1 )
NM_005628 solute carrier family 1 (neutral amino acid transporter), member 5 (SLC1A5), mRNA -0.71 ( -1.1 , -0.4 )
NM_015382 HECT domain containing 1 (HECTD1), mRNA -0.71 ( -0.8 , -0.6 )
NM_006827 transmembrane trafficking protein (TMP21), mRNA -0.7 ( -0.9 , -0.5 )
NM_006026 H1 histone family, member X (H1FX), mRNA -0.7 ( -1.3 , -0.1 )
NM_020438 dolichyl pyrophosphate phosphatase 1 (DOLPP1), mRNA -0.69 ( -1 , -0.4 )
NM_030884 microtubule-associated protein 4 (MAP4), transcript variant 2, mRNA -0.69 ( -1 , -0.4 )
NM_002874 RAD23 homolog B (S. cerevisiae) (RAD23B), mRNA -0.69 ( -1 , -0.4 )
NM_006267 RAN binding protein 2 (RANBP2), mRNA -0.69 ( -0.8 , -0.6 )
NM_015229 KIAA0664 protein (KIAA0664), mRNA -0.69 ( -1 , -0.4 )
NM_018703 retinoblastoma binding protein 6 (RBBP6), transcript variant 2, mRNA -0.69 ( -0.8 , -0.6 )
NM_014305 TDP-glucose 4,6-dehydratase (TGDS), mRNA -0.69 ( -0.8 , -0.6 )
NM_018639 WD repeat and SOCS box-containing 2 (WSB2), mRNA -0.69 ( -1 , -0.4 )
NM_003088 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) (FSCN1), mRNA -0.69 ( -0.9 , -0.5 )
NM_024745 SHC SH2-domain binding protein 1 (SHCBP1), mRNA -0.69 ( -0.9 , -0.5 )
NM_007126 valosin-containing protein (VCP), mRNA -0.69 ( -0.9 , -0.4 )
NM_004427 polyhomeotic-like 2 (Drosophila) (PHC2), transcript variant 2, mRNA -0.68 ( -0.9 , -0.5 )
NM_004229 cofactor required for Sp1 transcriptional activation, subunit 2, 150kDa (CRSP2), mRNA -0.68 ( -0.9 , -0.4 )
NM_182984 HpaII tiny fragments locus 9C (HTF9C), transcript variant 2, mRNA -0.68 ( -1.2 , -0.2 )
NM_006767 leucine-zipper-like transcription regulator 1 (LZTR1), mRNA -0.68 ( -0.9 , -0.4 )
NM_003255 tissue inhibitor of metalloproteinase 2 (TIMP2), mRNA -0.68 ( -1 , -0.3 )
NM_024658 importin 4 (IPO4), mRNA -0.68 ( -1 , -0.4 )
NM_001254 CDC6 cell division cycle 6 homolog (S. cerevisiae) (CDC6), mRNA -0.67 ( -0.8 , -0.6 )
NM_005607 PTK2 protein tyrosine kinase 2 (PTK2), transcript variant 2, mRNA -0.67 ( -0.9 , -0.4 )
NM_020824 Rho GTPase activating protein 21 (ARHGAP21), mRNA -0.67 ( -1.1 , -0.3 )
NM_006314 connector enhancer of kinase suppressor of Ras 1 (CNKSR1), mRNA -0.67 ( -1.2 , -0.1 )
NM_017921 nuclear protein localization 4 (NPL4), mRNA -0.67 ( -0.8 , -0.5 )
NM_003144 signal sequence receptor, alpha (translocon-associated protein alpha) (SSR1), mRNA -0.67 ( -0.8 , -0.5 )
NM_031284 ADP-dependent glucokinase (ADPGK), mRNA -0.66 ( -0.9 , -0.5 )
NM_032621 brain expressed X-linked 2 (BEX2), mRNA -0.66 ( -0.8 , -0.5 )
NM_004494 hepatoma-derived growth factor (high-mobility group protein 1-like) (HDGF), mRNA -0.66 ( -1 , -0.3 )
NM_014940 HSV-1 stimulation-related gene 1 (HSRG1), mRNA -0.66 ( -0.8 , -0.5 )
NM_002336 low density lipoprotein receptor-related protein 6 (LRP6), mRNA -0.66 ( -1 , -0.4 )
NM_006702 neuropathy target esterase (NTE), mRNA -0.66 ( -0.9 , -0.4 )
NM_014884 splicing factor, arginine/serine-rich 14 (SFRS14), mRNA -0.66 ( -1 , -0.3 )
NM_206835 TNF receptor-associated factor 7 (TRAF7), transcript variant 2, mRNA -0.66 ( -1 , -0.4 )
NM_182800 arsenate resistance protein ARS2 (ARS2), transcript variant 2, mRNA -0.65 ( -0.9 , -0.4 )
NM_020379 mannosidase, alpha, class 1C, member 1 (MAN1C1), mRNA -0.65 ( -0.7 , -0.6 )
NM_014669 nucleoporin 93kDa (NUP93), mRNA -0.65 ( -1.2 , -0.1 )
NM_014679 translokin (KIAA0092), mRNA -0.65 ( -1 , -0.4 )
NM_000598 insulin-like growth factor binding protein 3 (IGFBP3), mRNA -0.65 ( -0.9 , -0.4 )
NM_015057 MYC binding protein 2 (MYCBP2), mRNA -0.65 ( -1 , -0.3 )
NM_001618 poly (ADP-ribose) polymerase family, member 1 (PARP1), mRNA -0.65 ( -1 , -0.3 )
NM_015289 vacuolar protein sorting 39 (yeast) (VPS39), mRNA -0.65 ( -0.9 , -0.5 )
NM_005104 bromodomain containing 2 (BRD2), mRNA -0.65 ( -0.9 , -0.5 )
NM_033271 BTB (POZ) domain containing 6 (BTBD6), mRNA -0.65 ( -0.9 , -0.4 )
NM_003829 multiple PDZ domain protein (MPDZ), mRNA -0.65 ( -0.8 , -0.5 )
NM_001211 BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) (BUB1B), mRNA -0.64 ( -0.8 , -0.5 )
NM_145689 amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) (APBB1), transcript va    -0.64 ( -1 , -0.3 )
NM_015925 liver-specific bHLH-Zip transcription factor (LISCH7), transcript variant 1, mRNA -0.64 ( -1.1 , -0.2 )
NM_003900 sequestosome 1 (SQSTM1), mRNA -0.64 ( -0.8 , -0.5 )
NM_006818 ALL1-fused gene from chromosome 1q (AF1Q), mRNA -0.64 ( -1 , -0.3 )
NM_001904 catenin (cadherin-associated protein), beta 1, 88kDa (CTNNB1), mRNA -0.64 ( -0.8 , -0.5 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.64 ( -0.7 , -0.6 )
NM_023002 hyaluronan and proteoglycan link protein 4 (HAPLN4), mRNA -0.64 ( -0.9 , -0.3 )
NM_005085 nucleoporin 214kDa (NUP214), mRNA -0.64 ( -0.8 , -0.5 )
NM_182648 bromodomain adjacent to zinc finger domain, 1A (BAZ1A), transcript variant 2, mRNA -0.63 ( -0.9 , -0.4 )
NM_177438 Dicer1, Dcr-1 homolog (Drosophila) (DICER1), transcript variant 1, mRNA -0.63 ( -0.8 , -0.5 )
NM_207521 reticulon 4 (RTN4), transcript variant 5, mRNA -0.63 ( -1 , -0.3 )
NM_012470 transportin 3 (TNPO3), mRNA -0.63 ( -0.9 , -0.4 )
NM_006594 adaptor-related protein complex 4, beta 1 subunit (AP4B1), mRNA -0.63 ( -0.7 , -0.5 )
NM_016376 ankyrin repeat and FYVE domain containing 1 (ANKFY1), transcript variant 1, mRNA -0.63 ( -1 , -0.3 )
NM_182712 eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa (EIF3S9), transcript variant 2, m  -0.63 ( -0.9 , -0.4 )
NM_013241 formin homology 2 domain containing 1 (FHOD1), mRNA -0.63 ( -0.9 , -0.3 )
NM_020338 retinoic acid induced 17 (RAI17), mRNA -0.63 ( -0.8 , -0.4 )
NM_002575 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), mRNA -0.63 ( -1.1 , -0.1 )
NM_001067 topoisomerase (DNA) II alpha 170kDa (TOP2A), mRNA -0.63 ( -1 , -0.3 )
NM_033083 ELL associated factor 1 (EAF1), mRNA -0.63 ( -0.9 , -0.4 )
NM_014329 autoantigen (RCD-8), mRNA -0.62 ( -0.9 , -0.4 )
NM_006145 DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1), mRNA -0.62 ( -0.9 , -0.4 )
NM_004540 neural cell adhesion molecule 2 (NCAM2), mRNA -0.62 ( -0.9 , -0.4 )
NM_020123 SM-11044 binding protein (SMBP), mRNA -0.62 ( -1.1 , -0.1 )
NM_182919 TIR domain containing adaptor inducing interferon-beta (TRIF), mRNA -0.62 ( -1 , -0.2 )
NM_016128 coatomer protein complex, subunit gamma (COPG), mRNA -0.62 ( -1 , -0.3 )
NM_015292 likely ortholog of mouse membrane bound C2 domain containing protein (MBC2), mRNA -0.62 ( -0.8 , -0.5 )
NM_145693 lipin 1 (LPIN1), mRNA -0.62 ( -0.9 , -0.3 )
NM_000484 amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) (APP), transcript va    -0.62 ( -1 , -0.2 )
NM_013312 hook homolog 2 (Drosophila) (HOOK2), mRNA -0.62 ( -0.8 , -0.5 )
NM_030884 microtubule-associated protein 4 (MAP4), transcript variant 2, mRNA -0.62 ( -0.9 , -0.3 )
NM_170692 RAS protein activator like 2 (RASAL2), transcript variant 2, mRNA -0.62 ( -0.9 , -0.4 )
NM_003359 UDP-glucose dehydrogenase (UGDH), mRNA -0.62 ( -0.8 , -0.5 )
NM_004926 zinc finger protein 36, C3H type-like 1 (ZFP36L1), mRNA -0.62 ( -0.7 , -0.6 )
NM_001105 activin A receptor, type I (ACVR1), mRNA -0.61 ( -0.7 , -0.5 )
NM_145730 adaptor-related protein complex 1, beta 1 subunit (AP1B1), transcript variant 2, mRNA -0.61 ( -0.9 , -0.4 )
NM_014774 KIAA0494 gene product (KIAA0494), mRNA -0.61 ( -0.8 , -0.4 )
NM_012432 SET domain, bifurcated 1 (SETDB1), mRNA -0.61 ( -0.8 , -0.5 )
NM_058243 bromodomain containing 4 (BRD4), transcript variant long, mRNA -0.61 ( -0.9 , -0.4 )
NM_002018 flightless I homolog (Drosophila) (FLII), mRNA -0.61 ( -0.9 , -0.3 )
NM_005540 inositol polyphosphate-5-phosphatase, 75kDa (INPP5B), mRNA -0.61 ( -0.8 , -0.4 )
NM_198129 laminin, alpha 3 (LAMA3), transcript variant 1, mRNA -0.61 ( -0.6 , -0.6 )
NM_006464 trans-golgi network protein 2 (TGOLN2), mRNA -0.61 ( -1 , -0.2 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.61 ( -1 , -0.2 )
NM_018445 selenoprotein S (SELS), transcript variant 2, mRNA -0.61 ( -0.7 , -0.5 )
NM_001725 bactericidal/permeability-increasing protein (BPI), mRNA -0.6 ( -0.8 , -0.4 )
NM_023924 bromodomain containing 9 (BRD9), mRNA -0.6 ( -0.7 , -0.5 )
NM_000918 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide (p           -0.6 ( -0.6 , -0.6 )
NM_020967 nuclear receptor coactivator 5 (NCOA5), mRNA -0.6 ( -0.8 , -0.4 )
NM_002859 paxillin (PXN), mRNA -0.6 ( -1 , -0.2 )
NM_001102 actinin, alpha 1 (ACTN1), mRNA -0.6 ( -0.9 , -0.3 )
NM_153719 nucleoporin 62kDa (NUP62), transcript variant 1, mRNA -0.6 ( -0.7 , -0.5 )
NM_004587 ribosome binding protein 1 homolog 180kDa (dog) (RRBP1), mRNA -0.6 ( -0.7 , -0.5 )
NM_004749 transforming growth factor beta regulator 4 (TBRG4), transcript variant 1, mRNA -0.59 ( -0.8 , -0.4 )
BC016365 transmembrane emp24 protein transport domain  containing 5 -0.59 ( -0.7 , -0.5 )
NM_018188 ATPase family, AAA domain containing 3A (ATAD3A), mRNA -0.59 ( -0.8 , -0.3 )
NM_019058 DNA-damage-inducible transcript 4 (DDIT4), mRNA -0.59 ( -0.8 , -0.4 )
NM_002228 v-jun sarcoma virus 17 oncogene homolog (avian) (JUN), mRNA -0.59 ( -0.7 , -0.5 )
NM_001670 armadillo repeat gene deletes in velocardiofacial syndrome (ARVCF), mRNA -0.59 ( -0.8 , -0.3 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.59 ( -0.7 , -0.5 )
NM_004417 dual specificity phosphatase 1 (DUSP1), mRNA -0.58 ( -0.6 , -0.6 )
NM_015171 exportin 6 (XPO6), mRNA -0.58 ( -0.8 , -0.4 )
NM_000942 peptidylprolyl isomerase B (cyclophilin B) (PPIB), mRNA -0.58 ( -0.7 , -0.5 )
NM_007027 topoisomerase (DNA) II binding protein 1 (TOPBP1), mRNA -0.58 ( -0.8 , -0.4 )
NM_005194 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB), mRNA -0.58 ( -0.9 , -0.3 )
NM_002074 guanine nucleotide binding protein (G protein), beta polypeptide 1 (GNB1), mRNA -0.58 ( -0.8 , -0.3 )
NM_002394 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 (SLC   -0.58 ( -0.9 , -0.3 )
NM_001273 chromodomain helicase DNA binding protein 4 (CHD4), mRNA  -0.58 ( -0.6 , -0.5 )
NM_182712 eukaryotic translation initiation factor 3, subunit 9 eta, 116kDa (EIF3S9), transcript variant 2, mRNA -0.58 ( -0.7 , -0.5 )
NM_014753 BMS1-like, ribosome assembly protein (yeast) (BMS1L), mRNA -0.57 ( -0.7 , -0.5 )
NM_013449 bromodomain adjacent to zinc finger domain, 2A (BAZ2A), mRNA -0.57 ( -0.8 , -0.4 )
NM_002265 karyopherin (importin) beta 1 (KPNB1), mRNA -0.57 ( -0.8 , -0.3 )
NM_005898 membrane component, chromosome 11, surface marker 1 (M11S1), transcript variant 1, mRNA -0.57 ( -0.9 , -0.2 )
NM_002911 regulator of nonsense transcripts 1 (RENT1), mRNA -0.57 ( -0.8 , -0.4 )
NM_003129 squalene epoxidase (SQLE), mRNA -0.57 ( -0.6 , -0.6 )
NM_005184 calmodulin 3 (phosphorylase kinase, delta) (CALM3), mRNA -0.57 ( -1 , -0.2 )
NM_004417 dual specificity phosphatase 1 (DUSP1), mRNA -0.57 ( -0.9 , -0.2 )
NM_005505 scavenger receptor class B, member 1 (SCARB1), mRNA -0.57 ( -0.9 , -0.3 )
NM_024700 Smad nuclear interacting protein (SNIP1), mRNA -0.57 ( -0.9 , -0.3 )
NM_006015 AT rich interactive domain 1A (SWI- like) (ARID1A), transcript variant 1, mRNA -0.56 ( -0.7 , -0.4 )
NM_004380 CREB binding protein (Rubinstein-Taybi syndrome) (CREBBP), mRNA -0.56 ( -0.9 , -0.2 )
NM_016604 jumonji domain containing 1B (JMJD1B), mRNA -0.56 ( -0.7 , -0.4 )
NM_016612 mitochondrial solute carrier protein (MSCP), mRNA -0.56 ( -0.9 , -0.2 )
NM_033505 selenoprotein I (SELI), mRNA -0.56 ( -0.8 , -0.4 )
NM_001905 CTP synthase (CTPS), mRNA -0.56 ( -0.7 , -0.5 )
NM_024072 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 (DDX54), mRNA -0.56 ( -0.8 , -0.3 )
NM_005324 H3 histone, family 3B (H3.3B) (H3F3B), mRNA -0.56 ( -0.8 , -0.3 )
NM_020850 RAN binding protein 10 (RANBP10), mRNA -0.56 ( -0.6 , -0.5 )
NM_173079 RUN domain containing 1 (RUNDC1), mRNA -0.56 ( -0.7 , -0.4 )
NM_009643 AHNAK nucleoprotein (desmoyokin) (Ahnak) -0.56 ( -0.7 , -0.4 )
NM_005388 phosducin-like (PDCL), mRNA -0.56 ( -0.7 , -0.4 )
NM_006147 interferon regulatory factor 6 (IRF6), mRNA -0.55 ( -0.6 , -0.5 )
NM_001219 calumenin (CALU), mRNA -0.55 ( -0.8 , -0.4 )
NM_014756 KIAA0097 gene product (ch-TOG), mRNA -0.55 ( -0.8 , -0.3 )
NM_005034 polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa (POLR2K), mRNA -0.55 ( -0.7 , -0.4 )
NM_004336 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) (BUB1), mRNA -0.55 ( -0.7 , -0.4 )
NM_022842 CUB domain-containing protein 1 (CDCP1), transcript variant 1, mRNA -0.55 ( -0.7 , -0.4 )
NM_015296 dedicator of cytokinesis 9 (DOCK9), mRNA -0.55 ( -0.9 , -0.2 )
NM_004827 ATP-binding cassette, sub-family G (WHITE), member 2 (ABCG2), mRNA -0.54 ( -0.8 , -0.3 )
NM_152221 casein kinase 1, epsilon (CSNK1E), transcript variant 1, mRNA -0.54 ( -0.8 , -0.3 )
NM_198316 tensin like C1 domain containing phosphatase (TENC1), transcript variant 3, mRNA -0.54 ( -0.8 , -0.2 )
NM_005587 MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) (MEF2   -0.54 ( -0.7 , -0.4 )
NM_133370 splicing factor YT521-B (YT521), mRNA -0.54 ( -0.8 , -0.3 )
NM_004424 E4F transcription factor 1 (E4F1), mRNA -0.54 ( -0.6 , -0.5 )
NM_002540 outer dense fiber of sperm tails 2 (ODF2), transcript variant 1, mRNA -0.54 ( -0.7 , -0.4 )
NM_005628 solute carrier family 1 (neutral amino acid transporter), member 5 (SLC1A5), mRNA -0.54 ( -0.8 , -0.3 )
NM_014445 stress-associated endoplasmic reticulum protein 1 (SERP1), mRNA -0.54 ( -0.6 , -0.5 )
NM_001091 amiloride binding protein 1 (amine oxidase (copper-containing)) (ABP1), mRNA -0.53 ( -0.8 , -0.3 )
NM_014652 importin 13 (IPO13), mRNA -0.53 ( -0.8 , -0.2 )
NM_003819 poly(A) binding protein, cytoplasmic 4 (inducible form) (PABPC4), mRNA -0.53 ( -0.7 , -0.4 )
NM_003376 vascular endothelial growth factor (VEGF), mRNA -0.53 ( -0.8 , -0.3 )
NM_000210 integrin, alpha 6 (ITGA6), mRNA -0.53 ( -0.8 , -0.2 )
NM_003576 serine/threonine kinase 24 (STE20 homolog, yeast) (STK24), mRNA -0.53 ( -0.7 , -0.4 )
NM_032259 WD repeat domain 24 (WDR24), mRNA -0.53 ( -0.7 , -0.4 )
NM_003311 pleckstrin homology-like domain, family A, member 2 (PHLDA2), mRNA -0.53 ( -0.6 , -0.4 )
NM_020765 retinoblastoma-associated factor 600 (RBAF600), mRNA -0.53 ( -0.8 , -0.2 )
NM_006595 apoptosis inhibitor 5 (API5), mRNA -0.52 ( -0.7 , -0.3 )
NM_002689 polymerase (DNA-directed), alpha (70kD) (POLA2), mRNA -0.52 ( -0.8 , -0.3 )
NM_014847 ubiquitin associated protein 2-like (UBAP2L), mRNA -0.52 ( -0.7 , -0.4 )
NM_033671 cyclin B3 (CCNB3), transcript variant 2, mRNA -0.52 ( -0.8 , -0.3 )
NM_006924 splicing factor, arginine/serine-rich 1 (splicing factor 2, alternate splicing factor) (SFRS1), mRNA -0.52 ( -0.6 , -0.5 )
NM_007292 acyl-Coenzyme A oxidase 1, palmitoyl (ACOX1), transcript variant 2, mRNA -0.52 ( -0.7 , -0.4 )
NM_002155 heat shock 70kDa protein 6 (HSP70B') (HSPA6), mRNA -0.52 ( -0.7 , -0.3 )
NM_176800 PRP4 pre-mRNA processing factor 4 homolog B (yeast) (PRPF4B), transcript variant 2, mRNA -0.52 ( -0.7 , -0.4 )
NM_003579 RAD54-like (S. cerevisiae) (RAD54L), mRNA -0.52 ( -0.8 , -0.3 )
NM_175852 taxilin (DKFZp451J0118), mRNA -0.52 ( -0.8 , -0.3 )
NM_001008697 tuftelin interacting protein 11 (TFIP11), transcript variant 1, mRNA -0.52 ( -0.8 , -0.3 )
NM_005088 DNA segment on chromosome X and Y (unique) 155 expressed sequence (DXYS155E), trans     -0.51 ( -0.6 , -0.4 )
NM_004462 farnesyl-diphosphate farnesyltransferase 1 (FDFT1), mRNA -0.51 ( -0.6 , -0.5 )
NM_006979 solute carrier family 39 (zinc transporter), member 7 (SLC39A7), mRNA -0.51 ( -0.8 , -0.3 )
NM_003368 ubiquitin specific protease 1 (USP1), mRNA -0.51 ( -0.7 , -0.4 )
NM_003379 villin 2 (ezrin) (VIL2), mRNA -0.51 ( -0.7 , -0.4 )
NM_012197 RAB GTPase activating protein 1 (RABGAP1), mRNA -0.51 ( -0.7 , -0.4 )
NM_004584 RAD9 homolog A (S. pombe) (RAD9A), mRNA -0.51 ( -0.6 , -0.4 )
NM_023071 spermatogenesis associated, serine-rich 2 (SPATS2), mRNA -0.51 ( -0.7 , -0.4 )
NM_015518 DKFZP434C131 protein (DKFZP434C131), mRNA -0.51 ( -0.8 , -0.2 )
NM_006145 DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1), mRNA -0.51 ( -0.6 , -0.4 )
NM_025164 KIAA0999 protein (KIAA0999), mRNA -0.51 ( -0.8 , -0.3 )
NM_017857 slingshot homolog 3 (Drosophila) (SSH3), mRNA -0.51 ( -0.7 , -0.3 )
NM_004618 topoisomerase (DNA) III alpha (TOP3A), mRNA -0.51 ( -0.6 , -0.4 )
NM_001379 DNA (cytosine-5-)-methyltransferase 1 (DNMT1), mRNA -0.5 ( -0.7 , -0.3 )
NM_003760 eukaryotic translation initiation factor 4 gamma, 3 (EIF4G3), mRNA -0.5 ( -0.7 , -0.3 )
NM_000600 interleukin 6 (interferon, beta 2) (IL6), mRNA -0.5 ( -0.6 , -0.4 )
NM_012289 kelch-like ECH-associated protein 1 (KEAP1), transcript variant 2, mRNA -0.5 ( -0.7 , -0.3 )
NM_006868 RAB31, member RAS oncogene family (RAB31), mRNA -0.5 ( -0.8 , -0.3 )
NM_000201 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor (ICAM1), mRNA -0.5 ( -0.6 , -0.4 )
NM_002745 mitogen-activated protein kinase 1 (MAPK1), transcript variant 1, mRNA -0.5 ( -0.6 , -0.4 )
NM_013277 Rac GTPase activating protein 1 (RACGAP1), mRNA -0.5 ( -0.8 , -0.3 )
NM_203327 solute carrier family 23 (nucleobase transporters), member 2 (SLC23A2), transcript variant 2, mRNA -0.5 ( -0.7 , -0.3 )
NM_003330 thioredoxin reductase 1 (TXNRD1), transcript variant 1, mRNA -0.5 ( -0.6 , -0.4 )
NM_021996 globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 (GBGT1), mRNA -0.5 ( -0.7 , -0.3 )
NM_173470 transmembrane protein 32 (TMEM32), mRNA -0.49 ( -0.7 , -0.3 )
NM_007118 triple functional domain (PTPRF interacting) (TRIO), mRNA -0.49 ( -0.6 , -0.4 )
NM_000389 cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), transcript variant 1, mRNA -0.49 ( -0.6 , -0.4 )
NM_001696 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E isoform 1 (ATP6V1E1), mRNA -0.49 ( -0.7 , -0.3 )
NM_019063 echinoderm microtubule associated protein like 4 (EML4), mRNA -0.49 ( -0.6 , -0.4 )
NM_007189 ATP-binding cassette, sub-family F (GCN20), member 2 (ABCF2), nuclear gene encoding mito       -0.48 ( -0.6 , -0.3 )
NM_178155 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) (FUT8), transcript variant 1, mRNA -0.48 ( -0.6 , -0.4 )
NM_018428 hepatocellular carcinoma-associated antigen 66 (HCA66), mRNA -0.48 ( -0.6 , -0.4 )
NM_015922 NAD(P) dependent steroid dehydrogenase-like (NSDHL), mRNA -0.48 ( -0.6 , -0.4 )
NM_020440 prostaglandin F2 receptor negative regulator (PTGFRN), mRNA -0.48 ( -0.7 , -0.3 )
NM_033291 midline 1 (Opitz/BBB syndrome) (MID1), transcript variant 2, mRNA -0.48 ( -0.6 , -0.4 )
NM_032985 Sec23 homolog B (S. cerevisiae) (SEC23B), transcript variant 2, mRNA -0.48 ( -0.5 , -0.5 )
NM_145690 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide      -0.48 ( -0.6 , -0.4 )
NM_005225 E2F transcription factor 1 (E2F1), mRNA -0.48 ( -0.7 , -0.3 )
NM_005665 ecotropic viral integration site 5 (EVI5), mRNA -0.48 ( -0.7 , -0.3 )
NM_198244 eukaryotic translation initiation factor 4 gamma, 1 (EIF4G1), transcript variant 3, mRNA -0.48 ( -0.7 , -0.3 )
NM_016320 nucleoporin 98kDa (NUP98), transcript variant 1, mRNA -0.48 ( -0.6 , -0.4 )
NM_207113 solute carrier family 37 (glycerol-3-phosphate transporter), member 3 (SLC37A3), transcript va    -0.48 ( -0.7 , -0.3 )
NM_015214 DDHD domain containing 2 (DDHD2), mRNA -0.47 ( -0.6 , -0.3 )
NM_012289 kelch-like ECH-associated protein 1 (KEAP1), transcript variant 2, mRNA -0.47 ( -0.6 , -0.3 )
NM_017859 uridine-cytidine kinase 1-like 1 (UCKL1), mRNA -0.47 ( -0.6 , -0.4 )
NM_001933 dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) (DLST), m  -0.47 ( -0.6 , -0.3 )
NM_002073 guanine nucleotide binding protein (G protein), alpha z polypeptide (GNAZ), mRNA -0.47 ( -0.6 , -0.4 )
NM_005552 kinesin 2 60/70kDa (KNS2), mRNA -0.47 ( -0.6 , -0.4 )
NM_003139 signal recognition particle receptor ('docking protein') (SRPR), mRNA -0.47 ( -0.6 , -0.3 )
NM_007174 citron (rho-interacting, serine/threonine kinase 21) (CIT), mRNA -0.46 ( -0.6 , -0.4 )
NM_177926 CSRP2 binding protein (CSRP2BP), transcript variant 2, mRNA -0.46 ( -0.6 , -0.3 )
NM_005467 N-acetylated alpha-linked acidic dipeptidase 2 (NAALAD2), mRNA -0.46 ( -0.6 , -0.3 )
NM_030782 cisplatin resistance related protein CRR9p (CRR9), mRNA -0.46 ( -0.6 , -0.3 )
NM_006231 polymerase (DNA directed), epsilon (POLE), mRNA -0.46 ( -0.5 , -0.4 )
NM_006947 signal recognition particle 72kDa (SRP72), mRNA -0.46 ( -0.6 , -0.3 )
NM_025154 unc-84 homolog A (C. elegans) (UNC84A), mRNA -0.46 ( -0.6 , -0.3 )
BC016365 transmembrane emp24 protein transport domain  containing 5 -0.46 ( -0.6 , -0.4 )
NM_015120 Alstrom syndrome 1 (ALMS1), mRNA -0.45 ( -0.6 , -0.3 )
NM_182751 MCM10 minichromosome maintenance deficient 10 (S. cerevisiae) (MCM10), transcript varian    -0.45 ( -0.5 , -0.5 )
NM_018383 WD repeat domain 33 (WDR33), transcript variant 1, mRNA -0.45 ( -0.5 , -0.4 )
NM_182643 deleted in liver cancer 1 (DLC1), transcript variant 1, mRNA -0.45 ( -0.5 , -0.4 )
NM_004461 phenylalanine-tRNA synthetase-like, alpha subunit (FARSLA), mRNA -0.45 ( -0.5 , -0.4 )
NM_001969 eukaryotic translation initiation factor 5 (EIF5), transcript variant 1, mRNA -0.44 ( -0.6 , -0.3 )
NM_015635 DKFZP434C212 protein (DKFZP434C212), mRNA -0.44 ( -0.5 , -0.4 )
NM_001809 centromere protein A, 17kDa (CENPA), mRNA -0.44 ( -0.5 , -0.4 )
NM_006145 DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1), mRNA -0.44 ( -0.5 , -0.4 )
NM_014949 KIAA0907 protein (KIAA0907), mRNA -0.44 ( -0.5 , -0.3 )
NM_003938 adaptor-related protein complex 3, delta 1 subunit (AP3D1), mRNA -0.43 ( -0.6 , -0.3 )
NM_013402 fatty acid desaturase 1 (FADS1), mRNA -0.43 ( -0.5 , -0.4 )
NM_007190 SEC23 interacting protein (SEC23IP), mRNA -0.43 ( -0.5 , -0.3 )
NM_003185 TAF4 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 135kDa (TAF4),  -0.43 ( -0.5 , -0.4 )
NM_003716 Ca2+-dependent secretion activator (CADPS), transcript variant 1, mRNA -0.43 ( -0.5 , -0.4 )
NM_006310 aminopeptidase puromycin sensitive (NPEPPS), mRNA -0.43 ( -0.5 , -0.3 )
NM_021259 transmembrane protein 8 (five membrane-spanning domains) (TMEM8), mRNA -0.43 ( -0.5 , -0.4 )
NM_198896 RAB6A, member RAS oncogene family (RAB6A), transcript variant 2, mRNA -0.42 ( -0.5 , -0.4 )
NM_006990 WAS protein family, member 2 (WASF2), mRNA -0.42 ( -0.5 , -0.4 )
NM_020728 chr2 synaptotagmin (CHR2SYT), mRNA -0.41 ( -0.5 , -0.4 )
NM_017801 chemokine-like factor super family 6 (CKLFSF6), mRNA -0.4 ( -0.5 , -0.4 )
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